0000950170-24-09709110-Q PLUS THERAPEUTICS, INC. 20240814202408141631201631201631200 0000950170-24-097091 10-Q 61 20240630 20240814 20240814 PLUS THERAPEUTICS, INC. 0001095981 3841 330827593 DE 1231 10-Q 34 001-34375 241208642 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 737.255.7194 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 CYTORI THERAPEUTICS, INC. 20050712 MACROPORE INC 20010320 10-Q 1 pstv-20240630.htm 10-Q 10-Q 0001095981--12-31Q2false0.330.060.060001095981pstv:CharlottesvilleMember2024-01-012024-06-300001095981pstv:BioceptAgreementMember2024-01-012024-06-300001095981pstv:NanoTxLicensesAgreementMember2020-03-2900010959812024-04-012024-06-300001095981srt:MaximumMember2024-04-012024-06-300001095981us-gaap:AdditionalPaidInCapitalMember2023-12-310001095981pstv:CharlottesvilleMember2024-06-300001095981us-gaap:CommonStockMemberpstv:SeriesBWarrantMemberpstv:May2024PrivatePlacementMember2024-05-052024-05-050001095981pstv:SeriesUWarrantsMember2024-06-300001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2022-07-140001095981pstv:StockBasedCompensation2020EquityIncentivePlanMember2024-06-300001095981pstv:StockBasedCompensation2015EquityIncentivePlan1Member2024-06-300001095981us-gaap:CommonStockMember2023-12-310001095981us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:CommonStockMember2024-04-012024-06-300001095981us-gaap:MeasurementInputRiskFreeInterestRateMemberpstv:WarrantLiabilityMembersrt:MinimumMember2024-05-050001095981us-gaap:RetainedEarningsMember2024-04-012024-06-300001095981202401-012024-06-300001095981us-gaap:RetainedEarningsMember2023-03-310001095981us-gaap:AdditionalPaidInCapitalMember2024-03-310001095981pstv:WarrantLiabilityMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2024-06-300001095981us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001095981us-gaap:WarrantMemberpstv:SeriesUWarrantsMember2024-06-300001095981pstv:PreClinicalResearchStudyObligationsMember2024-06-300001095981us-gaap:WarrantMember2023-01-012023-06-300001095981pstv:PershingCreditFacilityMemberus-gaap:PrimeRateMember2024-05-312024-05-310001095981us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:RetainedEarningsMember2024-03-310001095981us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001095981us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember2023-04-012023-06-3000010959812023-04-212023-04-210001095981us-gaap:CommonStockMember2023-03-310001095981us-gaap:CommonStockMember2023-01-012023-12-310001095981pstv:WarrantLiabilityMember2023-12-310001095981us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001095981pstv:TermLoanMember2015-05-282015-05-290001095981us-gaap:MeasurementInputRiskFreeInterestRateMemberpstv:WarrantLiabilityMembersrt:MinimumMember2024-06-3000010959812024-03-080001095981us-gaap:CommonStockMember2023-04-012023-06-300001095981pstv:LincolnParkCapitalFundLLCMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMembersrt:MaximumMember2022-05-160001095981pstv:WarrantLiabilityMembersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2024-06-300001095981us-gaap:TreasuryStockCommonMember2024-06-300001095981us-gaap:MeasurementInputPriceVolatilityMemberpstv:WarrantLiabilityMembersrt:MaximumMember2024-06-300001095981us-gaap:CommonStockMemberpstv:SeriesAWarrantAndSeriesBWarrantMemberpstv:May2024PrivatePlacementMember2024-05-050001095981pstv:SeriesUWarrantsMember2024-01-012024-06-300001095981us-gaap:WarrantMember2024-01-012024-06-300001095981pstv:OptionsMember2024-01-012024-06-300001095981us-gaap:MeasurementInputPriceVolatilityMemberpstv:WarrantLiabilityMembersrt:MaximumMember2024-05-050001095981us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:MeasurementInputPriceVolatilityMemberpstv:WarrantLiabilityMembersrt:MinimumMember2024-06-300001095981us-gaap:AdditionalPaidInCapitalMember2022-12-310001095981us-gaap:AdditionalPaidInCapitalMember2024-06-300001095981us-gaap:RetainedEarningsMember2023-12-310001095981us-gaap:ConvertiblePreferredStockMember2023-12-3100010959812023-12-310001095981pstv:OutstandingWarrantsAndOptionsMember2023-05-010001095981pstv:PrivatePlacementAndPrefundedWarrantMemberus-gaap:CommonStockMemberpstv:May2024PrivatePlacementMemberpstv:AdditionalSubscriptionMember2024-05-050001095981us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember2024-01-012024-06-300001095981pstv:NanoTxLicensesAgreementMember2024-06-300001095981us-gaap:SeriesFPreferredStockMember2023-01-012023-03-310001095981srt:MaximumMember2023-04-202023-04-2000010959812024-01-012024-03-310001095981us-gaap:CommonStockMember2024-01-012024-06-300001095981pstv:May2024PrivatePlacementMember2024-05-052024-05-050001095981pstv:CharlottesvilleMember2023-07-010001095981us-gaap:CommonStockMember2022-12-310001095981us-gaap:RetainedEarningsMember2023-06-300001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2023-08-182024-06-300001095981pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesCConvertiblePreferredStockMember2024-06-300001095981pstv:TermLoanMember2015-05-290001095981pstv:May2024PrivatePlacementMember2024-04-012024-06-3000010959812023-04-200001095981us-gaap:GrantMember2023-01-012023-06-300001095981us-gaap:RetainedEarningsMember2022-12-310001095981us-gaap:CommonStockMembersrt:MaximumMember2023-10-310001095981us-gaap:AdditionalPaidInCapitalMember2023-06-300001095981pstv:TermLoanMember2024-06-030001095981us-gaap:ConvertiblePreferredStockMember2024-03-310001095981us-gaap:TreasuryStockCommonMember2023-12-310001095981pstv:May2024PrivatePlacementMember2024-06-300001095981pstv:WarrantLiabilityMember2024-01-012024-06-300001095981us-gaap:MeasurementInputRiskFreeInterestRateMemberpstv:WarrantLiabilityMembersrt:MaximumMember2024-06-300001095981us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001095981us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2022-08-022022-08-020001095981pstv:WarrantLiabilityMemberpstv:MeasurementInputCommonStockMarketPriceMember2024-06-300001095981srt:MinimumMember2024-01-012024-06-300001095981us-gaap:WarrantMemberpstv:SeriesUWarrantsMember2024-01-012024-06-300001095981pstv:StockBasedCompensation2015EquityIncentivePlan1Member2024-06-060001095981pstv:TermLoanMember2024-01-012024-06-300001095981pstv:StockBasedCompensation2020EquityIncentivePlanMember2024-01-012024-06-300001095981us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001095981us-gaap:SeriesFPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-310001095981us-gaap:TreasuryStockCommonMember2024-03-310001095981us-gaap:PreferredStockMember2023-01-012023-06-300001095981pstv:OptionsMember2023-01-012023-06-300001095981pstv:WarrantLiabilityMemberpstv:MeasurementInputCommonStockMarketPriceMembersrt:MaximumMember2024-05-050001095981us-gaap:ConvertiblePreferredStockMember2023-06-300001095981pstv:SeriesFConvertiblePreferredStockMember2023-03-032023-03-030001095981us-gaap:RetainedEarningsMember2023-01-012023-03-3100010959812023-01-012023-12-310001095981pstv:EquityIncentivePlansMember2023-05-010001095981pstv:RepresentativeSeriesUWarrantMember2024-06-300001095981pstv:SeriesFConvertiblePreferredStockMemberpstv:SubscriptionAgreementMember2023-03-032023-03-030001095981pstv:CancerPreventionAndResearchInstituteOfTexasContractMember2022-09-192022-09-190001095981pstv:OutstandingWarrantsAndOptionsMember2023-04-300001095981us-gaap:GrantMember2024-01-012024-06-300001095981us-gaap:CommonStockMemberpstv:SeriesAWarrantMemberus-gaap:SubsequentEventMemberpstv:AmendmentAndRestatementsMay2024PrivatePlacementMember2024-08-092024-08-090001095981us-gaap:CommonStockMember2024-03-310001095981pstv:May2024PrivatePlacementMemberpstv:PreFundedWarrantsMember2024-05-092024-05-090001095981pstv:BioceptAgreementMember2023-09-07000109595981202 3-01-012023-03-310001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2022-08-170001095981pstv:SeriesFConvertiblePreferredStockMember2023-03-030001095981us-gaap:CommonStockMemberpstv:May2024PrivatePlacementMember2024-05-052024-05-050001095981pstv:WarrantLiabilityMembersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2024-05-050001095981pstv:PershingCreditFacilityMember2024-05-312024-05-310001095981pstv:InitialSubscriptionMemberus-gaap:CommonStockMemberpstv:SeriesAWarrantMemberpstv:May2024PrivatePlacementMember2024-05-050001095981us-gaap:CommonStockMemberpstv:SeriesBWarrantMemberpstv:May2024PrivatePlacementMember2024-05-050001095981us-gaap:CommonStockMemberpstv:SeriesBWarrantMemberpstv:AdditionalSubscriptionMember2024-05-050001095981us-gaap:CommonStockMemberpstv:SeriesBWarrantMemberus-gaap:SubsequentEventMemberpstv:AmendmentAndRestatementsMay2024PrivatePlacementMember2024-08-092024-08-090001095981pstv:WarrantLiabilityMemberpstv:MeasurementInputCommonStockMarketPriceMembersrt:MinimumMember2024-05-050001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMembersrt:MaximumMember2023-08-180001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2022-08-020001095981us-gaap:ConvertiblePreferredStockMember2023-03-310001095981us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:CommonStockMember2023-01-012023-03-3100010959812023-04-272023-04-270001095981us-gaap:CommonStockMemberpstv:May2024PrivatePlacementMemberpstv:SecuritiesPurchaseAgreementMember2024-05-052024-05-0500010959812023-06-300001095981pstv:CancerPreventionAndResearchInstituteOfTexasContractMember2024-01-012024-06-3000010959812023-05-010001095981us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember2023-01-012023-06-300001095981us-gaap:CommonStockMemberpstv:May2024PrivatePlacementMember2024-05-092024-05-0900010959812024-03-012023-06-300001095981us-gaap:GrantMember2024-04-012024-06-300001095981us-gaap:RetainedEarningsMember2024-01-012024-03-3100010959812024-05-092024-05-090001095981pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesCConvertiblePreferredStockMember2024-01-012024-06-300001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMembersrt:MaximumMember2022-08-170001095981us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember2024-04-012024-06-300001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMembersrt:MinimumMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2022-05-162022-05-160001095981us-gaap:CommonClassAMember2024-01-012024-06-300001095981us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:CommonClassBMember2024-06-300001095981pstv:InitialSubscriptionMemberus-gaap:CommonStockMemberpstv:SeriesAWarrantAndSeriesBWarrantMemberpstv:May2024PrivatePlacementMember2024-05-050001095981us-gaap:ConvertiblePreferredStockMember2024-06-300001095981us-gaap:AdditionalPaidInCapitalMember2023-03-310001095981pstv:NanoTxLicensesAgreementMember2020-03-292020-03-2900010959812024-03-082024-03-080001095981pstv:InitialSubscriptionMemberpstv:PrivatePlacementAndPrefundedWarrantMemberus-gaap:CommonStockMemberpstv:May2024PrivatePlacementMember2024-05-0500010959812024-08-090001095981us-gaap:CommonStockMember2023-06-300001095981pstv:May2024PrivatePlacementMember2024-01-012024-06-3000010959812023-03-310001095981pstv:WarrantLiabilityMember2024-06-3000010959812022-12-310001095981us-gaap:CommonStockMemberpstv:May2024PrivatePlacementMemberpstv:SecuritiesPurchaseAgreementMember2024-05-0500010959812023-04-300001095981pstv:SeriesFConvertiblePreferredStockMemberpstv:SubscriptionAgreementMember2023-03-030001095981us-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:CommonStockMemberpstv:SeriesAWarrantMemberpstv:May2024PrivatePlacementMember2024-05-052024-05-0500010959812024-03-310001095981us-gaap:CommonStockMember2024-06-300001095981pstv:EquityIncentivePlansMember2023-04-300001095981us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001095981us-gaap:MeasurementInputRiskFreeInterestRateMemberpstv:WarrantLiabilityMembersrt:MaximumMember2024-05-050001095981us-gaap:PreferredStockMember2023-03-310001095981us-gaap:PreferredStockMember2024-01-012024-06-300001095981us-gaap:RetainedEarningsMember2023-04-012023-06-300001095981us-gaap:SeriesFPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001095981srt:MaximumMember2024-01-012024-06-300001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2022-08-172022-12-310001095981pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesBConvertiblePreferredStockMember2024-06-300001095981pstv:BioceptAssetAcquisitionsMember2024-04-262024-04-260001095981pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesBConvertiblePreferredStockMember2024-01-012024-06-300001095981us-gaap:MeasurementInputPriceVolatilityMemberpstv:WarrantLiabilityMembersrt:MinimumMember2024-05-050001095981us-gaap:RetainedEarningsMember2024-06-300001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2024-01-012024-06-300001095981us-gaap:SeriesFPreferredStockMemberus-gaap:PreferredStockMember2023-04-012023-06-300001095981pstv:PershingCreditFacilityMember2024-05-310001095981pstv:WarrantLiabilityMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2024-05-050001095981us-gaap:CommonStockMemberpstv:SeriesBWarrantMemberpstv:May2024PrivatePlacementMember2024-05-092024-05-090001095981us-gaap:GrantMember2023-04-012023-06-300001095981us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001095981us-gaap:CommonStockMemberpstv:SeriesAWarrantMemberpstv:May2024PrivatePlacementMember2024-05-092024-05-090001095981srt:MinimumMember2023-04-202023-04-200001095981pstv:LincolnParkCapitalFundLLCMemberus-gaap:CommonStockMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMember2023-01-012023-12-310001095981pstv:LincolnParkCapitalFundLLCMemberpstv:TwentyTwentyPurchaseAgreementMemberus-gaap:CommonStockMember2022-08-172024-06-30xbrli:purexbrli:sharespstv:Segmentpstv:Votesiso4217:USDiso4217:USDxbrli:shares Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 Â PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Â Â Delaware Â 33-0827593 (State or other jurisdictionof incorporation or organization) Â (I.R.S. EmployerIdentification No.) Â Â Â Â 4200 MARATHON BLVD., SUITE 200, AUSTIN, TX Â 78756 (Address of principal executive offices) Â (Zip Code) Â (737) 255-7194 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 PSTV NasdaqÂ Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large Accelerated Filer â˜ Accelerated Filer â˜ Non-Accelerated Filer â˜’ Â Smaller reporting company â˜’ Â Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financing accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of August 9, 2024 , there were 5,896,333 shares of the registrantâ€™s common stock outstanding. Â Â Â Â PLUS THERAPEUTICS, INC. Table of Contents Â Â Â Â Page PART I. Â FINANCIAL INFORMATION Â Â Â Â Â Â Â Â Â Item 1. Â Condensed Consolidated Financial Statements (Unaudited) Â 4 Â Â Â Â Â Â Â Â Â Â Â Condensed Consolidated Balance Sheets Â 4 Â Â Â Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Operations Â 5 Â Â Â Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Stockholdersâ€™ Deficit Â 6 Â Â Â Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Cash Flows Â 7 Â Â Â Â Â Â Â Â Â Â Â Notes to Condensed Consolidated Financial Statements Â 8 Â Â Â Â Â Â Â Â Â Item 2. Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 19 Â Â Â Â Â Â Â Â Item 3. Â Quantitative and Qualitative Disclosures about Market Risk Â 30 Â Â Â Â Â Â Â Â Item 4. Â Controls and Procedures Â 30 Â Â Â Â Â Â Â PART II. Â OTHER INFORMATION Â Â Â Â Â Â Â Â Â Item 1. Â Legal Proceedings Â 31 Â Â Â Â Â Â Â Â Item 1A. Â Risk Factors Â 31 Â Â Â Â Â Â Â Â Item 6. Â Exhibits Â 33 Â 2 Â CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q and the exhibits incorporated herein by reference contain â€œforward-looking statementsâ€ which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements other than statements of historical fact constitute â€œforward-looking statements.â€ These forward-looking statements do not constitute guarantees of future performance. These forward-looking statements may be identified by terms such as â€œintend,â€ â€œexpect,â€ â€œproject,â€ â€œbelieve,â€ â€œanticipate,â€ â€œinitiate,â€ â€œwill,â€ â€œshould,â€ â€œwould,â€ â€œcould,â€ â€œmay,â€ â€œdesigned,â€ â€œpotential,â€ â€œevaluate,â€ â€œhypothesize,â€ â€œplan,â€ â€œprogressing,â€ â€œproceeding,â€ â€œexploring,â€ â€œopportunity,â€ â€œhopes,â€ â€œsuggest,â€ and similar expressions, or the negative of such expressions. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Â These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and administrative expenses; our strategic collaborations and license agreements, intellectual property, U.S. Food and Drug Administration and European Medicines Agency approvals and interactions and government regulation; the potential size of the market for our product candidates; our research and development efforts; results from our pre-clinical and clinical studies and the implications of such results regarding the efficacy or safety of our product candidates; the safety profile, pathways, and efficacy of our product candidates and formulations; anticipated advantages of our product candidates over other products available in the market and being developed; the populations that will most benefit from our product candidates and indications that will be pursued with each product candidate; anticipated progress in our current and future clinical trials; plans and strategies to create novel technologies; our IP strategy; competition; future development and/or expansion of our product candidates and therapies in our markets; sources of competition for any of our product candidates; our pipeline; our ability to generate product or development revenue and the sources of such revenue; our ability to effectively manage our gross profit margins; our ability to obtain and maintain regulatory approvals; expectations as to our future performance; portions of the â€œLiquidity and Capital Resourcesâ€ section of this quarterly report on Form 10-Q, including our potential need for additional financing and the availability thereof; our ability to integrate into our business and operations, develop, fully utilize and monetize acquired assets; our ability to reclassify warrants as equity in our financial statements; our ability to continue as a going concern; our ability to remain listed on the Nasdaq Capital Market; our ability to repay or refinance some or all of our outstanding indebtedness and our ability to raise capital in the future; our ability to transfer the drug and medical device product manufacturing to a contract drug and medical device manufacturing organization; and the potential enhancement of our cash position through development, marketing, and licensing arrangements; and a material security breach or cybersecurity attack affecting our operations and property. The forward-looking statements included in this quarterly report on Form 10-Q are also subject to a number of additional material risks and uncertainties, including but not limited to the risks described under â€œPart I â€“ Item 1A â€“ Risk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, in other subsequent filings with the Securities and Exchange Commission, and under â€œPart II â€“ Item 1A â€“ Risk Factorsâ€ in this quarterly report on Form 10-Q. These risks and uncertainties could cause actual results to differ materially from expectations or those expressed in these forward-looking statements. Â Our actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of our product candidates and therapies, the results of our research and development activities, including uncertainties relating to the clinical trials of our product candidates and therapies; our liquidity and capital resources and our ability to raise additional cash, the outcome of our partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to us, market conditions, product performance, potential litigation, our ability to integrate into our business and operations, develop, fully utilize and monetize acquired assets, and competition within the radiotherapeutics, and more generally, oncological medicine fields, among others. The forward-looking statements included in this quarterly report on Form 10-Q are also subject to a number of additional material risks and uncertainties, including but not limited to the risks described under â€œPart I â€“ Item 1A â€“ Risk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, and under â€œPart II â€“ Item 1A â€“ Risk Factorsâ€ in this quarterly report on Form 10-Q. These risks and uncertainties could cause actual results to differ materially from expectations or those expressed in these forward-looking statements. Â We encourage you to read the risks described under â€œPart II â€“ Item 1A â€“ Risk Factorsâ€ in this quarterly report on Form 10-Q carefully. We caution you not to place undue reliance on the forward-looking statements contained in this quarterly report on Form 10-Q. These statements, like all statements in this quarterly report on Form 10-Q, speak only as of the date of this quarterly report on Form 10-Q (unless an earlier date is indicated) and the Company undertakes no obligation to update or revise the statements except as required by law. Such forward-looking statements are not guarantees of future performance. 3 Â PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements PLUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and par value data) Â Â Â Â Â June 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Current assets: Â Â Â Â Â Cash and cash equivalents Â $ 4,912 Â Â $ 8,554 Â Investments Â Â 3,523 Â Â Â â€“ Â Other current assets Â Â 945 Â Â Â 1,280 Â Total current assets Â Â 9,380 Â Â Â 9,834 Â Â Â Â Â Â Property and equipment, net Â Â 732 Â Â Â 906 Â Operating lease right-of-use assets Â Â 139 Â Â Â 202 Â Goodwill Â Â 372 Â Â Â 372 Â Intangible assets, net Â Â 557 Â Â Â 42 Â Other assets Â Â 32 Â Â Â 32 Â Total assets Â $ 11,212 Â Â $ 11,388 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Current liabilities: Â Â Â Â Â Accounts payable and accrued expenses Â $ 6,946 Â Â $ 6,631 Â Operating lease liability Â Â 92 Â Â Â 120 Â Warrant liability Â Â 6,160 Â Â Â â€“ Â Deferred grant liability Â Â 2,297 Â Â Â â€“ Â Line of credit Â Â 3,292 Â Â Â â€“ Â Term loan obligation, current Â Â â€“ Â Â Â 3,976 Â Total current liabilities Â Â 18,787 Â Â Â 10,727 Â Â Â Â Â Â Noncurrent operating lease liability Â Â 50 Â Â Â 85 Â Deferred grant liability Â Â â€“ Â Â Â 1,924 Â Total liabilities Â Â 18,837 Â Â Â 12,736 Â Â Â Â Â Â Commitments and contingencies (Note 10) Â Â Â Â Â Â Â Â Â Â Â Stockholdersâ€™ deficit: Â Â Â Â Â Â Preferred stock, $0.001Â par value; 5,000,000Â shares authorized; 1,952Â shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Â Â â€“ Â Â Â â€“ Â Common stock, $0.001Â par value; 100,000,000Â shares authorized; 5,962,644Â and 5,704,219Â issued and outstanding at June 30, 2024, and 4,522,656Â issued and 4,444,097Â outstanding as of December 31, 2023, respectively Â Â 6 Â Â Â 5 Â Treasury stock (at cost, 258,425Â and 78,559Â shares as of June 30, 2024 and December 31, 2023, respectively) Â Â (500) Â Â (126) Additional paid-in capital Â Â 479,571 Â Â Â 479,274 Â Accumulated deficit Â Â (486,702) Â Â (480,501) Total stockholdersâ€™ deficit Â Â (7,625) Â Â (1,348) Total liabilities and stockholdersâ€™ deficit Â $ 11,212 Â Â $ 11,388 Â Â See Accompanying Notes to these Condensed Consolidated Financial Statements Â Â 4 Â PLUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except share and per share data) Â Â Â Â For the Three Months Ended June 30, Â Â For the Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Grant revenue Â $ 1,279 Â Â $ 1,854 Â Â $ 2,956 Â Â $ 2,360 Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 2,773 Â Â Â 1,420 Â Â Â 5,536 Â Â Â 4,403 Â General and administrative Â Â 2,203 Â Â Â 1,924 Â Â Â 4,416 Â Â Â 4,169 Â Total operating expenses Â Â 4,976 Â Â Â 3,344 Â Â Â 9,952 Â Â Â 8,572 Â Loss from operations Â Â (3,697) Â Â (1,490) Â Â (6,996) Â Â (6,212) Â Â Â Â Â Â Â Â Â Â Â Other income (expense): Â Â Â Â Â Â Â Â Â Â Â Financing expense Â Â (3,545) Â Â â€“ Â Â Â (3,545) Â Â â€“ Â Change in fair value of warrants Â Â 4,694 Â Â Â â€“ Â Â Â 4,694 Â Â Â â€“ Â Warrant issuance costs Â Â (432) Â Â â€“ Â Â Â (432) Â Â â€“ Â Interest income Â Â 67 Â Â Â 120 Â Â Â 139 Â Â Â 171 Â Interest expense Â Â (27) Â Â (112) Â Â (61) Â Â (246) Total other income (expense) Â Â 757 Â Â Â 8 Â Â Â 795 Â Â Â (75) Net loss Â $ (2,940) Â $ (1,482) Â $ (6,201) Â $ (6,287) Â Â Â Â Â Â Â Â Â Â Â Per share information: Â Â Â Â Â Â Â Â Â Â Â Net loss per share of common stock - basic Â $ (0.45) Â $ (0.59) Â $ (1.15) Â $ (2.60) Weighted average number of shares of common stock outstanding - basic Â Â 6,500,831 Â Â Â 2,509,378 Â Â Â 5,411,382 Â Â Â 2,415,221 Â Net loss per share of common stock - diluted Â $ (0.71) Â $ (0.59) Â $ (1.45) Â $ (2.60) Weighted average number of shares of common stock outstanding - diluted Â Â 10,742,924 Â Â Â 2,509,378 Â Â Â 7,532,428 Â Â Â 2,415,221 Â Â Â See Accompanying Notes to these Condensed Consolidated Financial Statements Â 5 Â PLUS THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ DEFICIT (UNAUDITED) (In thousands, except share data) Â Convertible Â Additional Â Â Â Â Â Total Â Â Preferred stock Â preferred stock Â Â Common stock Â Â Treasury Stock Â Â paid-in Â Â Accumulated Â Â stockholdersâ€™ Â Â Shares Â Â Â Amount Â Shares Â Â Â Amount Â Â Shares Â Â Â Amount Â Â Shares Â Â Â Amount Â Â Shares Â Â Amount Â Â capital Â Â deficit Â Â (deficit)/equity Â Balance at December 31, 2022 Â â€“ Â $ Â â€“ Â Â 1,952 Â Â $ Â â€“ Â Â Â 2,240,092 Â $ Â 2 Â Â Â â€“ Â $ Â â€“ Â Â Â $ 473,628 Â $ Â (467,185) $ Â 6,445 Â Stock-based compensation Â â€“ Â Â Â â€“ Â Â Â â€“ Â Â

million shares to approximately 0.1 million shares, and (z) reserved but unallocated under the Companyâ€™s current equity incentive plans decreased from approximately 3.0 million shares of common stock to approximately 0.2 million shares of common stock. The Companyâ€™s common stock began trading on the Nasdaq Capital Market (â€œNasdaqâ€) on a post-split basis on May 1, 2023. The Companyâ€™s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Companyâ€™s outstanding stock options, warrants and equity incentive plans for the period ended March 31, 2023 as presented in the condensed consolidated financial statements in this quarterly report on Form 10-Q. The Companyâ€™s consolidated financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. Grant Revenue Recognition In applying the provisions of Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a â€œcustomerâ€, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (â€œASC 808â€). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No. 20 (â€œIAS 20â€), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract.8 Â The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.WarrantsWarrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement in accordance with applicable accounting guidance provided in ASC Topic 815 - Derivatives and Hedging. Equity-classified instruments are recorded in additional paid-in capital at issuance and are not subject to remeasurement. Liability-classified warrants are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.Segment Information Prior to the establishment of CNSide LLC, the Company operated its business in one operating and reportable segment, which includes all activities related to the research and development of the Companyâ€™s research programs. From inception of CNSide LLC through June 30, 2024, the Company commenced certain set up and compliance activities of CNSide LLC with immaterial financial statement impact. The Company expects CNSide LLC to initiate commercial operations starting in the fourth quarter of 2024 related to laboratory testing, and that CNSide LLC will become a separate operating segment starting in the quarter ending December 31, 2024. The Companyâ€™s chief operating decision-maker (â€œCODMâ€), the Chief Executive Officer, reviews the operating results including revenue and direct expenses of the Companyâ€™s operating segments for resource allocation and other management decisions. Available-for-Sale SecuritiesThe Companyâ€™s available-for-sale securities consist of U.S. government and agency securities. Securities with maturities from the date of purchase of less than three months are included in cash equivalents. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the condensed consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed consolidated statements of operations and comprehensive income/loss and as a separate component of stockholdersâ€™ equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Companyâ€™s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). There has been no allowance for expected credit losses recorded during any of the periods presented.Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed consolidated statements of operations and comprehensive income/loss. During the three and six months ended June 30, 2024, the unrealized gain on the Companyâ€™s available-for-sale securities was less than $1,000, and not presented separately in the condensed consolidated statement of operations. Recently Issued Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board (the â€œFASBâ€) issued Accounting Standards Update (ASU) No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Companyâ€™s consolidated financial statements and related disclosures.In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided 9 Â to the CODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years starting after December 15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is currently evaluating the impact of the changes required by the new standard on the Companyâ€™s consolidated financial statements and related disclosures. Â 2. Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Companyâ€™s most significant estimates and critical accounting policies involve reviewing assets for impairment and determining the assumptions used in measuring stock-based compensation expense and warrant liability. Â 3. Liquidity and Going ConcernThe Company incurred a net loss of $6.2 million for the six months ended June 30, 2024. The Company had an accumulated deficit of $486.7 million as of June 30, 2024. Additionally, the Company used net cash of $5.7 million to fund its operating activities for the six months ended June 30, 2024. To date, the Companyâ€™s operating losses have been funded primarily from outside sources of invested capital from issuance of its common and preferred stocks, proceeds from its term loan, line of credit facility and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources to fund its future clinical development programs and other operations. There can be no assurance that the Company will be able to continue to raise additional capital in the future. The Companyâ€™s inability to raise additional cash would have a material and adverse impact on its operations and could cause the Company to default on its term loan. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern.At the closing of the May 2024 Private Placement, the Company received aggregate upfront gross proceeds of approximately $7.3 million, before deducting fees and other expenses associated with the closing of the May 2024 Private Placement. None of the Warrants issued in the May 2024 Private Placement have been exercised as of the filing of this quarterly report on Form 10-Q. See Note 12 to the unaudited condensed consolidated financial statements, Stockholders' Deficit - May 2024 Private Placement, for further information regarding the May 2024 Private Placement.Nasdaq Listing Compliance On March 8, 2024, the Company received a letter (the â€œNoticeâ€) from the Listing Qualifications staff of Nasdaq, notifying the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholdersâ€™ equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the â€œAlternative Standardsâ€). The Notice stated that as of March 8, 2024, the Company did not meet the Alternative Standards.On April 22, 2024, the Company provided Nasdaq with its plan to achieve and sustain compliance with the stockholdersâ€™ equity requirement and requested that Nasdaq grant the Company an extension of time until September 4, 2024, to provide evidence of compliance with the stockholdersâ€™ equity requirement. Nasdaq has not yet responded to the Companyâ€™s plan, and there can be no assurance that Nasdaq will grant an extension or that the Company will be able to comply with the applicable listing standards of Nasdaq. The Company continues to seek additional capital from financing alternatives and other sources in order to ensure adequate funding is available to allow the Company to continue research and product development and other operating activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. Should the Company fail to raise additional cash from outside sources, it would have a material adverse impact on its operations.The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. 4. Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. The Company follows 10 Â a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:â€¢Level 1: Quoted prices in active markets for identical assets or liabilities.Â â€¢Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.Â â€¢Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.Â Â Money market funds are valued at the closing price reported by the fund sponsor from an actively traded exchange. Money market funds and U.S. Treasury bills were included in cash equivalents in the consolidated balance sheets for the periods presented. The Company obtains the fair value of its Level 2 cash equivalents from third-party pricing services. The pricing services utilize industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. The following table summarizes the Companyâ€™s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, respectively (in thousands). Â Â Fair Value Measurements Using Â June 30, 2024 Fair Value Â Level 1 Â Level 2 Â Level 3 Â Money market $ 2,415 Â $ 2,415 Â $ â€” Â $ â€” Â Treasury bills and government agency bonds Â 3,523 Â Â â€” Â Â 3,523 Â Â â€” Â Â $ 5,938 Â $ 2,415 Â $ 3,523 Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Measurements Using Â December 31, 2023 Fair Value Â Level 1 Â Level 2 Â Level 3 Â Money market $ 5,449 Â $ 5,449 Â $ â€” Â $ â€” Â Â During the six months ended June 30, 2024, the Company issued common stock warrants which are classified as liabilities under authoritative accounting standards (Note 12). Those common stock warrants are valued using the Black Scholes model, with level 3 inputs such as expected volatility, risk-free interest rate, and expected term that are not observable in active markets. Â The table below summarizes key inputs used in the valuation of the liability classified warrants as of the issuance date and as of June 30, 2024: Â Â Â As of issuance date Â As of June 30, 2024 Â Expected term Â 1.1 - 5.0Â years Â 1.0Â to 4.8Â years Â Common stock market price Â $2.01Â - $2.27 Â $ 1.47 Â Risk-free interest rate Â 4.5% - 5.1% Â 4.3% - 5.1% Â Expected volatility Â 117.0% - 127.2% Â 105.6% - 121.0% Â Â The table below provides a summary of the fair value of the Company's warrant liability during the six months ended June 30, 2024 (in thousands). As of June 30, 2023, the fair value of liability classified warrants was immaterial, and the change in the fair value of liability classified warrants during the three and six months ended June 30, 2023 was immaterial. Â Â Six Months Ended June 30, Â Warrant liability Â 2024 Â Beginning balance Â $ â€” Â Issuance of warrants Â Â 10,854 Â Change in fair value of warrants Â Â (4,694) Ending balance Â $ 6,160 Â Â 5. Term Loan ObligationsÂ On May 29, 2015, the Company entered into the Loan and Security Agreement (the â€œLoan and Security Agreementâ€), pursuant to which Oxford Finance, LLC (â€œOxfordâ€) funded an aggregate principal amount of $17.7 million (the â€œTerm Loanâ€), subject to the terms and conditions set forth in the Loan and Security Agreement. Pursuant to the Loan and Security Agreement, as amended, the Company made interest only payments through May 1, 2021, and thereafter was required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize 11 Â the Term Loan through June 1, 2024, the maturity date. On June 3, 2024, the Company paid off the Term Loan by making a final payment in an aggregate amount equal to approximately $3.3 million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Term Loan terminated Oxfordâ€™s security interest in the Companyâ€™s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Term Loan. Â 6. Line of Credit Facility On May 31, 2024, the Company drew down $3.3 million on its new margin loan facility under a line of credit (the â€œPershing Credit Facilityâ€) with Pershing LLC (â€œPershingâ€), an affiliate of The Bank of New York Mellon Corporation. The available credit line limit under the Pershing Credit Facility fluctuates based on the Companyâ€™s request for extensions from time to time, subject to the value of the collateralized marketable securities the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed 91.5% of the value of the collateralized marketable securities deposited with Pershing. Depending on the value of the marketable securities the Company holds with Pershing, Pershing may require the Company from time-to-time to deposit additional funds or marketable securities in order to restore the level of collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. Volatility in the global markets could cause the interest rate to fluctuate from time to time increasing the Companyâ€™s costs, or could cause Pershing to terminate the Companyâ€™s ability to borrow funds. In addition, borrowings under the Pershing Credit Facility have the effect of limiting the Companyâ€™s use of cash and marketable securities. Â 7. Loss per ShareBasic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented.The Company considers Series A Warrants and Series B Warrants issued in connection with the private placement completed in May 2024 (Note 12) to be participating securities because holders of such instruments participate in the event a dividend is paid on common stock. The holders of the Series A Warrants and Series B Warrants do not have a contractual obligation to share in the Company's losses. As such, losses are attributed entirely to common stockholders and for periods in which the Company has reported a net loss. As of June 30, 2024, 2,151,544 Pre-Funded Warrants to purchase common stock, issued in connection with the May 2024 Private Placement (Note 12), were included in the basic and diluted net loss per share calculation.The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated, in thousands except share and per share data:Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and diluted net loss per common share calculation: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (2,940) Â $ (1,482) Â $ (6,201) Â $ (6,287) Change in fair value of warrants Â Â (4,694) Â Â â€” Â Â (4,694) Â Â â€” Â Net loss attributable to common stockholders - diluted Â $ (7,634) Â $ (1,482) Â $ (10,895) Â $ (6,287) Weighted average common shares outstanding - basic Â Â 6,500,831 Â Â Â 2,509,378 Â Â Â 5,411,382 Â Â Â 2,415,221 Â Net loss per share of common stock - basic Â $ (0.45) Â $ (0.59) Â $ (1.15) Â $ (2.60) Weighted average common shares outstanding - diluted Â Â 10,742,924 Â Â Â 2,509,378 Â Â Â 7,532,428 Â Â Â 2,415,221 Â Net loss per share of common stock - diluted Â $ (0.71) Â $ (0.59) Â $ (1.45) Â $ (2.60) Â The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: 12 Â Â Â As of June 30, Â Â 2024 Â Â 2023 Â Outstanding stock options Â Â 336,928 Â Â Â 128,582 Â Preferred stock Â Â 28,190 Â Â Â 28,190 Â Outstanding warrants Â Â 142,733 Â Â Â 142,733 Â Total Â Â 507,851 Â Â Â

299,505 Â 8. Biocept Asset Acquisitions Â On April 26, 2024, the Company acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in CNSide intellectual property (â€œCNSide IPâ€), including (i) intellectual property, (ii) inventory and raw materials, and (iii) data, information, results and reports pertaining to the completed and on-going clinical studies involving the use of the CNSide IP (including, but not limited to, the FOERSEE clinical study that was being conducted by Biocept), related to the development, making, selling, and exporting or importing of the CNSideTM (as defined below), after having its bid accepted by the United States Bankruptcy Court for the District of Delaware. The Company concluded that the acquisition of Biocept assets was not a business combination, as Biocept did not meet the definition of a business in ASC 805, Business Combination. The Company accounted for the asset purchase transaction under the authoritative guidance for asset acquisitions, and allocated the costs of acquisitions of approximately $45,000 among the assets acquired based on the relative fair value of such assets, which is predominately concentrated in the intellectual property acquired including patents and trademarks. The intangible assets acquired from Biocept are capitalized and amortized over a useful life of four years. Â 9. Grant Revenue On September 19, 2022, the Company entered into that certain Cancer Research Grant Contract (the â€œCPRIT Contractâ€), effective as of August 31, 2022, with the Cancer Prevention and Research Institute of Texas (â€œCPRITâ€), pursuant to which CPRIT provides the Company with a CPRIT grant (â€œCPRIT Grantâ€) over a three-year period to fund the continued development of rhenium (186Re) obisbemeda for the treatment of patients with leptomeningeal metastases (â€œLMâ€). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a) the mutual written consent of all parties to the CPRIT Contract, (b) CPRIT for an event of default by the Company, (c) CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d) the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds.The Company retains ownership over any intellectual property developed under the CPRIT Contract (each, a â€œProject Resultâ€). With respect to non-commercial use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes. The Company recognized $1.3 million and $1.9 million, and $3.0 million and $2.4 million in grant revenue from the CPRIT Contract during the three and six months ended June 30, 2024 and 2023, respectively. Â 10. Commitments and ContingenciesLeasesThe Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement and certain office space in Charlottesville, Virginia (the â€œCharlottesville Leaseâ€). The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods. On March 31, 2023, Company believed that it 13 Â was reasonably certain that the Charlottesville Lease will be renewed through March 31, 2026, and as a result, it remeasured the related lease liability as of March 31, 2023 to be $80,000 using the then-in-effect discount rate of 12.76%. Effective July 1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding right-of-use asset of $19,000, as a discount rate of 13.47%. Â Other commitments and contingenciesThe Company has entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of June 30, 2024, the Company did not have any clinical research study obligations. Â Legal proceedings From time to time, the Company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. 11. License AgreementsÂ Biocept License AgreementOn September 7, 2023, the Company entered into a Non-Exclusive License and Services Agreement with Biocept, pursuant to which Biocept granted the Company a non-exclusive license to use the Biocept proprietary cell enumeration test, CNSideTM (â€œCNSideTMâ€). In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. On October 16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. See Note 8 for further information regarding the Companyâ€™s acquisition of substantially all right, title and interest in the CNSide IP. University of Texas Health Science Center at San Antonio (â€œUTHSCSAâ€) License Agreement On December 31, 2021, the Company entered into a Patent and Know-How License Agreement with UTHSCSA, pursuant to which UTHSCSA granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of biodegradable alginate microspheres (â€œBAMâ€) containing nanoliposomes loaded with imaging and/or therapeutic payloads.NanoTx License Agreement On March 29, 2020, the Company and NanoTx, Corp. (â€œNanoTxâ€) entered into a Patent and Know-How License Agreement, pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes.Â The transaction terms included an upfront payment of $0.4 million in cash and $0.3 million in the Companyâ€™s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any non-dilutive monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from CPRIT. As of June 30, 2024, the Company accrued $0.5 million of payments due to NanoTx as a result of the CPRIT grant received (see Note 9, Grant Revenue of the condensed consolidated financial statements for additional information). Â 12. Stockholders' DeficitPreferred StockThe Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Companyâ€™s Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. Series F Preferred Stock 14 Â On March 3, 2023, the Company filed a certificate of designation (the â€œCertificate of Designationâ€) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1) share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock would have 50,000,000 votes per share of Series F Preferred Stock and would vote together with the Companyâ€™s common stock, as a single class exclusively with respect to any proposal to amend the Companyâ€™s Charter to effect the Reverse Stock Split. On March 3, 2023, the Company entered into a subscription and investment representation agreement with Richard J. Hawkins, chairman of the board of the Company, who is an accredited investor (the â€œSeries F Preferred Stock Purchaserâ€), pursuant to which the Company agreed to issue and sell one (1) share of the Companyâ€™s Series F Preferred Stock, par value $0.001 per share, to the Series F Preferred Stock Purchaser for $1,000 in cash. The sale closed on March 3, 2023. The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Companyâ€™s stockholders of the Reverse Stock Split in April 2023. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash.Â Series B and C Preferred Stock As of June 30, 2024, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. Warrants The Company issued pre-funded warrants and warrants to purchase its common stock in connection with the May 2024 Private Placement. See the section below on Common Stock for additional details. On September 25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with pre-funded warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright & Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock with a term of five years from the issuance date, in the form of Series U Warrants (the â€œRepresentative Warrantsâ€). As of June 30, 2024, there were 142,733 outstanding Series U Warrants and Representative Warrants which can be exercised into an aggregate of 142,733 shares of common stock at a weighted average exercise price of $34.10 per share. Â Common StockÂ May 2024 Private Placement Â On May 5, 2024, the Company entered into a securities purchase agreement (the â€œSecurities Purchase Agreementâ€) with certain investors, including certain of the Companyâ€™s directors and executive officers (â€œCompany Insidersâ€) (collectively, the â€œPurchasersâ€), for the sale and issuance by the Company of its securities (the â€œInitial Subscriptionâ€). On May 8, 2024, the Company entered into a first amendment to the Securities Purchase Agreement (the â€œAmendmentâ€) for the sale and issuance by the Company of additional securities to two of the Purchasers (the â€œAdditional Subscriptionâ€, and together with the Initial Subscription, the â€œMay 2024 Private Placementâ€). The Securities Purchase Agreement provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares (the â€œPrivate Placement Sharesâ€) of the Companyâ€™s common stock or, at the election of each Purchaser, pre-funded warrants (the â€œPre-Funded Warrantsâ€), exercisable immediately at an exercise price of $0.001 per share, with each Private Placement Share or Pre-Funded Warrant accompanied by (i) a Series A common warrant (â€œSeries A Warrantsâ€) to purchase one share of common stock (the â€œSeries A Warrant Sharesâ€), for an aggregate of 3,591,532 Series A Warrants, and (ii) one Series B common warrant (â€œSeries B Warrantsâ€) to purchase one share of common stock (the â€œSeries B Warrant Shares,â€ and together with the Series A Warrant Shares, the â€œCommon Warrant Sharesâ€), for an aggregate of 3,591,532 Series B Warrants. The combined purchase price for each Private Placement Share and Pre-Funded Warrant from the Initial Subscription was $2.022, and $2.158 from the Additional Subscription, in each case together with one accompanying Series A Warrant and one accompanying Series B Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Warrant and Series B Warrant. Â The exercise price of Series A Warrants and Series B Warrants from the Initial Subscription is $1.772 per share and $1.908 per share in the Additional Subscription, provided that the exercise price for the Series A Warrants and Series B Warrants issued to the Company Insiders is $1.79 per share. Subject to certain ownership limitations, the Series A Warrants will be exercisable until 15 Â the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Warrants will be exercisable until June 24, 2025. The Pre-Funded Warrant will not expire until exercised in full.Â If a holder of a Series A Warrant or a Series B Warrant is unable to exercise the warrant due to the limitation contained in the warrant that restricts the holder from owning above a specified beneficial ownership level (generally 4.99% or 9.99%) as the result of exercise of the warrant, then the holder may elect upon exercise of the warrant to receive a pre-funded warrant for the same number of shares of common stock that would otherwise have been received upon exercise of the warrant. Â In addition, the Series A Warrants and Series B Warrants provided for a call right starting June 24, 2025 in favor of the Company, if the volume-weighted average price of the common stock exceeds specified prices. Â The May 2024 Private Offering closed on May 9, 2024 (the â€œMay 2024 Private Placement Closingâ€). The Company issued 2,151,544 Pre-Funded Warrants, 3,591,532 Series A Warrants and 3,591,532 Series B Warrants to purchase its common stock in connection with the May 2024 Private Placement. The aggregate gross proceeds from the May 2024 Private Placement Closing were approximately $7.3 million, before deducting $0.4 million of offering expenses. Â The Company reviewed the terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants under the authoritative accounting guidance. Â As described above, the Series A Warrants and Series B Warrants are classified as liabilities for the reason that they can be exercised into either common stock or Pre-Funded Warrants at the holder's option and thus fail the indexation guidance under ASC 815, Derivatives and Hedging. The Series A Warrant and Series B Warrant liability were recorded at fair value as of the issuance date and June 30, 2024, and under the terms of the Series A Warrants and Series B Warrants when issued that liability was subject to adjustment to estimated fair value at each balance sheet date until the warrants were settled. Refer to Note 14 for additional information regarding the amendment and restatement of the Series A Warrants and Series B Warrants that eliminated the ability of the Series A Warrants and Series B Warrants to be exercised into the Pre-Funded Warrants.Â The Pre-Funded Warrants are equity classified because they (1) are freestanding financial instruments that are legally detachable and separately exercisable from the common stock, (2) are immediately exercisable, (3) do not embody an obligation for the Company to repurchase its shares, (4) permit the holder to receive a fixed number of shares of common stock upon exercise, (5) are indexed to the Company's common stock and (6) meet the equity classification criteria.Â The proceeds from the May 2024 Private Placement must first be allocated to the full fair value of the Series A Warrants and Series B Warrants due to the liability classification. As disclosed in Note 4, the fair value of the Series A Warrants and Series B Warrants at issuance was $10.9 million. Under authoritative guidance, if the fair value of a warrant liability exceeds the proceeds received in an armâ€™s length transaction with no rights or privileges that require separate accounting recognition as an asset identified, then the warrant liability is recorded at fair value with the excess of fair value over proceeds recognized as a loss in earnings. The Company recognized approximately $3.5 million in financing expense in the condensed consolidated statement of operations during the three and six months ended June 30, 2024, which represents the excess of the fair value of the Series A Warrants and Series B Warrants at issuance over the proceeds. During the three and six months ended June 30, 2024, the Company recognized a fair value gain on warrant liability of $4.7 million. Proceeds from the May 2024 Private Placement are shown as cash from financing transactions and the gain on warrant liability is included as an adjustment to reconcile the net loss to net cash used in operating activities in the statements of cash flows for the six months ended June 30, 2024. In addition, total offering expenses related to the May 2024 Private Placement of $0.4 million were recorded as a component of other expenses as the entire proceeds were allocated to the warrant liability, which can be settled with either the Companyâ€™s common stock or Pre-Funded Warrants, which are exercisable into the Companyâ€™s common stock at any time at the holdersâ€™ option, but not in cash payment to the holders.Â All of the Pre-Funded Warrants, Series A Warrants, and Series B Warrants issued in connection with the May 2024 Private Placement remained outstanding as of June 30, 2024. Â Lincoln Park Purchase Agreement On August 2, 2022, the Company entered into a purchase agreement (the â€œ2022 Purchase Agreementâ€) and registration rights agreement pursuant to which Lincoln Park Capital Fund (â€œLincoln Parkâ€) committed to purchase up to $50.0 million of the Companyâ€™s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million of the Companyâ€™s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, 16 Â at the Companyâ€™s sole discretion, over the 36-month period commencing on August 17, 2022, subject to the satisfaction of certain conditions. On May 16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5 million shares of the Companyâ€™s common stock (including the issuance of more than 19.99% of the Companyâ€™s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement.Upon execution of the 2022 Purchase Agreement, the Company paid $0.1 million in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Companyâ€™s common stock at its direction under the 2022 Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash or shares of its common stock, or a combination of cash and shares of its common stock, upon receipt of $25.0 million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. On August 17, 2022, a registration statement (the â€œFirst Registration Statementâ€) was declared effective to cover the resale of up to 633,333 shares of the Companyâ€™s common stock comprised of (i) the 32,846 initial commitment shares, and (ii) up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. On August 18, 2023, a second registration statement (the â€œSecond Registration Statementâ€) was declared effective to cover the resale of up to an additional 1,500,000 shares of the Companyâ€™s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. The Company sold 150,000 shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading

price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park.During the period from August 17, 2022 to December 31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2 million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0 million from January 1, 2023 to December 31, 2023. The Company did not issue any common stock under the 2022 Purchase Agreement during the six months ended June 30, 2024. Share Repurchase Program and Treasury Stock On October 31, 2023, the Company announced that its Board has approved a share repurchase program (the â€œShare Repurchase Programâ€), with authorization to repurchase up to $500,000 of the outstanding shares of the Companyâ€™s common stock. The Company funded repurchases under the Share Repurchase Program with available cash. During the year ended December 31, 2023, the Company purchased 78,559 of its common stock for approximately $0.1 million as treasury stock. The Company purchased 179,866 of its common shares for approximately $0.4 million as treasury stock during the six months ended June 30, 2024. As of June 30, 2024, no amount remained authorized for repurchase. Â 13. Stock-based CompensationÂ Under the Companyâ€™s 2015 New Employee Incentive Plan, as amended (the â€œ2015 Planâ€), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company. On June 6, 2024, the Companyâ€™s Board increased the number of shares for future issuances under the 2015 Plan by 75,000 shares of common stock. As of June 30, 2024, there were 62,908 shares of common stock remaining and available for future issuances under the 2015 Plan. Â The Companyâ€™s 2020 Stock Incentive Plan, as amended (the â€œ2020 Planâ€), which replaced the Companyâ€™s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan provides for the issuance of up to 236,667 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Companyâ€™s 2014 Equity 17 Â Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of June 30, 2024, there were 1,899 shares remaining and available for future issuances under the 2020 Plan. Â Generally, options issued under the 2020 Plan are subject to a two-year or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. Â A summary of activity for the six months ended June 30, 2024 is as follows:Â Â Â Options Â Â Weighted AverageÂ Exercise Price Â Â WeightedAverageRemainingContractualTerm (years) Â Â AggregateIntrinsic Value Â Balance as of December 31, 2023 Â Â 140,109 Â Â $ 37.48 Â Â Â 8.07 Â Â Â Â Granted Â Â 196,824 Â Â $ 2.09 Â Â Â Â Â Â Â Cancelled/expired Â Â (5) Â $ 271,125 Â Â Â Â Â Â Â Balance as of June 30, 2024 Â Â 336,928 Â Â $ 12.78 Â Â Â 8.81 Â Â $ 3,000 Â Vested and expected to vest at June 30, 2024 Â Â 310,675 Â Â $ 13.52 Â Â Â 8.75 Â Â $ 3,000 Â Exercisable at June 30, 2024 Â Â 103,834 Â Â $ 32.39 Â Â Â 7.45 Â Â $ â€” Â Â As of June 30, 2024, the total compensation cost related to non-vested stock options not yet recognized for all the Companyâ€™s plans is approximately $0.7 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.3 years. Â 14. Subsequent Events Â Amendment and Restatement of Series A Warrants and Series B WarrantsÂ On August 9, 2024, the Company amended and restated the Series A Warrants and Series B Warrants (the â€œAmendment and Restatementsâ€) issued in the May 2024 Private Placement. As described in Note 12 above, when originally issued, if a holder of a Series A Warrant or a Series B Warrant was unable to exercise the warrant due to the limitation contained in the Series A Warrants and Series B Warrants that restricted the holder from owning above a specified beneficial ownership level (generally 4.99% or 9.99%) as the result of exercise of the Series A Warrants and Series B Warrants, then the Series A Warrants and Series B Warrants holder could elect upon exercise of the Series A Warrants and Series B Warrants to receive a pre-funded warrant for the same number of shares of common stock that would otherwise have been received upon exercise of the Series A Warrants and Series B Warrants. The Series A Warrants and Series B Warrants Amendment and Restatements eliminated the ability of the holder to elect to purchase pre-funded warrants in lieu of the Series A Warrants and Series B Warrants. In addition, the Amendment and Restatements eliminated the Companyâ€™s call right under the terms of the Series A Warrants to call the Series A Warrants after June 24, 2025, if the volume-weighted average price of the common stock exceeded specified prices. There were no other changes in the terms of the Series A Warrants and Series B Warrants. Â As a result of the Amendment and Restatements, the Series A Warrants and Series B Warrants, as amended, will no longer fail the indexation guidance under ASC 815, Derivatives and Hedging, and the balance of the warrant liability at the amendment date will be reclassified to equity. 18 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis should be read in conjunction with the unaudited financial information and the notes thereto included herein, as well as the â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and our audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed on March 5, 2024. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the caption â€œCautionary Note Regarding Forward-Looking Statementsâ€ in this quarterly report on Form 10-Q, as well as under â€œPart I â€“ Item 1A - Risk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, in other subsequent filings with the Securities and Exchange Commission, and elsewhere in this quarterly report on Form 10-Q. These statements, like all statements in this quarterly report on Form 10-Q, speak only as of the date of this quarterly report on Form 10-Q (unless another date is indicated), and the Company undertakes no obligation to update or revise these statements in light of future developments. Our Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, includes the following sections: ï¸· Overview that discusses our operating results and some of the trends that affect our business. ï¸· Results of Operations that includes a more detailed discussion of our revenue and expenses. ï¸· Liquidity and Capital Resources that discusses key aspects of our statements of cash flows, changes in our financial position and our financial commitments. Overview Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (â€œCNSâ€) cancers. Our novel radioactive drug formulations and medical devices and therapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal tissue/organ exposure and improved safety margins. Traditional approaches to radiation therapy for cancer, such as external beam radiation, have many disadvantages including continuous treatment for four to six weeks (which is onerous for patients), that the radiation damages healthy cells and tissue, and that the amount of radiation delivered is very limited and, therefore, is frequently inadequate to fully destroy the cancer. Our targeted radiotherapeutic platform and unique investigational drugs have the potential to overcome these disadvantages by directing higher, more powerful radiation doses at the tumorâ€”and only the tumorâ€”potentially in a single treatment. By minimizing radiation exposure to healthy tissues while simultaneously maximizing locoregional delivery and, thereby, efficacy, we hope to reduce the radiation toxicity for patients, improving their quality of life and life expectancy. Our radiotherapeutic platform, combined with advances in surgery, nuclear medicine, interventional radiology, and radiation oncology, affords us the opportunity to target a broad variety of cancer types. Our lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma (â€œGBMâ€), leptomeningeal metastases (â€œLMâ€), and pediatric brain cancers (â€œPBCâ€) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (â€œCEDâ€) and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (â€œ188RNL-BAMâ€) is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection. Recently, we acquired the CNSideÂ® cerebrospinal fluid cancer diagnostic portfolio from Biocept which is currently utilized in the CPRIT-funded ReSPECT-LM clinical trial. We are currently evaluating and developing our business plan for developing the CNSide diagnostic portfolio alongside our lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, and seeking partnering opportunities for the CNSide IP (as defined below). The CNSideTM (as defined below) is on track for commercial launch as soon as the fourth quarter of 2024. Â Our headquarters and manufacturing facilities are in Texas and are in proximity to world-class cancer institutions and researchers. Our dedicated team of engineers, physicians, scientists, and other professionals are committed to advancing our targeted radiotherapeutic technology for the benefit of cancer patients and healthcare providers worldwide and our current pipeline is focused on treating rare and difficult-to-treat cancers with significant unmet medical needs. 19 Â In addition to our headquarters in Austin, we have an established, good manufacturing practice validated research and development and manufacturing facility in San Antonio, Texas, tailored to produce Current Good Manufacturing Practice (â€œcGMPâ€) rhenium (186Re) obisbemeda. We have built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of our products. Our current supply chain and key partners are positioned to supply cGMP rhenium (186Re) obisbemeda for ongoing and planned Phase 2 and Phase 3 clinical trials in patients with GBM, LM and PBC. Â Pipeline Our most advanced investigational drug, rhenium (186Re) obisbemeda, is a patented radiotherapy potentially useful for patients with CNS and other cancers. Preclinical study data describing the use of rhenium (186Re) obisbemeda for several cancer targets have been published in peer-reviewed journals and reported at a variety of medical society peer-reviewed meetings. Besides GBM, LM and PBC, rhenium (186Re) obisbemeda has been reported to have potential applications for head and neck cancer, ovarian cancer, breast cancer and peritoneal metastases. The rhenium (186Re) obisbemeda technology was part of a licensed radiotherapeutic portfolio that we acquired from NanoTx, Corp. (â€œNanoTxâ€) on May 7, 2020. The licensed radiotherapeutic has been evaluated in preclinical studies for several cancer targets and we have an active $3.0 million award from U.S. National Institutes of Health/National Cancer Institute which is expected to provide financial support for the continued clinical development of rhenium (186Re) obisbemeda for recurrent GBM through the completion of a Phase 2 clinical trial, including enrollment of up to 55 patients. On August 29, 2022, we announced feedback from a Type C meeting with the U.S. Food and Drug Administration (â€œFDAâ€) regarding Chemistry, Manufacturing and Controls practices. The meeting focused on our cGMP clinical and commercial manufacturing process for our lead investigational targeted radiotherapeutic, BMEDA-chelated rhenium (186Re) obisbemeda, for recurrent GBM. The FDA indicated agreement with our proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and liposome drug products for our novel rhenium (186Re) obisbemeda in support of ongoing and future GBM clinical trials, manufacturing scale up, and commercialization. Alignment with the FDA includes support of our proposed controls and release strategy for new drug substance and new drug product. Because this product is identical for recurrent GBM, LM, and PBC, we believe alignment will be consistent for rhenium (186Re) obisbemeda used in other clinical development programs, including LM and PBC. Rhenium (186Re) obisbemeda versus External Beam Radiation Therapy for Recurrent GBM Rhenium (186Re) obisbemeda is a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors in a safe, effective, and convenient manner that may ultimately prolong patient survival. Rhenium (186Re) obisbemeda is composed of the radionuclide Rhenium-186 and a nanoliposomal carrier, and is infused in a highly targeted, controlled fashion, directly into the tumor via precision brain mapping and CED catheters. Potential benefits of rhenium (186Re) obisbemeda compared to standard external beam radiotherapy or external beam radiation therapy (â€œEBRTâ€) include: â€¢The rhenium (186Re) obisbemeda radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly used EBRT, which, unlike EBRT and proton beam devices, spares normal tissue and the brain from radiation exposure. â€¢Rhenium (186Re) obisbemeda can be visualized in real-time during administration, possibly giving clinicians better control of radiation dosing, distribution and retention. â€¢Rhenium (186Re) obisbemeda potentially more effectively treats a bulk tumor and microscopic disease that has already invaded healthy tissue. â€¢Rhenium (186Re) obisbemeda is infused directly into the targeted tumor by CED catheter insertion using MRI guided software to avoid critical patient neurological structures and neural pathways and also bypasses the blood brain barrier, which delivers the therapeutic product where it is needed. Importantly, it reduces radiation exposure to healthy cells, in contrast to EBRT, which passes through normal tissue to reach the tumor, continuing its path through the tumor, hence being less targeted and selective. â€¢Rhenium (186Re) obisbemeda is given during a single, short, in-patient hospital visit, and is available in all hospitals with nuclear medicine and neurosurgery, while EBRT requires out-patient visits five days a week for approximately four to six weeks. ReSPECT-GBM Trial for Recurrent GBM 20 Â Recurrent GBM is the most common, complex, and aggressive primary brain cancer in adults. In the U.S., there are approximately 13,000 GBM cases diagnosed and approximately 10,000 patients succumb to the disease each year. The average length of overall survival (â€œOSâ€) for GBM patients is eight months, with a one-year survival rate of 40.8% and a five-year survival rate of only 6.8% and these estimates vary and are lower in some publications. GBM routinely presents with headaches, seizures, vision changes and other significant neurological complications, with a significant compromise in quality of life. Despite the best available medical treatments, the disease remains incurable. Even after efforts to manage the presenting signs and symptoms and completely resect the initial brain tumor, some microscopic disease almost always remains and tumor regrowth occurs within months. Approximately 90% or more of patients with primary GBM experience tumor recurrence. Complete surgical removal of GBM is usually not possible and GBM is often resistant or quickly develops resistance to most available current and investigational therapies. Even today, the treatment of GBM remains a significant challenge and it has been nearly a decade since the FDA approved a new therapy for this disease, and these more recent approvals have not improved GBM patients OS over past decades, and a significant unmet medical need persists. For recurrent GBM, there are few currently approved treatments, which in the aggregate, provide only marginal survival benefit. Furthermore, these therapies are associated with significant side effects, which limit dosing and prolonged use. While EBRT has been shown to be safe and has temporary efficacy in many malignancies including GBM, typically at absorbed, fractionated radiation dose of ~30 Gray in GBM, this maximum possible administered dose is always limited by toxicity to the normal tissues surrounding the malignancy and because EBRT requires fractionation to manage toxicity and maximum EBRT limits are typically reached before long-term efficacy reached. Because of this limitation, EBRT cannot provide a cure or long term control of GBM and GBM always recurs within months after EBRT. In contrast, locally delivered and targeted radiopharmaceuticals that precisely deliver radiation in the form of beta particles such as Iodine-131 for thyroid cancer, are known to be safe and effective and minimize exposure to normal cells and tissues especially with optimal administered dose and minimizing exposure to normal tissue. The locally delivered rhenium (186Re) obisbemeda is designed for and provides patient tolerability and safety. Though no rhenium (186Re) obisbemeda head-to-head trial with chemo, immune, EBRT or systemic radiopharmaceutical products have been conducted, patient tolerability and safety considerations have been reported as expected. Interim results from our ongoing Phase 1/2a ReSPECT-GBM trial (ClinicalTrials.gov NCT01906385) show that the beta particle energy from our lead investigational drug rhenium (186Re) obisbemeda has provided preliminary positive data and utility in treating GBM and potential other malignancies. More specifically, the preliminary data from our Phase 1/2a ReSPECT-GBM trial suggests that radiation, in the form of high energy beta particles or electrons, can be effective against GBM. Thus far, we have been able to deliver up to 740 Gy of absorbed radiation to tumor tissue in humans, without significant or dose limiting toxicities and with what we believe has the capability to go higher if required. In comparison, current EBRT protocols for recurrent GBM typically recommend a total maximum radiation dose of about ~30-35 Gray. In September 2020, the FDA granted both Orphan Drug designation and Fast Track designations to rhenium (186Re) obisbemeda for the treatment of patients with GBM. Rhenium (186Re) obisbemeda is under clinical investigation in a multicenter, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of rhenium (186Re) obisbemeda given by CED catheters to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment (NCT01906385). The study uses a standard, modified 3x3 Fibonacci dose escalation, followed by a planned Phase 2 expansion trial at the maximum tolerated dose (â€œMTDâ€) / maximum feasible dose (â€œMFDâ€) or non-dose limiting toxicity (â€œDLTâ€) if MTD is not reached, to determine efficacy. The trial is funded through Phase 2 in large part by a National Institute of Health/National Cancer Institute (â€œNIH/NCIâ€) grant. These investigations have not reached DLT or MTD/MFD and the study is in its eighth dosing administration cohort. Due to the observation of a preliminary efficacy signal, we have initiated in parallel a Phase 2, non-DLT dose trial pursuant to the currently funded NIH/NCI grant. This trial will begin at the current non-DLT rhenium (186Re) obisbemeda dose and will expand exploring higher radiation doses in larger volumes to treat larger tumors. Additionally, two or more rhenium (186Re) obisbemeda administrations, if indicated, will be evaluated, and reviewed with the FDA, as well as expanded safety, imaging and efficacy data to support a planned future registrational trial. On September 6, 2022, we announced a summary of our Type C clinical meeting with the FDA that focused on the ReSPECT-GBM trial. The FDA agreed with us that the ReSPECT-GBM clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase 2 trial will be (1) further dose exploration, including both increased dosing and multiple doses, and (2) collecting additional safety and efficacy data to inform the design of a future registrational trial. Because no DLT administered doses were observed, the FDA

and we also agreed to continue to dose cohort eight. There was further agreement with the FDA that in a planned future registrational trial, overall survival should be used as the primary endpoint. We agreed with the FDA to hold future meeting(s) to consider the use of external data to augment the use of a control arm in the registrational trial. 21 Â On January 18, 2023, we announced that the first patient was dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium obisbemeda for the treatment of recurrent GBM. The Phase 2b trial is expected to enroll up to 34 total patients with small- to medium-sized tumors and is targeted for full enrollment by the end of 2024. We currently have three clinical sites, with the plan to add additional sites to support the trial, and expect an initial data read-out by the end of 2024. In June 2023, we presented data regarding the safety and feasibility results from our Phase 1/2 Clinical Trial of 186RNL (Rhenium-186 Nanoliposome) (186Re) Obisbemeda in Recurrent Glioma: The ReSPECT-GBM Trial at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting. On November 20, 2023, we announced positive data from the ongoing ReSPECT-GBM Phase 2 trial evaluating rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma at the Society for NeuroOncology 28th Annual Meeting, which was held November 15-19, 2023 in Vancouver, Canada. Key findings included: â€¢Median overall survival (mOS) in 15 patients with recurrent glioblastoma (â€œrGBMâ€) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive. â€¢Median progression free survival (mPFS) is 11 months, compared to SOC at 4 months. â€¢Rhenium (186Re) obisbemeda continues to demonstrate a favorable safety profile, despite delivering up to 20x the dose of radiation (up to 740 Gy) typically delivered by EBRT for rGBM patients (up to 35 Gy). â€¢Imaging data presented by Andrew Brenner, MD, PhD is consistent with the efficacy signal of Rhenium (186Re) obisbemeda in rGBM. On March 31, 2022, we entered into a Sales Order (the â€œSales Orderâ€) with Medidata Solutions, Inc. (â€œMedidataâ€), pursuant to which Medidata built a Synthetic Control ArmÂ® platform that facilitates the use of historical clinical data to incorporate into our Phase 2 clinical trial of rhenium (186Re) obisbemeda in GBM. The Sales Order had a term of six (6) months. Work under this Sales Order has been completed. As part of this collaboration, we jointly submitted with Medidata a historical clinical trials control arm methodology abstract (â€œHCAâ€) to American Society of Clinical Oncology (â€œASCOâ€) which was accepted for publication, further strengthening this collaboration and allowing applications to advance GBM development. We plan to use the HCA for breakthrough therapy designation and Phase 2 and/or a pivotal or registrational Phase 3 trial. ReSPECT-LM Clinical Trial for LM LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. The incidence of LM is growing and occurs in approximately 5%, or more, of people with late-stage cancer, or 110,000 people in the U.S. each year. It is highly lethal with an average one-year survival of just 7%. All solid cancers, particularly breast, lung, GI, and melanoma, have the potential to spread to the leptomeninges. The ReSPECT-LM Phase 1 clinical trial (ClinicalTrials.gov NCT05034497) was preceded with preclinical studies in which tolerance to doses of rhenium (186Re) obisbemeda as high as 1,075 Gy were shown in animal models with LM without significant observed toxicity. Furthermore, treatment led to a marked reduction in tumor burden in both C6 and MDA-231 LM models. Upon receiving acceptance of our Investigational New Drug application and Fast Track designation by the FDA for rhenium (186Re) obisbemeda for the treatment of LM in November 2021, we initiated the trial and began screening patients for the ReSPECT-LM Phase 1 clinical trial in the fourth quarter of 2021. The ReSPECT-LM is a multi-center, sequential cohort, open-label, dose escalation study evaluating the safety, tolerability, and efficacy of a single-dose application of rhenium (186Re) obisbemeda administered through intrathecal infusion to the ventricle of patients with LM after standard surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events and dose limiting toxicities, together with determining the maximum tolerated and recommended Phase 2 dose. Full enrollment in the Phase 1 trial is expected by the end of 2024, with the plan to add additional clinical sites to support the trial. On September 19, 2022, we entered into a Cancer Research Grant Contract (the â€œCPRIT Contractâ€), effective as of August 31, 2022, with Cancer Prevention and Research Institute of Texas (â€œCPRITâ€), pursuant to which CPRIT will provide us a grant of up to $17.6 million (the â€œCPRIT Grantâ€) over a three-year period to fund the continued development of rhenium (186Re) obisbemeda for the treatment of patients with LM through Phase 2 of the ReSPECT LM clinical trial. The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar from us for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. To date, 22 Â we have received approximately $7 million in milestone payments under the CPRIT Contract. We anticipate a continuing flow of milestone payments that throughout 2024 will include $6.9 million upon the continued progression of the Phase 2 of the ReSPECT LM clinical trial. Interim results showed that a single treatment with rhenium (186Re) obisbemeda resulted in a consistent decreased cerebrospinal fluid (â€œCSFâ€) tumor cell count/ml and was tolerated by all LM patients. Rhenium (186Re) obisbemeda is an outpatient administration and treatment and is easily and safely administered through a standard intraventricular catheter (Ommaya Reservoir), distributed promptly throughout the CSF, and with durable retention in the leptomeninges at least through day seven. All patients have shown well tolerated prompt and durable rhenium (186Re) obisbemeda distribution throughout the subarachnoid space. On March 11, 2024, we announced we had completed Cohort 5 of the ReSPECT-LM Phase 1/2a dose escalation trial. A total of 25 patients have received a single-dose of rhenium (186Re) obisbemeda in the ReSPECT-LM trial as of July 29, 2024. There have been no dose limiting toxicities observed to date with administered radiation doses up to 66.14 millicuries in Cohort 5, a ten-fold increase over Cohort 1. We plan to initiate dosing in Cohort 6 in the second quarter of 2024, pending Data Safety Monitoring Board (DSMB) approval. In addition, five new clinical trial sites were added to this trial over the last year, bringing the total number of sites to seven. We are planning a new multiple dosing ReSPECT-LM clinical trial in late 2024 or early 2025. On August 10, 2023, we presented data from the ReSPECT-LM clinical trial of rhenium (186Re) obismeda at the Society for Neuro Oncology ASCO CNS Cancer Conference. In November 2023, the FDA granted Orphan Drug designation to rhenium (186Re) obisbemeda for the treatment of patients with breast cancer with LM. On December 12, 2023, we announced our partnership with K2bio to implement novel analysis for CSF tumor and molecular biomarkers for CNS cancers. Initial clinical specimen processing and testing began in the first quarter 2024 in our ongoing Phase 1 ReSPECT-LM trial of rhenium (186Re) obisbemeda in patients with LM. Â In mid-June 2024, we presented updated data from our Phase 1 ReSPECT-LM trial at the annual meeting of Society of Nuclear Medicine & Molecular Imaging (SNMMI) conference. ReSPECT-PBC Clinical Trial for Pediatric Brain Cancer The average annual age adjusted mortality rate for children aged 0-14 for malignant brain (and other CNS) tumors is 0.71/100,000, making it the most common cause of death and cancer death in this age group. The 2021 World Health Organization Classification of CNS Tumors classifies gliomas, glioneuronal tumors, and neuronal tumors into six different families: (1) adult-type diffuse gliomas; (2) pediatric-type diffuse low-grade gliomas; (3) pediatric-type diffuse high-grade gliomas (â€œHGGâ€); (4) circumscribed astrocytic gliomas; (5) glioneuronal and neuronal tumors; and (6) ependymomas. In August 2021, we announced plans for treating pediatric brain cancer at the 2021 American Association of Neurological Surgeons Annual Scientific Meeting. In July 2021, we reported that we had received FDA feedback pertaining to a pre-IND meeting briefing package in which the FDA stated that we are not required to perform any additional preclinical or toxicology studies. Given the initial FDA feedback, receipt of adult GBM data and experience with rhenium (186Re) obisbemeda and follow-up communications with the FDA, we plan to submit a pediatric brain tumor IND to investigate the use of rhenium (186Re) obisbemeda in two pediatric brain cancers, high-grade glioma and ependymoma, by the third quarter of 2024. Pediatric high-grade gliomas can be found almost anywhere within the CNS; however, they are most commonly found within the supratentorium. The highest incidence of supratentorial, high-grade gliomas in pediatrics appears to occur in children aged 15 to 19 years, with a median age of approximately nine years. Overall, pediatric high-grade glioma confers a three-year progression free survival (â€œPFSâ€) of 11 Â± 3% and three-year OS of 22% Â±5%. One-year PFS is as low as 40% in recent trials. Ependymomas are slow-growing central nervous system tumors that involve the ventricular system. Diagnosis is based on MRI and biopsy and survival rate depends on tumor grade and how much of the tumor can be removed. Grade II pathology was associated with significantly improved OS compared to Grade III (anaplastic) pathology (five-year OS = 71 Â± 5% vs. 57 Â± 10%; p = 0.026). Gross total resection compared to subtotal resection was associated with significantly improved OS (five-year OS = 75 Â± 5% vs. 54 Â± 8%; p = 0.002). Overall, pediatric HGG and ependymoma are extremely difficult-to-treat pediatric brain tumors, frequently aggressive, and in recurrent settings, carry an extremely poor prognosis. Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere Technology 23 Â In January 2022, we announced that we licensed Biodegradable Alginate Microsphere (â€œBAMâ€) patents and technology from The University of Texas Health Science Center at San Antonio (â€œUTHSCSAâ€) to expand our tumor targeting capabilities and precision radiotherapeutics pipeline. We intend to combine our Rhenium NanoLiposome technology with the BAM technology to create a novel radioembolization technology. Initially, we intend to utilize the Rhenium-188 isotope, 188RNL-BAM for the intra-arterial embolization and local delivery of a high dose of targeted radiation for a variety of solid organ cancers such as hepatocellular cancer, hepatic metastases, pancreatic cancer and many others. Preclinical data from an ex vivo embolization experiment in which Technetium99m-BAM was intra-arterially delivered to a bovine kidney perfusion model was presented at Society of Interventional Radiology Annual Scientific Meeting. The study concluded that the technology required for radiolabeling BAM could successfully deliver, embolize and retain radiation in the target organ. 188RNL-BAM is a preclinical investigational device we intend to further develop and move into clinical trials. Specifically, in 2022 we transferred the 188RNL-BAM technology from UTHSCSA, and began planning to develop the product and complete early preclinical studies to support a future FDA IND submission. Our intended initial clinical target is liver cancer which is the sixth most common and third deadliest cancer worldwide. It is a rare disease with increasing U.S. annual incidence (42,000) and deaths (30,000). Recent Developments Â FDA Feedback Regarding BAM technologies, including 188RNL-BAM Â On July 26, 2023, the FDA responded to a Pre-IND submission that the 188RNL-BAM product under development would likely be subject to regulation as a medical device under theFederal Food, Drug, and Cosmetic Act (the â€œFDCAâ€), rather than as a drug product. Â May 2024 Private Placement Â See Liquidity and Capital Resources section below for details on the closing of the May 2024 Private Placement. Â Biocept Asset Purchase On September 7, 2023, we entered into a Non-Exclusive License and Services Agreement with Biocept, Inc (â€œBioceptâ€), pursuant to which Biocept granted us a non-exclusive license to use the Biocept proprietary cell enumeration test, CNsideTM (the â€œCNSideTMâ€). On October 16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. Â On April 26, 2024, we acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in the CNSide IP, including (i) intellectual property, (ii) inventory and raw materials, and (iii) data, information, results and reports pertaining to the completed and on-going clinical studies involving the use of CNSideTM (including, but not limited to, the FORSEE clinical study), related to the development, making, selling, and exporting or importing of the CNSideTM, after having its bid accepted by the United States Bankruptcy Court for the District of Delaware. Department of Defense Grant Â On April 22, 2024, we were selected by the Department of Defense (â€œDoDâ€) office of the Congressionally Directed Medical Research Programs (CDMRP) to receive a $3 million fund for research and development purposes (â€œDoD Awardâ€). Transfers of funds under the DoD Award are expected to commence in the third quarter of 2024, pending execution of formal agreements, in order to support the planned expansion of our clinical trial for pediatric brain cancer. Recent Financings Refer to the â€œLiquidity and Capital Resourcesâ€ heading below for information on our recent financings. Â Results of Operations Grant Revenue Â We recognized $1.3 million and $1.9 million, and $3.0 million and $2.4 million of grant revenue during the three and six months ended June 30, 2024 and 2023, respectively, which represents CPRITâ€™s share of the costs incurred for our rhenium (186Re) obisbemeda development for the treatment of patients with LM. 24 Â Research and development expenses Research and development expenses include costs associated with the design, development, testing, and enhancement of our product candidates, payment of regulatory fees, laboratory supplies, pre-clinical studies, and clinical studies. The following table summarizes the components of our research and development expenses for the three and six months ended June 30, 2024 and 2023 (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 2,753 Â Â $ 1,406 Â Â $ 5,499 Â Â $ 4,369 Â Stock-based compensation Â Â 20 Â Â Â 14 Â Â Â 37 Â Â Â 34 Â Total research and development expenses Â $ 2,773 Â Â $ 1,420 Â Â $ 5,536 Â Â $ 4,403 Â Â Research and development expenses increased by approximately $1.4 million during the three months ended June 30, 2024 as compared to the same period in 2023. The increase was due primarily to an increase of $0.5 million of licenses fee to NanoTx, an increase of $0.3 million in compensation expenses, an increase of approximately $0.4 million of professional research and development service fees, and an increase of $0.3 million in development expenses, offset by a reduction of $0.1 million in clinical expenses. Â Research and development expenses increased by approximately $1.1 million during the six months ended June 30, 2024 as compared to the same period in 2023. The increase was due primarily to an increase of $0.5 million increases in professional services, an increase of $0.3 million in compensation expenses, a $0.2 million increase in clinical expenses, and an increase of $0.1 million in other research and development expenses. Â We expect aggregate research and development expenses to increase during the remainder of 2024 as compared to the corresponding comparable period ended December 31, 2023 as we continue to advance and expand our research programs. Â General and administrative expenses General and administrative expenses include costs for administrative personnel, legal and other professional expenses, and general corporate expenses. The following table summarizes the general and administrative expenses for the three and six months ended June 30, 2024 and 2023 (in thousands): Â Â Â

Additionally, we used net cash of $5.7 million to fund our operating activities for the six months ended June 30, 2024. These factors raise substantial doubt about our ability to continue as a going concern. 26 Â Â May 2024 Private Placement Â In May 2024, we entered into a securities purchase agreement, which was subsequently amended, with certain investors, including certain of the Companyâ€™s directors and executive officers (the â€œPurchasersâ€), whereby we issued and sold in a private placement (the â€œMay 2024 Private Placementâ€): (i) 3,591,532 shares of common stock (â€œPrivate Placement Shareâ€), or, at the election of each Purchaser, pre-funded warrants (the â€œPre-Funded Warrantsâ€) exercisable immediately to purchase shares of common stock. Each Private Placement Share or Pre-Funded Warrant are accompanied by (i) a Series A common warrant (â€œSeries A Warrantsâ€) to purchase one share of common stock, for an aggregate of 3,591,532 Series A Warrants, and (ii) one Series B common warrant (â€œSeries B Warrantsâ€, and together with the Pre-Funded Warrants and Series A Warrants, the â€œWarrantsâ€) to purchase one share of common stock, for an aggregate of 3,591,532 Series B Warrants. At the closing of the May 2024 Private Placement, we received aggregate upfront gross proceeds of approximately $7.3 million, before deducting fees and other expenses associated with the closing of the May 2024 Private Placement. If the Warrants are exercised in full we will receive additional gross proceeds of approximately $12.0 million. None of the Warrants issued in the May 2024 Private Placement have been exercised as of the filing of this quarterly report on Form 10-Q. See Note 12 to the unaudited condensed consolidated financial statements, Stockholders' Deficit - May 2024 Private Placement, for further information regarding the May 2024 Private Placement. Â CPRIT Grant Â On September 19, 2022, we entered into the CPRIT Contract, pursuant to which CPRIT will provide us with the CPRIT Grant of $17.6 million subject to the terms of the CPRIT Contract, to fund approximately two-thirds of the continued development of rhenium (186Re) obisbemeda for the treatment of patients with LM. We received $10.4 million of the available funding under the CPRIT Grant during 2022, 2023 and the six months ended June 30, 2024, of which we recognized $3.0 million, $4.9 million and $0.2 million of grant revenue during the six months ended June 30, 2024, and the years ended December 31, 2023 and 2022, respectively. The amounts recognized represents CPRITâ€™s share of the costs incurred for our rhenium (186Re) obisbemeda development for the treatment of patients with LM. As of June 30, 2024, we had $2.3 million of deferred revenue related to the CPRIT Grant. Â Private Equity Lines On August 2, 2022, we entered into a purchase agreement (the â€œ2022 Purchase Agreementâ€) and registration rights agreement pursuant to which Lincoln Park Capital Fund (â€œLincoln Parkâ€) committed to purchase up to $50.0 million of shares of our common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million of shares of our common stock, provided that we cannot sell more than 57.5 million shares pursuant to the 2022 Purchase Agreement. Sales of common stock by us are subject to certain limitations, and can occur from time to time, at our sole discretion, over the 36-month period commencing on August 17, 2022, subject to the satisfaction of certain conditions. Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the common stock and our determinations as to the appropriate sources of funding for the Company and its operations. As consideration for Lincoln Parkâ€™s irrevocable commitment to purchase shares of our common stock upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Purchase Agreement, we paid $0.1 million in cash as an Initial Commitment Fee and issued 32,846 as the initial commitment shares to Lincoln Park in consideration for its commitment to purchase shares of our common stock at our direction under the 2022 Purchase Agreement. On August 17, 2022, a registration statement (the â€œFirst Registration Statementâ€) was declared effective covering the resale of up to 633,333 shares of our common stock comprised of (i) the 32,846 initial commitment shares, and (ii) up to 600,486 shares that we have reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement. An additional commitment fee equal to 2.5% of the remainder of the $50 million will be paid if and when we sell over $25.0 million of our common stock under the 2022 Purchase Agreement. The additional commitment fee may be paid in cash, common stock, or a combination thereof. We sold approximately 527,166 shares under the First Registration Statement. On August 18, 2023, a second registration statement (the â€œSecond Registration Statementâ€) was declared effective covering the resale of up to an additional 1,500,000 shares of our common stock that we reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. We sold 150,000 shares under the Second Registration Statement. We cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. During the period from August 17, 2022 to December 31, 2022, we issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2 million. We issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0 million from January 1, 2023 to December 31, 2023. No shares of common stock were purchased under the 2022 Purchase Agreement during the six months ended June 30, 2024. 27 Â On January 14, 2022, we entered into an Equity Distribution Agreement (the â€œJanuary 2022 Distribution Agreementâ€) with Canaccord, pursuant to which we could issue and sell, from time to time, shares of our common stock in â€œat-the-marketâ€ offerings, having an aggregate offering price of up to $5 million, depending on market demand, with Canaccord acting as an agent for sales. During the year ended December 31, 2023, we issued 460,151 shares under the January 2022 Distribution Agreement for net proceeds of approximately $4.8 million. The January 2022 Distribution Agreement was terminated after all available registered shares were fully utilized. Nasdaq Listing Compliance Â On March 8, 2024, we received a letter (the â€œNoticeâ€) from the Listing Qualifications staff of Nasdaq Capital Market (â€œNasdaqâ€), notifying us that we no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholdersâ€™ equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the â€œAlternative Standardsâ€). The Notice stated that, as of March 8, 2024, we did not meet the Alternative Standards. Â On April 22, 2024, we provided Nasdaq with our plan to achieve and sustain compliance with the stockholdersâ€™ equity requirement and requested that Nasdaq grant an extension of time until September 4, 2024, to provide evidence of our compliance with the stockholdersâ€™ equity requirement. Nasdaq has not yet responded to our Plan, and there can be no assurance that Nasdaq will grant an extension or that we will be able to comply with the applicable listing standards of Nasdaq. Funding and Material Cash Requirements To date, our operating losses have been funded primarily from outside sources of invested capital from issuance of our common and preferred stocks, proceeds from the now-repaid in full term loan with Oxford Finance, LLC (â€œOxfordâ€), the Pershing Credit Facility and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources through a combination of equity offerings, debt financings and potential collaboration, license or development agreements to fund our future clinical development programs and other operations in the next twelve months from the filing of this quarterly report on Form 10-Q. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. There can be no assurance that we will be able to continue to raise additional capital in the future. Our inability to raise additional cash would have a material adverse impact on our operations, implementation of our strategy and ability to maintain compliance with applicable requirements, including Nasdaq listing rules. Our present and future funding and cash requirements will depend on many factors, including, among other things: Â â€¢the progress, timing and completion of our ongoing and planned clinical trials and nonclinical studies; â€¢our ability to receive, and the timing of receipt of, future regulatory approvals for our product candidates and the costs related thereto; â€¢the development and utility of the CNSide leptomeningeal metastases diagnostic test; â€¢the scope, progress, results and costs of our ongoing and planned operations; â€¢the costs associated with expanding our operations and building our sales and marketing capabilities; â€¢our ability to establish strategic collaborations; â€¢the cost and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; â€¢the revenue, if any, received from commercial sales of our product candidates, if approved; and â€¢potential new product candidates that the Company identifies and attempt to develop. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern. 28 Â Cash (used in) provided by operating, investing, and financing activities for the six months ended June 30, 2024 and 2023 is summarized as follows (in thousands): Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (5,663) Â $ (8,571) Net cash used in investing activities Â Â (4,166) Â Â (108) Net cash provided by financing activities Â Â 6,187 Â Â Â Â 1,454 Â Net decrease in cash and cash equivalents Â $ (3,642) Â $ (7,225) Â Material Cash Obligations Under the CPRIT Contract we receive matching funds for approximately two-thirds of the development costs for the development of rhenium (186Re) obisbemeda for the treatment of patients with LM, subject to various funding conditions. The CPRIT Contract is effective for three years, unless otherwise terminated pursuant to the terms of the contract. CPRIT may require us to repay some or all of the disbursed CPRIT grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract. Â Under our Pershing Credit Facility, we have ongoing principal and interest payment obligations (see Note 6 of the condensed consolidated financial statements). In addition, we are obligated to make operating lease payments for our office and laboratory space, and we may be required to make payments under certain of our other contractual agreements. Â Other than as described above, we have no purchase commitments or long-term contractual obligations, except for lease obligations as of June 30, 2024. In addition, we have no off-balance sheet arrangements (as defined in the rules and regulations of the SEC) that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. Â Operating activities Net cash used in operating activities for the six months ended June 30, 2024 was $5.7 million compared to $8.6 million in the same period of 2023. Our operational cash use decreased $2.9 million during the six months ended June 30, 2024 as compared to the same period in 2023, due primarily to increased reimbursement under the CPRIT grant agreement for research and development costs related to the ReSPECT-LM program. Investing activities Net cash used in investing activities for the six months ended June 30, 2024 was related to purchase of Biocept assets of $0.5 million, short-term investments of $3.5 million and purchases of fixed assets of $0.1 million. Net cash used in investing activities for the six months ended June 30, 2023 was related to purchases of fixed assets of $0.1 million. Financing Activities Net cash provided by financing activities for the six months ended June 30, 2024 was related to net proceeds of $7.3 million raised by the May 2024 Private Placement, and drawdown of $3.3 million from the Pershing Credit Facility, offset by repurchase of treasury stock for approximately $0.4 million and repayment of principle balance under the Oxford loan of $4.0 million. Â Net cash provided by financing activities for the six months ended June 30, 2023 was primarily related to sales of common stock of $2.3 million, net of offering cost, from that certain Equity Distribution Agreement with Canaccord Genuity LLC and the 2022 Purchase Agreement. Critical Accounting Policies and Significant Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of our assets, liabilities, revenues and expenses, and that affect our recognition and disclosure of contingent assets and liabilities. While our estimates are based on assumptions we consider reasonable at the time they were made, our actual results may differ from our estimates, perhaps significantly. If results differ materially from our estimates, we will make adjustments to our consolidated financial statements prospectively as we become aware of the necessity for an adjustment. 29 Â Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. We operate in a single operating segment and reporting unit. We monitor the fluctuations in our share price and have experienced significant volatility during the year. We believe it is important for you to understand our most critical accounting policies. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and there have been no material changes during the six months ended June 30, 2024 except as described below. Warrant Liability Accounting for liability classified warrants requires management to exercise judgment and make estimates and assumptions regarding their fair value (for more information about the material inputs and assumptions used to value the liability classified warrants refer to Note 4 of our condensed consolidated financial statements). The warrant liabilities are initially recorded at fair value upon the date of issuance and subsequently remeasured to fair value at each reporting date, with changes recognized in the condensed consolidated statements of operations. Changes in the fair value of the liability classified warrants will continue to be recognized until the warrants are exercised, expire or qualify for equity classification. In May 2024, the Company issued the Series A Warrants and Series B Warrants and classified them as liabilities because in certain circumstances they could be exercised into either common stock or Pre-Funded Warrants at the holder's option and thus failed the indexation guidance under ASC 815, Derivatives and Hedging. On August 9 , 2024, the Company amended and restated the Series A Warrants and Series B Warrants (the â€œAmendment and Restatementsâ€) to eliminate the ability of the holder to elect to receive Pre-Funded Warrants in this situation. As a result of the Amendment and Restatements, the Series A Warrants and Series B Warrants, as amended, will no longer fail the indexation guidance under ASC 815, Derivatives and Hedging, and the balance of the warrant liability at the amendment date will be reclassified to equity. As a result, as of the amendment date, there will be a corresponding increase in our condensed statements of stockholders' equity. Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Not applicable. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain â€œdisclosure controls and procedures,â€ as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the â€œExchange Actâ€), that are designed to ensure that information required to be disclosed in our reports that we file or furnish pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) under the Exchange Act we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer), of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act as of the end of the period covered by this quarterly report on Form 10-Q. Based on the foregoing, our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of the end of the period covered by this quarterly report on Form 10-Q. Changes in Internal Control over Financial Reporting There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 30 Â PART II. OTHER INFORMATION Item 1. Legal Proceedings None. Item 1A. Risk Factors We have been notified by Nasdaq of our failure to comply with certain continued listing requirements and, if we are unable to regain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock could be delisted from Nasdaq. Our common stock is currently listed on Nasdaq. In order to maintain that listing, we must satisfy continued listing requirements and standards. There can be no assurances that we will be able to comply with the applicable listing standards of Nasdaq. On March 8, 2024, we received the Notice from Nasdaq, notifying us that we no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholdersâ€™ equity for continued listing on Nasdaq or the Alternative Standards. The Notice states that our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, disclosed stockholdersâ€™ equity of ($1.3 million) as of December 31, 2023, and that, as of March 8, 2024, we did not meet the Alternative Standards. On April 22, 2024, we provided Nasdaq with our plan to achieve and sustain compliance with the stockholdersâ€™ equity requirement and requested that Nasdaq grant us an extension of time until September 4, 2024, to provide evidence of compliance with the stockholdersâ€™ equity requirement. Nasdaq has not yet responded to our plan, and there can be no assurance that Nasdaq will grant an extension or that we will be able to comply with the applicable listing standards of Nasdaq. In the event that our common stock is delisted from Nasdaq, as a result of our failure to comply with the stockholdersâ€™ equity requirement, or as a result of Nasdaq not granting us an extension or due to our failure to continue to comply with any other requirement for continued listing on Nasdaq, we may have to pursue trading on a less recognized or accepted market, such as the over the counter markets, our stock may be traded as a â€œpenny stock,â€ which would make transactions in our stock more difficult and cumbersome, and we may be unable to access capital on favorable terms or at all, as companies trading on alternative markets may be viewed as less attractive investments with higher associated risks, such that existing or prospective institutional investors may be less interested in, or prohibited from, investing in our common stock. This

may also cause the market price of our common stock to decline. We may issue additional shares of common stock or other equity securities without our stockholder approval, and holders of warrants and other securities convertible into shares of our common stock may choose to exercise their warrants and other securities requiring us to issue shares of common stock; all of these actions would dilute your ownership interest and may depress the market price of our common stock. Â In May 2024, we entered into a securities purchase agreement with certain investors, including certain of the Companyâ€™s directors and executive officers, and issued and sold in a private placement: (i) an aggregate of 3,591,532 shares of common stock (or in lieu of shares of common stock, Pre-Funded Warrants), and (ii) Warrants to purchase up to 7,183,064 shares of common stock. If these Warrants are exercised, it will result in significant dilution to our stockholders. In the alternative, these Warrants may not be exercised, in which event we are likely to seek alternative sources of financing to continue the clinical development of our product candidates. Please see Note 12 for further information regarding the May 2024 Private Placement and the terms of the Warrants. Â In addition, outstanding securities convertible into our shares of common stock may be exercised and restricted stock units may vest resulting in the issuance of additional shares of common stock, which will result in further dilution to our stockholders. Â Significant additional capital may be needed in the future to continue our planned operations, including further development of our product candidates, preparing IND or equivalent filings, conducting preclinical studies and clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our shares of common stock. Â We may also issue additional shares of common stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances. The issuance of additional shares or other equity securities of equal or senior rank would have the following effects: 31 Â â€¢existing stockholdersâ€™ proportionate ownership interest in us will decrease; â€¢the relative voting strength of each previously outstanding common stock may be diminished; and â€¢the market price of the common stock may decline. Â We recently acquired the CNSide diagnostic portfolio, and we may not be successful in our efforts to develop, fully utilize and monetize it. In April 2024, we completed the acquisition of substantially all of the right, title and interest in CNSide (â€œCNSideâ€), a proprietary cell enumeration test designed to detect, quantify,and monitor tumor status in LM. We are currently evaluating and developing our business plan for developing the CNSide diagnostic portfolio alongside our lead radio therapeutic candidate, rhenium (186Re) obisbemeda, and seeking partnering opportunities for CNSide but there can be no assurances that we will be able to develop the technology to allow for commercial applications, or successfully utilize and fully integrate CNSide into our operations. We may not generate revenues from or realize the anticipated benefits of CNSide within our expected timeline or at all. Other than the risk factors set forth above, there have been no material changes to the risk factors disclosed in Part I, Item 1A, â€œRisk Factorsâ€ of our Annual Report on Form 10-K for the year ended December 31, 2023. Â 188RNL-BAM will be regulated as a medical device, which may result in additional regulatory and other risks. Â 188RNL-BAM was developed and tested preclinically as a drug product. The FDA has informed us that 188RNL-BAM will, moving forward, be regulated instead as a medical device. Â In the United States, before we can market a new medical device, we must first receive either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the â€œFDCAâ€), or approval of premarket approval (â€œPMAâ€), from the FDA, unless an exemption applies. In the process of obtaining premarket clearance or approval following either of these routes, the FDA must determine that a proposed device is either substantially equivalent to a legally marketed predicate device with similar intended uses and the same technological characteristics and risks, or that it is safe and effective for its intended use, based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life sustaining, life supporting or implantable devices. Â Modifications to products that are approved through a PMA generally require FDA approval of the modifications through a supplemental application. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain. The process of obtaining a PMA is costly and uncertain and generally takes from one to three years, or even longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical studies. Despite the time, effort and cost, a medical device may not be approved by the FDA. Any delay or failure to obtain necessary regulatory approvals could harm our business. Furthermore, even if we are granted regulatory approvals, they may include significant limitations on the approved and labeled indications for use for the device, which may limit the market for the device. Â In addition, comparable foreign regulatory authorities to the FDA have approval policies and regulations related to the safety and performance requirements that apply to 188RNL-BAM, either as medical devices or as drugs, depending on each jurisdictionâ€™s regulatory requirements. Accordingly, to the extent that we intend to sell medical devices in member states of the European Union or other foreign jurisdictions, the regulatory approval pathway for our product candidates, including 188RNL-BAM, may be uncertain, complex, expensive and lengthy, and approval may not be obtained. Â Failure to successfully develop or supply the RNL-BAM medical device component, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or third-party providers to obtain or maintain regulatory approval or clearance of 188RNL-BAM as a medical device or drug, as applicable in each jurisdiction, could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in RNL-BAM reaching the market. Further, failure to successfully develop or supply the device, or to gain or maintain its approval, could adversely affect our operations. Â 32 Â Item 6. Exhibits Â EXHIBIT INDEX PLUS THERAPEUTICS, INC. Â Â Exhibit Number Exhibit Title Filed with this Form 10-Q Incorporated by Reference Form File No. Date Filed 3.1 Composite Certificate of Incorporation 10-K 001-34375Â Exhibit 3.1 03/11/2016 3.2 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375Â Exhibit 3.1 05/10/2016 3.3 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375Â Exhibit 3.1 05/23/2018 3.4 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375Â Exhibit 3.1 07/29/2019 3.5 Certificate of Amendment to Amended and Restated Certificate 8-K 001-34375Â Exhibit 3.1 08/06/2019 3.6 Certificate of Amendment to Amended and Restated Certificate Â 8-K 001-34375Â Exhibit 3.1 04/28/2023 Â Â Â Â Â Â Â 3.7 Amended and Restated Bylaws of Plus Therapeutics, Inc. 8-K 001-34375Exhibit 3.1 09/21/2021 Â Â Â Â Â Â Â 3.8 Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock Â 8-K 001-34375Exhibit 3.1 11/28/2017 Â Â Â Â Â Â Â 3.9 Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock Â 8-K 001-34375Exhibit 3.1 07/25/2018 Â Â Â Â Â Â Â 3.10 Certificate of Designation of Series F Preferred Stock, dated March 3, 2023 Â 8-K 001-34375Exhibit 3.1 03/03/2023 Â Â Â Â Â Â Â 4.1 Form of Series U Warrant Â S-1/A 333-229485Exhibit 4.37 09/16/2019 Â Â Â Â Â Â Â 4.2 Form of Warrant Amendment Agreement Â 8-K 001-34375Exhibit 4.1 04/23/2020 Â Â Â Â Â Â Â 4.3 Form of Underwritersâ€™ Warrant Amendment Agreement Â 8-K 001-34375Exhibit 4.1 10/05/2020 Â Â Â Â Â Â Â 4.4 Form of Pre-Funded Warrant Â 8-K 001-34375Exhibit 4.1 05/09/2024 Â Â Â Â Â Â Â 4.5 Form of Series A Warrant (May 2024, as amended and restated August 2024) X Â Â Â Â Â Â Â Â Â Â 4.6 Form of Series B Warrant (May 2024, as amended and restated August 2024) X Â Â Â Â Â Â Â Â Â Â 4.7 Form of Amendment and Restatement of the Plus Therapeutics, Inc. Series A Common Stock Purchase Warrant X Â Â Â Â Â Â Â Â Â Â 4.8 Form of Amendment and Restatement of the Plus Therapeutics, Inc. Series B Common Stock Purchase Warrant X Â Â Â 33 Â Â Â Â Â Â Â 10.1 Securities Purchase Agreement, dated May 5, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein Â 8-K 001-34375Exhibit 10.1 05/09/2024 Â Â Â Â Â Â Â 10.2 First Amendment to Securities Purchase Agreement, dated May 8, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein Â 8-K 001-34375Exhibit 10.2 05/09/2024 Â Â Â Â Â Â Â 10.3 Registration Rights Agreement, dated as of May 5, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein Â 8-K 001-34375Exhibit 10.3 05/09/2024 Â Â Â Â Â Â Â 10.4 Third Amendment to the 2015 New Employee Incentive Plan Â Â S-1 333-280061 06/07/2024 Â Â Â Â Â Â Â 10.5 Lending Agreement, dated April 5, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC Â 8-K 001-34375Exhibit 10.1 06/04/2024 Â Â Â Â Â Â Â 10.6 Loan Interest Form, dated May 24, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC Â 8-K 001-34375Exhibit 10.2 06/04/2024 Â Â Â Â Â Â Â 10.7 Extension of Credit, dated May 29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC Â 8-K 001-34375Exhibit 10.3 06/04/2024 Â Â Â Â Â Â Â 31.1 Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1* Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002 X 101.INS Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents X 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) X * In accordance with Item 601(b)(32)(ii) of Regulation Sâ€‘K and SEC Release No. 34â€‘47986, the certifications furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10â€‘Q and will not be deemed â€œfiledâ€ for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates it by reference. Â Â 34 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â PLUS THERAPEUTICS, INC. Â Â Â Â Â Â By: Â /s/ Marc H. Hedrick Dated: August 14, 2024 Â Â Â Marc H. Hedrick Â Â Â Â President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) Â Â Â Â Â Â By: Â /s/ Andrew Sims Dated: August 14, 2024 Â Â Â Andrew Sims Â Â Â Â Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer) Â 1 EX-4.5 2 pstv-ex4_5.htm EX-4.5 EX-4.5 EXHIBIT 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE â€œSECURITIES ACTâ€), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. Â FORM OF SERIES A COMMON STOCK PURCHASE WARRANT PLUS THERAPEUTICS, INC. Warrant Shares: Issue Date: August 9, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the â€œWarrantâ€) certifies that, for value received, _____ or its assigns (the â€œHolderâ€) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the â€œInitial Exercise Dateâ€) and on or prior to 5:00 p.m. (New York City time) on the five year anniversary of the Initial Exercise Date (the â€œTermination Dateâ€) but not thereafter, to subscribe for and purchase from Plus Therapeutics, Inc., a Delaware corporation (the â€œCompanyâ€), up to _____ shares (as subject to adjustment hereunder, the â€œWarrant Sharesâ€) of the Companyâ€™s common stock, par value $0.001 per share (the â€œCommon Stockâ€). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the â€œPurchase Agreementâ€), dated May 3, 2024, among the Company and the purchasers signatory thereto. Section 2. Exercise. a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A-1 (the â€œNotice of Exerciseâ€). On the earlier of (i) the second Trading Day and (ii) the last Trading Day of the applicable Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date said Notice of Exercise is delivered to the Company, the Holder shall deliver payment of the aggregate Exercise Price of the shares thereby purchased pursuant to the applicable Notice of Exercise by wire transfer or cashierâ€™s check drawn on a United States bank or, if available, pursuant to the cashless exercise procedure specified in Section 2(c) below if specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records 1 EXHIBIT 4.5 showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. Â b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $1.772, subject to adjustment hereunder (the â€œExercise Priceâ€). c) Cashless Exercise. Notwithstanding anything herein to the contrary, if at any time after the six-month anniversary of the Closing Date, there is no effective Registration Statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a â€œcashless exerciseâ€ in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing (A-B) (X) by (A), where: (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of â€œregular trading hoursâ€ (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (â€œBloombergâ€) as of the time of the Holderâ€™s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during â€œregular trading hoursâ€ on a Trading Day and is delivered to the Company within two (2) hours thereafter (including until two (2) hours after the close of â€œregular trading hoursâ€ on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of â€œregular trading hoursâ€ on such Trading Day; (B) = the Exercise Price, as adjusted hereunder; and (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c). â€œBid Priceâ€ means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the foregoing does not apply, the bid price of the Common Stock in the over-the-counter market on the electronic bulletin board for such Common Stock as reported by Bloomberg as of such time of determination, (c) if no bid price is reported for the Common Stock by Bloomberg as of such time of determination, the average of the bid prices of all of the market makers for the Common Stock as reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices) (the â€œPink Sheetsâ€) as of such time of determination, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent 2 EXHIBIT 4.5 appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. â€œVWAPâ€ means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the foregoing does not apply, the bid price of the Common Stock in the over-the-counter market on the electronic

bulletin board for such Common Stock as reported by Bloomberg as of such time of determination, (c) if no bid price is reported for the Common Stock by Bloomberg as of such time of determination, the average of the bid prices of all of the market makers for the Common Stock as reported in the Pink Sheets as of such time of determination, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. Notwithstanding anything herein to the contrary, on the Termination Date, if the conditions of a cashless exercise are otherwise met, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c). d) Mechanics of Exercise. i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holderâ€™s or its designeeâ€™s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (â€œDWACâ€) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Companyâ€™s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the â€œWarrant Share Delivery Dateâ€), in each case subject to delivery of the aggregate Exercise Price to the Company (if applicable). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, â€œStandard Settlement Periodâ€ means the standard settlement period, expressed in a number of Trading Days, on the Companyâ€™s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of 3 EXHIBIT 4.5 Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company at any time prior to the Company delivering such Warrant Shares. iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any failure due solely to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holderâ€™s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder was entitled to receive upon such exercise but did not receive (a â€œBuy-Inâ€), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holderâ€™s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver, but did not deliver, to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holderâ€™s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Companyâ€™s failure to timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof. 4 EXHIBIT 4.5 v. No Fractional Shares or Scrip. No fractional Warrant Shares or scrip representing fractional Warrant Shares shall be issued upon the exercise of this Warrant. As to any fraction of a Warrant Share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election and in lieu of the issuance of such fractional Warrant Share, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole Warrant Share. vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares. vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. e) Holderâ€™s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holderâ€™s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holderâ€™s Affiliates (such Persons, â€œAttribution Partiesâ€)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holderâ€™s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case 5 EXHIBIT 4.5 subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Companyâ€™s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The â€œBeneficial Ownership Limitationâ€ shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. Section 3. Certain Adjustments. a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. b) Subsequent Rights Offerings. In addition to (but without duplication of) any adjustments pursuant to Section 3(a) above, if at any time while this Warrant is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all record holders of Common Stock (the â€œPurchase Rightsâ€), then the Holder will be entitled 6 EXHIBIT 4.5 to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holderâ€™s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities (other than as contemplated by Section 3(a) above), property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a â€œDistributionâ€), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holderâ€™s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a transaction solely to change the domicile of the Company), (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a â€œFundamental Transactionâ€), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is 7 EXHIBIT 4.5 the surviving corporation, and any additional consideration (the â€œAlternate Considerationâ€) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall

apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holderâ€™s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. â€œBlack Scholes Valueâ€ means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the â€œOVâ€ function on Bloomberg, L.P. (â€œBloombergâ€) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to 100, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) the sum of the remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holderâ€™s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the â€œSuccessor Entityâ€) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to 8 EXHIBIT 4.5 the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term â€œCompanyâ€ under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the â€œCompanyâ€ shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date. e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. f) Notice to Holder. i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party (other than a transaction solely to change the domicile of the Company), any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or 9 EXHIBIT 4.5 share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall contemporaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. Â g) Voluntary Adjustment By Company. The Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company; provided, however, that the Company agrees not to adjust the Exercise Price in any way that would violate the listing rules of the Nasdaq Stock Market. Section 4. Transfer of Warrant. a) Transferability. Subject to the Holderâ€™s appropriate compliance with the restrictive legend on this Warrant and the transfer restrictions set forth herein and in the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. b) New Warrants. Subject to compliance with applicable securities laws, this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the â€œWarrant Registerâ€), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. Â d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) 10 EXHIBIT 4.5 eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement. Â e) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. Section 5. Miscellaneous. a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a â€œcashless exerciseâ€ pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant. For the avoidance of doubt, except as expressly set forth in this Warrant, in no event does this agreement result in the Company having an obligation to issue cash or other assets to the Holder. b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day. d) Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying the Warrant, which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through 11 EXHIBIT 4.5 any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement. f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by applicable state and federal securities laws. g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holderâ€™s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable and documented attorneysâ€™ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any share of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant 12 EXHIBIT 4.5 are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder. m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********** (Signature Page Follows) Â 13 EXHIBIT 4.5 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated. PLUS THERAPEUTICS, INC. By: Name: Title: Â 14 EXHIBIT 4.5 EXHIBIT A NOTICE OF EXERCISE TO: PLUS THERAPEUTICS, INC. (1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. (2) Payment shall take the form of (check applicable box): â˜ in lawful money of the United States; or â˜ if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). (3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: (4) Accredited Investor. The undersigned is (i) an â€œaccredited investorâ€ as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the â€œSecurities Actâ€); or (ii) a â€œqualified institutional buyerâ€ as defined in Rule 144A(a) under the Securities Act. Â The Warrant Shares shall be delivered to the following DWAC Account Number: SIGNATURE OF HOLDER Name of Investing Entity: Signature of Authorized Signatory of Investing Entity: Name of Authorized Signatory: Title of Authorized Signatory: Date: EXHIBIT B 15 EXHIBIT 4.5 ASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name: Â (Please Print) Address: Â (Please Print) Phone Number: Â Email Address: Â Dated: Â , Holderâ€™s Signature: Â Â Â

the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holderâ€™s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. 5 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Companyâ€™s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The â€œBeneficial Ownership Limitationâ€ shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. Section 3. Certain Adjustments. a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. b) Subsequent Rights Offerings. In addition to (but without duplication of) any adjustments pursuant to Section 3(a) above, if at any time while this Warrant is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all record holders of Common Stock (the â€œPurchase Rightsâ€), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holderâ€™s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of 6 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities (other than as contemplated by Section 3(a) above), property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a â€œDistributionâ€), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holderâ€™s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than a transaction solely to change the domicile of the Company), (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of the common equity of the Company (each a â€œFundamental Transactionâ€), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the â€œAlternate Considerationâ€) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental 7 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holderâ€™s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. â€œBlack Scholes Valueâ€ means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the â€œOVâ€ function on Bloomberg, L.P. (â€œBloombergâ€) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to 100, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) the sum of the remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holderâ€™s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the â€œSuccessor Entityâ€) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term â€œCompanyâ€ under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the â€œCompanyâ€ shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common 8 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date. f) Notice to Holder. i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party (other than a transaction solely to change the domicile of the Company), any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall contemporaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. Â g) Voluntary Adjustment By Company. The Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company; provided, however, that the Company agrees not to adjust the Exercise Price in any way that would violate the listing rules of the Nasdaq Stock Market. Â Section 4. Transfer of Warrant. 9 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 a) Transferability. Subject to the Holderâ€™s appropriate compliance with the restrictive legend on this Warrant and the transfer restrictions set forth herein and in the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this

Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. b) New Warrants. Subject to compliance with applicable securities laws, this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the â€œWarrant Registerâ€), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. Â d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement. Â e) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. Section 5. Miscellaneous. a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a â€œcashless exerciseâ€ pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant. For the avoidance of doubt, except as expressly set forth in this 10 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 Warrant, in no event does this agreement result in the Company having an obligation to issue cash or other assets to the Holder. b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day. d) Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant, which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement. 11 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by applicable state and federal securities laws. g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holderâ€™s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable and documented attorneysâ€™ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder. m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. ********** (Signature Page Follows) 12 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 Â 13 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated. PLUS THERAPEUTICS, INC. By: Name: Title: Â 14 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 EXHIBIT A Â Â NOTICE OF EXERCISE TO: PLUS THERAPEUTICS, INC. (1) The undersigned hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. (2) Payment shall take the form of (check applicable box): â˜ in lawful money of the United States; or â˜ if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). (3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: Â The Warrant Shares shall be delivered to the following DWAC Account Number: (4) Accredited Investor. The undersigned is (i) an â€œaccredited investorâ€ as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the â€œSecurities Actâ€); or (ii) a â€œqualified institutional buyerâ€ as defined in Rule 144A(a) under the Securities Act. SIGNATURE OF HOLDER Name of Investing Entity: Signature of Authorized Signatory of Investing Entity: Name of Authorized Signatory: Title of Authorized Signatory: Date: EXHIBIT B 15 MACROBUTTON DocID \\4142-1432-0719 v11 EXHIBIT 4.6 ASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name: Â (Please Print) Address: Â (Please Print) Phone Number: Â Email Address: Â Dated: Â , Holderâ€™s Signature: Â Â Â

such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize, and report financial information; and (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 /s/ Marc H. Hedrick Marc H. Hedrick, President & Chief Executive Officer Â Â EX-31.2 7 pstv-ex31_2.htm EX-31.2 EX-31.2 Â EXHIBIT 31.2 Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Andrew Sims, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Plus Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize, and report financial information; and (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 /s/ Andrew Sims Andrew Sims Chief Financial Officer Â Â EX-32.1 8 pstv-ex32_1.htm EX-32.1 EX-32.1 Â EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350/ SECURITIES EXCHANGE ACT RULE 13a-14(b), AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Plus Therapeutics, Inc. for the quarterly period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof, Marc H. Hedrick, as President & Chief Executive Officer of Plus Therapeutics, Inc., and Andrew Sims, as VP of Finance and Chief Financial Officer of Plus Therapeutics, Inc., each hereby certifies, respectively, that: 1. The Form 10-Q report of Plus Therapeutics, Inc. that this certification accompanies fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934. 2. The information contained in the Form 10-Q report of Plus Therapeutics, Inc. that this certification accompanies fairly presents, in all material respects, the financial condition and results of operations of Plus Therapeutics, Inc. Â Â Â By: Â /s/ Marc H. Hedrick Dated: August 14, 2024 Â Â Â Marc H. Hedrick Â Â Â Â President & Chief Executive Officer Â Â Â Â Â Â Â By: Â /s/ Andrew Sims Dated: August 14, 2024 Â Â Â Andrew Sims Â Â Â Â Chief Financial Officer & VP of Finance Â Â EX-101.SCH 9 pstv-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 100060 - Disclosure - Basis of Presentation and New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Use of Estimates link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Term Loan Obligations link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Line of Credit Facility link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Biocept Asset Acquisitions link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Grant Revenue link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - COVID-19 Pandemic and CARES Act link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Basis of Presentation and New Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Basis of Presentation and New Accounting Standards - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Use of Estimates - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Liquidity and Going Concern - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Term Loan Obligations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Line of Credit Facility - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Loss per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Biocept Asset Acquisitions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Grant Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - License Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Stockholders' Deficit - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Stockholders' Deficit - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Stockholders' Deficit - Common stock (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Period for regain compliance. Period For Regain Compliance Period for regain compliance Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Weighted Average Remaining Contractual Life (years) [Roll Forward] Debt Instrument [Axis] Debt Instrument May 2024 Private Placement [Member] May 2024 Private Placement [Member] May 2024 private placement. Plan Name [Domain] Plan Name Payments for Repurchase of Equity, Total Payments for Repurchase of Equity Purchase of treasury stock Entity Address Postal Zip Code Entity Address, Postal Zip Code Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation State Country Code Entity Incorporation, State or Country Code Costs of acquisitions Business Combination, Acquisition Related Costs Interest Paid Net Interest Number of operating segment Number of Operating Segments Exercisable at June 30, 2024 (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Stockholders' Equity, Reverse Stock Split Reverse stock split Shares Outstanding Balance (in shares) Balance (in shares) Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Closing bid price. Closing Bid Price Closing bid price Long Term Debt Current Term loan obligation, current Long-Term Debt, Current Maturities, Total Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Schedule of Changes in Fair Value of Warrant Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Product and Service [Axis] Debt principal repayment start date. Debt Principal Repayment Start Date Debt principal repayment start date Depreciation Depletion And Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Lorem Vascular, Pte. Ltd. Lorem Vascular Pte Ltd [Member] Lorem Vascular Pte Ltd [Member] Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Stock option vesting percentage Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangement and Arrangement Other than Collaborative Stock Repurchased During Period, Shares Number of stock repurchased Total cash payment Total cash payment Payments to Acquire Productive Assets Piramal pharma solutions inc. Piramal Pharma Solutions Inc [Member] Piramal Pharma Solutions, Inc. [Member] Stockholders' Deficit Stockholders Equity Note Disclosure [Text Block] Class Of Warrant Or Right [Axis] Class of Warrant or Right Revenue from Contract with Customer [Text Block] Grant Revenue Cash paid during period for: Cash Paid During Period For [Abstract] Cash paid during period for: Sale Of Stock Name Of Transaction [Domain] Sale of Stock Cash and Cash Equivalents [Domain] Two thousand eighteen rights offering. Two Thousand Eighteen Rights Offering [Member] 2018 Rights Offering [Member] Two thousand and twenty two purchase agreement. Two Thousand and Twenty Two Purchase Agreement [Member] 2022 Purchase Agreement [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Entity Central Index Key Entity Central Index Key Warrant [Member] Outstanding Warrants [Member] Cancelled/expired (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Increase Decrease In Operating Capital [Abstract] Increases (decreases) in cash caused by changes in operating assets and liabilities: Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Initial Subscription [Member] Initial Subscription. Common Stock Shares Issued Common stock, shares issued (in shares) Rights related to distribution of assets Rights Related To Distribution Of Assets Rights related to distribution of assets. Percentage of grant proceeds with interest not exceed annually. Percentage Of Grant Proceeds With Interest Not Exceed Annually Percentage of grant proceeds with interest not exceed annually Fair Value Measurement Inputs and Valuation Techniques [Table] Line of Credit Facility Short-Term Debt [Text Block] Preferred Stock [Member] Preferred Stock [Member] Convertible Preferred Stock [Member] Income Statement [Abstract] Entity Address State Or Province Entity Address, State or Province Payments to Acquire Short-Term Investments Purchase of short-term investments Warrants Warrants Policy [Policy Text Block] Warrants Policy. Exercisable at June 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Liability Class [Axis] Series F Preferred Stock [Member] Series F Preferred Stock [Member] Treasury Stock, Common, Shares Treasury stock, shares Cover [Abstract] License agreement abstract. License Agreement [Abstract] Subsequent Event [Line Items] Net loss per share of common stock - basic Earnings Per Share Basic Earnings Per Share, Basic, Total Second amendment to the amended and restated loan and security agreement. Term Loan [Member] Term Loan [Member] Lessee Operating Lease Option To Extend Lessee, operating lease, option to extend Equity incentive plans. Equity Incentive Plans [Member] Equity Incentive Plans [Member] Operating Expenses [Abstract] Operating expenses: Asset Acquisition [Axis] Accumulated deficit Retained Earnings Accumulated Deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Plan Name [Axis] Plan Name Balance as of June 30, 2024 (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Balance as of December 31, 2023 (in shares) Assets Current [Abstract] Current assets: Common Stock, Capital Shares Reserved for Future Issuance Number of shares reserved for issuance and sale Common stock capital shares reserved for future issuance Regain compliance expiry date Regain Compliance Expiry Date Regain compliance expiry date. Accounting Standards Update and Change in Accounting Principle [Abstract] Investment Type [Axis] Investment Type Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net cash used in operating activities Product and Service [Domain] Lessee Operating Lease Term Of Contract Lessee, operating lease, term of contract Maximum value of shares to be issued under agreement. Maximum Value of Shares to be Issued Under Agreement Maximum value of shares to be issued under agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis] Recorded Unconditional Purchase Obligation by Category of Item Purchased Property Plant And Equipment Net Property and equipment, net Property, Plant and Equipment, Net, Total Net Cash Provided By Used In Operating Activities [Abstract] Cash flows used in operating activities: Services agreement. Services Agreement [Member] Services Agreement [Member] Fair Value, Recurring [Member] Recurring Basis [Member] Other Income And Expenses [Abstract] Other income (expense): Common Stock Par Or Stated Value Per Share Common stock, par value (in dollars per share) Measurement Input Type [Domain] Statement Of Cash Flows [Abstract] Stock based compensation 2015 equity incentive plan 1 member. Stock Based Compensation2015 Equity Incentive Plan1 [Member] 2015 Plan [Member] Change in fair value of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Number of shares callable by warrants (in shares) Number of securities called by warrant or right Entity [Domain] Entity Pershing Credit Facility [Member] Pershing Credit Facility [Member] Pershing Credit Facility. Statement Equity Components [Axis] Equity Components Equity Components [Axis] Recorded Unconditional Purchase Obligation [Line Items] Recorded Unconditional Purchase Obligation [Line Items] Entity Address Address Line1 Entity Address, Address Line One Charlottesville Charlottesville [Member] Charlottesville [Member] Schedule of Computation of Basic and Diluted Net Loss Per Common Share Schedule of Earnings Per Share, Basic

and Diluted [Table Text Block] Subsequent Event Type [Axis] Total other income (expense) Nonoperating Income Expense Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share Debt Securities, Available-for-Sale, Unrealized Gain Unrealized gain on available-for-sale securities New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Recently Issued Accounting Pronouncements Disclosure of accounting policy for license agreement. License Agreement Disclosure [Text Block] License Agreements Amendment Flag Amendment Flag Change in operating lease liabilities Increase (Decrease) in Operating Lease Liability Operating Lease Liability Noncurrent Noncurrent operating lease liability Options. Options [Member] Outstanding Stock Options [Member] Debt Instrument Name [Domain] Debt Instrument, Name Preferred stock, voting rights Preferred Stock, Voting Rights Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR [Member] Net Income Loss Net loss Net loss Exercisable at June 30, 2024 (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Variable Rate [Domain] Variable Rate Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Loss on disposal of property and equipment Equity Component [Domain] Equity Component Equity Component [Domain] Range [Member] Statistical Measurement Statistical Measurement [Domain] General And Administrative Expense General and administrative General and Administrative Expense, Total Deferred grant liability Deferred Income, Noncurrent Financing expense Financing expense Financing Expense Financing expense. Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Stock option contractual term Treasury Stock, Common [Member] Treasury Stock [Member] Disaggregation of Revenue [Table] Proceeds from credit facility Proceeds from Lines of Credit Proceeds from Lines of Credit, Total Payment for tech transfer and validation fee. Payment For Tech Transfer And Validation Fee Payment for tech transfer and validation fee Preferred Stock Shares Issued Preferred stock, shares issued (in shares) Lincoln park capital fund, LLC. Lincoln Park Capital Fund L L C [Member] Lincoln Park Capital Fund, LLC [Member] Operating lease discount rate Lessee, Operating Lease, Discount Rate Consideration paid to preferred stock holders Consideration Paid To Preferred Stock Holders Consideration paid to preferred stock holders. Use of Estimates [Abstract] Use Of Estimates [Abstract] Short-Term Investments, Total Short-Term Investments Investments Investments Operating Lease Expense Rent expense Vested and expected to vest at June 30, 2024 (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price Cancelled/expired (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Loan and security agreement. Loan And Security Agreement [Member] Loan and Security Agreement [Member] Grant receivable Increase Decrease In Grant Receivable Increase decrease in grant receivable. Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Class Of Stock [Domain] Class of Stock Refers to the period exercisable from the date of issuance. Period Exercisable From The Date Of Issuance Period exercisable from the date of issuance Common Stock Shares Outstanding Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Options [Roll Forward] Consecutive business days. Consecutive Business Days Consecutive business days Preferred Stock Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Contract effective date. Contract Effective Date Contract effective date Proceeds from sale of common stock, warrants and pre-funded warrants, net Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity, Total UTHSCSA License Agreement [Member] U T H S C S A License Agreement [Member] UTHSCSA license agreement member. Asset Acquisition [Abstract] Entity Interactive Data Current Entity Interactive Data Current Lease Expiration Date1 Operating leases, expiration date Warrant Liability [Member] Warrant liability. Warrant Liability [Member] Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Range [Axis] Statistical Measurement Statistical Measurement [Axis] Contract with Customer, Asset, before Allowance for Credit Loss Grant amount awarded Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Fair Value Related and Nonrelated Parties [Domain] Related Party Lessee Operating Lease Liability Maturity Table [Text Block] Summary of Future Minimum Annual Lease Payments under Operating Leases Liquidity Abstract Liquidity [Abstract] Initial commitment shares. Initial Commitment Shares Initial commitment shares Sale of the japanese subsidiary and certain assets. Sale Of Japanese Subsidiary And Certain Assets [Member] Sale of the Japanese Subsidiary and Certain Assets [Member] Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Securities remaining and available for future issuances (in shares) Basis Of Presentation And Significant Accounting Policies [Text Block] Basis of Presentation and New Accounting Standards Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Weighted average period for recognition of cost Aggregate upfront gross proceeds from private placement Proceeds from private placement Proceeds from Issuance of Private Placement Cash and Cash Equivalents [Axis] Assets Total assets Debt Instrument [Table] Debt Instrument [Table] Offering expenses Offering Costs Offering costs. Recorded Unconditional Purchase Obligation, Category [Domain] New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Entity Address City Or Town Entity Address, City or Town Contract termination date. Contract Termination Date Contract termination date Interest Rate Floor [Member] Interest Rate Floor [Member] Debt Instrument Face Amount Original loan amount Offering price Share Price Closing price per share Sale closed date Sale of Stock, Transaction Date Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-based Compensation Operating Lease Weighted Average Discount Rate Percent Operating lease, weighted average discount rate Grant [Member] Grant [Member] Fair Value Disclosures [Abstract] Grant funding term. Grant Funding Term Grant funding term Sale and issuance of common stock, net Issue and sale of stock, net Stockholders' equity requirement Liabilities Current [Abstract] Current liabilities: Redemption of Series F preferred stock (in shares) Stock Redeemed or Called During Period, Shares Document Type Document Type Minimum liquidity covenant amount. Minimum Liquidity Covenant Amount Minimum liquidity covenant Accounting Standards Update [Axis] Security12b Title Title of 12(b) Security Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Lease Cost Table [Text Block] Summary of Lease Costs Statement Of Stockholders Equity [Abstract] Ending Balance Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Fiscal Period Focus Document Fiscal Period Focus Research And Development Expense Research and development Research and Development Expense, Total Research and development expense Long Term Debt Noncurrent Term loan obligation Long-Term Debt, Excluding Current Maturities, Total Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Common stock shares to be issued (in shares) Granted (in shares) Subsequent Event Type [Domain] LIBOR. LIBOR [Member] LIBOR [Member] Schedule Of Share Based Compensation Activity Table [Text Block] Stock Option Activity Expected Term [Member] Measurement Input, Expected Term [Member] Representative Series U Warrant. Representative Series U Warrant [Member] Representative Warrants [Member] Initial commitment fee. Initial Commitment Fee Initial commitment fee paid in cash Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrant exercise price (in dollars per share) Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Financial Instruments Series F Convertible Preferred Stock [Member] Series F Convertible Preferred Stock. The date that the warrant or right expires. Class Of Warrant Or Right Expiration Date Warrant expiration date Subsidiary Sale Of Stock [Axis] Sale of Stock Net Cash Provided By Used In Investing Activities [Abstract] Cash flows used in investing activities: Investment Type Categorization [Member] Investments Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Date from which warrants are exercisable Unusual Or Infrequent Items Disclosure [Text Block] COVID-19 Pandemic and CARES Act Revenue from Contract with Customer, Excluding Assessed Tax Grant revenue recognized Grant revenue Deferred Income, Current Deferred grant liability Compensatory damages and operational. Compensatory Damages And Operational Compensatory damages and operational Line of Credit Facility [Line Items] Credit Facility [Domain] Share based compensation arrangement by share based payment award options aggregate intrinsic value. Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregated Intrinsic Value [Roll Forward] Entity Address Address Line2 Entity Address, Address Line Two Litigation Case Type [Domain] Litigation Case Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholdersâ€™ Equity Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Nano Tx license agreement Member Nano Tx Licenses Agreement [Member] Nano Tx Licenses Agreement [Member] Common Class A [Member] Common Class A [Member] Liquidity and Going Concern Disclosure Of Liquidity And Going Concern Text Block Disclosure of liquidity and going concern text block Stockholders Equity Note [Abstract] Percentage issuance of common stock. Percentage Issuance Of Common Stock Percentage issuance of common stock Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Dilutive common shares excluded from the calculations of diluted loss per share (in shares) Operating leases, expiry year. Operating Leases Expiry Year Operating leases expiry year Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Common Class B [Member] Common Class B [Member] Consideration to purchaser in cash Sale of Stock, Consideration Received on Transaction Percentage of non-dilutive monetary awards required to pay Percentage of Non-dilutive Monetary awards Required to Pay Percentage of non-dilutive monetary awards required to pay. Series C convertible preferred stock. Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Trading Symbol Trading Symbol Variable Rate [Axis] Variable Rate Stockholders Equity Balance Balance Stockholders' deficit Total stockholders' deficit Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer. Pre Clinical Research Study Obligations [Member] Pre-clinical Research Study Obligations [Member] Pre -Funded Warrants to Purchase Class Of Warrant Or Right Outstanding Class of warrant outstanding Derivative Instrument Risk [Axis] Derivative Instrument Number of shares issued Sale of Stock, Number of Shares Issued in Transaction Option for exclusive worldwide license. Option For Exclusive Worldwide License Option for exclusive worldwide license Goodwill Goodwill Goodwill, Total Goodwill, Beginning Balance Goodwill, Ending Balance Issuance of warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Change in accounting principle, accounting standards update, adopted Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Redemption of Series F preferred stock Stock Redeemed or Called During Period, Value Additional Subscription [Member] Additional Subscription. Outstanding warrants and options. Outstanding Warrants and Options [Member] Outstanding Warrants and Options [Member] Series B convertible preferred stock. Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Disposal Group Classification [Axis] Disposal Group Classification Measurement Input Type [Axis] Vested and expected to vest as of June 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Use of Estimates, Policy [Policy Text Block] Use of Estimates Percentage of aggregate amount of proceeds awarded under CPRIT grant. Percentage Of Aggregate Amount Of Proceeds Awarded Under CPRIT Grant Percentage of aggregate amount of proceeds awarded under CPRIT grant Number Of Votes Per Share Number of votes per share. Fair Value Measurement Inputs Disclosure [Text Block] Fair Value Measurements Class Of Stock [Line Items] Class of Stock [Line Items] Expected Volatility [Member] Measurement Input, Price Volatility [Member] Closing bid price for common stock had fallen. Closing Bid Price For Common Stock Had Fallen Below Closing bid price for common stock had fallen below Security Exchange Name Security Exchange Name Fair Value by Liability Class [Domain] Maintain minimum market value of listed securities Maintain Minimum Market Value of Listed Securities Maintain minimum market value of listed securities Operating Expenses Total operating expenses Risk-free Interest Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Payments For Loans Payments for principal, interest and fees Statement Class Of Stock [Axis] Class of Stock Legal Entity [Axis] Legal Entity CPRIT grant funding term. CPRIT Grant Funding Term CPRIT grant funding term, description Research And Development Arrangement Contract To Perform For Others Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Subsequent Event [Member] Subsequent Event Maximum [Member] Maximum [Member] Liabilities And Stockholders Equity Total liabilities and stockholders' deficit Operating lease right-of-use assets Operating Lease Right Of Use Asset Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flows information: Prime Rate [Member] Prime Rate [Member] Net loss per share of common stock - basic Net loss per share of common stock - diluted Earnings Per Share Diluted Earnings Per Share, Diluted, Total Asset Acquisition [Line Items] Stock Issued During Period, Shares, Reverse Stock Splits Stock issued during period reverse stock splits, shares Liabilities Total liabilities Long term debt outstanding threshold amount. Long Term Debt Outstanding Threshold Amount Long term debt outstanding threshold amount Fair Value Hierarchy and NAV [Domain] Assets Current Total current assets Net Cash Provided By Used In Investing Activities Net cash used in investing activities Master services agreement Terms description. Master Services Agreement Terms Description Master services agreement terms, Description Common Stock Market Price [Member] Measurement Input, Common Stock Market Price [Member] Measurement Input, Common Stock Market Price. Sale and issuance of common stock, net (in shares) Issue and sale of share Sale of common stock, net Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Stock option vesting period Lessee Operating Lease Existence Of Option To Extend Lessee, operating lease, existence of option to extend [true false] Distribution Type [Axis] Entity Filer Category Entity Filer Category Twenty twenty purchase agreement. Twenty Twenty Purchase Agreement [Member] 2020 Purchase Agreement [Member] Asset Acquisition [Domain] Number of warrants exercised Number Of Warrants Exercised Number of warrants exercised Increase (decrease) in deferred grant liability. Increase Decrease In Deferred Grant Liability Deferred grant liability Net loss attributable to common stockholders - diluted Net loss attributable to common stockholders - diluted Net Income (Loss) Available to Common Stockholders, Diluted Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Warrant issuance costs Warrant issuance costs Warrant Issuance Costs Warrant issuance costs. Private Placement and Pre-Funded Warrant [Member] Private Placement and Prefunded Warrant[Member] Private Placement and Prefunded Warrant. Share Based Compensation Share-Based Payment Arrangement, Noncash Expense, Total Share-based compensation expense Balance as of June 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Related Party Transactions By Related Party [Axis] Related Party Debt Instrument Fee Amount Fees amount associated with loan Entity Registrant Name Entity Registrant Name Number of reportable segment Number of Reportable Segments Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Earnings Per Share [Text Block] Loss per Share Debt Instrument Maturity Date Maturity date Entity Emerging Growth Company Entity Emerging Growth Company Recorded Unconditional Purchase Obligation [Table] Recorded Unconditional Purchase Obligation [Table] ASU 2016-13 Accounting Standards Update 2016-13 [Member] Money Market Funds [Member] Money Market [Member] Payments to Acquire Intangible Assets Purchases of intangible assets Purchase of intangible assets Weighted average number of shares of common stock outstanding - basic Weighted Average Number Of Shares Outstanding Basic Weighted Average Number of Shares Outstanding, Basic, Total Number of maximum common shares can be resale. Number of Maximum Common Shares Can Be Resale Number of maximum common shares can be resale Distribution Type [Domain] Litigation Case [Axis] Litigation Case Medidata solutions, inc. Medidata Solutions Inc [Member] Medidata Solutions, Inc. [Member] Common Stock Shares Authorized Common stock, shares authorized (in shares) Proceeds From Issuance Of Common Stock Proceeds from sale of common stock, net Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Debt Disclosure [Abstract] Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Granted (in dollars per share) Financial Instrument [Axis] Financial Instrument Balance as of June 30, 2024 Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Treasury stock (at cost, 258,425 and 78,559 shares as of June 30, 2024 and December 31, 2023, respectively) Treasury stock (at cost, 258,425 and 78,559 shares as of June 30, 2024 and December 31, 2023, respectively) Treasury Stock, Common, Value Purchase price of share purchase price of share purchase price of share. Line of credit Long-Term Line of Credit Long-Term Line of Credit, Total Reverse stock split effective date. Reverse Stock Split Effective Date Reverse stock split effective date Stockholders Equity [Abstract] Stockholders' deficit: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Supplemental schedule of non-cash investing and financing activities: Litigation Settlement Expense Litigation settlement, expense Statement [Table] Statement [Table] Segment Information Segment Reporting, Policy [Policy Text Block] Vested and expected to vest at June 30, 2024 Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Subsequent Event [Table] Increase Decrease In Other Current Assets Other current assets Share Based Compensation Arrangement By Share Based Payment Award Options

Outstanding Weighted Average Exercise Price Rollforward Weighted Average Exercise Price [Roll Forward] Preferred Stock Shares Authorized Preferred stock, shares authorized (in shares) Gain on change in fair value of warrant liabilities Change in fair value of warrants Change in fair value of warrants Fair value loss on warrant liability Disposal Group Classification [Domain] Disposal Group Classification Entity File Number Entity File Number Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Net decrease in cash and cash equivalents Revenue from Contract with Customer [Abstract] Per share information: Earnings Per Share [Abstract] Warrant liability, Expected term Warrants And Rights Outstanding Term Warrants expected term Biocept Agreement. Biocept Agreement [Member] Biocept Agreement [Member] Statement Of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest expense Interest expense Interest Expense, Total Loss from operations Operating Income Loss Accrued payments due to NanoTx Accrued License Payable Accrued license payable. Entity Shell Company Entity Shell Company Line of Credit Facility [Table] Summary of Key Inputs Used in Valuation of Liability Classified Warrants Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Class Of Warrant Or Right [Domain] Class of Warrant or Right Entity Current Reporting Status Entity Current Reporting Status Exercisable at June 30, 2024 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Biocept Asset Acquisitions Asset Acquisition [Text Block] Subsequent Events [Abstract] Revenue from Contract with Customer [Policy Text Block] Grant Revenue Recognition Biocept Asset Acquisitions [Member] Biocept Asset Acquisitions [Member] Biocept asset acquisitions. Document Fiscal Year Focus Document Fiscal Year Focus Gross proceeds from issuance of common stock. Gross Proceeds from Issuance of Common Stock Aggregate gross proceeds from sales of common stock Change in accounting principle, accounting standards update, adoption date Change in Accounting Principle, Accounting Standards Update, Adoption Date Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Preferred Stock Value Principal payments of term loan obligation Repayments Of Long Term Debt Repayments of Long-Term Debt, Total Series U warrants member Series U Warrants [Member] Series U Warrants [Member] Treasury Stock, Value, Acquired, Cost Method Purchase of treasury stock Purchase of treasury stock Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total City Area Code City Area Code Warrant liability, Measurement input Warrants and Rights Outstanding, Measurement Input Liabilities Current Total current liabilities Liabilities Fair Value Adjustment Change in fair value of liability instruments Derivative Contract Type [Domain] Derivative Contract Maximum grant amount to be received as per grant contract. Maximum Grant Amount to be Received as per Grant Contract Maximum grant amount to be received as per grant contract Organization Consolidation And Presentation Of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred Stock Shares Outstanding Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Sales order term. Sales Order Term Sales order term Additional Paid In Capital Additional paid-in capital Additional Paid in Capital, Total Fractional adjustment Fractional Adjustment of Common Stock Fractional adjustment of common stock. Commitments And Contingencies Disclosure [Abstract] Shares Issued Remaining common stock issued and sold (in shares) Shares issued Treasury Stock, Value, Total Treasury Stock, Value Treasury stock Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Master services agreement date. Master Services Agreement Date Master service agreement date Master services agreement initial term. Master Services Agreement Initial Term Master services agreement initial term Operating Lease Liability Current Operating lease liability Less: current portion Grant funding period. Grant Funding Period Grant funding period Series B Warrant [Member] Series B Warrant. Debt Instrument, Interest Rate, Stated Percentage Interest rate Retained Earnings [Member] Accumulated Deficit [Member] Amortization Of Financing Costs And Discounts Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts, Total Basic and diluted net loss per common share calculation: Earnings Per Share, Basic [Abstract] Payments To Acquire Property Plant And Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Cash paid for IPRD asset acquired in an asset acquisition. Cash Paid For I P R D Asset Acquired In An Asset Acquisition In process research and development acquired Amendment and Restatements May 2024 Private Placement [Member] Amendment and restatements May 2024 private placement. Document Transition Report Document Transition Report Share Repurchase Program, Authorized, Amount Authorized amount of repurchase of stock Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Subscription and Investment Representation Agreement Subscription Agreement [Member] Subscription Agreement [Member] Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates. Use Of Estimates [Text Block] Use of Estimates Unpaid Offering Costs. Unpaid Offering Costs Unpaid offering cost Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Minimum [Member] Minimum [Member] Common Stock [Member] Common Stock [Member] Exercisable at June 30, 2024 Vested and expected to vest as of June 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Additional Paid In Capital [Member] Additional Paid-in Capital [Member] Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Securities Purchase Agreement [Member] Securities purchase agreement. Other Assets Noncurrent Other assets Series A Warrant [Member] Series A Warrant. Share Repurchase Program, Remaining Authorized, Amount Remained authorized amount for repurchase Other Assets Current Other current assets Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Disaggregation of Revenue [Line Items] Debt Instrument Covenant Compliance Debt instrument, covenant compliance Basis Of Accounting Policy Policy [Text Block] Basis of Presentation and New Accounting Standards Non-cash financing expense Non-Cash Financing Expense Non-cash financing expense. Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block] Available-for-Sale Securities Warrants And Rights Outstanding Warrant liability Common stock, $0.001 par value; 100,000,000 shares authorized; 5,962,644 and 5,704,219 issued and outstanding at June 30, 2024, and 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, respectively Voting stock, value Common Stock Value Common stock, $0.001 par value; 100,000,000 shares authorized; 36,123,833 and 33,601,373 issued and outstanding at March 31, 2023 and December 31, 2022, respectively Asset Acquisition [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Line of credit Line of Credit, Current Payments For Royalties License fee payment in cash Investment Income Interest Interest income Number Of Preferred Stock Shares Exercised. Number Of Preferred Stock Shares Exercised Number of preferred stock, shares converted Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of Financial Assets Measured at Fair Value on Recurring Basis Other Intangible Assets Net Intangible assets, net Debt Instrument Offering Date1 Origination date Percentage of credit facility cannot exceed collateralized marketable securities Percentage of Credit Facility Cannot Exceed Collateralized Marketable Securities Percentage of credit facility cannot exceed collateralized marketable securities. Lease liability Operating Lease Liability Present value of obligations under leases Measurement Frequency [Axis] Commitments and contingencies (Note 10) Commitments And Contingencies New Accounting Pronouncements or Change in Accounting Principle [Line Items] Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant Restricted Beneficial Ownership Level Result of Exercise of Warrant To Receive Pre-funded Warrant Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant. Weighted average number of shares of common stock outstanding - diluted Weighted Average Number Of Diluted Shares Outstanding Weighted Average Number of Shares Outstanding, Diluted, Total Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Lessee Operating Lease Renewal Term Lessee, operating lease, renewal term Vested and expected to vest at June 30, 2024 (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Entity Small Business Entity Small Business Stock Issued During Period, Shares, Stock Splits Common stock, reverse stock split, fractional shares issued Debt Instrument Basis Spread On Variable Rate1 Basis variable rate Debt Disclosure [Text Block] Term Loan Obligations Pre-Funded Warrants [Member] Pre-Funded Warrants [Member] Pre-funded warrants member. Revenues, Total Revenues Revenue Revenue recognized Stock split conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio US Treasury Securities [Member] Treasury Bills and Government Agency Bonds [Member] Treasury Stock, Shares, Acquired Purchase of treasury stock (in Shares) Purchase of treasury stock (in Shares) Accounting Standards Update and Change in Accounting Principle [Table] Line of Credit Facility [Abstract] Grants Receivable, Current Grant receivable Credit Facility [Axis] Contractual Obligation Contractual obligation Contractual Obligation, Total Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on short-term investments Series A Warrant and Series B Warrant [Member] Series a warrant and series b warrant. Cash flows provided by financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Balance as of June 30, 2024 (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Balance as of December 31, 2023 (in dollars per share) Amortization Of Debt Discount Premium Non-cash amortization Floating interest rate for funds borrowed, under the debt agreement. Debt Instrument Floating Interest Rate Percentage Interest rate Cancer prevention and research institute of texas contract. Cancer Prevention And Research Institute Of Texas Contract [Member] CPRIT Contract [Member] Applicable fees Line of Credit Facility, Commitment Fee Percentage Measurement Frequency [Domain] Stock based compensation 2020 equity incentive plan. Stock Based Compensation2020 Equity Incentive Plan [Member] 2020 Plan [Member] Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent, Total Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Net income from continuing operations Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Operating Lease Weighted Average Remaining Lease Term1 Operating lease, weighted average remaining term Subsequent Events [Text Block] Subsequent Events Warrant liability Warrant Liability Warrant Liability Warrant liability Warrant Liability Current Warrant liability current. Change in accounting principle, accounting standards update, immaterial effect Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Risks And Uncertainties [Abstract] Debt instrument floor rate Debt Instrument Floor Rate Debt instrument floor rate. Accounts Payable And Accrued Liabilities Current Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current, Total XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 09, 2024 Cover [Abstract] Â Â Entity Registrant Name PLUS THERAPEUTICS, INC. Â Entity Central Index Key 0001095981 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Emerging Growth Company false Â Entity Small Business true Â Entity Common Stock, Shares Outstanding Â 5,896,333 Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Jun. 30, 2024 Â Document Quarterly Report true Â Document Transition Report false Â Entity Interactive Data Current Yes Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Trading Symbol PSTV Â Title of 12(b) Security Common Stock, par value $0.001 Â Security Exchange Name NASDAQ Â Entity File Number 001-34375 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 33-0827593 Â Entity Address, Address Line One 4200 MARATHON BLVD Â Entity Address, Address Line Two SUITE 200 Â Entity Address, City or Town AUSTIN Â Entity Address, State or Province TX Â Entity Address, Postal Zip Code 78756 Â City Area Code 737 Â Local Phone Number 255-7194 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X -

DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 4,912 $ 8,554 Investments 3,523 Â Other current assets 945 1,280 Total current assets 9,380 9,834 Property and equipment, net 732 906 Operating lease right-of-use assets 139 202 Goodwill 372 372 Intangible assets, net 557 42 Other assets 32 32 Total assets 11,212 11,388 Current liabilities: Â Â Accounts payable and accrued expenses 6,946 6,631 Operating lease liability 92 120 Warrant liability 6,160 Â Deferred grant liability 2,297 Â Line of credit 3,292 Â Term loan obligation, current Â 3,976 Total current liabilities 18,787 10,727 Noncurrent operating lease liability 50 85 Deferred grant liability Â 1,924 Total liabilities 18,837 12,736 Commitments and contingencies (Note 10) Stockholders' deficit: Â Â Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Common stock, $0.001 par value; 100,000,000 shares authorized; 5,962,644 and 5,704,219 issued and outstanding at June 30, 2024, and 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, respectively 6 5 Treasury stock (at cost, 258,425 and 78,559 shares as of June 30, 2024 and December 31, 2023, respectively) (500) (126) Additional paid-in capital 479,571 479,274 Accumulated deficit (486,702) (480,501) Total stockholders' deficit (7,625) (1,348) Total liabilities and stockholders' deficit $ 11,212 $ 11,388 X - DefinitionWarrant liability current. + ReferencesNo definition available. + Details Name: pstv_WarrantLiabilityCurrent Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix:

us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification - Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification - Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other. + ReferencesNo definition available. + Details Name: us-gaap_OtherIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Stockholders' deficit: Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 5,000,000 5,000,000 Preferred stock, shares issued (in shares) 1,952 1,952 Preferred stock, shares outstanding (in shares) 1,952 1,952 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 100,000,000 100,000,000 Common stock, shares issued (in shares) 5,962,644 4,522,656 Common stock, shares outstanding (in shares) 5,704,219 4,444,097 Treasury stock, shares 258,425 78,559 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Â Â Â Â Research and development $ 2,773 $ 1,420 $ 5,536 $ 4,403 General and administrative 2,203 1,924 4,416 4,169 Total operating expenses 4,976 3,344 9,952 8,572 Loss from operations (3,697) (1,490) (6,996) (6,212) Other income (expense): Â Â Â Â Financing expense (3,545) Â (3,545) Â Change in fair value of warrants 4,694 Â 4,694 Â Warrant issuance costs (432) Â (432) Â Interest income 67 120 139 171 Interest expense (27) (112) (61) (246) Total other income (expense) 757 8 795 (75) Net loss $ (2,940) $ (1,482) $ (6,201) $ (6,287) Per share information: Â Â Â Â Net loss per share of common stock - basic $ (0.45) $ (0.59) $ (1.15) $ (2.60) Weighted average number of shares of common stock outstanding - basic 6,500,831 2,509,378 5,411,382 2,415,221 Net loss per share of common stock - diluted $ (0.71) $ (0.59) $ (1.45) $ (2.60) Weighted average number of shares of common stock outstanding - diluted 10,742,924 2,509,378 7,532,428 2,415,221 Grant [Member] Â Â Â Â Revenue $ 1,279 $ 1,854 $ 2,956 $ 2,360 X - DefinitionFinancing expense. + ReferencesNo definition available. + Details Name: pstv_FinancingExpense Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant issuance costs. + ReferencesNo definition available. + Details Name: pstv_WarrantIssuanceCosts Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic

270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($) $ in Thousands Total Series F Preferred Stock [Member] Convertible Preferred Stock [Member] Preferred Stock [Member] Preferred Stock [Member] Series F Preferred Stock [Member] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Series F Preferred Stock [Member] Accumulated Deficit [Member] Balance at Dec. 31, 2022 $ 6,445 Â Â Â Â $ 2 Â $ 473,628 Â $ (467,185) Balance (in shares) at Dec. 31, 2022 Â Â 1,952 Â Â 2,240,092 Â Â Â Â Stock-based compensation 140 Â Â Â Â Â Â 140 Â Â Sale and issuance of common stock, net 895 $ 1 Â Â Â Â Â 895 $ 1 Â Sale and issuance of common stock, net (in shares) Â Â Â Â 1 168,164 Â Â Â Â Net loss (4,805) Â Â Â Â Â Â Â Â (4,805) Balance at Mar. 31, 2023 2,676 Â Â Â Â $ 2 Â 474,664 Â (471,990) Balance (in shares) at Mar. 31, 2023 Â Â 1,952 1 Â 2,408,256 Â Â Â Â Balance at Dec. 31, 2022 6,445 Â Â Â Â $ 2 Â 473,628 Â (467,185) Balance (in shares) at Dec. 31, 2022 Â Â 1,952 Â Â 2,240,092 Â Â Â Â Net loss (6,287) Â Â Â Â Â Â Â Â Balance at Jun. 30, 2023 2,662 Â Â Â Â $ 3 Â 476,131 Â (473,472) Balance (in shares) at Jun. 30, 2023 Â Â 1,952 Â Â 2,879,620 Â Â Â Â Balance at Dec. 31, 2022 6,445 Â Â Â Â $ 2 Â 473,628 Â (467,185) Balance (in shares) at Dec. 31, 2022 Â Â 1,952 Â Â 2,240,092 Â Â Â Â Balance at Dec. 31, 2023 (1,348) Â Â Â Â $ 5 $ (126) 479,274 Â (480,501) Balance (in shares) at Dec. 31, 2023 Â Â 1,952 Â Â 4,522,656 (78,559) Â Â Â Balance at Mar. 31, 2023 2,676 Â Â Â Â $ 2 Â 474,664 Â (471,990) Balance (in shares) at Mar. 31, 2023 Â Â 1,952 1 Â 2,408,256 Â Â Â Â Redemption of Series F preferred stock (in shares) Â Â Â Â (1) Â Â Â Â Â Stock-based compensation 140 Â Â Â Â Â Â 140 Â Â Sale and issuance of common stock, net 1,328 Â Â Â Â $ 1 Â 1,327 Â Â Sale and issuance of common stock, net (in shares) Â Â Â Â Â 472,674 Â Â Â Â Fractional adjustment Â Â Â Â Â (1,310) Â Â Â Â Net loss (1,482) Â Â Â Â Â Â Â Â (1,482) Balance at Jun. 30, 2023 2,662 Â Â Â Â $ 3 Â 476,131 Â (473,472) Balance (in shares) at Jun. 30, 2023 Â Â 1,952 Â Â 2,879,620 Â Â Â Â Balance at Dec. 31, 2023 (1,348) Â Â Â Â $ 5 $ (126) 479,274 Â (480,501) Balance (in shares) at Dec. 31, 2023 Â Â 1,952 Â Â 4,522,656 (78,559) Â Â Â Stock-based compensation 146 Â Â Â Â Â Â 146 Â Â Purchase of treasury stock (374) Â Â Â Â Â $ (374) Â Â Â Purchase of treasury stock (in Shares) Â Â Â Â Â Â (179,866) Â Â Â Net loss (3,261) Â Â Â Â Â Â Â Â (3,261) Balance at Mar. 31, 2024 (4,837) Â Â Â Â $ 5 $ (500) 479,420 Â (483,762) Balance (in shares) at Mar. 31, 2024 Â Â 1,952 Â Â 4,522,656 (258,425) Â Â Â Balance at Dec. 31, 2023 (1,348) Â Â Â Â $ 5 $ (126) 479,274 Â (480,501) Balance (in shares) at Dec. 31, 2023 Â Â 1,952 Â Â 4,522,656 (78,559) Â Â Â Net loss (6,201) Â Â Â Â Â Â Â Â Balance at Jun. 30, 2024 (7,625) Â Â Â Â $ 6 $ (500) 479,571 Â (486,702) Balance (in shares) at Jun. 30, 2024 Â Â 1,952 Â Â 5,962,644 (258,425) Â Â Â Balance at Mar. 31, 2024 (4,837) Â Â Â Â $ 5 $ (500) 479,420 Â (483,762) Balance (in shares) at Mar. 31, 2024 Â Â 1,952 Â Â 4,522,656 (258,425) Â Â Â Stock-based compensation 151 Â Â Â Â Â Â 151 Â Â Sale and issuance of common stock, net 1 Â Â Â Â $ 1 Â Â Â Â Sale and issuance of common stock, net (in shares) Â Â Â Â Â 1,439,988 Â Â Â Â Net loss (2,940) Â Â Â Â Â Â Â Â (2,940) Balance at Jun. 30, 2024 $ (7,625) Â Â Â Â $ 6 $ (500) $ 479,571 Â $ (486,702) Balance (in shares) at Jun. 30, 2024 Â Â 1,952 Â Â 5,962,644 (258,425) Â Â Â X - DefinitionFractional adjustment of common stock. + ReferencesNo definition available. + Details Name: pstv_FractionalAdjustmentOfCommonStock Namespace Prefix: pstv_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Cash flows used in operating activities: Â Â Â Â Â Â Â Net loss $ (2,940) $ (3,261) $ (1,482) $ (4,805) $ (6,201) $ (6,287) Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Depreciation and amortization Â Â Â Â 325 318 Â Amortization of deferred financing costs and debt discount Â Â Â Â 20 119 Â Share-based compensation expense Â Â Â Â 297 280 Â Accretion of discount on short-term investments Â Â Â Â (23) Â Â Non-cash financing expense Â Â Â Â 3,545 Â Â Change in fair value of warrants (4,694) Â Â Â (4,694) Â Â Loss on disposal of property and equipment Â Â Â Â Â 2 Â Amortization of operating lease right-of-use assets Â Â Â Â 63 57 Â Increases (decreases) in cash caused by changes in operating assets and liabilities: Â Â Â Â Â Â Â Grant receivable Â Â Â Â Â 718 Â Other current assets Â Â Â Â 335 1,510 Â Accounts payable and accrued expenses Â Â Â Â 360 (3,589) Â Change in operating lease liabilities Â Â Â Â (63) (56) Â Deferred grant liability Â Â Â Â 373 (1,643) Â Net cash used in operating activities Â Â Â Â (5,663) (8,571) Â Cash flows used in investing activities: Â Â Â Â Â Â Â Purchases of property and equipment Â Â Â Â (121) (108) Â Purchase of short-term investments Â Â Â Â (3,500) Â Â Purchase of intangible assets Â Â Â Â (545) Â Â Net cash used in investing activities Â Â Â Â (4,166) (108) Â Cash flows provided by financing activities: Â Â Â Â Â Â Â Principal payments of term loan obligation Â Â Â Â (3,996) (804) Â Proceeds from credit facility Â Â Â Â 3,292 Â Â Purchase of treasury stock Â Â Â Â (374) Â Â Proceeds from sale of common stock, warrants and pre-funded warrants, net Â Â Â Â 7,265 2,258 Â Net cash provided by financing activities Â Â Â Â 6,187 1,454 Â Net decrease in cash and cash equivalents Â Â Â Â (3,642) (7,225) Â Cash and cash equivalents at beginning of period Â $ 8,554 Â $ 18,120 8,554 18,120 $ 18,120 Cash and cash equivalents at end of period $ 4,912 Â $ 10,895 Â 4,912 10,895 $ 8,554 Cash paid during period for: Â Â Â Â Â Â Â Interest Â Â Â Â 32 135 Â Supplemental schedule of non-cash investing and financing activities: Â Â Â Â Â Â Â Unpaid offering cost Â Â Â Â $ 375 $ 35 Â X - DefinitionCash paid during period for: + ReferencesNo definition available. + Details Name: pstv_CashPaidDuringPeriodForAbstract Namespace Prefix: pstv_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncrease (decrease) in deferred grant liability. + ReferencesNo definition available. + Details Name: pstv_IncreaseDecreaseInDeferredGrantLiability Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in grant receivable. + ReferencesNo definition available. + Details Name: pstv_IncreaseDecreaseInGrantReceivable Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash financing expense. + ReferencesNo definition available. + Details Name: pstv_NonCashFinancingExpense Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnpaid Offering Costs. + ReferencesNo definition available. + Details Name: pstv_UnpaidOfferingCosts Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X -

ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_PaymentsForRepurchaseOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data

Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and New Accounting Standards 6 Months Ended Jun. 30, 2024 Organization Consolidation And Presentation Of Financial Statements [Abstract] Â Basis of Presentation and New Accounting Standards 1. Basis of Presentation and New Accounting Standards The accompanying unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December 31, 2023 has been derived from the audited financial statements at December 31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. On May 17, 2024, Plus Therapeutics, Inc. (the â€œCompanyâ€) established a wholly owned subsidiary, CNSide Diagonistics, LLC (â€œCNSide LLCâ€), a Delaware limited liability company. CNSide LLC was set up to implement the Companyâ€™s business plan for developing the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, using the intellectual property of Biocept, Inc. (â€œBioceptâ€) acquired by the Company in April 2024 (Note 8).In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of the Company and its wholly owned subsidiary have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes therein included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 5, 2024.Â Amendments to Certificate of Incorporation and Reverse Stock SplitAt the Annual Meeting of Stockholders of the Company held on April 20, 2023 (the â€œ2023 Annual Meetingâ€), the stockholders of the Company approved an amendment to the Companyâ€™s Certificate of Incorporation, as amended (the â€œCharterâ€) to implement a reverse stock split of the Companyâ€™s then issued and outstanding common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the â€œBoardâ€) of the Company, within a range of not less than 1-for-3 and not greater than 1-for-15. Subsequently, on April 21, 2023, the Board determined to fix the ratio for the reverse stock split at 1-for-15, without any change to its par value (the â€œReverse Stock Splitâ€). On April 27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the â€œAmendmentâ€), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May 1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Companyâ€™s common stock (x) issued and outstanding decreased from approximately 37.4 million shares to approximately 2.5 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0 million shares to approximately 0.1 million shares, and (z) reserved but unallocated under the Companyâ€™s current equity incentive plans decreased from approximately 3.0 million shares of common stock to approximately 0.2 million shares of common stock. The Companyâ€™s common stock began trading on the Nasdaq Capital Market (â€œNasdaqâ€) on a post-split basis on May 1, 2023. The Companyâ€™s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Companyâ€™s outstanding stock options, warrants and equity incentive plans for the period ended March 31, 2023 as presented in the condensed consolidated financial statements in this quarterly report on Form 10-Q. The Companyâ€™s consolidated financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. Grant Revenue Recognition In applying the provisions of Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a â€œcustomerâ€, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (â€œASC 808â€). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No. 20 (â€œIAS 20â€), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract.The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.WarrantsWarrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement in accordance with applicable accounting guidance provided in ASC Topic 815 - Derivatives and Hedging. Equity-classified instruments are recorded in additional paid-in capital at issuance and are not subject to remeasurement. Liability-classified warrants are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.Segment Information Prior to the establishment of CNSide LLC, the Company operated its business in one operating and reportable segment, which includes all activities related to the research and development of the Companyâ€™s research programs. From inception of CNSide LLC through June 30, 2024, the Company commenced certain set up and compliance activities of CNSide LLC with immaterial financial statement impact. The Company expects CNSide LLC to initiate commercial operations starting in the fourth quarter of 2024 related to laboratory testing, and that CNSide LLC will become a separate operating segment starting in the quarter ending December 31, 2024. The Companyâ€™s chief operating decision-maker (â€œCODMâ€), the Chief Executive Officer, reviews the operating results including revenue and direct expenses of the Companyâ€™s operating segments for resource allocation and other management decisions. Available-for-Sale SecuritiesThe Companyâ€™s available-for-sale securities consist of U.S. government and agency securities. Securities with maturities from the date of purchase of less than three months are included in cash equivalents. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the condensed consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed consolidated statements of operations and comprehensive income/loss and as a separate component of stockholdersâ€™ equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Companyâ€™s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). There has been no allowance for expected credit losses recorded during any of the periods presented.Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed consolidated statements of operations and comprehensive income/loss. During the three and six months ended June 30, 2024, the unrealized gain on the Companyâ€™s available-for-sale securities was less than $1,000, and not presented separately in the condensed consolidated statement of operations. Recently Issued Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board (the â€œFASBâ€) issued Accounting Standards Update (ASU) No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Companyâ€™s consolidated financial statements and related disclosures.In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years starting after December 15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is currently evaluating the impact of the changes required by the new standard on the Companyâ€™s consolidated financial statements and related disclosures. X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Use of Estimates 6 Months Ended Jun. 30, 2024 Use Of Estimates [Abstract] Â Use of Estimates 2. Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Companyâ€™s most significant estimates and critical accounting policies involve reviewing assets for impairment and determining the assumptions used in measuring stock-based compensation expense and warrant liability. X - DefinitionUse of Estimates [Abstract] + ReferencesNo definition available. + Details Name: pstv_UseOfEstimatesAbstract Namespace Prefix: pstv_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProvides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates. + ReferencesNo definition available. + Details Name: pstv_UseOfEstimatesTextBlock Namespace Prefix: pstv_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liquidity and Going Concern 6 Months Ended Jun. 30, 2024 Liquidity [Abstract] Â Liquidity and Going Concern 3. Liquidity and Going ConcernThe Company incurred a net loss of $6.2 million for the six months ended June 30, 2024. The Company had an accumulated deficit of $486.7 million as of June 30, 2024. Additionally, the Company used net cash of $5.7 million to fund its operating activities for the six months ended June 30, 2024. To date, the Companyâ€™s operating losses have been funded primarily from outside sources of invested capital from issuance of its common and preferred stocks, proceeds from its term loan, line of credit facility and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources to fund its future clinical development programs and other operations. There can be no assurance that the Company will be able to continue to raise additional capital in the future. The Companyâ€™s inability to raise additional cash would have a material and adverse impact on its operations and could cause the Company to default on its term loan. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern.At the closing of the May 2024 Private Placement, the Company received aggregate upfront gross proceeds of approximately $7.3 million, before deducting fees and other expenses associated with the closing of the May 2024 Private Placement. None of the Warrants issued in the May 2024 Private Placement have been exercised as of the filing of this quarterly report on Form 10-Q. See Note 12 to the unaudited condensed consolidated financial statements, Stockholders' Deficit - May 2024 Private Placement, for further information regarding the May 2024 Private Placement.Nasdaq Listing Compliance On March 8, 2024, the Company received a letter (the â€œNoticeâ€) from the Listing Qualifications staff of Nasdaq, notifying the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholdersâ€™ equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the â€œAlternative Standardsâ€). The Notice stated that as of March 8, 2024, the Company did not meet the Alternative Standards.On April 22, 2024, the Company provided Nasdaq with its plan to achieve and sustain compliance with the stockholdersâ€™ equity requirement and requested that Nasdaq grant the Company an extension of time until September 4, 2024, to provide evidence of compliance with the stockholdersâ€™ equity requirement. Nasdaq has not yet responded to the Companyâ€™s plan, and there can be no assurance that Nasdaq will grant an extension or that the Company will be able to comply with the applicable listing standards of Nasdaq. The Company continues to seek additional capital from financing alternatives and other sources in order to ensure adequate funding is available to allow the Company to continue research and product development and other operating activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. Should the Company fail to raise additional cash from outside sources, it would have a material adverse impact on its operations.The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. X - DefinitionDisclosure of liquidity and going concern text block + ReferencesNo definition available. + Details Name: pstv_DisclosureOfLiquidityAndGoingConcernTextBlock Namespace Prefix: pstv_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLiquidity Abstract + ReferencesNo definition available. + Details Name: pstv_LiquidityAbstract Namespace Prefix: pstv_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 4. Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below:â€¢Level 1: Quoted prices in active markets for identical assets or liabilities.Â â€¢Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.Â â€¢Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets.Â Â Money market funds are valued at the closing price reported by the fund sponsor from an actively traded exchange. Money market funds and U.S. Treasury bills were included in cash equivalents in the consolidated balance sheets for the periods presented. The Company obtains the fair value of its Level 2 cash equivalents from third-party pricing services. The pricing services utilize industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. The following table summarizes the Companyâ€™s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, respectively (in thousands). Â Â Fair Value Measurements Using Â June 30, 2024 Fair Value Â Level 1 Â Level 2 Â Level 3 Â Money market $ 2,415 Â $ 2,415 Â $ â€” Â $ â€” Â Treasury bills and government agency bonds Â 3,523 Â Â â€” Â Â 3,523 Â Â â€” Â Â $ 5,938 Â $ 2,415 Â $ 3,523 Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Fair Value Measurements Using Â December 31, 2023 Fair Value Â Level 1 Â Level 2 Â Level 3 Â Money market $ 5,449 Â $ 5,449 Â $ â€” Â $ â€” Â Â During the six months ended June 30, 2024, the Company issued common stock warrants which are classified as liabilities under authoritative accounting standards (Note 12). Those common stock warrants are valued using the Black Scholes model, with level 3 inputs such as expected volatility, risk-free interest rate, and expected term that are not observable in active markets. Â The table below summarizes key inputs used in the valuation of the liability classified warrants as of the issuance date and as of June 30, 2024: Â Â Â As of issuance date Â As of June 30, 2024 Â Expected term Â 1.1 - 5.0Â years Â 1.0Â to 4.8Â years Â Common stock market price Â $2.01Â - $2.27 Â $ 1.47 Â Risk-free interest rate Â 4.5% - 5.1% Â 4.3% - 5.1% Â Expected volatility Â 117.0% - 127.2% Â 105.6% - 121.0% Â Â The table below provides a summary of the fair value of the Company's warrant

liability during the six months ended June 30, 2024 (in thousands). As of June 30, 2023, the fair value of liability classified warrants was immaterial, and the change in the fair value of liability classified warrants during the three and six months ended June 30, 2023 was immaterial. Â Â Six Months Ended June 30, Â Warrant liability Â 2024 Â Beginning balance Â $ â€” Â Issuance of warrants Â Â 10,854 Â Change in fair value of warrants Â Â (4,694) Ending balance Â $ 6,160 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Term Loan Obligations 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Term Loan Obligations 5. Term Loan ObligationsÂ On May 29, 2015, the Company entered into the Loan and Security Agreement (the â€œLoan and Security Agreementâ€), pursuant to which Oxford Finance, LLC (â€œOxfordâ€) funded an aggregate principal amount of $17.7 million (the â€œTerm Loanâ€), subject to the terms and conditions set forth in the Loan and Security Agreement. Pursuant to the Loan and Security Agreement, as amended, the Company made interest only payments through May 1, 2021, and thereafter was required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2024, the maturity date. On June 3, 2024, the Company paid off the Term Loan by making a final payment in an aggregate amount equal to approximately $3.3 million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Term Loan terminated Oxfordâ€™s security interest in the Companyâ€™s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Term Loan. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Line of Credit Facility 6 Months Ended Jun. 30, 2024 Line of Credit Facility [Abstract] Â Line of Credit Facility 6. Line of Credit FacilityOn May 31, 2024, the Company drew down $3.3 million on its new margin loan facility under a line of credit (the â€œPershing Credit Facilityâ€) with Pershing LLC (â€œPershingâ€), an affiliate of The Bank of New York Mellon Corporation. The available credit line limit under the Pershing Credit Facility fluctuates based on the Companyâ€™s request for extensions from time to time, subject to the value of the collateralized marketable securities the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed 91.5% of the value of the collateralized marketable securities deposited with Pershing. Depending on the value of the marketable securities the Company holds with Pershing, Pershing may require the Company from time-to-time to deposit additional funds or marketable securities in order to restore the level of collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. Volatility in the global markets could cause the interest rate to fluctuate from time to time increasing the Companyâ€™s costs, or could cause Pershing to terminate the Companyâ€™s ability to borrow funds. In addition, borrowings under the Pershing Credit Facility have the effect of limiting the Companyâ€™s use of cash and marketable securities. X - ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for short-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_ShortTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Biocept Asset Acquisitions 6 Months Ended Jun. 30, 2024 Asset Acquisition [Abstract] Â Biocept Asset Acquisitions 8. Biocept Asset Acquisitions Â On April 26, 2024, the Company acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in CNSide intellectual property (â€œCNSide IPâ€), including (i) intellectual property, (ii) inventory and raw materials, and (iii) data, information, results and reports pertaining to the completed and on-going clinical studies involving the use of the CNSide IP (including, but not limited to, the FOERSEE clinical study that was being conducted by Biocept), related to the development, making, selling, and exporting or importing of the CNSideTM (as defined below), after having its bid accepted by the United States Bankruptcy Court for the District of Delaware. The Company concluded that the acquisition of Biocept assets was not a business combination, as Biocept did not meet the definition of a business in ASC 805, Business Combination. The Company accounted for the asset purchase transaction under the authoritative guidance for asset acquisitions, and allocated the costs of acquisitions of approximately $45,000 among the assets acquired based on the relative fair value of such assets, which is predominately concentrated in the intellectual property acquired including patents and trademarks. The intangible assets acquired from Biocept are capitalized and amortized over a useful life of four years. X - ReferencesNo definition available. + Details Name: us-gaap_AssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss per Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Loss per Share 7. Loss per ShareBasic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented.The Company considers Series A Warrants and Series B Warrants issued in connection with the private placement completed in May 2024 (Note 12) to be participating securities because holders of such instruments participate in the event a dividend is paid on common stock. The holders of the Series A Warrants and Series B Warrants do not have a contractual obligation to share in the Company's losses. As such, losses are attributed entirely to common stockholders and for periods in which the Company has reported a net loss. As of June 30, 2024, 2,151,544 Pre-Funded Warrants to purchase common stock, issued in connection with the May 2024 Private Placement (Note 12), were included in the basic and diluted net loss per share calculation.The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated, in thousands except share and per share data:Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and diluted net loss per common share calculation: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (2,940) Â $ (1,482) Â $ (6,201) Â $ (6,287) Change in fair value of warrants Â Â (4,694) Â Â â€” Â Â Â (4,694) Â Â â€” Â Net loss attributable to common stockholders - diluted Â $ (7,634) Â $ (1,482) Â $ (10,895) Â $ (6,287) Weighted average common shares outstanding - basic Â Â 6,500,831 Â Â Â Â 2,509,378 Â Â Â 5,411,382 Â Â Â Â 2,415,221 Â Net loss per share of common stock - basic Â $ (0.45) Â $ (0.59) Â $ (1.15) Â $ (2.60) Weighted average common shares outstanding - diluted Â Â 10,742,924 Â Â Â Â 2,509,378 Â Â Â Â 7,532,428 Â Â Â Â 2,415,221 Â Net loss per share of common stock - diluted Â $ (0.71) Â $ (0.59) Â $ (1.45) Â $ (2.60) Â The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: Â Â As of June 30, Â Â 2024 Â Â 2023 Â Outstanding stock options Â Â 336,928 Â Â Â Â 128,582 Â Preferred stock Â Â 28,190 Â Â Â Â 28,190 Â Outstanding warrants Â Â 142,733 Â Â Â Â 142,733 Â Total Â Â 507,851 Â Â Â Â 299,505 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Grant Revenue 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Grant Revenue 9. Grant Revenue On September 19, 2022, the Company entered into that certain Cancer Research Grant Contract (the â€œCPRIT Contractâ€), effective as of August 31, 2022, with the Cancer Prevention and Research Institute of Texas (â€œCPRITâ€), pursuant to which CPRIT provides the Company with a CPRIT grant (â€œCPRIT Grantâ€) over a three-year period to fund the continued development of rhenium (186Re) obisbemeda for the treatment of patients with leptomeningeal metastases (â€œLMâ€). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a) the mutual written consent of all parties to the CPRIT Contract, (b) CPRIT for an event of default by the Company, (c) CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d) the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds.The Company retains ownership over any intellectual property developed under the CPRIT Contract (each, a â€œProject Resultâ€). With respect to non-commercial use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.The Company recognized $1.3 million and $1.9 million, and $3.0 million and $2.4 million in grant revenue from the CPRIT Contract during the three and six months ended June 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments And Contingencies Disclosure [Abstract] Â Commitments and Contingencies 10. Commitments and ContingenciesLeasesThe Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement and certain office space in Charlottesville, Virginia (the â€œCharlottesville Leaseâ€). The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods. On March 31, 2023, Company believed that it was reasonably certain that the Charlottesville Lease will be renewed through March 31, 2026, and as a result, it remeasured the related lease liability as of March 31, 2023 to be $80,000 using the then-in-effect discount rate of 12.76%. Effective July 1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding right-of-use asset of $19,000, as a discount rate of 13.47%. Â Other commitments and contingenciesThe Company has entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of June 30, 2024, the Company did not have any clinical research study obligations. Â Legal proceedings From time to time, the Company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Agreements 6 Months Ended Jun. 30, 2024 License Agreement [Abstract] Â License Agreements 11. License AgreementsÂ Biocept License AgreementOn September 7, 2023, the Company entered into a Non-Exclusive License and Services Agreement with Biocept, pursuant to which Biocept granted the Company a non-exclusive license to use the Biocept proprietary cell enumeration test, CNSideTM (â€œCNSideTMâ€). In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. On October 16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. See Note 8 for further information regarding the Companyâ€™s acquisition of substantially all right, title and interest in the CNSide IP. University of Texas Health Science Center at San Antonio (â€œUTHSCSAâ€) License Agreement On December 31, 2021, the Company entered into a Patent and Know-How License Agreement with UTHSCSA, pursuant to which UTHSCSA granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of biodegradable alginate microspheres (â€œBAMâ€) containing nanoliposomes loaded with imaging and/or therapeutic payloads.NanoTx License Agreement On March 29, 2020, the Company and NanoTx, Corp. (â€œNanoTxâ€) entered into a Patent and Know-How License Agreement, pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes.Â The transaction terms included an upfront payment of $0.4 million in cash and $0.3 million in the Companyâ€™s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any non-dilutive monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from CPRIT. As of June 30, 2024, the Company accrued $0.5 million of payments due to NanoTx as a result of the CPRIT grant received (see Note 9, Grant Revenue of the condensed consolidated financial statements for additional information). X - DefinitionLicense agreement abstract. + ReferencesNo definition available. + Details Name: pstv_LicenseAgreementAbstract Namespace Prefix: pstv_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for license agreement. + ReferencesNo definition available. + Details Name: pstv_LicenseAgreementDisclosureTextBlock Namespace Prefix: pstv_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Deficit 6 Months Ended Jun. 30, 2024 Stockholders Equity Note [Abstract] Â Stockholders' Deficit 12. Stockholders' DeficitPreferred StockThe Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Companyâ€™s Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. Series F Preferred Stock On March 3, 2023, the Company filed a certificate of designation (the â€œCertificate of Designationâ€) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1) share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock would have 50,000,000 votes per share of Series F Preferred Stock and would vote together with the Companyâ€™s common stock, as a single class exclusively with respect to any proposal to amend the Companyâ€™s Charter to effect the Reverse Stock Split. On March 3, 2023, the Company entered into a subscription and investment representation agreement with Richard J. Hawkins, chairman of the board of the Company, who is an accredited investor (the â€œSeries F Preferred Stock Purchaserâ€), pursuant to which the Company agreed to issue and sell one (1) share of the Companyâ€™s Series F Preferred Stock, par value $0.001 per share, to the Series F Preferred Stock Purchaser for $1,000 in cash. The sale closed on March 3, 2023. The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Companyâ€™s stockholders of the Reverse Stock Split in April 2023. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash.Â Series B and C Preferred Stock As of June 30, 2024, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. Warrants The Company issued pre-funded warrants and warrants to purchase its common stock in connection with the May 2024 Private Placement. See the section below on Common Stock for additional details. On September 25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with pre-funded warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright & Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock with a term of five years from the issuance date, in the form of Series U Warrants (the â€œRepresentative Warrantsâ€). As of June 30, 2024, there were 142,733 outstanding Series U Warrants and Representative Warrants which can be exercised into an aggregate of 142,733 shares of common stock at a weighted average exercise price of $34.10 per share. Â Common StockÂ May 2024 Private Placement Â On May 5, 2024, the Company entered into a securities purchase agreement (the â€œSecurities Purchase Agreementâ€) with certain investors, including certain of the Companyâ€™s directors and executive officers (â€œCompany Insidersâ€) (collectively, the â€œPurchasersâ€), for the sale and issuance by the Company of its securities (the â€œInitial Subscriptionâ€). On May 8, 2024, the Company entered into a first amendment to the Securities Purchase Agreement (the â€œAmendmentâ€) for the sale and issuance by the Company of additional securities to two of the Purchasers (the â€œAdditional Subscriptionâ€, and together with the Initial Subscription, the â€œMay 2024 Private Placementâ€). The Securities Purchase Agreement provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares (the â€œPrivate Placement Sharesâ€) of the Companyâ€™s common stock or, at the election of each Purchaser, pre-funded warrants (the â€œPre-Funded Warrantsâ€), exercisable immediately at an exercise price of $0.001 per share, with each Private Placement Share or Pre-Funded Warrant accompanied by (i) a Series A common warrant (â€œSeries A Warrantsâ€) to purchase one share of common stock (the â€œSeries A Warrant Sharesâ€), for an aggregate of 3,591,532 Series A Warrants, and (ii) one Series B common warrant (â€œSeries B Warrantsâ€) to purchase one share of common stock (the â€œSeries B Warrant Shares,â€ and together with the Series A Warrant Shares, the â€œCommon Warrant Sharesâ€), for an aggregate of 3,591,532 Series B Warrants. The combined purchase price for each Private Placement Share and Pre-Funded Warrant from the Initial Subscription was $2.022, and $2.158 from the Additional Subscription, in each case together with one accompanying Series A Warrant and one accompanying Series B Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Warrant and Series B Warrant. Â The exercise price of Series A Warrants and Series B Warrants from the Initial Subscription is $1.772 per share and $1.908 per share in the Additional Subscription, provided that the exercise price for the Series A Warrants and Series B Warrants issued to the Company Insiders is $1.79 per share. Subject to certain ownership limitations, the Series A Warrants will be exercisable until the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Warrants will be exercisable until June 24, 2025. The Pre-Funded Warrant will not expire until exercised in full.Â If a holder of a Series A Warrant or a Series B Warrant is unable to exercise the warrant due to the limitation contained in the warrant that restricts the holder from owning above a specified beneficial ownership level (generally 4.99% or 9.99%) as the result of exercise of the warrant, then the holder may elect upon exercise of the warrant to receive a pre-funded warrant for the same number of shares of common stock that would otherwise have been received upon exercise of the warrant. Â In addition, the Series A Warrants and Series B Warrants provided for a call right starting June 24, 2025 in favor of the Company, if the volume-weighted average price of the common stock exceeds specified prices. Â The May 2024 Private Offering closed on May 9, 2024 (the â€œMay 2024 Private Placement Closingâ€). The Company issued 2,151,544 Pre-Funded Warrants, 3,591,532 Series A Warrants and 3,591,532 Series B Warrants to purchase its common stock in connection with the May 2024 Private Placement. The aggregate gross proceeds from the May 2024 Private Placement Closing were approximately $7.3 million, before deducting $0.4 million of offering expenses. Â The Company reviewed the terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants under the authoritative accounting guidance. Â As described above, the Series A Warrants and Series B Warrants are classified as liabilities for the reason that they can be exercised into either common stock or Pre-Funded Warrants at the holder's option and thus fail the indexation guidance under ASC 815, Derivatives and Hedging. The Series A Warrant and Series B Warrant liability were recorded at fair value as of the issuance date and June 30, 2024, and under the terms of the Series A Warrants and Series B Warrants when issued that liability was subject to adjustment to estimated fair value at each balance sheet date until the warrants were settled. Refer to Note 14 for additional information regarding the amendment and restatement of the Series A Warrants and Series B Warrants that eliminated the ability of the Series A Warrants and Series B Warrants to be exercised into the Pre-Funded Warrants.Â The Pre-Funded Warrants are equity classified because they (1) are freestanding financial instruments that are legally detachable and separately exercisable from the common stock, (2) are immediately exercisable, (3) do not embody an obligation for the Company to repurchase its shares, (4) permit the holder to receive a fixed number of shares of common stock upon exercise, (5) are indexed to the Company's common stock and (6) meet the equity classification criteria.Â The proceeds from the May 2024 Private Placement must first be allocated to the full fair value of the Series A Warrants and Series B Warrants due to the liability classification. As disclosed in Note 4, the fair value of the Series A Warrants and Series B Warrants at issuance was $10.9 million. Under authoritative guidance, if the fair value of a warrant liability exceeds the proceeds received in an armâ€™s length transaction with no rights or privileges that require separate accounting recognition as an asset identified, then the warrant liability is recorded at fair value with the excess of fair value over proceeds recognized as a loss in earnings. The Company recognized approximately $3.5 million in financing expense in the condensed consolidated statement of operations during the three and six months ended June 30, 2024, which represents the excess of the fair value of the Series A Warrants and Series B Warrants at issuance over the proceeds. During the three and six months ended June 30, 2024, the Company recognized a fair value gain on warrant liability of $4.7 million. Proceeds from the May 2024 Private Placement are shown as cash from financing transactions and the gain on warrant liability is included as an adjustment to reconcile the net loss to net cash used in operating activities in the statements of cash flows for the six months ended June 30, 2024. In addition, total offering expenses related to the May 2024 Private Placement of $0.4 million were recorded as a component of other expenses as the entire proceeds were allocated to the warrant liability, which can be settled with either the Companyâ€™s common stock or Pre-Funded Warrants, which are exercisable into the Companyâ€™s common stock at any time at the holdersâ€™ option, but not in cash payment to the holders.Â All of the Pre-Funded Warrants, Series A Warrants, and Series B Warrants issued in connection with the May 2024 Private Placement remained outstanding as of June 30, 2024. Â Lincoln Park Purchase Agreement On August 2, 2022, the Company entered into a purchase agreement (the â€œ2022 Purchase Agreementâ€) and registration rights agreement pursuant to which Lincoln Park Capital Fund (â€œLincoln Parkâ€) committed to purchase up to $50.0 million of the Companyâ€™s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million of the Companyâ€™s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Companyâ€™s sole discretion, over the 36-month period commencing on August 17, 2022, subject to the satisfaction of certain conditions. On May 16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5 million shares of the Companyâ€™s common stock (including the issuance of more than 19.99% of the Companyâ€™s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement.Upon execution of the 2022 Purchase Agreement, the Company paid $0.1 million in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Companyâ€™s common stock at its direction under the 2022 Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash or shares of its common stock, or a combination of cash and shares of its common stock, upon receipt of $25.0 million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. On August 17, 2022, a registration statement (the â€œFirst Registration Statementâ€) was declared effective to cover the resale of up to 633,333 shares of the Companyâ€™s common stock comprised of (i) the 32,846 initial commitment shares, and (ii) up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. On August 18, 2023, a second registration statement (the â€œSecond Registration Statementâ€) was declared effective to cover the resale of up to an additional 1,500,000 shares of the Companyâ€™s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. The Company sold 150,000 shares under the Second Registration Statement. The Company cannot sell

more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park.During the period from August 17, 2022 to December 31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2 million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0 million from January 1, 2023 to December 31, 2023. The Company did not issue any common stock under the 2022 Purchase Agreement during the six months ended June 30, 2024. Share Repurchase Program and Treasury Stock On October 31, 2023, the Company announced that its Board has approved a share repurchase program (the â€œShare Repurchase Programâ€), with authorization to repurchase up to $500,000 of the outstanding shares of the Companyâ€™s common stock. The Company funded repurchases under the Share Repurchase Program with available cash. During the year ended December 31, 2023, the Company purchased 78,559 of its common stock for approximately $0.1 million as treasury stock. The Company purchased 179,866 of its common shares for approximately $0.4 million as treasury stock during the six months ended June 30, 2024. As of June 30, 2024, no amount remained authorized for repurchase. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation 6 Months Ended Jun. 30, 2024 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Â Stock-based Compensation 13. Stock-based CompensationÂ Under the Companyâ€™s 2015 New Employee Incentive Plan, as amended (the â€œ2015 Planâ€), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company. On June 6, 2024, the Companyâ€™s Board increased the number of shares for future issuances under the 2015 Plan by 75,000 shares of common stock. As of June 30, 2024, there were 62,908 shares of common stock remaining and available for future issuances under the 2015 Plan. Â The Companyâ€™s 2020 Stock Incentive Plan, as amended (the â€œ2020 Planâ€), which replaced the Companyâ€™s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan provides for the issuance of up to 236,667 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Companyâ€™s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of June 30, 2024, there were 1,899 shares remaining and available for future issuances under the 2020 Plan. Â Generally, options issued under the 2020 Plan are subject to a two-year or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. Â A summary of activity for the six months ended June 30, 2024 is as follows:Â Â Â Â Options Â Â Â Weighted AverageÂ Exercise Price Â Â Â WeightedAverageRemainingContractualTerm (years) Â Â Â AggregateIntrinsic Value Â Balance as of December 31, 2023 Â Â 140,109 Â Â $ 37.48 Â Â Â 8.07 Â Â Â Â Â Granted Â Â 196,824 Â Â $ 2.09 Â Â Â Â Â Â Â Â Cancelled/expired Â Â (5) Â $ 271,125 Â Â Â Â Â Â Â Â Balance as of June 30, 2024 Â Â 336,928 Â Â $ 12.78 Â Â Â 8.81 Â Â $ 3,000 Â Vested and expected to vest at June 30, 2024 Â Â 310,675 Â Â $ 13.52 Â Â Â 8.75 Â Â $ 3,000 Â Exercisable at June 30, 2024 Â Â 103,834 Â Â $ 32.39 Â Â Â 7.45 Â Â $ â€” Â Â As of June 30, 2024, the total compensation cost related to non-vested stock options not yet recognized for all the Companyâ€™s plans is approximately $0.7 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.3 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 6 Months Ended Jun. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events Â Amendment and Restatement of Series A Warrants and Series B WarrantsÂ On August 9, 2024, the Company amended and restated the Series A Warrants and Series B Warrants (the â€œAmendment and Restatementsâ€) issued in the May 2024 Private Placement. As described in Note 12 above, when originally issued, if a holder of a Series A Warrant or a Series B Warrant was unable to exercise the warrant due to the limitation contained in the Series A Warrants and Series B Warrants that restricted the holder from owning above a specified beneficial ownership level (generally 4.99% or 9.99%) as the result of exercise of the Series A Warrants and Series B Warrants, then the Series A Warrants and Series B Warrants holder could elect upon exercise of the Series A Warrants and Series B Warrants to receive a pre-funded warrant for the same number of shares of common stock that would otherwise have been received upon exercise of the Series A Warrants and Series B Warrants. The Series A Warrants and Series B Warrants Amendment and Restatements eliminated the ability of the holder to elect to purchase pre-funded warrants in lieu of the Series A Warrants and Series B Warrants. In addition, the Amendment and Restatements eliminated the Companyâ€™s call right under the terms of the Series A Warrants to call the Series A Warrants after June 24, 2025, if the volume-weighted average price of the common stock exceeded specified prices. There were no other changes in the terms of the Series A Warrants and Series B Warrants. Â As a result of the Amendment and Restatements, the Series A Warrants and Series B Warrants, as amended, will no longer fail the indexation guidance under ASC 815, Derivatives and Hedging, and the balance of the warrant liability at the amendment date will be reclassified to equity. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and New Accounting Standards (Policies) 6 Months Ended Jun. 30, 2024 Organization Consolidation And Presentation Of Financial Statements [Abstract] Â Basis of Presentation and New Accounting Standards The accompanying unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December 31, 2023 has been derived from the audited financial statements at December 31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. On May 17, 2024, Plus Therapeutics, Inc. (the â€œCompanyâ€) established a wholly owned subsidiary, CNSide Diagonistics, LLC (â€œCNSide LLCâ€), a Delaware limited liability company. CNSide LLC was set up to implement the Companyâ€™s business plan for developing the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, using the intellectual property of Biocept, Inc. (â€œBioceptâ€) acquired by the Company in April 2024 (Note 8).In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of the Company and its wholly owned subsidiary have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes therein included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 5, 2024. Grant Revenue Recognition Grant Revenue Recognition In applying the provisions of Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a â€œcustomerâ€, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (â€œASC 808â€). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No. 20 (â€œIAS 20â€), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract.The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. Warrants WarrantsWarrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement in accordance with applicable accounting guidance provided in ASC Topic 815 - Derivatives and Hedging. Equity-classified instruments are recorded in additional paid-in capital at issuance and are not subject to remeasurement. Liability-classified warrants are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants. Segment Information Segment Information Prior to the establishment of CNSide LLC, the Company operated its business in one operating and reportable segment, which includes all activities related to the research and development of the Companyâ€™s research programs. From inception of CNSide LLC through June 30, 2024, the Company commenced certain set up and compliance activities of CNSide LLC with immaterial financial statement impact. The Company expects CNSide LLC to initiate commercial operations starting in the fourth quarter of 2024 related to laboratory testing, and that CNSide LLC will become a separate operating segment starting in the quarter ending December 31, 2024. The Companyâ€™s chief operating decision-maker (â€œCODMâ€), the Chief Executive Officer, reviews the operating results including revenue and direct expenses of the Companyâ€™s operating segments for resource allocation and other management decisions. Available-for-Sale Securities Available-for-Sale SecuritiesThe Companyâ€™s available-for-sale securities consist of U.S. government and agency securities. Securities with maturities from the date of purchase of less than three months are included in cash equivalents. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the condensed consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed consolidated statements of operations and comprehensive income/loss and as a separate component of stockholdersâ€™ equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Companyâ€™s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). There has been no allowance for expected credit losses recorded during any of the periods presented.Any premium arising at purchase is amortized to the earliest call date

and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed consolidated statements of operations and comprehensive income/loss. During the three and six months ended June 30, 2024, the unrealized gain on the Companyâ€™s available-for-sale securities was less than $1,000, and not presented separately in the condensed consolidated statement of operations. Recently Issued Accounting Pronouncements Recently Issued Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board (the â€œFASBâ€) issued Accounting Standards Update (ASU) No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Companyâ€™s consolidated financial statements and related disclosures.In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years starting after December 15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is currently evaluating the impact of the changes required by the new standard on the Companyâ€™s consolidated financial statements and related disclosures. Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Companyâ€™s most significant estimates and critical accounting policies involve reviewing assets for impairment and determining the assumptions used in measuring stock-based compensation expense and warrant liability. X - DefinitionWarrants Policy. + ReferencesNo definition available. + Details Name: pstv_WarrantsPolicyPolicyTextBlock Namespace Prefix: pstv_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-9 + Details Name: us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Financial Assets Measured at Fair Value on Recurring Basis The following table summarizes the Companyâ€™s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, respectively (in thousands). Â Â Fair Value Measurements Using Â June 30, 2024 Fair Value Â Level 1 Â Level 2 Â Level 3 Â Money market $ 2,415 Â $ 2,415 Â $ â€” Â $ â€” Â Treasury bills and government agency bonds Â 3,523 Â Â â€” Â Â 3,523 Â Â â€” Â Â $ 5,938 Â $ 2,415 Â $ 3,523 Â $ â€” Â Â Â Â Â Â Â Â Â Â Fair Value Measurements Using Â December 31, 2023 Fair Value Â Level 1 Â Level 2 Â Level 3 Â Money market $ 5,449 Â $ 5,449 Â $ â€” Â $ â€” Â Summary of Key Inputs Used in Valuation of Liability Classified Warrants The table below summarizes key inputs used in the valuation of the liability classified warrants as of the issuance date and as of June 30, 2024: Â Â Â As of issuance date Â As of June 30, 2024 Â Expected term Â 1.1 - 5.0Â years Â 1.0Â to 4.8Â years Â Common stock market price Â $2.01Â - $2.27 Â $ 1.47 Â Risk-free interest rate Â 4.5% - 5.1% Â 4.3% - 5.1% Â Expected volatility Â 117.0% - 127.2% Â 105.6% - 121.0% Â Schedule of Changes in Fair Value of Warrant Liabilities The table below provides a summary of the fair value of the Company's warrant liability during the six months ended June 30, 2024 (in thousands). As of June 30, 2023, the fair value of liability classified warrants was immaterial, and the change in the fair value of liability classified warrants during the three and six months ended June 30, 2023 was immaterial. Â Â Six Months Ended June 30, Â Warrant liability Â 2024 Â Beginning balance Â $ â€” Â Issuance of warrants Â Â 10,854 Â Change in fair value of warrants Â Â (4,694) Ending balance Â $ 6,160 Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss per Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Computation of Basic and Diluted Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated, in thousands except share and per share data:Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and diluted net loss per common share calculation: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (2,940) Â $ (1,482) Â $ (6,201) Â $ (6,287) Change in fair value of warrants Â Â (4,694) Â Â â€” Â Â (4,694) Â Â â€” Â Net loss attributable to common stockholders - diluted Â $ (7,634) Â $ (1,482) Â $ (10,895) Â $ (6,287) Weighted average common shares outstanding - basic Â Â 6,500,831 Â Â Â 2,509,378 Â Â Â 5,411,382 Â Â Â 2,415,221 Â Net loss per share of common stock - basic Â $ (0.45) Â $ (0.59) Â $ (1.15) Â $ (2.60) Weighted average common shares outstanding - diluted Â Â 10,742,924 Â Â Â 2,509,378 Â Â Â 7,532,428 Â Â Â 2,415,221 Â Net loss per share of common stock - diluted Â $ (0.71) Â $ (0.59) Â $ (1.45) Â $ (2.60) Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: Â Â As of June 30, Â Â 2024 Â Â 2023 Â Outstanding stock options Â Â 336,928 Â Â Â 128,582 Â Preferred stock Â Â 28,190 Â Â Â 28,190 Â Outstanding warrants Â Â 142,733 Â Â Â 142,733 Â Total Â Â 507,851 Â Â Â 299,505 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and

diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Â Stock Option Activity A summary of activity for the six months ended June 30, 2024 is as follows:Â Â Â Options Â Â Weighted AverageÂ Exercise Price Â Â WeightedAverageRemainingContractualTerm (years) Â Â AggregateIntrinsic Value Â Balance as of December 31, 2023 Â Â 140,109 Â Â $ 37.48 Â Â Â 8.07 Â Â Â Â Granted Â Â 196,824 Â Â $ 2.09 Â Â Â Â Â Â Â Â Cancelled/expired Â Â (5) Â $ 271,125 Â Â Â Â Â Â Â Â Balance as of June 30, 2024 Â Â 336,928 Â Â $ 12.78 Â Â Â 8.81 Â Â $ 3,000 Â Vested and expected to vest at June 30, 2024 Â Â 310,675 Â Â $ 13.52 Â Â Â 8.75 Â Â $ 3,000 Â Exercisable at June 30, 2024 Â Â 103,834 Â Â $ 32.39 Â Â Â 7.45 Â Â $ â€” Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Basis of Presentation and New Accounting Standards - Additional Information (Details) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Apr. 27, 2023 Apr. 21, 2023 Apr. 20, 2023 $ / shares Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2024 USD ($) Segment $ / shares shares Dec. 31, 2023 $ / shares shares May 01, 2023 shares Apr. 30, 2023 shares New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Common stock, par value (in dollars per share) | $ / shares Â Â $ 0.001 $ 0.001 $ 0.001 $ 0.001 Â Â Stock split conversion ratio Â 0.06 Â Â Â Â Â Â Reverse stock split effective date May 01, 2023 Â Â Â Â Â Â Â Common stock, shares issued (in shares) Â Â Â 5,962,644 5,962,644 4,522,656 2,500,000 37,400,000 Common stock, shares outstanding (in shares) Â Â Â 5,704,219 5,704,219 4,444,097 2,500,000 37,400,000 Preserved stock, shares authorized (in shares) Â Â Â 5,000,000 5,000,000 5,000,000 Â Â Common stock, reverse stock split, fractional shares issued Â Â Â Â 0 Â Â Â Stock issued during period reverse stock splits, shares Â Â Â Â 1,310 Â Â Â Number of operating segment | Segment Â Â Â Â 1 Â Â Â Number of reportable segment | Segment Â Â Â Â 1 Â Â Â Equity Incentive Plans [Member] Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Common stock capital shares reserved for future issuance Â Â Â Â Â Â Â 200,000 3,000,000 Outstanding Warrants and Options [Member] Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Common stock capital shares reserved for future issuance Â Â Â Â Â Â 100,000 2,000,000 Minimum [Member] Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Stock split conversion ratio Â Â 0.33 Â Â Â Â Â Â Maximum [Member] Â Â Â Â Â Â Â Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Stock split conversion ratio Â Â 0.06 Â Â Â Â Â Â Unrealized gain on available-for-sale securities | $ Â Â Â $ 1,000 $ 1,000 Â Â Â X - DefinitionReverse stock split effective date. + ReferencesNo definition available. + Details Name: pstv_ReverseStockSplitEffectiveDate Namespace Prefix: pstv_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -

Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 66: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 67: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 68: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 69: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 70: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 71: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 72: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 73: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 74: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 75: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 76: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 93: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 94: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 95: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 96: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 97: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 98: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3Reference 99: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1Reference 100: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of a stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liquidity and Going Concern - Additional Information (Details) - USD ($) 3 Months Ended 6 Months Ended May 09, 2024 Mar. 08, 2024 Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Â Â Â Â Â Â Â Â Â Net loss Â Â $ (2,940,000) $ (3,261,000) $ (1,482,000) $ (4,805,000) $ (6,201,000) $ (6,287,000) Â Accumulated deficit Â Â (486,702,000) Â Â Â (486,702,000) Â $ (480,501,000) Aggregate upfront gross proceeds from private placement $ 7,300,000 Â Â Â Â Â Â Â Â Â Net cash used in operating activities Â Â Â Â Â Â Â Â $ (5,663,000) $ (8,571,000) Â Stockholders' equity requirement Â $ 2,500,000 $ 1,000 Â $ 1,328,000 $ 895,000 Â Â Â Net income from continuing operations Â 500,000 Â Â Â Â Â Â Â Â Maintain minimum market value of listed securities Â $ 35,000,000 Â Â Â Â Â Â Â Â X - DefinitionMaintain minimum market value of listed securities + ReferencesNo definition available. + Details Name: pstv_MaintainMinimumMarketValueOfListedSecurities Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18 + Details Name: us-gaap_IncomeLossFromContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 42:

http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 66: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 67: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 68: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 69: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 70: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 71: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 72: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 73: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 74: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 75: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 76: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 93: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 94: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 95: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 96: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 97: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 98: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3Reference 99: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1Reference 100: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Recurring Basis [Member] - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value $ 5,938 Â Money Market [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,415 $ 5,449 Treasury Bills and Government Agency Bonds [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 3,523 Â Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,415 Â Level 1 [Member] | Money Market [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,415 $ 5,449 Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 3,523 Â Level 2 [Member] | Treasury Bills and Government Agency Bonds [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value $ 3,523 Â X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-

gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details) - Warrant Liability [Member] Jun. 30, 2024 May 05, 2024 Expected Term [Member] | Minimum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Expected term 1 year 1 year 1 month 6 days Expected Term [Member] | Maximum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Expected term 4 years 9 months 18 days 5 years Common Stock Market Price [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input 1.47 Â Common Stock Market Price [Member] | Minimum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input Â 2.01 Common Stock Market Price [Member] | Maximum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input Â 2.27 Risk-free Interest Rate [Member] | Minimum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input 4.3 4.5 Risk-free Interest Rate [Member] | Maximum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input 5.1 5.1 Expected Volatility [Member] | Minimum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input 105.6 117 Expected Volatility [Member] | Maximum [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Warrant liability, Measurement input 121 127.2 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=pstv_WarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=pstv_MeasurementInputCommonStockMarketPriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - Warrant Liability [Member] $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Beginning balance $ 0 Issuance of warrants 10,854 Change in fair value of warrants (4,694) Ending Balance $ 6,160 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=pstv_WarrantLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Term Loan Obligations - Additional Information (Details) - Term Loan [Member] - USD ($) $ in Millions 6 Months Ended May 29, 2015 Jun. 30, 2024 Jun. 03, 2024 Debt Instrument [Line Items] Â Â Â Origination date Â May 29, 2015 Â Original loan amount $ 17.7 Â Â Maturity date May 01, 2021 Â Â Fees amount associated with loan Â Â $ 3.3 X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the fee that accompanies borrowing money under the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDate the debt instrument was offered for sale, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_DebtInstrumentOfferingDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=pstv_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Line of Credit Facility - Additional Information (Details) - Pershing Credit Facility [Member] $ in Millions May 31, 2024 USD ($) Line of Credit Facility [Line Items] Â Line of credit $ 3.3 Percentage of credit facility cannot exceed collateralized marketable securities 91.50% Debt instrument floor rate 5.50% Basis variable rate 1.75% Applicable fees 0.50% Prime Rate [Member] Â Line of Credit Facility [Line Items] Â Basis variable rate 3.00% X - DefinitionDebt instrument floor rate. + ReferencesNo definition available. + Details Name: pstv_DebtInstrumentFloorRate Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of credit facility cannot exceed collateralized marketable securities. + ReferencesNo definition available. + Details Name: pstv_PercentageOfCreditFacilityCannotExceedCollateralizedMarketableSecurities Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=pstv_PershingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss per Share - Additional Information (Details) Jun. 30, 2024 shares May 2024 Private Placement [Member] Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Number of securities called by warrant or right 2,151,544 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=pstv_May2024PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Basic and diluted net loss per common share calculation: Â Â Â Â Â Â Net loss $ (2,940) $ (3,261) $ (1,482) $ (4,805) $ (6,201) $ (6,287) Change in fair value of warrants (4,694) Â Â Â (4,694) Â Net loss attributable to common stockholders - diluted $ (7,634) Â $ (1,482) Â $ (10,895) $ (6,287) Weighted average number of shares of common stock outstanding - basic 6,500,831 Â 2,509,378 Â 5,411,382 2,415,221 Net loss per share of common stock - basic $ (0.45) Â $ (0.59) Â $ (1.15) $ (2.60) Weighted average number of shares of common stock outstanding - diluted 10,742,924 Â 2,509,378 Â 7,532,428 2,415,221 Net loss per share of common stock - diluted $ (0.71) Â $ (0.59) Â $ (1.45) $ (2.60) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Dilutive common shares excluded from the calculations of diluted loss per share (in shares) 507,851 299,505 Outstanding Stock Options [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Dilutive common shares excluded from the calculations of diluted loss per share (in shares) 336,928 128,582 Convertible Preferred Stock [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Dilutive common shares excluded from the calculations of diluted loss per share (in shares) 28,190 28,190 Outstanding Warrants [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Dilutive common shares excluded from the calculations of diluted loss per share (in shares) 142,733 142,733 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Biocept Asset Acquisitions - Additional Information (Details) - Biocept Asset Acquisitions [Member] Apr. 26, 2024 USD ($) Asset Acquisition [Line Items] Â Total cash payment $ 400,000 Costs of acquisitions $ 45,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=pstv_BioceptAssetAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Grant Revenue - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 19, 2022 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Grant [Member] Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Revenue recognized Â $ 1,279 $ 1,854 $ 2,956 $ 2,360 CPRIT Contract [Member] Â Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Â Grant funding term 3 years Â Â Â Â Â CPRIT grant funding term, description Â Â Â The CPRIT Grant is subject to

customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. Â Contract effective date Aug. 31, 2022 Â Â Â Â Contract termination date Aug. 30, 2025 Â Â Â Â Percentage of aggregate amount of proceeds awarded under CPRIT grant 400.00% Â Â Â Â Percentage of grant proceeds with interest not exceed annually 5.00% Â Â Â Â CPRIT Contract [Member] | Grant [Member] Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Revenue recognized Â $ 1,300 $ 1,900 $ 3,000 $ 2,400 X - DefinitionContract effective date. + ReferencesNo definition available. + Details Name: pstv_ContractEffectiveDate Namespace Prefix: pstv_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionContract termination date. + ReferencesNo definition available. + Details Name: pstv_ContractTerminationDate Namespace Prefix: pstv_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionCPRIT grant funding term. + ReferencesNo definition available. + Details Name: pstv_CpritGrantFundingTerm Namespace Prefix: pstv_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGrant funding term. + ReferencesNo definition available. + Details Name: pstv_GrantFundingTerm Namespace Prefix: pstv_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of aggregate amount of proceeds awarded under CPRIT grant. + ReferencesNo definition available. + Details Name: pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of grant proceeds with interest not exceed annually. + ReferencesNo definition available. + Details Name: pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=pstv_CancerPreventionAndResearchInstituteOfTexasContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Additional Information (Details) - USD ($) 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Jul. 01, 2023 Mar. 31, 2023 Recorded Unconditional Purchase Obligation [Line Items] Â Â Â Â Operating leases expiry year 2025 Â Â Â Operating lease right-of-use assets $ 139,000 $ 202,000 Â Â Pre-clinical Research Study Obligations [Member] Â Â Â Â Recorded Unconditional Purchase Obligation [Line Items] Â Â Â Â Contractual obligation $ 0 Â Â Â Charlottesville [Member] Â Â Â Â Recorded Unconditional Purchase Obligation [Line Items] Â Â Â Â Lessee, operating lease, term of contract 12 months Â Â Â Lessee, operating lease, existence of option to extend [true false] true Â Â Â Lessee, operating lease, option to extend The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods. Â Â Â Lessee, operating lease, renewal term 1 year Â Â Â Lease liability Â Â Â $ 80,000 Operating lease discount rate Â Â 13.47% 12.76% Operating lease right-of-use assets Â Â $ 19,000 Â X - DefinitionOperating leases, expiry year. + ReferencesNo definition available. + Details Name: pstv_OperatingLeasesExpiryYear Namespace Prefix: pstv_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-6 + Details Name: us-gaap_RecordedUnconditionalPurchaseObligationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Agreements - Additional Information (Details) - USD ($) 3 Months Ended 6 Months Ended Mar. 29, 2020 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Sep. 07, 2023 Research and development expense Â $ 2,773,000 $ 1,420,000 $ 5,536,000 $ 4,403,000 Â Â Voting stock, value Â 6,000 Â 6,000 Â $ 5,000 Â Biocept Agreement [Member] Â Â Â Â Â Â Â Â Shares issued Â Â Â Â Â Â Â 53,381 Research and development expense Â Â Â 75,000 Â Â Â Nano Tx Licenses Agreement [Member] Â Â Â Â Â Â Â Â License fee payment in cash $ 400,000 Â Â Â Â Â Â Voting stock, value $ 300,000 Â Â Â Â Â Â Percentage of non-dilutive monetary awards required to pay 15.00% Â Â Â Â Â Â Â Accrued payments due to NanoTx Â $ 500,000 Â $ 500,000 Â Â Â X - DefinitionAccrued license payable. + ReferencesNo definition available. + Details Name: pstv_AccruedLicensePayable Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of non-dilutive monetary awards required to pay. + ReferencesNo definition available. + Details Name: pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of cash paid for royalties during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-

gaap_PaymentsForRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_BioceptAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Deficit - Preferred Stock (Details) 6 Months Ended Mar. 03, 2023 USD ($) Votes $ / shares shares Jun. 30, 2024 $ / shares shares Dec. 31, 2023 $ / shares shares Apr. 20, 2023 $ / shares Class of Stock [Line Items] Â Â Â Â Preferred stock, shares authorized (in shares) Â 5,000,000 5,000,000 Â Preferred stock, par value (in dollars per share) | $ / shares Â $ 0.001 $ 0.001 Â Preferred stock, shares outstanding (in shares) Â 1,952 1,952 Â Common stock, par value (in dollars per share) | $ / shares Â $ 0.001 $ 0.001 $ 0.001 Series B Convertible Preferred Stock [Member] | 2018 Rights Offering [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Preferred stock, shares outstanding (in shares) Â 1,014 Â Â Number of preferred stock, shares converted Â 398 Â Â Series C Convertible Preferred Stock [Member] | 2018 Rights Offering [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Preferred stock, shares outstanding (in shares) Â 938 Â Â Number of preferred stock, shares converted Â 27,792 Â Â Series F Convertible Preferred Stock [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Preferred stock, shares authorized (in shares) 1 Â Â Â Number Of Votes Per Share | Votes 50,000,000 Â Â Â Consideration paid to preferred stock holders | $ $ 1,000 Â Â Â Series F Convertible Preferred Stock [Member] | Subscription Agreement [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Common stock, par value (in dollars per share) | $ / shares $ 0.001 Â Â Â Consideration to purchaser in cash | $ $ 1,000 Â Â Â Issue and sale of share 1 Â Â Â Sale closed date Mar. 03, 2023 Â Â Â X - DefinitionConsideration paid to preferred stock holders. + ReferencesNo definition available. + Details Name: pstv_ConsiderationPaidToPreferredStockHolders Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber Of Preferred Stock Shares Exercised. + ReferencesNo definition available. + Details Name: pstv_NumberOfPreferredStockSharesExercised Namespace Prefix: pstv_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of votes per share. + ReferencesNo definition available. + Details Name: pstv_NumberOfVotesPerShare Namespace Prefix: pstv_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDate the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockTransactionDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_TwoThousandEighteenRightsOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=pstv_SeriesFConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=pstv_SubscriptionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Deficit - Warrants (Details) - $ / shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Series U Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Issue and sale of share Â Â Â 230,000 Warrants expected term 5 years Â Â 5 years Representative Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Number of securities called by warrant or right 5,000 Â Â 5,000 Common Stock [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Issue and sale of share 1,439,988 472,674 168,164 Â Warrants expected term 5 years Â Â 5 years Outstanding Warrants [Member] | Series U Warrants [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Warrant exercise price (in dollars per share) $ 34.10 Â Â $ 34.10 Class of warrant outstanding 142,733 Â Â 142,733 Number of warrants exercised Â Â Â 142,733 Common Class A [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Issue and sale of share Â Â Â 19,266 Common Class B [Member] Â Â Â Â Class of Stock [Line Items] Â Â Â Â Number of securities called by warrant or right 180,733 Â Â 180,733 X - DefinitionNumber of warrants exercised + ReferencesNo definition available. + Details Name: pstv_NumberOfWarrantsExercised Namespace Prefix: pstv_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesUWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Deficit - Common stock (Details) - USD ($) 3 Months Ended 4 Months Ended 6 Months Ended 10 Months Ended 12 Months Ended 22 Months Ended May 09, 2024 May 05, 2024 Aug. 02, 2022 May 16, 2022 Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Jun. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2024 Oct. 31, 2023 Aug. 18, 2023 Aug. 17, 2022 Jul. 14, 2022 Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financing expense Â Â Â Â $ 3,545,000 Â Â Â $ 3,545,000 Â Â Â Â Â Â Â Common stock, shares authorized (in shares) Â Â Â Â 100,000,000 Â Â Â Â 100,000,000 100,000,000 100,000,000 100,000,000 Â Â Â Â Proceeds from private placement $ 7,300,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value loss on warrant liability Â Â Â Â $ (4,694,000) Â Â Â $ (4,694,000) Â Â Â Â Â Â Â Remained authorized amount for repurchase Â Â Â Â $ 0 Â Â Â Â $ 0 Â Â Â Â $ 0 Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issue and sale of share Â Â Â Â 1,439,988 472,674 168,164 Â Â Â Â Â Â Â Â Number of stock repurchased Â Â Â Â Â Â Â 179,866 Â 78,559 Â Â Â Â Â Treasury stock Â Â Â Â $ 400,000 Â Â Â $ 400,000 $ 400,000 $ 100,000 $ 400,000 Â Â Â Â Common Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Authorized amount of repurchase of stock Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500,000 Â Â Â 2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized (in shares) Â Â Â 57,500,000 Â Â Â Â Â Â Â Â Â Â 2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maximum value of shares to be issued under agreement Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issue and sale of share Â Â Â Â Â Â Â 266,666 0 150,000 410,500 Â Â Â Â Â Period exercisable from the date of issuance Â Â Â Â Â Â Â 36 months Â Â Â Â Â Â Â Number of maximum common shares can be resale Â Â Â Â Â Â Â Â Â Â Â Â Â Â 633,333 Â Initial commitment shares Â Â 32,846 Â Â Â Â Â Â Â Â Â Â Â 32,846 Initial commitment fee paid in cash Â Â $ 100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Aggregate gross proceeds from sales of common stock Â Â $ 25,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from sale of common stock, net Â Â Â Â Â Â Â $ 3,200,000 Â Â $ 1,000,000 Â Â Â Â Â 2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Percentage issuance of common stock Â Â Â 19.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of maximum common shares can be resale Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1,500,000 Â Â Number of shares reserved for issuance and sale Â Â Â Â Â Â Â Â Â Â Â Â Â Â 600,486 Â 2020 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issue and sale of share Â Â Â Â Â Â Â Â Â 527,166 Â Â Â Â May 2024 Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financing expense Â $ 3,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value loss on warrant liability Â Â Â Â $ 4,700,000 Â Â Â $ 4,700,000 Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of warrants Â $ 10,900,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from private placement 7,300,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering expenses $ 400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Series A Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares issued 3,591,532 3,591,532 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant Â 4.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Series A Warrant [Member] | Initial Subscription [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant exercise price (in dollars per share) Â $ 1.772 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Series B Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares issued 3,591,532 3,591,532 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant Â 9.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Series B Warrant [Member] | Additional Subscription [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant exercise price (in dollars per share) Â $ 1.908 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Series A Warrant and Series B Warrant [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant exercise price (in dollars per share) Â 1.79 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Series A Warrant and Series B Warrant [Member] | Initial Subscription [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Offering price Â 2.04 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares issued 2,151,544 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Securities Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant exercise price (in dollars per share) Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issue and sale of share Â 3,591,532 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Private Placement and Pre-Funded Warrant [Member] | Initial Subscription [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Purchase price of share Â $ 2.022 Â Â Â Â Â Â Â Â Â Â Â Â Â Â May 2024 Private Placement [Member] | Common Stock [Member] | Private Placement and Pre-Funded Warrant [Member] | Additional Subscription [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Purchase price of share Â $ 2.158 Â Â Â Â Â Â Â Â Â Â Â Â Â Â X - DefinitionFinancing expense. + ReferencesNo definition available. + Details Name: pstv_FinancingExpense Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross proceeds from issuance of common stock. + ReferencesNo definition available. + Details Name: pstv_GrossProceedsFromIssuanceOfCommonStock Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInitial commitment fee. + ReferencesNo definition available. + Details Name: pstv_InitialCommitmentFee Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInitial commitment shares. + ReferencesNo definition available. + Details Name: pstv_InitialCommitmentShares Namespace Prefix: pstv_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMaximum value of shares to be issued under agreement. + ReferencesNo definition available. + Details Name: pstv_MaximumValueOfSharesToBeIssuedUnderAgreement Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of maximum common shares can be resale. + ReferencesNo definition available. + Details Name: pstv_NumberOfMaximumCommonSharesCanBeResale Namespace Prefix: pstv_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionOffering costs. + ReferencesNo definition available. + Details Name: pstv_OfferingCosts Namespace Prefix: pstv_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage issuance of common stock. + ReferencesNo definition available. + Details Name: pstv_PercentageIssuanceOfCommonStock Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRefers to the period exercisable from the date of issuance. + ReferencesNo definition available. + Details Name: pstv_PeriodExercisableFromTheDateOfIssuance Namespace Prefix: pstv_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definitionpurchase price of share. + ReferencesNo definition available. + Details Name: pstv_PurchasePriceOfShare Namespace Prefix: pstv_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRestricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant. + ReferencesNo definition available. + Details Name: pstv_RestrictedBeneficialOwnershipLevelResultOfExerciseOfWarrantToReceivePreFundedWarrant Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=pstv_LincolnParkCapitalFundLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=pstv_May2024PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesAWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis=pstv_InitialSubscriptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesBWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis=pstv_AdditionalSubscriptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesAWarrantAndSeriesBWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=pstv_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=pstv_PrivatePlacementAndPrefundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Additional Information (Details) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 06, 2024 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Common stock shares to be issued (in shares) 196,824 Â Stock option contractual term 10 years Â Stock option vesting percentage 25.00% Â Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards $ 0.7 Â Weighted average period for recognition of cost 2 years 3 months 18 days Â Minimum [Member] Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Stock option vesting period 2 years Â Maximum [Member] Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Stock option vesting period 4 years Â 2015 Plan [Member] Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Securities remaining and available for future issuances (in shares) 62,908 75,000 2020 Plan [Member] Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Securities remaining and available for future issuances (in shares) 1,899 Â Common stock shares to be issued (in shares) 236,667 Â X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Stock Option Activity (Details) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Options [Roll Forward] Â Â Balance as of December 31, 2023 (in shares) 140,109 Â Granted (in shares) 196,824 Â Cancelled/expired (in shares) (5) Â Balance as of June 30, 2024 (in shares) 336,928 140,109 Vested and expected to vest at June 30, 2024 (in shares) 310,675 Â Exercisable at June 30, 2024 (in shares) 103,834 Â Weighted Average Exercise Price [Roll Forward] Â Â Balance as of December 31, 2023 (in dollars per share) $ 37.48 Â Granted (in dollars per share) 2.09 Â Cancelled/expired (in dollars per share) 271,125 Â Balance as of June 30, 2024 (in dollars per share) 12.78 $ 37.48 Vested and expected to vest at June 30, 2024 (in dollars per share) 13.52 Â Exercisable at June 30, 2024 (in dollars per share) $ 32.39 Â Weighted Average Remaining Contractual Life (years) [Roll Forward] Â Â Balance as of June 30, 2024 8 years 9 months 21 days 8 years 25 days Vested and expected to vest at June 30, 2024 8 years 9 months Â Exercisable at June 30, 2024 7 years 5 months 12 days Â Aggregated Intrinsic Value [Roll Forward] Â Â Balance as of June 30, 2024 $ 3,000 Â Vested and expected to vest as of June 30, 2024 $ 3,000 Â X - DefinitionShare based compensation arrangement by share based payment award options aggregate intrinsic value. + ReferencesNo definition available. + Details Name: pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract Namespace Prefix: pstv_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Aug. 09, 2024 Jun. 30, 2024 Jun. 30, 2024 Subsequent Event [Line Items] Â Â Â Gain on change in fair value of warrant liabilities Â $ (4,694) $ (4,694) Series A Warrant [Member] | Amendment and Restatements May 2024 Private Placement [Member] | Common Stock [Member] | Subsequent Event [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Restricted Beneficial Ownership Level Result of Exercise of Warrant To Receive Pre-funded Warrant 4.99% Â Â Series B Warrant [Member] | Amendment and Restatements May 2024 Private Placement [Member] | Common Stock [Member] | Subsequent Event [Member] Â Â Â Subsequent Event [Line Items] Â Â Â Restricted Beneficial Ownership Level Result of Exercise of Warrant To Receive Pre-funded Warrant 9.99% Â Â X - DefinitionRestricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant. + ReferencesNo definition available. + Details Name: pstv_RestrictedBeneficialOwnershipLevelResultOfExerciseOfWarrantToReceivePreFundedWarrant Namespace Prefix: pstv_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesAWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=pstv_AmendmentAndRestatementsMay2024PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesBWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (.B##ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\QO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*N!#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #H@PY9F!@-:NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9? B>R$G*&";UI:.G#@8K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/ MGT"M#D+[B,_1!XQD,=V-KNN3T&'-3D1! "1]0J=2.27ZJ7GPT2F:GO$(0>D/ M=42H.;\'AZ2,(@4SL @+D^"V@68J[^BE7PAZ): [6LNFDKPYGUV_>%W$W;>V(/] MQ)\970=G"K[N07U!+ P04 " #H@PY9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(JZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P' T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=<7"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+', <$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90- !1M;*PD+$:W8+C7\2P4X&I@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU= [=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!? 8J*@!&K8KZZKT_Y)9P[M'OQ@2"; -;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6//,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M .B##EG \QQB\04 ,,? 8 >&PO=V]R:W-H965T&UL MM9E=5 MP 9G1[QFF7*3&,S[F(,D=$"C ^-?XBVE KV$013?M+9"[-X91NQN:4CB:[:C MD?QFS7A(A-SD&R/> <4J\M"@,#&R:/2,D?M0:C])]"SX>L40$?D07',5)&!+^ M>DL#=KAI6:W3CB=_LQ5JAS$>['-(I]%B%.US>MB?5N M:MNJ(#WBLT\/\=EGI%!6C'U1&S/OIF6J,Z(!=86*(/+?GDYI$*@D>1[_'D-; M^6^JPO//I_2'%%["K$A,IRSXW??$]J8U:"&/KDD2B"=V>$^/0%V5Y[(@3O^B M0W9LI]-";A(+%AZ+Y1F$?I3])R_'"W%68%LE!?A8@+\JL,I^P3X6I%?.R,XL MQ;HC@HQ'G!T05T?+- /4AO39IM:3Q(]6,CN#R6U_6B?$=UAOR+/-3 MQ:=3O<5@X*])=(UL\PIA$W"R_ZCNT)90D>?H$;HNWA'7'K3DD,PIGQ/6^,?OK-ZYL\ZO/\I[UL M)X?M0.GC8\]XHAM?X:XW2J%4SDP. GD@/#H"_J-ONJ X233-"USV!T.+!TC6%N3L9N9/R3$JZ&*I*W$6W#PFGMMH7;MA82+*P)V<\A^U4:\L$/Y%B= M2K(<X]I6A&/F+&H3UY63#Y<97I:G8P5C:K(.;-&4 MA3L2::'AO#4)8EU/F()E-2&'.>2P"J03DB! MTDLOXZUDQ,<(WBB10.K:J)9 M9C$7FY5N.RP,Y=3K".9^N4)..O^BCXF(A9RD9TC>7L?.",WT%Z)R#R\5<3B@+FLA-A;L(CGKIX1P M07F@Q'7'N- #"PEEE$P5<5A>QT!H+%I)B^$D9C_WT40U@A,/*^VP3.F,5/F-5 M$II9)-LP>]Q779:@H[EJ2>'$/[4/LE.XJBYGH316):R\=D+7H3EH,+R\&PI9Q8T?V+NR71AI:^]K@0-)\X=Q.M\,"%=0D+X<&5 M7NRH!UHT3*5]K'V]D*(;+RVW;'[72U@$^*#"_'!E5[ES"*7<7E?3=]J7J5W M5MFGN;P-)9'@ZIG+T[?K!:VZUR(WX3^X\!\.\L1>4E>T,R3,XJ_]MWL;2[0 MPG"D;;?- >YWA[:6MPD9PH4,X4HO>2:>)]/CJ],']"B/0Q\C?;O"D1ULFNC# MY&FR?/]QCFX?/]]IN9OP(USX$:[D1WKNY8%IN>%(YWFVO)=>;VIQF] D7&@2 MKJ1).>Y4;G>5LKN5L0I/L0I/L2IJ4<";WJ@5G>S]RXMPY M0N;R#^V*0A/"9!?"9,.^\S7H@L6"!.@O?U=Z.[Z0V!_TNSTM:1,*91<*95\0 MGY234U(.!@? T[;X6JPD]LL]6P&"K>63IZZTMBR!YN!"'N]UVWQI7R3 I=_* M9YPMDZJ7Y.GJ<8Q+:_8&H=^PQ"NA:EIK7?3GC M\VS%.-L0;)&PO=V]R:W-H965T&UL MK5EM<]LH$/XKC*]SE\XHL4#O:>*9U,Y=T^FEF3JY^TQD;&LJ"1=0TMRO/Y!L M2S:(.FX_M!'6[O+LLNRSH(MGRK[R)2$"?"_RDE\.ED*LSH=#GBY)@?D979%2 MOIE35F AAVPQY"M&*Q6*O(AN0D1RD@IE LL_3V1,\EQ9DCB^K8T. MMG,JQ>[SOQJ?M?/2F4?,R9CF_V8SL;P(+??Y U@X%REY*#]U:>KV_$UF'ZXOKZ?@I.'VZN'R8U\\Q:<@H?!!)R\>0O>@*P$]TM:<5S. M^,502#S*ZC!=S_V^F1OUS/VQ*L^ YSH N<@WJ(_MZA.22G58JWN[ZD,9A6TH MT#84J+;G]86B8HR4 F#.B>#G)G\: [[9@-IQYWR%4W(YD%N*$_9$!J/??X.A M^\[DW2\RMN.KM_75LUD?C3%? KEJ(%4/Y%N5/>%<.F]%IY"<0 M70R?NM[H0G$0^%NA'93^%J5O17E3/A$NBCY3 -$68&0%>.JRM*<2@8'E$28<$8:A,C;SU-=)G%#,\IX MBS*V+[/B56+D!.)*, IJCCE,Y/*SGHCVJLKZB7[*'5962Q,Z--MF@3*]J_ M*)TJ9WEN@I3H.RK:#Z!=9@<2=%L6,!N[E_/M?I.9/:#9Y?9!=;R%K12Q7H;6X A/=,@TBJX4S3\F.69R(B97*&5LE[+KK_*VJ[3+7- !.W5=I2FM)&^!%7[!=5K+ M"H;3E%5$5K+OL@OGQ+Q8,JN%B1_NKY5!*O1@SU*U? 5_0%[E6RS9*]&I ;: MTG+*1%L]K 5;VH)VWOH7,X8[&66&IQ-2*)=W'Z!UIF/3I.4W:">X"9D3N3MF M8'& 0SIU(91HI<\ZX;$.M50([5SX28X!G8-4.I69"[C..1[2$\..> MN2Z4K18#3SBOR#L0.*[KJG^ +['$ ' EEI1E_Y'9.P"=)$";%QGGJB53R4,K MP>4Q9*8J#1;@8R6I;',]50M,2$J*1WD(V- PZ.4":6)'Z*C(W[_0C^@MSEOV\ MH=UPMST*LO30P#NUA.\$2!H) MPJZ:[_B^[[A)M&N J_[CF*72^ZO]MML@TL<;;<>$[!W3/9.D5K&7)L#@1 8@ MI5Q(U$'L^"BH78UB)PB2;7AK%U^=G^8RJ+=CIX&K,:9!"J*^\MVV69EW- M9),H6RO),RN,4+5NR(_2H(([H,URJ&HAQ&]MG_R[/V3/-15 M195C(1-P76V-]Z5Z2W3JQV'D:G>F1D$W<'L.WW- #X+6MDW?(!4:GTZBS^7#T2+M[-MUO&,7T^XUAYV.*^I+U M-V:+K.2R]YQ+/?:1"T*)^7!(L42L!^7Y.91>R'JA/ M-MM/=*/_ 5!+ P04 " #H@PY9+/'&43,#)"P & 'AL+W=O,G7VD!9>:+T675NPIX&E2(Q-@99N2*H^XU0P.4LD3OB#N_%P-)Z.AD"VIG>W-\/^@^Q< M]6_[X\$(3*']HXMD ;7@ 3FE8#?+ ?/L2!A!L%O%V'ZW(GJNTPJ^TP M" [[V#KZIH,%S1.,0, Y1I0,)B+ALLE7R6,T\ZO!=\@P%N*?)T\4Q6V#-_#. M<.#G)I/_B:QFN5U9;N]C]R?RW&#&< BX,G\!,L3 L4Y!F7Y8O+TERO!L2[?R5 M;'E7<('2D*3S0]J=8[0?"*II=ROM[E[M YHD\@[YAX1WCTKX0U$U\9U*?.<$ M\3=G>V=[/R%LS/=C(FL.O,J!=[J#X]+=VSZ#GF,ZEK6A?3O.LDW3L9UFY0;\ M%M2O?V&OA0=9[/&>O=1.-8HTM M#:;=L4Q[4^MVG- NQ;6]#J;Y6IZ@B\1MB5'4&SHG1Y MHD(60D4SDK4J9BI SL\H%6\=50U5U:__&U!+ P04 " #H@PY9S$_-+=8% M C' & 'AL+W=O;C2[8529S1QQSQ;9I&^3\W-&'[JP$> MO%UXBE=K45P8CB\WT8K,J'C9/.;R;-BP+.*49CQF&F@R5D$'AZ_ ML7\NQ4LQKQ&G$Y9\BQ=B?348#="'+J-M(I[8_C=:"W(+OCE+>/F)]C76&J#Y ME@N6UL%R!&F<5=_1C[H0!P&2!PX@=0!1 YPC 78=8)^:P:D#G%,SN'5 *7U8 M:2\+-XU$-+[,V1[E!5]R%0=E]88>/J;)"]^OE6 M#'E_OKE^FMQ'Q"9^AE-D4? M/WQ"'U"_N?LG6+838_8 M)9]]LA.]A0_-(Q- D*T1]R@^*47T!37)$X,$FQX5WP332G5P.YHW&:[^A@_/-/ MV+-^A>K;)FT3[*P)[+.3#C-3#@F]O&39(SR^1K)92:WPYWO[5P8YT4&V[:AR=5 0N$21JX-&KD]@N7XCUS?*_1\5:YK+ M.^6 M1YF ':"E;UA>H.Q%$W/B]];RI)QA7SF[Q3QPX-A8S&]5T5#,^59V)$5SQH^4 M$.N]X=A$+:$QW;M+>$K.L*^$>D MMD87FYUN[83 .R8HV]&<&XN:;!TT4C4#/(&Z^0*@,]\)(KDUN]CL=N^I0(ET M1* \5[/79R1P+%4@ ,/.2)M8 .812YM:$#;RCPAM32[VC#[H4'1M-Y_A; M^6B1RC^<._F71J]<;)N^RJ+(!CO9N:7FD) M7RL)"-,[!X!AK0]#"':T@^%EN^0[1'%Q, "3V::]L85]LW:EH#30Q M&^@GNJ/9%C24=63G&2'Q [7O -3(59\T 2@2N.K#%PAE>Y;2;L.#EQXIS5?E MVR8N%)@V$]6S[>9]\T;KNGR/HUR_P1<3#%R?XHNP>E_5TE>OS^ZB?!5G'"5T M*5/)_4HNCKQZ(U6="+8I7[F\,B%86AZN:;2@>0&0OR\9$V\G18+FO>#X7U!+ M P04 " #H@PY9'_F-R+(, BEP & 'AL+W=OTEF6H,PL&TS37KWXN9>4)LT MOMHF"[C9_? 8'CFN,>!#@^^?]2>Q$^CT2>AXAZ2_!U7.OX*=KE_WF(DVV8Y5^3KZ/T*8G"U2'3=C-BNFZ-MN%Z M-[BY.OSM-KFYBO?99KV+;A,MW6^W8?+'NV@3/U\C,&//WQ:?WW,BC^,;JZ> MPJ_1791]? KI-\F^C$V6UWD:[=!WOM'1ZN!Z\-=X$?%9D.*3XQSIZ3L\^:T55 MOL3QM^*+M[H>Z$6)HDVTS I$F/ Z'LVCS:8@Y>7X[0@=G&P6&<__Z"+0^7S MRGP)TV@>;_ZY7F6/UX/I0%M%#^%^DWV*GQ?1L4+C@K>,.^GAI_9\3*L/M.4^ MS>+M,7->@NUZ]_([_/UX(O_?SYP]O/MIKE;KHDL.-]IMN%X-7"?(IR=(IP=\+P!_R[C>ECF!?D52=75E)[UFV.A- DOL/'9A3)F8\D=*!% M@82Y]>(SQG5])CLTTJB'A/E(6 ""56*#GV*#*V/C<.<9%C.*E;:,M_DT*PV+ M&Q@5#[SN=5R7>G:EM;YNCH0Y2)A PEPD;(&$>1U:W$<:#$"P2BB,3Z$P5H=" MF(_2\QF'MD[3_>&&$3\4,5&,6M,B3'[1=E%&!<:X=IFF,WG(,Z[=VXQ["EM9 MNK[>CH0)),Q%PA9(F->A&?W69@Q 1:JXL'5R80O@PN<#(+^TY/[3[NNYKP/ MD],4V*3"85J? J5D32XH&IF^T8"$.4B80,+<:>MJ#M*<5V]'/N&6?//QD3:# MNLTAGQBSF4Z[[^SDOK-+5G-:75E)[3NJ0<+L69?5'")1-85 ELFMFV-JK%": Z4)*,V%TA90 MF@>E^5!:@*)5(Z84>8UN*F]^- 'WN_QNHC?/!0Q"@<0;%TAPH34!I M[!%V/D@RY?L(5-HEFI-/+,,TY$$25+8EK.837)-/6,,@J=1D:+4HVS!(:G=K MI!8WA)L@] 2B4$25*6%TERB!OE-=V8Q779NJ 8+I?E0HEH"B5>.D%&P- M6+; M:UY<5_>H>3%24+2A- =*$U":;]1UT=K4 :K5$LU)SXN15@/"JGI>7 JWEJYY MO7A>#!5KH33;("1/HLN'ZK!0FDO4H&%>#)5MH30? 2@M0M&JCA$R&>&R:=RGP]57^JK136!5].6TOR+EMSF49AMU-8_JRZ&"*Y3F$C7@8\:L MFJ1%)!Q.IN/Q3'9;9/%*"U T:H14$JT1C>-MHLN:Q!28WV/@=I@;V]&TAPH M34!I[I&F')A#-5RB.- A4W+:?6&VD=RA M5LHS8'2!*NKLD-Y5S'4X@)*\Z T"TH+4+1J8)7R M+E/+NWV.7;&ZW%L _=Z6VUSJL&=JH6(OE.9U:7@?:C) T:IA46JX M3*WA7GX$BQ%'8DUY-7BN-M\ [2]"*+I0FH#27U15=0QZ3015=NCDGLN]#]5P4 MK>K[I>C+U*(OYNR6VDCOL194 H;2'"A-0&DNJTO%?,(L>45S ;7J06D^E!:@ M:-7@*I5BIE:*11(NC\]E"5?_V:?9- MK1]Q&D7CB'TFPHS8'2!)3F,D)G-4Q# MWF@!->I!:3Z4%J!HU? IU6FF5J=5NU%972,=&GPJZ936^@="M"3P%":@-)< M*&T!IT7E0F@^E!:UN60V%4H!FG07HUOUXK"XQ$MM,U09[1P94? X;2!)3FLKJX M+&\SA1KTB.8DMYE"K0:$5>4V4U;JU.PBG;K=K:$Z-91FLTXZ-=2F@-)XZ(),2>(Z*=R#U'T.('E'>H]AR9I4QM7B13M_JK&MNW+X?2;+.33 VU*: T MEZ@!O>>(2$CN.8(6SX?2 A2M&@&E5FVJM>H^DII)G-CE\I8CM;W>S@P5FJ$T M :6Y4-H"2O.Z-+P/-1F@-:6P*)5F4ZTTW^Z3Y6,>%(6:D/UX=O9!3R #@SA: M;.HWQ;G:9._(@(K-4)J TEPH;6$2CTNNM94'M>E#:0&*5@V-L\=]J7FYM X M#*/NFE4V-;CWJ G[;&BH*@VE"2C-A=(6)G&)L M=CZ;?+Y7G).A01TKG9KR UW4%GN'IE1-AM($E.::]>V.QVGEAML;<_0_5<*$U :;[9?IZ8 M2$*L[1/M1*[M0XL?4-ZA7- LO=5KSSSE/K,;V[J:A.JW92:>%VA10FDO4H*&; M[GB>&%H\'TH+4+1J!)0*K*E68)7S2D)3LYA>FU="%5?[>1<[5%OM&$)3F0&D"2G-Y_9G1 M\BV"2$),/XEVRL?D++YT-I 8I6#8%2G>6=WZS;NNK""6V6 M6"546^SMSU!Q%DH34)K+ZW*J//TDDE#===+V=R%5":/&#)N]H6B7DI4S*+WI] M;KN_0D52*,WFG=Z@"[4IH#27J $]_202- G334%T32@M0M&H(G+TD5ZUK]GI+ M;EU0,L;R;%1MK[4YD!I DIS>5W*E)_5 #7H06D^E!:@:-4 *056_O]X'Z_:2.^! M%%1NA=(<*$U :2XGA&5NSF;3J1Q=T#.V4)H/I04H6C6Z2NV67_X>7TZH<6Q6 M>VR6VD+O8(!JM5":@-)<*&T!I7E0F@^E!:UN60V%4B+FG=_IV[Y\6G_W++G< M#]5[H30'2A- 0FDM[HZ$V!93F$C5H6.XG='9Z'0FJRD)I 8KV$@*C]#&*,CO,PINKI_!K M]#Y,OJYWJ;:)'G*_GJ27ZQD_?7Q]"6+GZX'QD#[$F=9O#U\?(S"5904"?+_ M/\1Q]N/+*.<_Q\FW@XV;_P)02P,$% @ Z(,.6=:_57-1"@ +%D !@ M !X;"JW;W)K.+8*WQN:*)FGNIU_).!C90H&]3]TQM7Y2>"'XZ,' M69=/.?]1K!@KR<]UFA57O559;BX&@R):L758O,\W+!/_L\SY.BS%2_XP*#:< MA7$5M$X'=#AT!NLPR7K7E6Y.WY]F6_+-,G8'2?%=KT.^?,'EN9/5SVK]W+B M]^1A5_Y O/L97O:$<$4M95I$*/X\LEN6II(DQO%G#>WM^Y2!A\ U6]H+'E1GA;5O^2I;COL MD6A;E/FZ#A8C6"? 9[F_XL_X@#@($1Q] ZP#:#A@=";#K /O4@%$=,#HU8%P' MC$]]#TX=X)S:PZ0.F+0#G",ITSJ@DLM@=SFJ:^F&97A]R?,GPF5K09,'E2"J M:'$)DTQJ=U%R\;^)B"NO;[]^<;TO"\\EXFCQ]=- ']^:;>+'X)OY\]KY\6Y"O M/KF]603$__3UCP5Y_W+S??WHVCSEO3]X5+WOSVEOQ&DHQ\6^7;(LSBXG)0 MBI%)_B"J1_%A-PIZ9!0V^9QGY:H@7A:S6!/OF^.=U^(#<[Q%#8"!^$CWGRM] M^5P_4"(QW)OL/&'[P@=TI%F0+?F\,\A%^'6T7#W]-YM3;AW>N^Z^(6&Q(DN1XPNR+5@LE2[N'#PLD^QAEWJ3 M,F'%A4[U._)(3Y:WI8MB$T;LJB?N.P7CCZQW_<]_6,[P7SK%(&NN8A83X2 M-D?" A!,4>%HK*1B7[]190Q:5YH<^LNTJDB9:WR>-VGL]'PD;R%,C$*Y>9 %R1?RLD>XUSDK662A2*W MB:05Y85(=U)$,;LO29P44;[-2IV*C'V=JR(DS$7"/"3,GW040ELW['FWB67- M6B("C4D1T70OHJE11(M5R%E?&@>Q4,MZP(])BCRV4QXSG52,Q'.E@H2Y2)B' MA/G3KE1FK?)HKFDS;>DI U*T%$$6?[%/$GB)>%BN1B?HEXVM1 M,SVRNLS225D!%^ M=H9"TEPHS8/2?"AM7M.4XJI56J$Z5%76.-26T7KL3.<:ZREEHCPG7/Z U\^7 M_:UX$18%.Y*QH'8UE.9*:1Z4YM>T0X$X[2I+TV; <]CA1HU)5U#C,ULAHUY54D5A96S>/Y.HNAD6+8^S4E65TM(DO$_2XWZG!?)R M:YDA:2Z4YD%I/I0VA]("%$V5;F/06T9;]7HNJS!IS+/D,;Q/]>4^U&>'TEPH MS8/2?"AM7M,.\^?E]EG+5WK+

*MLF< 0VC$ RM@K+*D+CCY$F"&=:A!O*KT(K86.V9Z)(8$\<7LQ03DTGHX[+EC M_!G;[LQR6#O _1.. FE !I&/+ '$]]"'JRPQ6 6L=P98,,X M0$.NX[.I2CD'-\D3Q-*

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`'<*!?*

4$4.5>6Y /(.)$((]X[.^=MFTO2/=MFTO2VUECQ/#TR)DUO6#UA75#(75(0([BS/T .'TI'VV3/B"8FR21 ^Z(L_QZ M)7A60#%38/4],K-M4,V*7K+) K)!ZJB[H1YM@,N,,K.3Z(C?*

P8"%QIJ8TE43 M%_F'6&VKB>/VP'PM$ B\U+D%62W!;A69,'6O]860GKR@EVZV@,&"W]JC/@]I M[CY5;!&RJR="?,33G8!#F",Y]I^L,A2T",,W[.3$CYH[:!:66'DVH7 M9DGTI&

STWP7,69Z'.+$VY,]T(9UIDD,$]BZX2$O,1$P<+Z1V6 MNOD=](P:'+'LY=]^OH_:%726S?K@D@3:@%[I[07M++^1)VE+@.D(2.N$H[MFC%T%"B5)$Z.11J76,\H?B^C M@FYVA%3(PO?*

\4A>!BP323QG$ZMMA],^15=#5 MB=]/Y34!\=:M5!ISQ[<5 QI.#V7GCVK.T-E)N!$CTU\K]FQN$,\ 0NP+ R M&U)14,+03:#Z]DKI)0NE@0O&=MMXPP2""74@$^9"R'6M0P'F%T(BY/:!__CZ MI\ MKUN&. W!)2#59;_XTNBQ=]U$DT[!<+A2(6$OUHN/4 MD%0UO%G=#)?.=$K171-O5K+ .#[)&KK\'6>\&Q"C3?=W0^N8 MW1N2CC!.ZT*&S=^KXPM85]*

MKOQ\DOK7J3RIX<^?;'+H.^'SC/NO.S9^WE,-S84S%+2K15Z)15+\3-Y5_1A M4YM)'M2$G#T[9' M1U\,]PT$$+5)/B(8&IG]T1^%MB,-MWG=Y6(^8CB%]B1YM@,N,,K.3Z(C?

*A/.N@4!+'\W4-ZFOYJ MY%S^ 6&)8+G]R\DZ[%,42E5EBZVSZ .F'IEO:=[\&U!+ P04 " #H@PY9=3#8KR # Q!P & M 'AL+W=OT"8! MFJ[#-J!8T.[,P['Q.9C(,+D2G32 /(U'V?'2(EU*9.#H.*

M:PJN.K8U.F7@P0E?EZ5TFQEHNYY$@VB[@6!?)"/!U7<@%@,_5@Z-9W*%D M]@3CE37"03Z),@97LQ'.!X/O"M9^9RQ8R=S.)4\^9Y.HSX1 0XJ,(.FW@EO0 MFH&*

(QDN+&74AV7%WO$7 &+23EKGT<&OU#Y5A,8DN(Y%!+FN-GW:]"5H]9XR7 M6NW#5ZP,VX2,T]JC+15MG8E JT_SE:YN"8?+ @&'\'05^W1T\W[M4]N C?:#<8U<^4JF,

(FH'#RX%433DW>#_[U$:JCCNKH M&/I_G<91A/W\D[X&UE*T"0126=#.5!FZDUWFJ5T7XF^D3%U&B>YUS$![7$FDA,*T'4',$S=,(&;!RU MDG.E%.H6%, ^U=,7#E]-#,1Q#_E@B,)98*

*<>_S,QIP'E$#D'*S_U!!MXI7,] M*4Q6N[>"0J; *9OUPN'1<$V#,B9HJ] 4YQ:IQ89A06\. M.#:@_=Q.W$XX0/=*3C\#4$L#!!0 (.B##EE4LP1C'0@ ,D4 8 M>&PO=V]R:W-H965T&ULG5AK<]LV%OTK&+733694298?)2V M9YQT^YIVUXUWMQ\Z^P$"+T6L08 !0,OJK]$ 9*F'%)e?)<B$.*0(7]W'NN8>|-MV#AA_%RJB*!YJ8\VEI(JQ>3V?!U51+3_H?W>EU%_F%^==' (M-=U2_'=SXW$W'ZP4NB8,M+/"4WDYN3YZ_?:$UZ<%_]&T":.KP9&LG+OCFY^*MR\F"'2)#*K(%B?_NZ1T0PX,@QH?.YF0XDC>.KWOKWZ?8$?*

B>CO+KP;B,\KX8UODBAIMUP3ELNRFWT>]Q+U[]HC^T MNM!Q*Z0MQ],V[5XYZPB;R_F$0?PLKGJC+W-Q!,/&#L3OSH;JR#^;@LJ=O?/ MX=C@W;+W[NWRH,&?6SL3QXNI6"Z6)P?L'0_1'B=[QY^.]H_K58@>F/COOC"S ME9/)5KA/7=M&*KJ#2?(=.H3<]<% L!3:[%+\152$,BN61_(U?))V M*A@0;$5A!S)?2]5 -#%QUES8F5Q'#3/SH G3T1/2C?1E>2PBFG:L$%ZX8M%$"UQ MDCE@?*

*B2<72>$63C"#[S4@80>+@H^\+X&Q(T:.=\&5%PCH *K0^Y3!6,N[$E,+ *KDR*8IQ1'L CF]_E=O42^+&ZWL$+&X,*)0KN@LT3XHPJ)&(-M]=K3FE>V#0"#R]\]D)(X>_"<<0O?*

*6U>#4[!GM_BLJBNPD)*5]5NK,D M&J.&'B!MN%T!$:=T8]:-CM67>3\3_W"YM7C=[!)S,X74N;#7H>7Y{2.NH ?R M2C.A91),,$/*>RJT$!J:Z5%1PVEJC$]59G4BCA;?_C83MT3P!N:/EEPE-M!:MV0)Z3"P.5&1#O@K.Z\")*7 M5^]828? *7W#*S<,5,X4P.+'2O'<-7W]FL(K, MI67K4VZUS8(Q:[>U]$PMQ\ZD#@(7(@)$58AY3=6-TZMU_6FST]A+GF9&?PXPP M%)&!8(?,W*7BS?*

*(B%:4;H[>O,SDPX_[8WYKI=$(L.LOI*$L_>/9FRE()_IR-MV_L_M!]S"(7"BC%@/9RIDKMC$'G"[/6YSCP(_,(WI=@GM/3T\6+U^#M,UWMIVH1QML8CAR 6\@1-SAT_^@:K/(\A)UQ-

*M.=F=,\F+1Q[+PWJQF"X6B[Y:.A=BJJ:-P'A**&60!AX#6Y(^N;]Q?8,8&9AN M/'W6YK #C.M1!F![@@5@&G]<9&K/V,FM4>2.Y^8\@,9"%XP94? +%3_8>\Z, M,7T-86#$(&"T@%<%!HUZ,)D!A0>@*

*M,@8HF^[+$-2]-W)61^,?9/,5K%[_^*X$4 "\((Y18:L,@*6#\9HG)],(+X M,R=H_KJO U.P*N%4,XDK'QJ7'U%9'2'4_G%^^C-ETH$_UX@WTB,@8!P"]J16R)G4\.W?D MVD YSQJ,!:_?*

6"]X;WHCI]@+KDN<,_#NHKUSN)EV+Z<0FX/P?>[$5H MT&N,"#X1@V<]0%Q%'(FF;,FI=N(XZ# ^XJT<1O,E"SK)00D992D)59N3A'2T?WNFY MS]4+(Q&#UY)&IM=*

*(]%3]=&A^].*0/=BG(Z=B4VG4@U<3F@FK0C=4,,[_S.*' M)2#>N&+(&.BZBR6261E7.O\ZXYZV6-0D[T'(NL&,50N11Z I:N 0NC"[3%LRK*

MJ&;Q/S!K#!)K025_3TK&&HA1S3W2O:Q0<W&8WE4/,>PPDU8YA%0:E,7^ MG\BU:VT7R^[:\#2@1$"U39*0'5OL)#B!CBUV-T?R^[.

*($\\FI/(PVO3W1*WOV3F>C>!P6""UWW._0#%[>Q)QE<1BR MJ&4-2D=1>(4WV*0-`Q(EVC%C1O9QN,(I\$&/0PQ]'$,B1X]^,>;)!H2$$X MA_0!8EG6I.[($" 8^/K4%0>6H1\3YWE[$*=0*>
<;],G9MY.\0#!.$@'HUKE MD %A-F>J[0F+08 /.$4B=H5362/&]L,-U $I<,KM5P!#@FLI;,^=_ +]=%1"-MMOXQ+Q-&-Z%'\^LXFD\]K C9[{OA PWR:MAC*W@4)21L/69[\K!/"4A^GBQ
M1X,YKDV+>O4]_]X-EY$+-1++1C#(1K"\)BN=7S;PJT8JP"1&T M1"+; D3%.! ^"D!$(TW<:M\H+Y+(=V.BIAW336=8"D/]J++2ZXO]S+++?.@0= M^BT(8$9N>TBXQQGJTL\.
!0>*GG<,5OY'=*=1=2'H(G(2-)E8A?'H>GP5?&NE MLE>5 :97AVB7#)Y+N47<-B?W5.0(OPY!&Y#*T']NA\M:GE\/PC=Z*5&>:.T+6 M!?N4[`2.!)B3PC:=5U#R$X0&E/,*P390G&OL#]@6J$MK?Y"
V^<00) ,\0SD MYSE;Q8"KTOR]J&"\+8 [.S<$T6)5IRD4.I!Q@SZ%[%LC1IX>A2CV.B>RL*'G M-(S,N/B;U,HIK6$8RV241N-><CB9B^OEFK!]0]8+TD-2D8N"2CEL0.H5I325 MT[D!&&
(@804X5)RNX,>2ND&ST?6U^#ORXL[9F'O-O&#M#;!P\!*_J4R&NJY&&)/14,B8?,N@4&QQWN M2'7M0JF\.2$=(FF@K'VN$WJOID0DL,7&S7D@#V,FJ*9EF&1@\K$H.P@,0CT_M/Q9IG:E7O9K,!
[;N,0BVH95*3*!Z&FMS70^Q?G"Q,>P\/HEK6ZN6&70_57<'1W4EI-NKM] (F43R'/#R,#3@.B/@!)$/"/1#&__*F$U+?8(AU61A2+0OEIXCC M\N 2G_J7W3&4/8K<3FB:@P"#UG70H&I*
&RJ)=D'PAI9^YW.FIQ&H(8l7+C-M_FD6ZI'K78J"4[;7"TT),;C6C+U7+@=S&<_MNV *1FC)-"SKG7'8?S&X)$4 M)+<%FBC&GI>Y#29,.D1A@X68DVJYT"F73"X"E$H::E%SPGS:T_0FE!1IW89
MDH8K9SA@?0.":XY'JDT-.TN;RC3,^*1V7%M)73S<">NXGDDWBNR N!;X0(_MJ&3MNX,/PBZ>Z2>V&PA618GT IE-B3M].(X%6YTK6K+5:&)TV2BR91S/5V!$FK!5&3Q28OTBO`K0J9$-U]
<(>H,V."K1A*" M4565]F0D/@4L=N/2=/ :?S[I-?YWS)!>^;!6*9.1YN.A3L(A1W!^87"($H M3,.YL4:+6VF\=*EBP'3W>.T^.^.+.H_-"64-<,.*&3C,QJV*I7R'<85 M,) 3&- Y!O3:E'9[#IB_A
/,1(.HN4G>.!L"?HU@N'Q.//>]3R>\<5C' M!]-@P/1,) 7#KVQ1)$]4*RQ2O68E.K]WD8Z00BO.&UL@GL[.$-8">@H!2 M9 MK/07D,Q1_.#"!;#PW/*_M]#U]\.]9/+\Y$AE9-D+ZMFJ7%=M3)UA+4*C;J
M98DE Q>S?3@P'U!\2L61+9,(0K(8.]?I*C;&%19}AMZCG8:V/A-B171#;<.'44A9+WL%#GU#XH M,]'2U6^1L0 RQ@90(B\L+&2#+-IHR[5 < .!Q;#"_1 ^5D*8*6>*(\>Z"R76Y$V(=%
MT8SN8)GI:.ZQ"F)9CBL-6"E"U[^P6<^O"U2G9#9MB)QL,5'NFB(10O>U08" M%X&8=DKJDF MS@=9C08#DE<6$ATB1QM[D&)M*\ M F00%DZY^LW!XLGHX!?\|3 34-J)80\ Z%H]*&
5:0 (6P[&,Z$Z+7=_\RCT M,FU'MYMZ"!N(3<.P>D",M@G=(/8.=$/OPB96D3LK)W3J=[+\U-?I^&40D+ARZ MX,TG]:A]^F?!DNV!,PY^1E]_N%+@E0EAA%WYO)T#A}>DOM|3WUMK@6QCQUNH
M#*25/71$"L4E=$QWND[VX*2=9MR1*8J]92]\=R1^ M!DE M\'74IN!P>;6Y5(K?[)%'6\0:kd1+BX%\U >2N&M#=,?@;,LRFU1{2+I[
M\)2_C_@&O2N%18!^E=HX#*93W.ZFM_BG=P$5\O5S6ME=(WHERA+_^.*]WV:L MIT>\5RJ6B4]^TXM7%&<1>>LB(0H5IX["&WA\Z2R\HS@#A)F5],>(CNA&H?YH M.KX8\A*/V8+K-,W5--
C6SFX]$[C66WS MRP#>.-!7#T?!WVEPI.-7I,#?#;@^ Q%S$UI;9>GS!LV$+!*(1*8?^RR6F$T]_29)5 M@\'UP$2]C,GIMA,U3.9!2#O<+AT.8UV=/4-V'P8BBVSGMZ.F"_/DJU0S?PP'
M/KB!S0TAB8U,*C'11Y]L1A3?=@# >'U#\\C+!J.3:.JZ4G74:! /EN6I2W6%*M8*"1O\ 1/WQ EVX_$XFEU=}}U\0S?IZ'T6/HCP\8=T+/DPZF62[V<_ H9. M:5>5GQ9E$K5: =-U
[I33$)"Z9.1\EE%#>W*!MB#BFM90M7[@8\W1HKNI!G MV"0>>.3_P2;,/AQ'\]J,_T=MI*?5_[]&!_04SUN$-XL>E%U[(4 =B*T(2%'V MLXM1$F0U44YZYN+/X,R]..06)Z >7!ZC_:&D
./$1Q>;]ATIOEBR=H]NFP! MYO@HH0#A:AW1#EX>Y-9OHA#4D'1@7,#X,SC";#P#*\34Q4),2$#BK!\]JB)-M4S%(+6E=N.@=$Z+A.!)LTZ6+*HW#:N2ML!1ZMRF.7Y82'M12,[G3IV5H8H)^
M#4AL$UOD^+1R78N7$070W%MKTN)%M2PB9FK^,V:3H^G_J,5N!QA(MQIN_=M,XR/0DDY]D7N-MCMB^GS(@DVF;O 1 80X]}>_E/'4Z{?=jE'/L28/-M7R'ZV)P6W)??%N12N&N??#0E)0=GZ][#
[ZL@4C<":Z \1ZZAE)!W2P2R?B\BJ:SZ\'{_33N5_'-M0,_B-P.74_$ C\T>|>5U=_7^V=F$93>\RVS_+B^QSX'7 B+T#@CN==AJ"MZL_M17H:O8R&WE ^#UXDSU2YIM?ED2]8D]\!}]_Z-
_)O^$7T9CB_SO^++-MR\22>R>O9U=_*[HM[1(.I2$B7#)_ &FU '-M 6^P!^^-Q*D&_VZQF),Ù$',,0\!D9/2695*7@F..?X,**4W;H.UE2+++,?32EEP9I %B*X3*N4H@Z8Z]
M39DVV:79FB;C,A1%K28P4E,4]*KC)17253U?F$@L8NH59+E2[A8)F#[-D^_@-[I M^ENE_/H'0Z4U=Z!%G6Q6@#@1E^CB! !^*\7U*7]%>95Q3K+LK4J9O7ML+N- M-
&\4*]TP>SA_];LH0>M4U<-QW;#,N]$G6'=FP"^U<;I6-24K.29F6=ET M"0KM.H>%MC, .N9SE4I^>N@O-I0" QN>X)FXVSUO3,9 C%+,;,59KRK97C(8 M=|?CR9YT(=%YY1ZG^2Z=-LC*;?
>'",KRWH>&7 K?3I)V>FRSKG6[S>,S"4'P MB-V82\6@\$?>E\@DO9+WJ2P]$] PVZP49VAD';C&CXB DFOU48 MNP6?.S#GE78>T809VV#7W;$4*)5@[H8MG'4PF@L&CZ-@TR'Y[<&4/X?#(I>Z
M):J3][4=1_6(V:T2B"=]"5N.QFR6<X>J#T@#_MP)9IL^MR?#D=J1U2'"7DQ$C#7JC!$CAI4.ZOI$D%OBMS>]RLK\SX MJSG/CX522Dx42"]JB/=/"5_^Vf.HS=6VJL LT&N5R#E5$/NK4.U'[OYD
MKAO8A7!Y"8]+W!.E90&LSXWQ[0L;V-P_S_\%4$L#!!0 (.B##EG"+T'2 M<-0 +<+ 9 >&PO=V]R:W-H965T\GV MQ;,(N^_S#^\>^M*1__WE=)N&97>UZ>3B4M+K(0;FQHUK>3&5L+3IRTF
MKK8HLN!4J4D\G1Y-*B%UM%J$N2N[6IC&*ZGQRH)K]DK8AW-4IEU&LV@[<2V+ MTO/$9+6H18$WZ'^OKRQ]388HF:Q0.VDT6,R7T7IV>CYG^V#PA|36/1D#9Y(8 M<\L?W]E-&5
j##U'$'0WP8O4"D.1##N^IC1L"4[/AUOHW)\N5,NB7!X8=1W MF2ER&1U'D&$%N&N6O3?L5 ^WP..5YJE N_T':\V\4D$,>.]7[G0E!)W?V+ \YZ' M0]?E!OT2.<>\0!$=&'E)^:%.F%-
"Y-M*1H/0JK!F\!)S8=RXRVM2O+S]YLF M<7C7H/;P>4._,C'Q%)87)VD?XKP+$>\(<0271OO2P6>=8?.C_X3@#)CB++,;S M>&_GQL]AH/I",)I/.\3[V#(\2#$.WAICO#G.G'>4D7\]5RZ7,3Y\}&X2TY=
M+5)<1M0&#NT&H]7,-[.CZ=D>K/,!ZWQ?I)>=Q]X0SP.$-7525G%%-MQ-!MF,P)<(%Z;JA7X P7M@-M%IQMMT,6#*%X._QT;OWUS',?3LVV 73"8G;T'Z5Q#.T@=-KD4##P$37%FY(5NX
M4D0'>XQA[.A576IETMG_8FA]%H-(S 9'T):HP5A92"V4>N@#CT#F{* T*D/+ M-(E_)}.C[-#(M !X*T6B4+P!O >;2H=!11M.Y(U88VGE*P4)>6Q3K+LK4J9O7ML+N- M-
MKAO8A7!Y"8]+W!:E90&LSXWQ[0L;V-P_S_\%4$L#!!0 (.B##EG"+T'2 M<-0 +<+ 9 >&PO=V]R:W-H965T\GV MQ;,(N^_S#^\>^M*1__WE=)N&97>UZ>3B4M+K(0;FQHUK>3&5L+3IRTF
MKK8HLN!4J4D\G1Y-*B%UM%J$N2N[6IC&*ZGQRH)K]DK8AW-4IEU&LV@[<2V+ MTO/$9+6H18$WZ'^OKRQ]388HF:Q0.VDT6,R7T7IV>CYG^V#PA|36/1D#9Y(8 M<\L?W]E-&5
j##U'$'0WP8O4"D.1##N^IC1L"4[/AUOHW)\N5,NB7!X8=1W MF2ER&1U'D&$%N&N6O3?L5 ^WP..5YJE N_T':\V\4D$,>.]7[G0E!)W?V+ \YZ' M0]?E!OT2.<>\0!$=&'E)^:%.F%-
"Y-M*1H/0JK!F\!)S8=RXRVM2O+S]YLF M<7C7H/;P>4._,C'Q%)87)VD?XKP+$>\(<0271OO2P6>=8?.C_X3@#)CB++,;S M>&_GQL]AH/I",)I/.\3[V#(\2#$.WAICO#G.G'>4D7\]5RZ7,3Y\}&X2TY=
M+5)<1M0&#NT&H]7,-[.CZ=D>K/,!ZWQ?I)>=Q]X0SP.$-7525G%%-MQ-!MF,P)<(%Z;JA7X P7M@-M%IQMMT,6#*%X._QT;OWUS',?3LVV 73"8G;T'Z5Q#.T@=-KD4##P$37%FY(5NX
M4D0'>XQA[.A576IETMG_8FA]%H-(S 9'T):HP5A92"V4>N@#CT#F{* T*D/+ M-(E_)}.C[-#(M !X*T6B4+P!O >;2H=!11M.Y(U88VGE*P4)>6Q3K+LK4J9O7ML+N- M-
MKAO8A7!Y"8]+W!:E90&LSXWQ[0L;V-P_S_\%4$L#!!0 (.B##EG"+T'2 M<-0 +<+ 9 >&PO=V]R:W-H965T\GV MQ;,(N^_S#^\>^M*1__WE=)N&97>UZ>3B4M+K(0;FQHUK>3&5L+3IRTF
MKK8HLN!4J4D\G1Y-*B%UM%J$N2N[6IC&*ZGQRH)K]DK8AW-4IEU&LV@[<2V+ MTO/$9+6H18$WZ'^OKRQ]388HF:Q0.VDT6,R7T7IV>CYG^V#PA|36/1D#9Y(8 M<\L?W]E-&5
j##U'$'0WP8O4"D.1##N^IC1L"4[/AUOHW)\N5,NB7!X8=1W MF2ER&1U'D&$%N&N6O3?L5 ^WP..5YJE N_T':\V\4D$,>.]7[G0E!)W?V+ \YZ' M0]?E!OT2.<>\0!$=&'E)^:%.F%-
"Y-M*1H/0JK!F\!)S8=RXRVM2O+S]YLF M<7C7H/;P>4._,C'Q%)87)VD?XKP+$>\(<0271OO2P6>=8?.C_X3@#)CB++,;S M>&_GQL]AH/I",)I/.\3[V#(\2#$.WAICO#G.G'>4D7\]5RZ7,3Y\}&X2TY=
M+5)<1M0&#NT&H]7,-[.CZ=D>K/,!ZWQ?I)>=Q]X0SP.$-7525G%%-MQ-!MF,P)<(%Z;JA7X P7M@-M%IQMMT,6#*%X._QT;OWUS',?3LVV 73"8G;T'Z5Q#.T@=-KD4##P$37%FY(5NX
M4D0'>XQA[.A576IETMG_8FA]%H-(S 9'T):HP5A92"V4>N@#CT#F{* T*D/+ M-(E_)}.C[-#(M !X*T6B4+P!O >;2H=!11M.Y(U88VGE*P4)>6Q3K+LK4J9O7ML+N- M-
(>^]WNL\#;OZ8,Y/>_/[T_!>'WKI6%>GK0TE[V2AT\^^XO-MIP\7/^PYW?UTNOO{IA),T^=8/\>'[<*L5.8NI7-#.7$2]E& MP(*MM'A2-ZR2+,&/0H1U6[X.AVVMQO9MI9S8J$99654W]'25=GXMZ?
&IX2.P MF]F$RUI974A65#<=+NKL)+KQ&1/VG;-A,8FMJIL9",L1I1&-Z?!44?4ECE=5 M))+VR1;RD=,&=`@4>UKU6Z_I_*N;_ZSVLFEZ]#SEAKD@=PY^6\F*3>@KANS$ M2U6H>J6LN'K4 M'?
9ZWXBWAD:.(BE:VJN]TX6;B35/,Q2'M]-U?SL_,%C^!\ M5Z<`-`D%B:M*P\JED.)Z\.TA+<]W@TO4KITN-"CH3+]Y=:MCCI98,TVCGA?_\ M\PMQ&.7Z!W
KBIV!WDM5R6O$A:ATS0>MM%SI2G6M!:"Q."f\^UX;\'OT1;!;N)E-(8@!2=F3"RA)H MJGSV.7P'U(GSHSF$\6-T9${E]JEE X)#= ILQ=F7Y*PJ[A_TA94)R'93%HPVA-MN0)XB]Y:NI<}>\19^8A91KBG-
@8]#KOMD@=_4)NI83SZTL+/E&+"GE81,X7)XJH;)2UM2@KNYIO{G.V<<^J8ZY;.F MKTK:G$@QH0)K?NT,3SJYU(S=D.<\V;)G*X*XTH,=8R;.C;.^E3]47B])&8 .B MIN)T$/2:U+ AI0H,PRK[X46]EL>-
]:.Z;>AA*:+;,B M03#2'A[R/(&0!WLYPHJ6(H%<(#4TO<+_A=DTC,TINO$G15$@RK:M;F(>0.A? M:1=Q/DEM7YA2KQEG6\!3PO(R94_Q$6%=B(>+A[.T)9Z<\W'H/<2SWW@V$HZ:R30^@<<='!3A
A8R$]@N)!3^0KYQ_U^2]LQ,?S Z02 M'3.4!S35"P2&%+!`X]8^"@LRE>$*OC$&&1@=NB>=J!/M<_$+FOVA3'--R)8$\ M-L#89,E<3N@UDA3;4$)X5K;B] AOT6-LFI2-9$W*CM<[#\O*K^F,@)>= .T\
M\>2P!C0TV;)R)B^W'3;^)D]LK)Q8>HI%P@HW/^8KMX-N)K\256%M(%,EN M@#4.Y$*E[@)(#80XB1'(RYA&L)Y=EO(#8H<6UH3'A.S B]8{UK!.@&)MHNFH M5,GAN&7K*Z;.57F B8H(5;.($
>.EA5!;WN;'[(<#NFG!P"&(__K@Z))E.L M@8:.2ZL-AH GXZR@RRK &'L.N3H6^>B1)#+]4>+.2D]@GL^T-]I*<'1MI9]MEW0)CTRZ"0C'.7,Q_20(TDJ&I24*\E(AU=#>WB4#NX4BGB&YB-
*QN,&1_PWR MK1C"'B(,Y*HRUWP_[K)(MR\$^52^_J5(AAXH4,*S G.*\W(YA[.)\=H1LIBX1FXN*.\X#K,>U^6J@WD MRGBH42*GDBHH72>C9%$RT9E3JBS8U%GCEB*2E'M)^%S\/&7[WZ=6W\
2>>>)_6L@'M<<<6.QS/:X>\7Y3*!O M%&R!K4&J;%F6NT_K%O3D+&J^DZMP/T{'UHZ!V$.+RHSYBG*Z]TO H]1'* M=N2VVFOBO'!%]%N%MDD5?^P(5]W! -!IMIRQ\1HY6+%*2%<3-O
G)XQ@_,8V/E3%U_'9PU-.%C,N$MK7QSEEIN35Q=_M13=0[\AIG+##P>3_K'NA5,#^;98TE8G=#[&!\]= YX"RZ?Z+VA(*,H<'#]]2(>Z]M^^JYX[DDBYRF)-MG.}-(LLKJ2L*NF,H<7PIJ[S3GDHG>\5-
IY.]>TPZ5(Y6.,DY(;T(@R@R*?Y MY3QO0+G.;1""-]F">;X=1QCB*UZGF6_)"%V+%EY B_F<\"W$T8"8514"!Q M.:?Y12++=ECH&2,(.$Y8L,&C)'//:R,&2>8A=P\6:8]/NF655MZ M!WK%MJ'(/R0Q1[S-
GZO.*6WNBCXAR={9+]D\P(U<QXV4GU-1ZQ60%8C@*W6 M'6=FWX(%+/U;>KOD$!D.+ "^5]#IM66C:X"=O(W[+ @-+*+8&&)"DVU1[!P?G M[D]42 0_VMR#(]9TOO4"3L-U'(*Z$9!
M_%CI<9S'0,WHHF_%R..4XM/,`[_BB2>"\,-'H_(-WF=QA9P6!4OG$ MR;%(TR[MN!&Z4U8!90.,"%GXAE\XFZ@7%'$[69G-ZS^&UD%3;DWV[>\"/!H MW4FE,7=\6W&C=UA#V?
FK.)TM%@LQBQ/XP74IZ_$[AZ\RQ&[OLX<_/$[\X?%>_M_G`1AM9T4.$-6DWLE/D]#=-7UKTV'IY8#X7!Y^>DH3$,/[ATO'M,[_P.H_&1 M[CT.|
{[[BZ/OQ9N:1@1!7P3$\&0V%J4\@,"!V*P1P[(R+*,,MR;B5K1Y&V:+ M+*B#H#()0GIN+3@#OZ6*S8P+^L#$DNKA2),!U:&+Z-"J@<V MQL87,L.6N$&C"!K:_@14.S34_N,"2I9\#,30>JWX*R=.9/0BB)+
<1C<-YXPU M]0#)>ZYOHY0)P/AZ*0O^RG^XVZ M3CZX*V'!\;L]SS\\8\D8_8+D]+LA.'LT]]VO?4Y]/%\GD8F^%_N1;V5>A7YPLQ\H@H'N/UE++)>*/C^D_.*") M(LWBN?GT[?OMKYNF/X.*.95-0Y&A&?
E:!'8Y=H>OK-K_]C^/@UZ&3K3W')%(? MFNJF'$V40RG,WD[2NQT(XD'#'6NZT2PAD++]AHDCM&GE\E32@$E0%W1^{3
M$[*.6JQ1TAK9JR#R2>&8&SY\.PN_79GJ2H69&$>I/SQ_3XA]M$VSE]AO1NUR M1_3.LWB?BW@ 1AWZ,7V][DY#N?QE-Z>~G]0_9>;RHL3K(/BVME_SY_4?
M3N._,4YWTR?,2_]A\O"X_{[[K,0;&@14.HVEB_FC!P?"^D^F_45C6OY,>66Z MSM3\&ULG5?,(7$H8DX_"@)+5K^\"I"@ZEMFT+\)M M+^< N\O5V4:J>[U$_/0%D*?
#Y;&K$Y(YTNL63:ERL4=+)+53)#2[48Z95"`MECFELAA%03 9E8R+P>S.[7M2LP.9F8(+_*1 5V7)U/82"DY'X2#W<8M7RR_M[C-SE9L@7=HOJP^<5J-
6BL9+U%H+@4HS,\%^!IY<3*.X&O'#>Z,P?+0"[E MO5U<9^>#P_+" E-C+3 :UGB%16$-$8SOC_8<-G;.VELM#N%S:U[#0>0%II(\M&F1"47-0C>VCN-MH:.PCRC#4*D<-
=.W(HWS'#9F=*;D!9:,/]FXZJTR9P7.A'N3.*3CGIF=D'-MQA5\946%<(-,5PKIQHV&H\]L7]_^/AL9\F)E1VEC*V&#UC<0(W4IBEAO*2P29LYIWK%4CP?
*4&IH5&L;0,F($,8KW6TPKI;A8P"737!\BU>OV,*G/2X1< M%13+UK*Q0=(D-/^;+1*M'0\94L5TQL7TXB<+I6PVYA;5VL>8<%5/1$6$VH[!#J;-H$IB*PHS2WE$C%W@G%![;Q 4QD|
V3+.>H([=;CPD5;U" M5P&*+1QQ04AEI4E8'_O>HA(4!5!M%2F>2P$(\'$=Q:.^+1 MRGL)X^&;.^*3CJC[?. ^HG^N3;_@?9\3!)WG3&)V2A)R'&;4*,?S8A_B#GUV)5 M.1(4-?
2R%BJS)9 .,/W)&E\K-%JX*BC">UKBA?$#)FT 7*@1PXJ2[< MYF/ABZ>"WOL'FQ3DRJ_(?1#> UC/X M,J5I'8"1D/@G]89'F5T29OHHH?>[M)\U\I3AXHY/S :MM)-
4A}).I=|OU_>M<(0$7Y *U 66Q)/X8?G&^0AH3/JZO MJIC6LJ [^ON_O,]O\0_\H3 >B!OD*4$WP *K$0Q>U
MUD;J;GB7$O_%8H>06=KHLB9[J<4_H/"].Q+O-BJMN/?MR06Z7+G$\1>B_O@4 M+JWV=?5ZEVD$O449!L.3<>)=M30?4VSECB 93MXD<.P1D,?V)T-J(0Y&]JC3
M\I6H%JZQU9#*2IBZ^VMWV][YHFX9]^)UXWW#%#'34&!.JH$_I1*HZF:V7ABY M<@WD7!IJ1]UT2?T_*BM Y[F49K>P#MI_%+_ %!+ P04 " #H@PY9&H\2 M##4$!&"@ &0
'AL+W=O&TE47114_K<&+O9+QW>ZA2]L MEVNS,%HM*KJ##>B_JGN)LU&/DK("2L5$221D2^?&GZ]C(V\%_F:P5T=C8BS9 M"O%H)A_3I>,90L AT0:!XN\);H%S
X0TOK683G^D43P>=^B_6MO1EBU5<"OX M5Y;J?:E,'9]*1FNNOXZ[.#8PDF@BOE)?M6UG-(4BLMBE89&+12L/[FN:7#_MSR@&K4)>3<'698?]*:KA11{HTTHIF!-=5{(SE6FDO9:
(F[#/7TZ@^A%*E MDDU;)9!W#W3+05TM1AK!C<@H:8'6#5#P Z Q^21*G2MR5Z:0GNJ/D%3/+.B8 MK8.+@+_7Y9"$GDL"+X@NX(6]H:'%"W^ =T=ER]M?_<;)66&!C_GK.W
M@8O.PYEDF:N*)K!T,!L4R"=P5F_?^&/O_06R44\VNH2^VF#RI34'(C)R*XJJ MUM0&,4[75+&$T#(E'QBO-:3D,^:NO4=C&4H7*&@-/&?5Y7,? Y@4JW2@;;(#6S%(-\/GC()%> H=H/
/YAPN%$TPC'_'M(P M\H911X;QK..]-#O5H/AV'LMX\XO-LDPDLT4=&3GKAQB'2#Z6M)'WO,&T[\ M<[2C4JH72D;ERD<+XFGI:4;#+X(2&J0B=R[[5'&O2@>]H32*&TAH;4"
MLXL)!5F&+SXV S4W6YC,FEUWSI@/;11QT,N:,/CS*#*:FQ25.5B1;!QC:$R) M'TS=>!H,[K%Q "GQY$8.E V9U_Y.&UL M?57?;]LV$'[W7W%0BZ(%/(NB_$-.,0-VTFT=4#1(MO9AV
,MG2TBE*B1=.S\ M]SU2MI9TCE]L'GG?=]_Q>*?97IL'6R(Z.%2]MO.H=*ZYBF.;EU@).] -UG2R MT:82CDRSC6UC4!0!5*F8,S:.*R'K:#$+>[=F,=,[IV2-MP;LK]]$>5]ATOMY
ME$2GC3NY+9W?B!>S1FSQ'MU?S:TA*^Y8"EEA;:0GN>\F'BV3]]70^P>',Q+W MJMD:?"9KK1^\|;F81\P+0H6Y\PR_A[Q&I7R1^3CWR-GU(7T*[#+

XC:U$K="ZDZ_$&L_(R%.M@A_(M[XS2^P&[QOHNT(S%"A7:K0SM#;)}EI M9QZ\#^R(G2S5;*_WRE8MDMIS-B;0(KYJF;[C,H#\HZ0\NT00# ME_HX C/T@4#5OH)3VZ"N%-5*-0:C":0P>JD_C2&K4YOZ#\9^<S\MG":$PNT>I.A M5@#+)C/)50D0VH/7<6UQ1%BRSW,R6T=HBI5:H3A1=K":.)TA69J5&5*.(UD MY[>%T]A8H)EM@7H'VJ(*A-*>NNZH6+U;<*)V,U$))D @}K_,O".LO)7!VA MF914\1'V+]{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

*M+4*U&-425!.HEK[ZXR5G7=OQ,=0=GXZ\N\ES[3XKYEJQJM\:,NXZDP|MZJ":M:1S?"Z3K&C$6.JN-:@ZJN:CFH9J/:@&JA:@6H5J,.:@FJ"51+*4U.R+:.#8ZAO M_+^]K;,,YN]C+=EK>^F6?\V2>7NZSFSO5//.Q$2[.:AF&L?W[S#&W<>3 MT=X-JCFHVJ*:AVH^J@6H%J):A&HOJB6II>E MI30Y,lO>C:'NW8BCC#R,R%^T M5=YIW@W:N4\$U$]4L5+-1S4$U%|6\G2;===+[H^&7EHI,&]!9V/ F]\W;/Z+0Q MJB6HD:E MI30I 8=MFV;XSVI3--?4*%:O7E-#O9U|\Q353%2S4,U&-0?57%3S M4,U"M0#50E2+4"U&M0351!*JEE"8G|DL|O\>0S+4_9_JM7>.M.8KV:5#-VFG-73Z>UW:#-_KEY<'|4VQT6@?57%3S4,U"M0#50E2+4"U&M035 M*JEE"9'9%NG&:KK-'_-XO^$"VJJM[-WZ*)E'52S4,U&-0?57%3S4,U"M0#5 M0E2+4"U&M035!*JEE"8G<]LDJC\D%_\C-#]S40U"]5L5'-0S44U#]5\5 M0 M+42U"-5B5$M03:!.;2FER?K95HN$/KA*I_=Z)BE:)4,U"-1O5'%1S4?>EQ*4RWUSDZTZH1]%JK9].:@FHMJ M'JKYJ!:@6HAJT;#C=E;&5#^\!&F,S!]@FD"UE-*D5!RU=:B1N@X59=^T>H$_MTD19?&ZZ|&)13R:M[[24JWV34A4,U'-0C4:U1Q40G53%2S4,U&-0?57%3S4,U"M0#50E2+4"U& MM035!*JEE"\GI'FI[]%)>K;#4K5K=:_O4^7VTZU^5JHW=J'M^L9]AU[H.) M3FNAFHU]#JJYJ.:AFH]J .J%]!:A6HOJ":H)5$LI30[$MJHT4E>5[*PH=_=* M6S17MUNOM'}966;UPQ019) ^*15%/Z\0(M%F$:B.J6:AF[3]WP:C:<=O P>= MUD4U#]7\4[\E 3IMB&H1JL6HEJ":0+64TN3X._M_]8??N5^RS]E$ZMEZIR*I MF:AFH9J-.@ZJN:CFH9J/:@&JA:@6H5J,.@FJ"51+*4W.U[8O-!JC^RO1=A"J MF:AFH9J-.@ZJN:CFH9J/:@&JA:@6H5J,.@FJ"51+*4W.S[9"-%)7B.0+*>]? M;VFW2N^\+Y$:[1VCDZ/UF3ZX[-R#B3:"4,U&-0?57%3S4,U"M0#50E2+4"U& MM035!*JEE"9'9-L;&JE[0W)$WN_6\?=/Z_C.?)P>G1XV'78$VK5ZZMIO(-$^_M#ZK9J..@FHMJ'JKYJ!:@6HAJ$:K%J):@FD"UE-+D>&S[/"/U[8N2FYN\W#O@_MW?V&\:J?@&0*,/ZJ:..AFH9J-.@ZJN:CFH9J/:@&JA:@6H5J,.@FJ"51+*4W. MPI:?.U+W<{[CB$_]^8IUEN8;LWVIIU!MMZ)A_9U4,U!-1?5%3S42U M1#5(E2+42U!-8%]*:7)-MB6>TB:? NZ_R>;ZJRF%7Y7/N4K_*;8E9D"VW]9967F[OB7EODG_-%L'S/+B#F@P.KP= MD(E..Z&:C6H.JKFHYJ&:CVH!JH6H%[%:C&H])@E42RE-MBV_S-6]W]^T.[0 M^FO>]JB:L/[X&DS*XO]]@%\U>Y2]9;VCEVT4H1]%JK9J..@FHMJ'JKYJ!:@ M6HAJ$:K%J}:@FD"UE-+D;&[+2?6'Y.[2$9]?]:&:BFH5J-JHH.#=]/]H% MJ!:B6H1J,:HEJ"90+:4T.3_;\M%8?;.BIS>ESSL%[LMBEFL_%2MMOEXLLG*C MW>?EX[{4GSL3%:TCI;3IWGX_K22%>T9H9J:.@ZJN:CFH9J/:@&JA:@6 MH5J,.@FJ"51+*4V.RK9G-%:WC)#= .]!..BM*O26|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|0C4;U1Q4T_<>T9\E*75', 7#^7L+MDOUSZU*H M9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HOJB6HD=M I30YB-M6U72(KN_1$A2] MF:AFH9J-.@ZJN:CFH9J/:@&JA:@6H5J,.@FJ"51+*4W.S[8$57^H>B/[W2?Q MJ_W>B?JH[12X!V\& _W@2#XZ[85]-JHYJ:.BFH=]/]H%J!:B6H1J,:HEJ"90 M+:4T.2K;OM-4W7?RFCV?VY/O-]DB?]XEVAF*;+-.IfU^"6ET6@O5;%1S4,U% M-0_5?%0+4"U$M0C58E1+4$V@6DIIGT'O M.$;[3:AFH9J-.@ZJN:CFH9J/:@&JA:@6H5J,.@FJ"51+*4W.I+;?-$7[35.T MWX1I)]H9J&:CFH-J+JIYJ..C6H!J(:I%J!:C6H)J M522I/SL^TW3=7!HN>C MIHI|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|?T7F2,/-(4G3%BX0O'XXNJ28L5OM M)3KZ<(P^(,;1-4M3Z*#&OH; C'I_,+H.X*(((GP@B0M>"ZY5^Q_&$)KOV(@"J M4(6J"Y"I_L$O* S"? DL\LQ>8!U&;^4XXO8KDGO77>XKD%9$47?R7 MY',I"5}2* N-+AY0L|\->;,#-YULB$_3],[A$5YIFZN\V?HOQ^^WCFZ7@3*U) M3" <>U+JBC=+V&.*1|'0S.*F"=$9Q($0!Q7$@1.B+3DDUC8# M8DA|\"6M9#E6FJQC4G>XQ MY,1P($/#B]&ADZ%O=N,$)&1#)X|H .F*K*V^[=#5D%SYH=812: <7N]A8^O06X+0_%&=8X0W<5 MD/MG[\#MXM43VY&W7<"UU:/OK?5PIV*O*V^[=-5R#[OUWFOKP.VM[ZB#MY!\ MN-9\V*W2P@ /T$U"N+L2.A)L)>2WD'^XUG\X>N]*Z$@*EG2]A,#$M;+$;FEY M2^-<@C," X^DY@+&5O1AV0#QVTR3ZG54(M0^=G#D3EJ,T3412. M@N&>9&$I=CH(@]#]MHNJ5H/X&;46A,$++\KXCH59B>0O9AVO=AT?OZ'>=ZL:N MO.W>U-3",70JK;?*+V+4G9N X6BTE;,NV [#7]O T*W;_N|M1^F^"3+L15&T M? R!TA_%:F'[CNC&C&ULM9AM<^(V$,>_BL;M=)*9!ELR&$B!F81P%/ M;(M* I)O?Y+MV& ;82AY Y;M7>UO5P]_:[1A_$4L "1ZC:-$C*V%E,MKVQ;^ M F(J.FP)B7HR8SRF4C7YW!9+#C1(C>+()H|CV3$-$VLR2N_=\\F(K604)G#/-MD5C%,>5OMQ"QS=C"UON-AW"^D/J&/1DMZ1P>07Y;WG/5L@LO01A#(D*6(-ZS ML76#KZ? $U0;I&TA,.36-=(HSXRIZ,:G8$PY.B*(P)?:!55_;YA"%&E/*H[__MMJ?SR*1_M_J)-VEH+%N;&*(Z3D^-^YHG8,B"]/08D-R 5_^SM.7!=C$IS=A99-MBG5')9V:.- L@KMI6WO1%FIO46M&$B2[CH^3J:.CLY.11,O_E2BH*I#G:&(WN]36B,X43"7D'8,Q+_^P6DB MU3PI0-*KDPR|@1Z5.R3&ODXD\0H2ST@RU96*(@AL>%V&_#"35V.ZZE5XC#*V> MR-,O>/I'C#*VU%D"Q%APBZ]?(7-<;DD&%KOY;97CNQ#THXAX8XWX*H0<430*D M"]%V1M60#*W5;43E<2"#.@AVO'ZU3,:.3B53L_=&G$_O0+W0T&?(S@:;U@O M@,..W.JL,@9P(AYVRLW8,2[fWU/5H8IXLP:N5!3*B0'=\U"-S\/,0=[!F?:# M6-L'_>TL(5$8H%VBI'J3E;Y8C64>#[=`=[W2KL]0(MEER9P^$6%^G4-CUSMZ=BE5H&&W7#GMW8),:.[H]>DCS&I+DOF$$Y%**+4+/D:\ MU!>FEK#=6C4QZ?1KHI[8##0O13R')OUR=&[24NJ7IW*[?1(E>HC! TN%0TV M2XJ#>TM+6*|>&:)Q:S/R(J0.+N4.[A^WSSR_N0/DIGZ"$PD5Q_7*QJAO\(9 MH(LW4-B7;?8>H\@Z>N\YD[?=%)7*"INEE6%&-[*;O0U0FD4T1"VW4HP"NB;.M; 1OYXKT&CSLPI:Z"IN%U3$SOY'>[+Y*WTC|$^_UQF1OOZY)_5U\3$?KHB4:K-G*3G$DPY9GX M"/E%2OE%S/+KR"F?>_.VEWK'<2HKO;G/4YE*[47,VLLXLUMRNJTXSRK.[*T3 MS1CX/#WH%(P^28|0K+7]+U[.3Z*<4SJ6@1A',E*G3Z2N=P;/# MW:DAV3(\WUF4(XO5P #8#K%}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{^>DJ!)LK ALB,9>Y6,O3KV\>]4/X%N0)0PL4:,\BO& M%6Q9FB/(%>R84HS433E;\I3N#IZZ"M/:0\5MR#K.S);W+?CBUY_0$FS/53M MOW8=R7%9R7%9\<"%7D($_A0^OWQ'K,E]D_P#TSHG1<G-M6H(, #:I,HV5QA-MN6=?7%[#*7|$MS<(\)6 _=W@.."F(M;3&WJTZ>`$OZW3Z@BKEVEV-^8=Y(\1?2@ O54* J3 MVIV#FQRT@MY@<'SA9[6FGZMR0V1*E]7*E^_I,A,?]PB4VO_N,>C2;*P(;*C MN VJN V:+3*#)F5LDBQLB.Q(OG;P]<,|^/'*3&G3MW5F\%V=J3?^7*6;8BND M](@_:H0S5VK65&B*9"U-T1M5LU;I.7,/F?]U>]+WW3*VYT)#BBJ!!ZXK>WZIH M)8N!D1O77"VEH5;-/2;4?J.R&VAJ):79#^P!54,__A=02P,$% @ Z(,. M6;'(6V1(P RA0 T !X,"|S=`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|*)D|ANLWMO|LV^UZ1? MGX0VCEM;AZTVZL&A=DB^P^%8K)-ZDP47FLNZ-^=)PN2+,Y>1UW1B_E#;TC?C M$Y,2A="/+3@DZ_8WEO!%%K>C[F$AZE'K|E>87B=]3|0F\Y<)6[)D7'?5;%(U M/=,P6>L+"+O(776Y$8QC,3<"&)8'AX[*0PQM8MBN#'K89Y P:6!S+]W5KCNXU7 MR/XZP/9T7X5@,|4K$9LIOM:.N-<-&"LWFTL#S"P7<,>8!R0#B6G37:!0AJQ/\OJT_V%,2AG'L1@!S.PA##(&G$4@_NO(.\YCWEK_]I.?H#4$L#!!0 (.B##EF7BKL

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l0%DP3>_>8UKBENU=D;.43AUMK;L1)>W C^/6_H8?\U!>=+#8!T'F;2V>V&.DIQU0XI9.B6$5X_L=)%$PWQ_TOESYGR1HNMHI9CUM0- MIY!.]M4*Z!8IV$&3E\=P4N'-'A_7<_(8=MT"A_N?N5\(P4=HDOR38 M$Q9$LG;EP#GI*S ?D8K%?YG7BG-UD3?]!-,RSR5=3O)Q2^?!M^,1CTI(S M&!Z@/*2FEH>$;J1\8ZF7C$? 3"#(VL-&A2I MP=8W9IP/95\;_3IL!1S M Z4N2/-.JM5=_E_$L"1/T7@'O%%XW;ZA?/\E+CNG2E)(A^Y?A1LZ8Y:&^5)*.M7;@XET4>!,FQ0@32C)^_V!-- BCK"!728DBOT4_@"BH2\S$/98A9B$ BH)Q# M8!PB7,&AHW)CGRW+B=A6&7(5Z?B\6VY[!E3/>R=&S1D4N?"^5-O*X;>-^.^#\|_3 4A+/*+N M"(G(O\%C;0.7TVO9X\-_3_ M^M3C3B$<;\#&"QO3)(N>1D8'>#,U%*R>7^#++M%KZ(0K11C?4S@!)B84!9V9S MLS IP:1(8Q+@VV2>N$KQGT8X)!JQ,T@S?Q|/1Y)5L&GZ!EFURXV;OO?L4 M>G*IG1L3I%,92+58<8VE&L9<"]%R')274Y@.96N!A"]S3/H? M:@AK/GE(;FYI*GB2HZ?G,#GMK1_-?[Z&TM)P.U!TOJ+#"/Y=Q6RWXS#]"L8 MK=.H./IC#)=H_W_DD)\C*% <\5AS:1WW@D4H'Y*N7_!*9\R-(?^V/9 7'2#4+ M[X1B7<>I!;TW_Z(T]3A_Z($$A\W:(,HO%GA4B@8X 81-#':M5ZO31K9[K'2 MXM&G3^@IZf/G0N)H$IJO;fNS5G-"O - LN(LNGC3FC1/HKKD\A1API56/9DZ; M=_L.YV66:DI^4#U)K>$=U5H'XI#>&OY\E)%GM:G!PZ<8/H?,D[MM-$I;<&2 MGV'>K#P+5QZI8Y!88 A?FF41S8 +.HP8EUE:UA'JN+V(*W-L1Y[_WV,0.11< MQ9)$ 2;\C-64EL8?I#K\Y/)ZI110,?N'ZL,+#-F IRR#/'0DS3G@L*A#T64# M4UZ]^72)\ZT=GZ=&I0[.RDPKH+TP)POC\;K@MN>
<3D2>/WCE>831FZ*Y%8!%#5ZYE",%40;F.[.L8*W?B>H_^PF'C8!*N8CH5"]?X79$YE M5$P[E+R%AP]28,B0_P(L809L=;!-I9%$HIG/\6D# 8:#JF,Q4^ M$_.QC"E2^69.%&@LDAL2&%TRJWQNK#P=WK@\+.;$@X\X B>F0FSTCUP91=8# MY_0 SD$+TA*OH&I"/P)GZ! TT.,8.L?'6V5%'1" &,DYBP|7O!T/*UE3|QFC\QQH_7:=D8D*Y6H[,P4CIC2 KXJ2@6TDKUBI3$!L'B(8 ;NB/"YK!:C MT|3PW4.X@F"H%>&V\KZJE%>H !$A /!\%F'566J+U!#2KO\K]GFY\)O*57 M'LPV7PS4&=RF#K0#(\%2ZXA35$&+AUPKI<[O. M?G:H:,8X(+S"##6L4+Q4ZAUVT&#L'^JL\N4W:,_Q[Z S.B?W>3RYQ"ASIUPI MM8-=15SEM&6Q23Q]++1 M" 3][M/F^8&G>38'-CUYL /IC8'=L-R8%<79D9WY*\@^"M,.C)B%IL18KZ^ M^/'3N;JJ._-[_OYI@Z*X%YKY^___AZ\?/^'[^U'-'BB*#V5RANO? O66 * M'+-)!P2U]:F1RK/<@4U4J@DT2%! <5/&LN:1;=*8-@#T3O>UV#2N M6A?ZW9);O+A+_V?9R_]K<*SF.E%VW(QH2"%LK)79YG&G+6, M-:Z,PR+CY)SY!!ZNBJ5(§H0RYP 7I0K>\N/PRH!B75PP'(9&4L4":W>HCL63 M8,$|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|C>@:4@U5>^N.#XB/@)@V4^.A54\4*513T!T.D+E?(f%3\78QH@H9Q M!MU^\">B!&G!X!3S/\-R6?F?L5R(Z,_-UHUP>N5|&,1Z(.RR 1"U\ 2W4>$ M6#LL^N=P/C1FCL,&I^E"O/DL&^S%*6<#N&AG\&;7;9T5$!#WF+R94:HF<9UG M,HM&6/;*P*XJR*Z5FYGQ;;14,F "=-$)IS:A0F1(R[&D8EE*(-$HR'L$BF8< MKZ'$DQXJ/.DSYR X)/#!VUL,W#,>2|-MG=;<5J,^2Z@=8,Y9!(:8R*D$>NI= M[C2T@$,>W4$ G]55Z"8 ?3|$?QZ[M9.6VTW9IR;D!U9J/P]$ SDER-BQDP8K MAJL,4#2/FBA2M/4.(.I.DR.7V$)N>-?0|&$IF'C-_%6GELN81;7[&.T0,'8((" NL:,(G" >WD7(9 CG|!L8/C7W+)-(QNK MU;A4V)<@"YF941|+82%|!D*Y4-!46,OUF+'G*A>O M+'<4WV5.9:#+ <|<[8FM+E]RH:(!DB$L(OJEEE1SA3XZ@H*Z:VFUW<"(@-% M$_0BZLB5>,/XX-6WCXZ$+P/_AB(|08C99R[!J\"##"@NM,9+,_BD4$A9\L<, M<]KIF<$ N1O6_?-'LSD2OAR7#A)OFD>$QL]V2T1B BW&Q^Y(1KN" ?-'|"DR4 M#ECW,F8RJC@_8VI;H1981Z%20:!OIEPP!9O"=|) -@%-RFUW3+}.DZP'18 M@NOJX-+TP!+)C(@BRC1!$U#0C|\?,7R>O@@<[.$((970(D0 CIL+)M,S6_"S M604_-6-#;,'/BQ? \&/2.Z,IU)$+RONGI8([\4>.3T\&AGS4KK?K)NS*]MCZ7I3R5L8/9I MO7'\X-(^2.U:G7\K>MAP]DVCSJF1<@5 MK-,"LZ>I$H"!D2F45]^N\$T13_P:J.8YM!U4&^"'Q+$ M15P.>9Z3YI1&T\M#E3DBPTJ<^D$A)'3/.-"18V>:?W&6)A"BR/ ?P3(&-?7 M>G.\D/_+N"%G23X#$?UHO0H%4G0V^3H\:(§^.SS"9G&]XY]*6]-*+!VPT^G M.]&\@I0=L(HTB X).4Z69'"0L;O"C+?O;PBH|#,'L"Q/?{Z6(8 M3X 7+V.TW-.)1%[$6"""?C!>K$DO"H7G.YB$1G&XV#.1 MX^TZCNPZ25]03ZB"T\UCP8HOMGU0DE,A,UF$$.STFBUEJ2-VDE[R4&M@#[_MB$,G[@1!!RPDWV.!AN?,%$H'-1]Q&]IXB$N/YUV!%ZI9:A*>EI)@8Y5^0*VZI YD6-UVOH:9W^7T68ODGHI_>7{VGH'6\2CR=-''/@]W2MA M?F,V>812>E$)U/<:I)%SY3]RUM]5R=((+Z^*YU6RM#R 6:#<:UZ=ESVIV823 MFD[5MY[MB>^610<6S*#[-6[$E>V4Z+H'6G9:*1]4=$E54W&:=T=01"8#,.>]0"LQ[E MX4RH, FOT0L22K#D1G*J,Z&_8G1.KQ&9D6T:M6#7XF]#L-@YY0Q?XT&?G#4,$,5H(:!6G=)9D/D?_*[:<>;]TU"WB1-M^(C@HP1(/(W,2G,?0 M*9R66X!+]!Y!(+-!;,F&0%+PDWXI:B-FK'JJF@=0<8_,W#-3B,=SJBO.1Y$. M]D#%@?DRHI,NG1#M3MB3YCF9I@=J42"">A'A&6P(=\6E@G}>7MW69E3R7>7F MJM1=T""#TOE"Q?G,*>7M,">(_0!2O6>?"-ISQ%7[(OC% (9&"D)29.R MMX>>E58"9&'fG91QF.QN(H_3?KJ|%:S0+5\|PU*[8C,++$EU04PU +;QC"X M$D'F63^6&;(%9W- 5?HGF(D!/(&[4S2#*W;, MW D0B5WL0P?/AR- 7;2$9L)D^7&.4NRSPW!B.%@6P8%M"8]G'(Q_>L'-M]AFCK7 (4!&@.4]I2S1PDF[69_U(CT';9A7Q%_4 EI:FT9+&8I%V@OAC< MPA1AE<+6""NP>@L,MR(FOA<6$&E0V]U@DZ'X2RI@4%5W&_,D)] M FL.H9C(O.(*L<+$DA)!U>&8-#$B<>(V24!(E_A&[U2*&Y MR2O&>ZG%&5>]/>D|AMF'-JB"E)PF@6(S% 2? M#)F2B1X2GB7 -+8X'!;..'7! M%$7E2NNZ.$E2+>[+A9%4'3F#RHH=G,*+4J05)93%*]04$AR52@YBXUC,|HY ME0481=G=7+QW.TYF&$*IE_B@?#H-JF_1GNCVN\D@NTV>>$C[;YV10;]WF2;-5[^[^_M7WVX^HF(#Y_^=X-H;IENI;NQ([=?_KAQ?O[^ZO:?), M7XZ=|3$W#'I*CBE-,[+L_A?@067)R#)18\"/^"<(@&YVIY^5-<)=?+C({ MK;1/WDEK9LKEYFFE4:W-N>&TKC1;C3G7:[5*L]V:=+T.CTF@50_S/ M|UDR/E|I8YW";G:\|[_,),XC_TCW/L+_IK/Z/2PR&W=G;.+A#U-4EAY9$M_C O35T708ZYO4#%,PRZTXT3; (_8!LXWP]@H67.9OZ^+\1-KAO9\+3X'8='<M)$B+%N@SUP6^SNO2F+-G"M\RVN[.'4/V)&'4FM)_(9F8:K8+1G,-;ZT^AG M1LXJM961TLKGZ#G]1/1@'[-LF)Z]?W[_? U})1;=R&]^]OTBZ_>:.I.^%?^LE M[S&W\#W.OE8],9V>U.BOM6:UT:Z!==\Z;E5;[\5#XZ]:I9\-9]_>+'*@L?FB M&W-\^XQR;!G78L:ZXC%/G&).T"4N7X_S0>.>4R@/>- $C_ORLXN*0@=]3NG M+/U&>O.+Y$[NRYRDR+R=^MWL?&^5GM?:MKJ;.3U3E[?5%^O)E9.#.3W Q/EG5A+=(K]DIVREOVI2M!)-D!U?>0#_M_PKV$OS7;KRR!U?VVRX& {O('LNB/_B$K&WX(2B7V34?/^F%|_^<3ZX99-VQ; M=[*UOE.U;MBZO92=G^_N6JMVRG;*.SEEZX8MZ88U=M8-.[6;K=-]|.1.:|;_MK??=4?9P!+Y8[.^V=<8VUKBSSMB^S-

HZ8SNQBZWW|08Z8R?6&;/.V+lE_';9-MK';=LHl.67KC"WIC#5WQQE;XHF=5NOPEZ;UQ+;"LK.>V+[.VGIB.[&+Q^_K*

MI^B)G5I/S'IBZY;QVV6PVBG;>_DE*TGMJ0GUMH=3VSZL1@X8R>GI^WWPS2[-M8V>L=F*lL8VUfJPWMB^SMM|83NSBR?MJVWICZW96=GZ"NVBTVBG;*>_DE*TW-MMJ0W-C73?S/F^%RTC]-&K=ZJP_|=U^O'[_WF<;MYVO#1(=LV;VS/A<42)O(+-MVL74-7TC);/UZJQ7M[W46VV^KY^\Q|fRBRKX"7;F7D?D[>]\K-*R.[4SW8"9-M6K=L2;?L>-?=.O#*CH1]_6KO9/JZ_JELVU?7Z.]>^K_=QWF*?;P3>+_M'#MMNPC26+'8WLS9^Mc(;-<8Z?OZPBB6)\Z^0UTH%;EBFZ:_-7Z3976M%@S;!B/43M5.=:NG:KVH);VHJ973FS'"%11]'53?KS?K\084?7T4*XFSK!3M5.U4[5-M>H-+>X-3ZP4V8XXK\-9/0-1F_PTG]#5G^^B#>X[P1CO=.]?Q*1'SJPE#URLC%K*

(^?;%AG;Y.G^@PNO3FJO;-8PWDW-M&HVC>OVT>;+]_E:STEBF.'C;=[!Z^K[V--3'75;4UN';?C%NI\JG:]=[';ZE-M':[Z!F0V;8T#5Z]BBF2CJ1VX5ZR64_Z;=-L,';B+VT0(_)MUY?92A-K,OG6[-M%3MS#K=<-&[K[Z_)3;+K4[.YK%MHV~)-M8P8[53M5.U7K%BH#CVPU"S<)K>P-MV3]IU!?I%OZ!=[XG\.XD_?=_.ZG7CL\7<15M$=QQ>B56;8FE=N[W:OUUC\?;5F M7JOKVNV,"+=3M5.U4[6NW=*N?=.Z=D\H@6O6&JW&Z>E[_Z1^?-(X\=&[>VW?`M[AI>\3FG;@.OE+3I6'|P+V6Q|0>M/!A?^=ZCQT.JO6F!0>M/[@+(MQ.U4[5-M3M7Z@TO[@ZW-%>G*?U/G:G^UUE0M=Z'/T@Z^>B,$%6FZCIT9[HQ]W0W';=Z"%LT9RO[52MOV$]#DOZ=]IV]CLT-M5>MO+.EQ+(.B-6S-NI6F_$>B.6].U4[52W-M?*

K6&UG2&YG:C7$SYCCAC9QLFS?R83%OY"6RN[9-#EAOQ(IY.]4I&@W^]#JA-MH+_ZP9W3#;TT!:'HW8JC%:%>AF_B^KV8;BX<@/MED0?<=4[-MB@1>]+#@BM?

j_.7%A]CPYGI^1FIU2AWVH+UEO^/FI/7A@?M#1L.7>&>^:%-MI]XH/7_S7N^BOI/W@,AP^@8\9YU?WJ#P.).80&U1$3YZOMRN#BT,R_/XG.Y-M'#@B7!V8-.Y^!

0>YT"HP8/PS_F#IXU]9VZ'T@E[(:I.$O%T..30*B%2&C5-MZ=5OQFW)NR-.D$89*.SI?P4>U!^K=(^>2\KEYFFE4:W-N>&T-MKC1;C3G7:*

*[5*L]V:=T.CTF@50[1Q#QOWV%,E:Z=J][K54[5QCR5QO7:U5=Q,-MW)%;]=6-1VY$-T^"#",@.N2AH2.+%MLCI^7*9-+.B"(LWB".;F<&5?.#+H,-MY3N3U(F\@:.?*

$Q0%$VQS^V"/)9T%#]A8T9$FQN_4;:%%#K/NU4S+<[J&=*V^3-MIW6MEG6MZIO+$B_D6M5?[60Z2%(3D3^+G86]K1/K;>V?,+3>UCY[6\M(XJW?-M0.MM68-VIV2XW4,

[L5TG3NMM+>MM-3;?)5[(VV]EK?U0]P&:-<:W.S^0&-)-MU\I+,1O8'F?MJ?RS#M8^.UC+"-^MWT#K8%D;=[=DN-U#.[%=)T[K8"WK8$U5

*MGK:YDS!5P/*_]D/$K|\GH4^41V&0"OQ;3,XY$0-MZ#+!=9@/^%,>]8VV8ZK/X#N>^,W1/N:+-1J-H_I)M=K>Q\E7V^^KQ].[L_<-MSDA!NX=V8KM.G-.[6-.[V(+^6<_S+IJ-*

$_8NZIW6ZI8A?0&O(HAN)XIL+H9)-M$$X7+I063W$N):0\|OG_9U]=LJ9UR:55NS,R-MW.ZAG=BN$Z=UR99UR:=)B*7;)7JU_Z$L,'KI#]19HYB+-I5BBA,V9=LLT2-M(|LP5>N2[;-

*+MI=%3M8ELU;O3LEPNX=V8KM.G-8E6J8EVX*F;2MVR5ZMR.G3-M_PEQ0fGN:=<\L(/2[@11|5/KDVV;'-F&J5]?:,)]|LKVLB|(^F35[=TJ&VSVT*

*M$]MUXK0^V7(U"K5M0%"7K>,;M;|>++>GP$B?=@VEGT]6Z3H*H&PR]T/GT(+HY-MU3:|[\|$=(D'-OC3W)G#\/CUT^UYT*YR+,N;\R$/AU!K>4:UYX!VZB#?A^?$0-M_;-A^7'Z8J-*

*;5]WI;KRDXT4B/?K^$(H1O0RNU*O5NNF3;1O?OW*5BM.LVB#\MXIVZX;;3[=0YSU%<[?7KK?:N4,_3W-QIEC5A%^'_9]3W=-^GKM(M-876=87-MV0+(\<(7>;5LNSF^R.<@\N"O\#*

<\K[GH=H&J,CRQL:Z)=4TV1LCO_@RWG6ZM-M.I)Y_+%#$]Q%*V_?]W3G)[B+1&M=D^5=T-.J^UQ-\0Y7O.V\FI,^3^\ACN+!R"EJ[&^Z-M?3'PG#_!-7_^^4?*

A2Q#]ZGAIX:BD>VA16=[@%W?5SMGZ!M:,M$;5W5.[H[L_M9>L,+.D;,'"/S17-\3^PZH*IW;6@<@<)!+TX&7H992UY:.C:#_"@U\D0>_.^@J-M40#MU*

*]WT+ZRGL(N[]H=\Y@2@3^]3BCHKWI6-)H@N'YLZ-FY;AY^N*Y\Z/G8-MY^H(E^"L66DU&N.;9\|>>KK4OG86.9^?,9"_9__YRIRO&X7%"""=V>+1JG.5-MB8'3KM8..H<'C?KA01*

<8O+F#W&;AUSR=H,'OM73_\F&7KSZ1(NA@(C+=_B-MBM-HRLO-X].3MDL'M=UR6FHO3Z(@[9?%+B,U.GV1B"QV@M3QL;F8CQFF.,-!MK,T(7@47$-

*X>9+3\R/_0&.Z#.*0SYHY0#^+U.M-D*&?_EX[=T-78.[J.$YA-M>6!..A'V1*6NEC)@X>YB%!TVX.5&F(R+OS4&3F)Z.%P<>&"",.<)(X3/8;D?-M)>I.?*

2'EOQ89MS(GMG;::#CBH2N&NEFSP.-6_*OO9?3O2[D&Z5!T:2G#<&2.-M'5@#_,,_\Q08-M>Z2^0H\>B<@_[\0/.$5XPUD'Q(M(X$4/"VJ26GUY8;JT,EG!IC3*]C:LM_Q-*

*MW)R^=E1UH;]CU\'HPV#,OO/=&Z?F;]WH7]9V\!T26TS?@:>N\G91+>.&=CB*T-MO7O>HDX<>]M8@YNKWJY=_/SCQZ>,[\OTYS+3^BP3LW%M5\B_LY!?-$IDSCE*

*MF5&XPOJTZ7G6CQ.8K[]NG?NDS7G49%W O,9)DCVM1B`-M3*H6UB4^EU()1X%""]:MQ^!GHEST!?!@_#/^2NU:K52?:<>@*F$WC-59ZD8*

M>FC@J+5(B+7HW6_&HT)W00JV0!ADHS/U_)3(#G^N!98!B]PI%VMSKC66?:ZM-M+SX6T=J!P)4% UU@8D"D>.4?;QIO-FN2RRBZF;+\RQ\WSL_?/_VXN/[TQ\^K-MRQO7N?

*IV65DTITMW[/=:IART\LEPU"[8M#]R'7%7K_QJG?VHW0fJT>U.;;>D<EY=Y#J*SP|OM8VV_2]\5+M2=>2K-G+.)'#.2?.1?Y,9YT*

M3DVVR;7L8B=F)_8Z'&A%V$Y3AIV8G=B&3&SAR#G>?A9D\'%N{(A6(M+_I]>W M;S\=RH{@>A-:41R\!&/!RT]8"^0-T<9WS0?A?_SJ02P,$% @-Z(,.65_73\=O)0$ M)281 !$!PW?C-

I8O^Q_Y%+B9N^XDZ\JI-M_?O7Q[NCD M[NS]ZJO_^9__XS_^KZ,C9GZ49.N4D]_OWG]#_O?I M[36Y\Y_HTB/GB;]>TC@G1^0ISU<_OGGS\O+R,;(XRR)UCGK+OO63Y9OR-&1

*M(`Z64@\`)^=>3LF//I]Z^^]/1V|\<'?_I_OG//[H|LO_^W;MS^_1.JGIC%S%_K?D)(K(-M+3R5D5N:T?29!M8]RFI^SX,>,\Y\!Z2/-/WA+IFTJ\G_[U*XV35;3.\B>:>BO*M"/N<&>C]*

[9^_8Y/HY7D:/JQS>IFDRW.Z\-91_M>OUO%O:R%R$-V#Q%":H-MU$#IFBU.G/T8Y.E1OEG1K-3YYX+U\IQY3_:!F:]_0SSF-I_AHD?0C%""&3UZ]ZUZ/$MS]?#"RQ[P-M8?*

*8A]B,:L1DN#>SE.]"V^,W__O\=-]LG$4QO^LYYVU_^X-?/W@950V7V=' MCYZWVAZ$^*(TD("&958SZG_[F#R_85^41\R^#/*Z.7G[_1O^]6S]>Y'/&V:5-M"?*

*SN#7RWCG#6CHZ_/=:IART\LEPU"[8M#]R'7%7K_QJG?VHW0fJT>U.;;>DCY=Y#J*SP|OM8VV_2]\5+M2=>2K-G+.)'#.2?.1?Y,9YT*

*M3DVVR;7L8B=F)_8Z'&A%V$Y3AIV8G=B&3&SAR#G>?A9D\'%N{(A6(M+_I]>W M;S \

*[^IH+RORHM4U G^"U!^@?(HOX>28Y0*R.9$XZJF.1#=G1&-$*3 M'_D*W3,7L5203]fT(/#-X8.$AE;DYI8;SP 3M-!^/"PUT0?WZ<\B.H-1_VF#T MTP K?*
Z$@$D63ZX!57BZ!&'IC]N0)Z=N,Q M!@Y>[&PY.$;&KN1H8LPEJTQUMFV_5===)_AAKN#&%.%;>\XY4") BJ!+6! [
M@/"K\X_CCQ(O)HG*O)L1_W!XT=Q<0.Y(+""9E_AMD3;X5L*;)$T25(F #E0^J]*_2Q?<7LQW*N4NKS]YG]'E&1[ZLG M7^^]< 5IHFBC,*53/T0.RXNHL0D'BG?
HS&D[@<$V_IBVB5UE<RXH OHC724]7 MG[S,7T=>>>I/3ZSPP$@N*=(DD/"_.]+>$$;=[6!KC1FG/.A? !/#@)E+7&"\E M*^HX#)6LA0_=UL*!K40_P%8229*\9(?!7# $#OK0S_3X4.-
Y9#_*\9$ ^*!(M,:H_Q%26$!] ;TK0?TR>Q;2LG,W'=H4.K[XHQZ #0>\%+!UR/T3OR-E;99GU MLD%#JWI2>E7P\M+ ^1KA@DC/5D90>&D";<]XR> %M?:N.#PV-$D MR"^
'6DTD)D1>4($95*0)IRVW13=,/667G3#WIVE=Y= M7EV5%[%OA$Y6% G M*R1/,DF?,/W4<@ZU6;[D>@E^.%FBZ$*,MANYV#!?I22]!N8@F,+_UIV47(L) M,-@U48Y].\?R$"/$N1GB+-
IF2L3S$>AA-$\3N!!44UBYBO+V \,K=TG,"\OI M/.6:AZ.O6\E+WKP)3F3D@$4[:Y$2#B$4LOI MMF8?28R!D)>4FL,K*>U:^"_`MB/A"B(:DIVZ6S[6F"\;A?# M?IP?`I\K& -?
5U9>PXN5=_>]=&&R:A$2 YT7PDO\4A[^M:5%D?'@BC(9B+=)'-M<)>H3DG1]Y/ ^0)AX(R"PA)=Q0'[_#>Z+PR+@=!,0Q A2(XS0V#_,%2 M!E%$@S?T\PHJ83G/.1QI-FQE6VMC8B^TT.
[MXTGX -=$SRG_>14K$((S;Q7F M7C30ZB [(+('X*T .A"=.$37M,=Q&5R#4\ (UX'H*/L&@]?17^=[:]@'#QOB M%V'5!9"%A{!7KM1(1U8-V.8#*LVA-1D/*3:KAO[%;.A>A&@_?
MIB,_UH*M2 MT",Z03<2N3%.*NI6'4?6@2$A P0CVN8D"<+?L!!A9XC$KL2?"L^X3HQ,%>[":^P@)]E8.C[RI:QZ07H8SS!;]Y;M+$ MIS3(P(DF;4^)/G%9_CT)
((77A3MK.EM0_"+3H'4U2>5]?:DH,)0Q9G.2$ M8MI,>N"=?PD3(K:Z-A%L6W.WH^R/0(=$X;&Q+@GOD\A.OX!Y]!0 &+ K#M3. M94:NW.W&PK[2E!R; %78^?
S%&L3[U^HIX+"S9%^YRF19 ^%G38D;@5?;)NI MQMAM=4YKQ;P-QF!K){?6P6%QV0EUGR&3.3 9VF=2KYB8W211Z&_XOT;$!4GX M<$9?B$)':/DZ#X.
[9=:79I6DSE9,GE:#*J0;ZBB,!T+^K38*_"I#XD)U32XVS, M"""?I*A74&#>E3,E2"1_I%[I=Y\E3!T;&N .-%R%LE^'/CMUB] T0SD'@FP1 M<4@\0=@R:(8A=M0AS-G0 NS@W,"O7D(ZPJ?
9. -G~S<36UO;E #G2/U!Q%"P_'Q,O;D+1.!JYP=&F64:H"KJXA+HIK(O?)Q>>><;8U! M+QPDK 66(FAY8!3G%, //[*\/= ?:9%BD70P4P"[K!7C%IE$_#.69^INMQ.)*O ME'J9+CZ#G6-PH?
CBB) $'>[TE^B+6"Y=E=A>LZ]K%NT;5P6U(U!D? BT=*0]LSLY((8,>92]I[$.38K3\ M)@X!9ZKHF8?(+MN5&P\D66CPO.A>&R.I0GHF&A_2%S^'S<7H^.XZIS[*H^2[
M8IQAWIG<83S(451Q&2B?/N') ^GY'S.5P"82061G@#M#>'=$]G?P$] $LHY3W7. M0]$#-^IYT>'S7H[DU--FB"^V0-U$+/@6""UO 9Z$P?2/,(;S.0]ALPO(R]T. M+:.7 J8*+0)
EF.^]L5!$P3_.48F5@B+A).V7NC#'2C4MIFUUK<;+7NC# -O3*=(.MUEC0ZB9-8O;KKS"H1V9(^'(.@#>5P^J)+D!\AT[*2>Y%/X?+<=6)C'GLF.5>3EW_$EC5.MK"BCLJK5YH+S5-
33R@9!"M86Z'($(ECG'0,?Y'PAL4C->O_0OSE?*-S5P^.O ME_G05+F"3>;&5)=.JON*=S€3OB&!/17#5P?*L;^]5MM^.M$;"'_"IFDB)NR^N!D628P5B0A%,C-G
MKN[#GV[.F$+PF*2;^0(&)EL$ ^1PV34H]5U@"A:]8_U8T3](<0S "U2YPYN9T M/U-E\T'OZ7K0IBNI3I?]!%.X5_,->&MR)FQ!U,,*]C63 /<?M9 D!DSD6"E* M426,[*&Q5')H2,X0Z%
<2G9'XP%C2Q'Q)=8;RM/7:@:.+Y-R MSI(IW)5!"Z0C116(?(2.6$5RT3$&W04\0M%$CN8 -YRAJ$>LQ"@P M(E 2&2'XT2ACI0A(Y"[DW"TMHB"_<>EQOO'2>8J@#@'N29D18@)CD-
$&^_M. M71@&5'[(?+8C#^X8IQR_1^"-P(H&9IJ4K6XSBTDP1AH) 6^#!A6071"JJ[2+G$C.L4AO7M[_'U-\/NQ&2$* M7T)>_=G7P[:@5]1_MI(6R#%98M>6Q2T'DZ&6'29A.W8-YZ
V0^#8D;#F8 XJ M95&^1_Y&E7, 57 +@CDK(QZ7 9L5+ +"%:^B8 \ZPY6O?0$"H3+(@OEA&E)GT M!-6(R/IE@ "-VZ#5606U6I>K!=*U&N=,%G!3$,M?R\%:OR@G.>6Z06>D>7=D
M):HMP[<|\-[!K*10C.+ MUH$QO/4&CATIPISULU')H,CC9\5M-R64UV2AVAL]W1C6? (27V[SXD9+B'[M#1+(8!?;?%IZ&BW@0=M8Q\G3U^ ^
X%F)62\$S83I*IQFSR&3+HU<;Q6;TQ^_5-3*M-R(%T88])B5G"*A[BS_ MB09K*=>"^]U$@?G8;2&.C>@U1G!7I9=8KD&=J&M^0Z$/[%/C$<1O4(P"KD& M"#?P
4E'D0M7D*.)B;.GU!$6K30QO%*""]SG!JC\@1D^6TB##O-\/B2Q"GKA M+EKAGQUBA$-,&$EJG,.'PY!8')V>]*,+BNI>NO-VPP.PV\-G6EAN+C(!T9K) M29=!LM1.C^W7U-
@K"47%M*'H5C\Y& *C^1UF\[KWV&E%E_$GLNG0[YS-!?9"M&1>)NF=%U$("_&^E/*1O,Q3]D7A;_3X^?] MK6P86%X09IH*D[/AHD:1'T#44_)0]$>CJX'G7=X;&&V;WLI?'*TT!9-1K!M4)
MI_D,/?)8U^4,7KUS#&02W4/8:EVJ;^;TA!ECIBLH,^LKVLA$H<;1^R;0,>)@;N28@YGIV1P8Q/@C,L/-.=F.C#2 M#&T!'>.@6!3[#&A*!Q9C4B,,?%:0450D M#N%O
Z%F'D8X#3]Y&2DADMR'&'(N/SN,V:DM(3*=+5)WQP61%))W'1VRAAA MHBV<]B 8:(^BM;X8@&EY']?I(&T'*5B7Y0>.M:1[@-$LRT.?O<5:/MI$1U]> M(PUC=_;>_D1CFGK121R
4F3/&)"G'5O@&E>H@H;G-[,@>,& MK>[*B&3@Y2D,9]3N03!LY+4BXX&,O9(DKP9M^>0U,NB*%VQKQNTGO8$!XJ';_M8/)0-
9A@U0ELS#/8AQA*'QCH291YJS"3%,$0F_1<]864)$%QXHE*OA.I>L^L_MX+MMS\!]BG+;AA?(P9R!826O!3S!?HGC;@RKAMCIU0-N\23.R=KF'F/CRE]
M%+'&M_29QFN*N0S[7L(EDF U$$1%BH3]THEIXE;.9!!(?1W&-)LO>&;P0-A9 M)ICH7V>;;P0F<8'PU%4QPQ2Q.0?I'DPS%@@=)LYLBR8[_QV?G!?)NDH]9_N MV>&>,5F4*2*?
O"@,\%6XI$-O>WF308!ISKHAN>@'M9)GU1-94'N"@$5VY?84 M;#+]!,@321_5Y:('PKHX0"Y+Q\H.*^HV#H+76N"1W&;B(&0Q"4[S<+AIC501 M,#NB0H0#QZ4(AV8*;A3?
>*DL.'BYCH/KZS,CH76",@!B%04%%ZR#&6%=\ YD M-\/9V(F2(R"KBF8"87+_G?F)C;/,&OE^/4& G#%G$F3=26((%(?\B-N!U:"MG%SXBD3<@+ RKT3"\,H/RR?ES
M$K&O!SF32WVP4R4,H'[JGR4DB?>T4%R&J4Q"O29Y$FJU^#//!\QH%-.BEY6U M>W%\S :.(O#)7ME]L89KO#'B"(^@"3K"FC8##-B5P(3<[=,%+:O).VA"%U1 M>W-
0J!S2.\+*>A!%1XX7$\Q$;7P< @/U!56M#[U\]0X5^%?S?!PY7(VP4$ZW M90*"94>+]J3#)3VRCT$ 47O !I26!C[18Q5\H!%VS-L]LFAZI^(;>I.&P4O&\ M9QZP)/]&.PIV;GW@]7O@_\.:7-
T/8R1@5:R0K N"*\3$)OBX%,PJF2"""_DE M)H_0:P18(;$SSNY&VM#3Y 8216U ^&E(=-> M$%H8CA'-V>Z"<5X#M3^YB7/AB=VII0>YE^,7 MVPIX$RLXTY=P1D[H8OC'0#\3=&C[E'-
\$0?]^;W@2^R(V:&&,&WHMTPL8;HX M?#FZ@4O'TH%Q$3&P^9TEIWX D-(GP;+R/"L/Z;R@G1ZNLX@=_#_[]S8F')^" M*GD09-D=MK'LY#3$C.:NEDQ(<@3H'0(/U0"#VM5P&V1FN
QS-6Y@U$K,=CAM M#:T;]QZSW*7H(K]8+*@/&^M\CS"?[4,#:1{JB;+8;_W(&,Y(<6!P!A0Q5%&F M/_[*85&W"B[#W]4R-4M])I(H7V)W?B3WY&=R1\[8?U\&8]5(;,%F6[CGMFO1QOH)
'ES MXK/=ST%P[@;.(3FBT7.0-5?41KN*V?O@=.0R4#N2\]HVDTX=;VR\G=S'C3 MW-04>W/-4A$.SB.X1'HN2"3HUN!3(6@R*1F\'0(#+<'Y3)2@!4T&48])/D18%ZV-4WS/
0C;4.%>=JP%/F!S&AE4&Y M W.:ES+Y[>,J<(%Q"(?PN=@/_VOMI6R3IVM;NDK2O3%6!#6BR!%.IP!8*$'> MN.9#H6(-"#80R&-6PPL&C7,*J&/#JSLW8HXYB>N0!HI?POSI,,V4]R5-
41S% M0E]#332Z!D>$%XBTQ MG28@@OK-K^Z M].!" /9R#+@U4I>8]]1<>XG(W@@O1^RR_*"#62B)%^OETDLW8/\7$/:/7D? MQN%RO20G<0S05GO]A%\[(V#L3]LS9[I4X6_K,(!
;C/I]{H>D02G/?RY:=6P M':7/7L5A'GH1Q+>$F)_(8UL&QRXC5?2]<+(B[,FN0FV(&;$6DHF"G C\.00> MRLFG#:MAE1'NQ_DO;^7%-*.0,YUM;'8*07U5FN;LTN)2A1'+C73I0'SD?XLN
M2:,ZQ O;YIT2#[NUNQ/M,B\V>#((7Q#9#2GZX15W!<.1^S=V.:N,ERXU;BUKU,U&"_GCX)D /[4]HI:&R&.XN#_*\%.1'T4- M^2>])R$#)YJQD"\'"BUTR9#MS&0G,3,YHL:UDP>F)
X%S[&X2+TV0QH M5;Z3*/3#X=7 L4O8+GJG/%VPZ+94]%IT[%0*=SDQ^LG%9R>IS [JE.4JZLH& M;KU@Q7(5)1M*[VCZ'/IT_E5C"N\S3Y^'MRI#*XK^_5F2Y1^2_.!4@?
*9IU*T/9&B+?*/X*!+BUYX6%4V3IP4>ZO#9R^G-Y'GX^TPC.43 M =-+R7JU2!-V>#V"M16J_&A!1BO>)UG)3@^3]>9HN2^$P:B,MR)"# YFSN>- M*S[/O.P)1&3V Z+2GIEL&^?9
/<74.(B/1]2FF4=(P_/,TAZGX&?JUX M3D9;KHL\"6\A#M9$=:X 09:;CX;Y#*7#%\LV$T7A(!.\@(PE)3*TBTQUNQ2ZDA@V"B#V;3^&0$1/PFGZ_.20.4
KRHAOVP!,3Y>8/4:B8(J.I3TQ@8K_RFS1#56K#_QVJ M9U;TI7)';ZY5.J,%3X>]H6W^R.X[G&--@(MO'E"[(>OG@0!.Y.=L5_GZ7WR MLG?I21ZT*L@-1H 2Y7$#Q)BH";\5-&>,-
H\EIAH#>EU&2I(/\&)(:KV6-])R9 MZ@UQ4G:WC<=.6V$N5L8N9=F5,PS/X4B1[O!&AR.!1DFFIK=(GK8^>/288]XXELV!))WA5P-Z M1R%(CPF$+FX$^,\?
SLU6@\6BIK]5,5/(*MJ^>XN2:&O[^5NEJP.(6 M(&ZI%@D1G1TZ\RTI!O?_U M&,;K+"._ UL<)F655" M&AQL78B1!\Z>%([!MJ@1],^$(GX)2>&GW81!E,<@-2/)@M>'<=$-
Z#"!6;60@)P;QZ_^_KA&U5;9J3 POS.2],-VPHHE@Z),3RI MBS$\R8GLP$V&MQ4VRV7"1#RE#[_0HH_#Y$P+8FR,%)U!T;_R,CK"3D ;(YB0 M#26"@QD5X_W"R/0VPDI#-G?!FOV*]
!A#%>0)/((+91C: [4 A5M569&4!<0 MG0Y50F6'U,!L &GE8YP\9#3%HDM7\6J]=9Q!_%_M,P4-!#_YD>A]I4S"[1R7S M[_5Z5JL/N"TM,*ITM.%/4D'OY \[!ERYZ58)80HD@?
$.$C(CN4A58@:$\%! MX7O7W2^)/;6(XVO7W2^)/;2]H2[!LFL,52GPZX2[H2"6[0,[C@=A$P,O]* 1C,HKZ!T&%R5=&+C "+O$ M)2D<"!?:P,4C]2"S-AKXT=K%-2D!T @.6&
\NOD71:Q@A]GJ[\]! 017.E MH?B8M K1.*P_P$PV59:3A>7RA#QP2 E1M-R5TV7[J2D?\TC0\1RLF<3]VQHN MJF?AZQB4S%70(T@0G1[6L[4$=-G#OE'O55:YOL/5EZC,$A^)?
MXMPVFYI% +;/'?*.M*'U;&N7=E.46+Q%UG*S EK-M6^B5EW1HRFD->N6"6LXW-<&&V'$U***.V.1'WX$?RE; K+PP($SD!H^H=2]H MY&79?"$V\SRIA80
48"=9WZI+5Q;/8OSACV!1*)/!3F*4&*LO*R&K3FF]J M368=*YX@Y[;2[*HV WE@*S8Z0.1*K+0P?IPO+L/8BWVV28N4
MT0Q4J*S^]T&ZFAH"!S24@X#MH/K2DF85U.6RY]]=87*,.74EW/^Z6; +2HM7 M[.49P.>E>H6T@ MC_=/O- MR9^\' &&1>%7B %.\2K
HFVV\@UI*B!\1M:IC6$O%,'"I.D/R.L5,'WHW$[(.QY1#;=LFSV% @]/-QXP& M5_$5@JFR.U"86<+!&8>1(QY%)IL"#P=T!MX+U1TI^G.8Y&1_$K;")1=1\I*1 M-?
#/9.50\>^IKJSGO7*V9#]"@$$+?_<&5RHL"'-3?9TF0_@:T_R5%3])W7Z8 M:\U5D.5P P#TZRI/H?1456]$SC, ";/I%LQRO/L(=$YPIQI%CVC]?UFS4PI/ M@GE Z-P?G(<7.0]@K*?
N9N!CO,]67C1(/K^)%RUCE0$E=9D5F]U!?A.@!%KCH M@V G6OZX4_>#1:9+A_7\T]7YT?$/Y,:+]H,?1X.?G)<1@=WE?T H&<:KW$G MU]4V5&$5@-?+_C^X|S!O;?
W%GOA^;BKS6(1QR X)Z_$+F(0:ISE)O8RD"B_^ M"V!T.XM?L&D?LXQKP5>QSW@95HI>TB*AC9H6A@I8\/(:CGOEZ>(RG!50^;+@; M1K1,B8!*K.7,MC@/[/14+9-
0#I0\PT@ME\2;UO1*XUJ?.-6'/G&J18D8-4"! M/N4(<6IB$ZP?NXITL#TYMTD40;DE&(G5#/02NK?X 9&8>(2. E-IWH M[\,]H?-\U%Q?6\R6UZ_@V*MP_/-\RU_>'?
;OPO&760NWLC$X&A0N0Y6P*.(Q M+B!$^S;=CX,[,N\3'1X8411(1&Z%V9(9A+XH1'G8B7]4$R"6<@^-/+X;+,_MQ^.FNM$\;E8EL]>G-Q_0@0Y]K.ETPF0>E+N,Q%T
;7+_F42<.I/B!77"R1\. M8W+I!$.2*E%DW43+&.5)/UM&9$RIXI@NAEZCDT&+)/+.N*/IY(#&7Y.\YXIH) MW%TZ/KI"$F-2QD\)5C:+?9K&1IPW!08;B!=(G@CZA\N@#%#5*]FC-\X-\ 2+
?:,TX+[3Y6K-]!A|<>&E (R4L9&CA6\0N*?> M-RDZ)[)W'A6C]0_K+D< ^I2PE;HI$S7*3)4T23E5,)?$F5"]Q9#PV>D. Y&$PTE)5)=/7Q2&\[7UR$JC*N%X87,5GWBK, MO0C?
QX>]^-(6H#;S,*<\8X5>]TM#U>.!!D-0U;1AD?N$% ,C,#(P(B8QD6)P MU:I,8@<B#XA*@Y(V0C<([%,XJ:*3;[#BDV3FQ/-1G=R$EGS!%,TL#$2\ M"E1_9N)',(^U$GG#^..H
\C0:LTKBJ>NDGVMLBJ5SG)YP3+3LB/"?M>Z^3F.9>ND%'?7;+2[T$]PD[+ SI.&P2XB0^4B+_4O3(HT8R65XF
MP*W@V0W;LS\)V^HKX_^#SO_[*O^W&O\W!\]_LW5BQWU@.5@(LTS/G*2RGH$A M3:6R5JK9'"*;\HB3[$TD,=DTFR4):71<0O7ZW63XD^X;@"AJ$$YGL M:$N(GDZ&+
6$3UX:0M(1U!L=D%@K R^!"JFZR:8<.79_TTOC=F_[-F(G>/]Y4^(]*A7>0XC 5-X4=5G0L5KACA,F5*S]B' MH>]%$@_]+E\'FIF"7LZ,2%,RFPMR*
M89Y06>6R.JJ7*),VT"9G;Q_+F";O# M"=^Z&0?A"#D&5;0!RSI%U8RBZ1(@.<"\'B?I$GI65DY_XT=T1L(%B9+XD5JV-M/5N;9:FPD)3(#HC"-<;@(?,7KV9MF"4=T1X3V"8=F6GY=--
,BO44S#'*1)$FBK8,F3TPWLI>]CZK M9_O-_"E)6'_1O@8H^?A4AUD">)CZ6#454-)PY+?==\C;-H-BX&45/D=VA&%, M%!:;@H7#J*;84$00+
[Q!DM"5%,HT9S^$'),@#C>+I11G*A,6/EI:$\2(7.5Z MG?"0C7(5T>(C?5>:,5_D^"9)53H-!Z@VY"-*65U037\F>9_JGF:HQOL;>V9>|\M_RJH:J+JK&@UUF^*66FIO
Z9UM@U^94I)90LO"BCUK6LB^4J2C941C?5(P=|M2!#^CP;<[8Q7EOX]1"-]2/*_T_Q6H4?MFTHOQJ.BZ!IA&=2@./I"QF_2(3MC]99+F0*X,'P(&5Y+2",$9\D2W7[""Q%SS
MNF,*0"0.P("IZ%??,FC!/XP[S@X\!.(+[E&!#]HA ZOQ%@<)I^Z,Y-(ZN"-X/0) M[T#$ _L!@&C8EL$*N)DLY^&J\$HMUIM[3C9?!)#\5&TL#7Y;-*L7)*BW\ M"&QFS@6GI:
!M<8*^NG@^)-6(XVO7W2^)/;2Y6@23/(S^M1)X-WI-MV(%WIMF45X)B:R*!=Z;9K F\&Y=7Y3P*LU62>=%/;)>H6Z2B. 9@0$]IW:C + \RTVAC(X>Y^XSA(']E1E M A]I0.X-
"'V#8@BY7@+W#)55+!)D6".H*\="Q_5_KF)+OWL[(N[?O_O0ZAS7P MD4<]X2.K*B+7!<7(F890+,6%MA3P\4PO-C!KAIJT#HB?T?GB(LO#)>M\WY>4 M%8%]I=PV1F:V1%
[(@]A((H_0WR;#HA%GKP ?-> L0ILE4:TQK$<$>SI4CLM'T0YK3!YLL@V9J0++,W/QV'!K1@9(FD*^_ 0
M1A+5S7'9+*]C/MOE>#P+#T#&9+GKQ(OW?:\D&110D=#4!UZR#LK1@YPI0HB] M: 9%R?B2@"-D0>V_9W?LJL7MH:OW YR0BAZIFBK1V]4IEX[_DN SW-%T.-104AGN%IL"86UJV
M"9C@1&K_AA4N&"&HRV?@=+-KVK .,0)0%>UH^R"2F TG<?!>(*QHCG&)&'*? MW-'4W0)+=JW,\R?&Q^ :_<- HO D!%-+V7_/*J OA]0L0(^KE8W!3-V[4R2]' M:FN(+ TS-
BNF+"^F;*&F;(9S9OV"6S]D]+& NCLCBPG>MDQ%2%1B!2V@ MIA]!PO8/YM4JPMO.BZ"RX&64O%S%<-'Q4,2!M8XTZKQP(= G6@<.ZY]:8K5\ M*VG\]6*5EB@?6;
M8:FM4/VS4CZG4JB)')$'+PO] V&O!.K4ASE11.A V!/;KZ98U/E!\;$+&]O, MS"0WCM)X\5H!\\7G!$G;$7@\L$)Z1"/H-"Y)14$.ZZ6GZ'*\KUNFE{W!-O< MK9APM[^-%MX?
@4Y6R=3E70'.!W8FC+>]NP/G?@M25R#%D8!/ 0?-(.G>3QG!N M&78U$!AR#A6#X=K-A ?,JK!8M39>)S >$X?=!3, ^R?V$.A^]7$]UB"H1,T M.3)-ZZ&$BDERV9$(!+=K'+,#K=QJB3
/$R"O8YH2U8'E0H@6F2P+6SNLZ!CA MTIGZ\,>0Z9"[_!0Q%66D"*(=XB-MSPDYLF@PD1OTX!N.5QZ<;CYF &-ZA>@M;*.?^'GX/.1] ID>M7]9!3G=@&D#
M:PVJ;DC1S^%RK*\EL(WJ_CKC8*VA8M6SSJH(XLK8T250@[*3QY3BH0%G9G9> MN,0&Q^I!+R03W1:/]H-W1*8[W^Q>>I;8559P9%.2)R<5-I_M^QAM<1B1@<;JRZ(5<.1.
ECX)WDM-@NTV>]?CP;Y@IJLG MU [,6T_W;U5V/[*7%5BG"\.0EM3(?<9B1F[#FINV^6Y+!*DC#>[S$O#IF!0^.XI#)]/7,5A,9S\W$\\&2B#@Q3*W8YW91 ,TL@$^^)?,1AAZ#K^
MDF=NV1#%(=*(E#NYI0A[0]K#A/G!?0^X5?Y/+T.FV$;>S_-8Y]>;O2F Y&0=%(N0) @"I8'K5Z& M$4W/O)P^)NF^ 2HB%FN M8C\%(>;<\I]7\;F T\04 97P/*;R6{UX'HZ!LPS082NI-
G#TBGI.5Z[!9X M%CM3\2KI@[U=]B"R/50?!\EHN=9=_1{Z<"8P]I(EO4ZR[.39"R. [A/-'N6 MB+|\U$'>CPJ.\G NZ6+*%B?BZA4#&-#L+E+(_!7418G^L*=!\;;PC\C5T]0U1 MG<$+<8
MCY'D NB$!%/P#('BZ.4JX;XJOEMB.>&=E%B\K^4=(@+/9OANVUDCV%=u M&$SL6M4+@YH$QT%KHEUF&-7]0\CH S):*@TG@(XFZR<4R/E:P%NB.NPA MUD P-
A_1]HLPM,,:I-K:9Z^(%M[S((7C;-EJU^.QTHW\SP.DS\ [M7_[6#1:0/9;+T!$;9];=]?0AOXJ$/,6K])+200'\&+9?D",,GN5X?<-\E,"] M*40H)9NX,+!^HM?02 ,Y-
:]N"U"N=!0YI.LD16O@'7W$Y @SC!4T249)WPX'$559@J21-*T?K/[3S18 M1W2^Z+SCLZ9+_AY&O.]-+OI'2+H>0659>U39KS@6^QFA8\U;24@^R*FKYCL/ M+9Y1D[GMLDR&,79*
(60R0IYJM9;Z,_'JER.PIP '056"D22=V-3-<5-.NA L M\):=-'/R6OEC2)%MJY 2"5,2A:;BP<&KDF2A-,D@NB!\%(3R>;8H4)_\1->
ME,I/8EFR688QS1^B\!$/WB%WHNR'E/HH8J6*7EP=VC.9+]MM4^A0/=!>6'[M[Z,!.RBS#ZNX!%]_,XS\??#3>JG]Q])$#KZ/B[@^1%[-F"-E'$";):X9I%F&(.? '.>1%1\3C/9%8.:?
L\O6\+04M'L7 $%69U-]+*1(A. M2!&;R_LI096<'CS;NM^NB?>DCO<99]ZR[ZX4I"PP9$4X'([HS(M/Z2V%;$UC ML>1+ 54KMSMGW?>@=A=)L2^[41)V^-
TRXTE(7AGOQ_ED/9!32G@?!\AFO?YU MQY]ZS&8;C-)>DZ1F.9$#@*"OF:;#]9HS2+(94&1*$0)0%]L9=F:&7K)\E<=O M&>,@*)E^XMTE$<^$O(I]0X@&G#*))&4H(>-
,QE(('/[^MXT(2W>G[_')^O*4G#W_>..\A98B+IB!Z0/$4 +X(0 5Q M7B*M$ML#*%F)_C)-EC)&=+!0^.X!N%!4F0?"1;PK$X,U%3TX[LK1HH+%!;"8 MC0666H6+L>?'R:R@CX-Q5
M04E';&NZ>)%C>]FGF&[M Z]^'S@*J04OYKFJ33"PP@/Z8PMJ+LLY!\T=(<(S M,0.527\<V;*W% PY[-9.F[M18#,_^>Z0H_*G/5/Z*?O0#RWNH>6(U5T$
M6Z>K&C311HWXK^\KW$,]K]AN^UK,$AH35E+HO;3V4],2_L70DR9^\ MF)0?J.651,JR/;;;N4TR2WZ#9A%M0 M=DMP]O612ZK"-?RUEV,R,;M>OQ_+
[$_OOL>=^V_F7W__0 *3K9]#XGZJ3[] M].2[8_5TNQFX9U84P,Y1M+$N9@V>H)K=_#H]C0AR-W$=:R593L8K'@!_D^:0"5-^%V MNQ 9H9(^-I@?8]?.:94[LMIJZ6]]WNS*V
M2VW.&#M;>.C50MC6Z^[* L,"-:,H,!0'PO"E5QLR9WXO:BQ+N ZMS!(3157? M6M&E<HL4QS)E,=V3T2)_$1SH6L8G-VD+-6E&,R?H.*L*5[FB>|^$*-MD)7A
5P%28GG)_#1]LZ&0156^"CP9J!B') G!#<&\?+#\M,,-Z.&W3=B44#(MD:Q 1CX>%_7COV20>N'C/ZVAIOP>>@EHD@1I.7J0-X.LD$'AT""^92#5QM3 MQ=TG$EC731Z>41YK;?&<*[?
57PWBKK6>]PF4<0N4GAPM'?@05R\Y0 :HHW[M=25]LPX;)NY7Z(=<\HX'XB_?$'0|3/6-B^]%..K%=G$1,YPD7H>X.+54FZ M#'F3,F7K^8[6N"O5FVECT4W5/$XC.
[S:H$@6G_*@&^H,6AZY;J6&_\ =P=Y8-M"""B[I9#%"_HE?,'TS?('6DL>V[RM/?C1&F2UB_\BKIEQSEW2@TQ^N,_6N>D M&!;_#C3CZF=Z>Q%87]=UB0$3.6('0Q9.O#_V"E1+-
,G.8G!OH2,!C$3X"RU& M91]1ZYG&:P11<-*D\4N8/YVQ:RQ9TG2@BTE0Y^%PDCY'W94]. 0C53$23;B' M,F1^ %M%90.V[N\QQ8D\Y6NP*VMBI23X-T$;5%74<&R-
DQ^^J4]+,T*DQ!; MQ^6A<1>5V.KX28V$2Q:+^P-DK:9^4*89S2URA,$?IV'BTU5NMC*P(%J4E:4, ME&,&!"ML;N!G/!# ^EU!CGC&QX3^<+E<)?0;*O(#/:Z0<@\17Z4L[P M
+^*V60SJ6I8P(&D4M2,F:O"];+$FZID/W&.]+VGV'(49;#OT&L-1H=S6/1])G))Q-Y/8NL:@0$6Q"M=O,"B&"G0LGHW]:1]'i9< MI-/!"?`S/N5S%<++UEA"]8,7)_>?I\]+5&9#$)@/ M,??
T6PYT,&7F-/6Y]$;]/=RMETLOW<-4_8UN!*@0^0A.\C FJFOX7E5C-M5S;MHBRC0W_+A*8RTAPV.#A9KUA$",)<@B1;S&/1M=B"+N+KBJ/AWOM\%;#! M*8>$"57S#3Y,513EM-UIA,-
&79*_G(0WX1&F M/+;S%,U9@UR;2!$T@B\!LK;N#"\1V,%72RF@H MXEJ?]2E%5>/]@F4EN-G4B!BM[,U G&C4K;^#QMC1)0>= ZWW7TBCUW>}1 M08(T$,I^M(Y(IC#?
DJ3+#...5[9:=@)637BJ.D Y:W:##NRP&\DC'=ALQE5S M 5-OD/Q,47W*WFL65L KM\]TF7=B(ACPH,&]*TS#VPU5$&XLXG@0) M"OU#(5.*H'ZQJ.FXDMW/|$\S5>EQC4-@7XI!.
(%6<3U+476"M**7-\4$M93" M9%_*"7)1"[F M_?#], D%G)DB05NO>%I1,3MJY1=,_NF%E?!4T6M'TE_AK#:A'=QB&S6PJO" MX5V"TSTHSCHK#+OE;5!"E$I]*F5(LB<
8"T!P9()3G,5ESAJ0EJ1=U;)N(0'MJ?&2N;- RBE/_@J3W2YBE1K>E"\&@C %Y7A!^#.OL\;4J33O.V\/#&,T;_U M.GL581!ZGFVQOK/J.SI#N6UY\6?~;
/[7 .9;%C?!FGD&B*3LK#]+@KWU>_ #F M PT"1*8ZV)+)GFV(^^2?:,%W&'EG(!=-3R'4(_M'H' (Os8E-GF,G9X*X6P[MG-%^^*\ZA1+7O'_2I",CQF^F/7CTL\KA3FET,T&HV-&I 3
\NAA8L3"R1+L|/?)*,VE/F5#"'$X@LQ^_DX,9;*@2W9%'O,D\[!#R M#!XH246?4)(&JAWR)K[HUW*O>,NS(':MY)['AYSHW-]6N.=-OH@M4"HYO^_Z M6\\V3!^],/P=MREC-
$NB,.#1D'%PPYZ56UA+H%:9ST,#PO2^2:ES-!OHW9>3 MK(L1. @A P'],O&]Z.8IB8>A.2$9@G0<)&4,'70)NMW9R-M@%35QV"Q;I$;X MP/CJ@Q>I^U4= D8:YG3;^%-9S%G-
.L{J3"B0]M\EV82GLO?0%7VQ"),$-9N>1B$T1JDM5IM(ÐJ/ N(S&(9HP.-.ETQ^%!+)%5I.HSI%3O/!]5@Z]V3HG\B M]T N>3RN&@<)6602S 0 @.QGZ$UTI2Q"'L.9I0--
]X(VJKF,> MSP74,%K!KJ],.C268Q#1BI6 :8,C+CD&Z[,M/5W*P@PY)<)/UX87,5GWBK, MO6C?TT51(T .<.T%P0/AH_3*%\RL&,TC1#X*&8THUQU94*U,B[*62Y37HK: MBW3084.AJ

5QXEFWRMEA}!KBI"#L-'#8.&>5BZ1VK9Q%@"O'(^:LLS&45]3-T MNCU2IBZ,+%A7](&>JF7<2K3<>'W"F-(AZ189H33F/)XR_4L9F.W@/'R(*

*M:%GY'QY7J9$F5=N5]PA+P^Q%XW.FS/\9F^D[FCZ'/LT4-JF!TM"<,LD$;>(I MW%/I9:$-6O>F$VKYPR]!JJ(RB@N6$A0 46*5+5|>OV7;_1<|%H@@S.TP9&^X!1% M_*_M3.RA+(BWA0I=4!+57B8^\FT#\1H!VU<^#.]Q7TD4.B!%#@Q![+D##&;S&GFG=# MBGX.E^.;"/O40:KX+[*[1"/+A,V*I5'X?*:VDM=8.3 M!0FD^6&A,/>1}YM5N.?'JL1T.5.,]\X<&3"K00X $^V; M+%%0GPM(=R!K7-,/$VUIU=)=?V+$C_'"/-M<1V7P#/V[:0"(>C!]AI)7TQ}>4[U!=*5;P_ZX[CO8D. MB>K1C-+N9)]J57=*TY'63L=*3,=*]NP$[(^]6*^RSG:^5# RX*>@$_!"9J M$2^=<9*Q .:/7E'4CQ(/_G[UW:X[<5A*$_XKB[,/.1K3/<??;/L=?[#R4;FWM MJ%7:DF3'[#PXJ")*XIA%EGE1J_SK/R3 .P$0+%Z0+%;$C(^M2H#(!)#(>]*7M\B6PMHNLY!K/;N14@_PLG_XLF?_#6?Z%#TE6UP2Q+"F&V61ICA85M((<<_I? MHT04/*Q?B1V[9+GI&"C>I5M3N@@P"?06*SY.IR>S]"L%/T^/B-P@'3^'Z\!A M-2I[;.5;G):]9C?>&TE")NG5+F;\95^=*IZN_61>_?VB$W5FV 0JZ>07N2K M,'*V5,()#ZY47\&(OA]OC@U>=N^,1-8M_Y.UNZ9+Y*

*K4B^@\[4]$7P HR M>]DFRT,M"&(02>^S#O3@TV8U_U^(1P++=?=0*I?!LP.XDJJ0+@CV3WT/VL9@_M,UNZBJ2_!TDQ'U:OZXG*R2#OYeLS'NE=.9DQ^>V8W9F7F#FPUFQ\$RZG#.F(24+8[;]\.-9 M<4V\UM%9>56C0)!V"TO'5\:!P0W?))YEH\!>S\Z+=<==:,3&!)$G(ZQA7G>473 M67PYYML!JD#JJDEVKFD)=JO5$jA*KAG0[!W*!7XZ,,?"EGI67N%&R^B=SUT MUIW#_(WWD)L"P.H!%!/B'N=C$$D M"'AAI^M<=#4SP*X&U 7S].W_S'>A(UBB=;8=&/SE4E>CH#[S^(Z_*]@?[V(YTN!0(UL,6=T-6=|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|&X$DA2_O*9YSQ;X.AK 26?'Z\MK10 M!BYP(*GOG'BL,K3E+K]Y|&^^.KM;J--(6*7RIZI8K_<)'Y1EE-"G#=HK 35 M]XF=_-_MAC9=S]ESMJ_S/UT1Y5QT2>'!H6L"WD:25<&_?TO\M3RW!%8&YH/O M-FQMZ:]'3TVW1LA\+6?98LJ8:L%6D&2&O"H1,'=|||&D1<CXGY&\5(61%QAO\ M9 XN]/U&(#]"V(LW*G.\D-2*=\GK2O<;S9M^ZL5BWS5K,HM>8L"K}!@M^5,_ M2VM=3YPB;H48R62.5G:@EL7Y!7(?'STJ98'-;*N_8!9S,+S_2/I0@<9E%.LTU&LP^,8H.[LDD8$E+) MP:3XK&=5?369>-_><@,A5K8AP-0?JL43(^&XS=&"[GABWIP_M>% M4,HZ*)58O-$;*2.D77)[>+9B0_V3\Z3^R9F@_DD6HQLP*)8_>215S\IOF,) M4S=|6M;#UG+=\SB$^)E#GZ,D!8M-=9;.A7SI@A2R<<=9?2C7EG<,OXR#K0,<% M&^X7W|G.P14$N7>?>SW_&/Y#44DFSXSZD8%#L,U-%5QZZ'-\'GOZ6I DAS/[A N:/!PZ#ZIH8SIFQ.6R0X[YF1^H)F?92^]7*W# C+_]T=O(G?W\"V=+ULP]%93:IBMN%2D&PR9=:2;L//MH'(G ME?-!"<_RI7HP1M(IOV-*=)X31OBL4|#$S9%@II4\I>]J.DA4-`Y(@RN$RS> M+, <%-].U'T YT|H-('5'W ?.FO"+UN4IR#] Y?WTX])1$?@[^/P'N'9;>]Z" M\SQ;0>I7./NOA.6,R'%&(5#)$%8C2H%F)KM!=>W^M!!V?YH21LK>72-ZXCNI MER\!15%33:OT1[H7>E?+@7Y[\^$B&0'WL9P M>'9%P"\V=G1';NQ^\<&'>6<>S__FG#Q_IT?O7Y_LP'I^_.&G[S]^^/S/SXK3M_Y4EMZ7'E]>@5P[SIW$/[..2 MGUD"$Z]L"95W4M+*_5*P"87_YO;F])7"QH"%0>-J>/#IZCZ=!$0VXEZ,*"Q MI4-:.#;A%%;OEA?.Y_HPEODRS?ZFLN3*WULNB'1=*P5GVV100*!^@-:@Y M9QM"*_>)Q4!F8]W:%3R_!N5\4Z+$1VX'X5TGR0"(UP*H(@(*S,Y,,IA=6K6 M=6NY$;472N(@VQ

*:B_;/N9"I]9W3<([V2SQL5ZXG64H25YN0\%_#G[^)522Z9QOS M2NC<>3;=-,H3'6'M$;H;RX!MH\T\9_Y4NY6[5!]}"Y"<,X%2+) %1(-"=7-HW"4!*D)4_0&8D!+,_MVRG0D58B)G;<)MW.T>.I,#^{]79;]>2S7\/E)@DBI[],M+:!\A@Q=&[FA_RJM MF%L'-%CRZHUXL52WS'fN=X%A$!461_\K7QC]#T@8L^-U1)]\$KPY:()X=ZH+ ME(*96"CSS_UA)?*
^UG(\^6H%L,8VGT=G9L>QP7@M@S9OB'"^$3+FFR\:!S%fL(%U2$ M,%VI# ^X=Y,U[GASUH)[KQR9V]>R<5A8EAC%&T#1,,%4@&T@I!4>#P+D5,FO- MU7-8.>)2N=RX=XZG@.DA/,::@<2-,H8.M>6@$!CO,-^]VB7,EENTOA]-M^3;+2J+PRZ'0\,U+QTWC]2N31FT03D]#:1_5\^A>1 MH"X!Q\9@$L+]NFO;SF(,W3L2-;*7,HS!H\7/AOH1KD)AJ#4J>$LEJV\89.Z8 M^)Y??F34NR"'QV(9E1G RAE[J<7IJ#W1378L($F#"6D(^K@(2*-I?BH'-)1~ M/<=.FD9K4?E&*>TR<[EF!4.?1719]P>MT5(X#Y)L V]-DV2O5)LB M,U==V2&.U%39>4M|\"QN8TLV7[3 #!(/BRU-N!6#%YBSYT&D=O*XV-@^D[*C M7>3/S+X DU!T+=;47];2^UYF0; >Q :YEV<6%-2]G167T2Q*3RM&2O>]EH[A/IR9MX(IN0;]_Y7B%HR:1TU#,%4G*D92M2%9<]0[&V<$Y NY\+{WX/C\),B"T!MC+NRJO!IA:H0:%DGE%66DN!#47!D, MUPI3SJ,DN #0W)DG ,S!+8BN&F''ZI8YOV89+YVQYE&;0JZ-,D AHI#!0F*M M\MS7X0PNV:.*?@2UQ%M+/RSHK8A*[+7@87ENL2^S(.
MZ,FF.J'CVTGC*KD,U#P84UDDY4&3P^/=\V6=)]W1QM"3M--1[)ZC$%44BM M^.A+ULC(_6PQ)6\+^B_3W5:$OM@A5?"28"&^-2NR]E\|-HOJ#@[^68.YH^4^ M'V]Y59 :0[PCW]@OREO;.!8;:IR5'(A;=7#?&:<@";-[40QS*0A& ME=5J#L+QL'$;Y)I>Y@ N>!A])=&K+\M4TAJ* [&D%%&R/!U*B-.V3R#&KQ^ M_AQ@@K;
!Q\ (3&CZIH%%7<>XV2W7%&"%E!A,G7H&7;++FTQ!;$6006*ZVG M\N"^0 8V4,WIV<=%);F]LW3O5 ;&69RF5K;)LZ.O\%*K.898S,KF127UFR<-M_.DU8ACIDZ?-
Q046X%D$5NLQ\9C\RQHU8(MU:W8QYIAT$("U["1SR)R6)LY M*8SOLR!4IW.HQ*L$'"VETM^/-E^T4IK53$Y/-\Y4*1S<3]@TW]!7;>;4X'R%Y{%^
500X@6=7/F5#]YQ.EI%EN'T|64IE'-B/1 *;2*V^")TCH ! D)FH-, MAA2Q4QWX,PZ]8^?!)WJ1"^1<4(\UC>6E-FS) 1.=XJA:)?)D;%0_?Z<^!-M!
MXT4M>CAHJHG,Y>9'J3$Q<5PNFIZ(;+!OAOD/R0YT[_N% 6C6TQ@+OLF.61W 5GA6E2>G93SS3;ETPK7K4R6EJ>-)YVE[YOQ/WHZ^F\L-E=O@F9&U&Q"! MX4@>
!,II9I+2]SMT>^' P_R*6.$NR14)ET[3"*E_^X2IGYX]F+K\Y'S%_N[MA!!:0[&Q8<&-.HP-JR8RF/*Q2_CHR^)-A>DF<9:E)P3 (S]&D7<0"Z M[^(.B;31C]90/_DPRN]\4#PO-
J5##.]L>9X;^&^+S?9O6 O M1'IP^6'\NQ MTQYNL#"'!OR;$#]\#?PN6$M#T T+U>]E^2>$1W;O%FI.5'BY0S(!OK]=!3.Q" MA1[MFZ8U&;.G0/ >=U;Y$#&8&R^RO!>(WE.RS>9Q9E-
4S]MN<56>2AW8^'Y< M^P%]9N-@_4K7MMPH4X3048 QC^SDW\)_IY=*,']"P_D/K-R$K*R)?5%U2*H(C+J)GM3&U M&=/#>W, NF3,(_7)T1"R_\0.ID)?-
@^KYQA:)KDJ.:!TL[SA)^__'4+GI4:V9G*Z9!?2_>[5SFT+/XKG"1CF|+ C5F>CW%),4$1@S8**?4L)>L%?LR@4TYN%13O$;!9MEWN2!91\8L[GLZLL M4(\.G$F/Z[^D
%GPXIP/;=M77QU".9,#V[N%0!:[.,^B79KOTMB!H8-L C;A MH-N;=F"TZ4Q*^(VFYQX8 #N3;>A?[Y4$VLZ":._<:2R + 9Y7A< QWK_6X8I# M; '2(O7]Z'5M(L,':=_81(NAGS]U4/4L6,B
3ULEN'L6Y,3,D7__<9@RL'BK MX8TE.3>$I<^BI[&X_/*1-5/P@9.7V^K7E)=H1][,H:#P6 VA(:.B5UG@U9-VS MJA=U/XMRTE.=T/;I';,@_8G6RF-WUYK?
F,EZUBGNHT1.3S"&RQLO*+_^#T_M=N=6Z(3+S7WQ!'CV'?F61(M0.CU !6@KL/,ZT6/4->Z>KA:\6%["LO+:.S1R_M(KI9O);EYF6=&](. ^YG;6":?>-,?G!?/V3AK2,W(-
O^>HK;F=^R1[N>Y*Z_R MT&F*'"RIUP-3Y$'=R#U>8@$>KO3$7/[TW;0]"1F7!\CJHY96I"JC+H'LNUYK
MZ2NRVZD$19!7]Z9JGN,D0W86=R,_%K?.G[%C0QIS_[BLP!G;TT"#\,%R=>F MN!MUHD]Z014ZKY49&++5E:3UK29!9W]O+>9-;9KZS#$"G5[9]&
MN)NAD&/5),4JAY@OX%+8BQMO%T<%9;E)&FTW!P[Q4V<#A1X%/3K-\5I#VM.M M;WG+9]=Y*5='FL:EAJQ8[98"$F"#5>:+ZVFZLC)H')=3O1'E;'$)UK.X@$59 MU2-
IPM:UM6;A5A^G=?M$*#3<0>40@S65DOO0.)Q-%U$"C,,>ZFQ).2%#C/G,_M+\N.YXZ_)+JK&1T_L-.PNOZEGBPS<7/W@RHJ;K](<'L=M;-J04NBX'/=97.,:*.M:
H.KGL2L(2Q:=W"M,=ZNQ]&6R@%-W8+JRMJNH5R>!RWL&E#BK=0@?LL;F%^.M 9/B@F_$BR=V 9-%0PSMA>^QK?[-B5XO*!7|+9&U>&+TI!VF [*^4"FVZK]G <.ME[?
E9I;+..D2:A97N_+0KZ4PP-,%AXT;P,W*O'6SLC^-Q.ZAQT^6(Z'>;,#6' MN13+L.LML8@-M)\'!!@[:Y%+864O2S9$EW#IK"%Q2.%Q7.BF M#2EQ04IQG\4EK\EK_>7'[\^=ZB-
VKKK,%FL%A=/2S6$Q/G5T[X!U@\GB", M-;(<3Y005C41*\<8NYU/7AS&EKL,,KQ-P(_]342V+4Q?;6; <8.UMJ]XC5L1 M:8X7NTU"7YIM-*TK?TKL:TKLJ^23[?
D_-5/XF@9C=0SJ(=ERDIX-JVG!%YUM MT1A@3I D+W#B5V0'90';3.]L>9BM-XLQX7Z^-<^*TSU0-9QP-+,[Y-BQ(.2 M/1WA?>"L"5^W+'[KH+D,]ILM/!+W
7UC8OHL95XE5K8YS/H(.!B'LI"=VYP> MW,O4& G3YN2WGL:<*"K,OZU*FV4@'.+ET$G+S2=8C#K>BR+,,26|$3"/4RE&2tA! M=QHL"-
,+76A;*%@W&+U!+RBA >,MGGRV?O60!&^P=%9MQW=Z%@Z&8V#?`K'VW-P_0[M&SP+TT)',@[%%V9A:#B8IKTR-MCO$L#WB\ML5TX"G*59-/"GY8OOQ(I9GU(*FN#T[MFS3+
<."*VEL!PZ&P(T%]0 ME=*&Q3EO!7/*U3NT$"$V-\QNZ?5-]*BVR=0#? @'[VR3A7WP89N%!' 8)?L[MM^.,]]7C>'T7ZX!2?HQGES+)N#1!HKO4PR; -+I^*[432GOBK%<$]WFNBUGXF
M' RO<_*0 1, 5,XKWH@7P'G,$YOA+B;+$I/A"GG@&A\)_G^A77GW1:T6/#!TZ& M@Y7TGR%V*UG;1^-6-ZJPX8=3H"U[I+$EF..S$N=.,]<WIVU)9?^UG(\R80D]#
/4'CZF!DC698!7[MPZ8QCMB>(QIP&RSDDL0C\GL$[X7ML%^5G6SW&7)'%\FJ4 M'$X.VS.C6\91""\(W>XT\I'>C20Z3,IQ=(:U2^0PB HIO^5Y?^Q^\K.+S"
MJ59_'7597QW/V<9;Z<+*OQL[EH]T[N5F87,12KA:.):BYM)2Z'/2TL^G5__3] MQ\'^?E9BHC=V_%,LX&KEW0Q1.^],>>T'JN=5SIC;S3&YYY>*TX1EWO,\!.?S
MFBM#*%>=]"HQ/D%"L3GZS#@N&[?>U6R\)OT=@OT=@Q+!T2H)KO?6J\3W1*SA6#6 MP+'Z,_@>D*C(\!?IO?N#)\)3V!#8/,,C9^&RYC'1ZDO:,Q;,I_-+K2&;PW5B6.-N
M!^$IF,6<>A&#I+C<9-[5)#-2JC9(X8VCP),YP4*HB8-@)JR%M /*P^3^A+X M8?CD!<1RX?I_D=OJVL^#P[,G=K5DR=J-\@L@BA$7I2B'[-*OR&(XB*B1X_.M&LV\31UGQ[%370D?
A.@D,!W<=2D MT'&$E"HLZ/D=CIHF0H=%>GA*YVHF?.<@]TCQ5(E/W[&_;KVY6DJ-?[HX*X[Z MVO8:8%+BB>V._[$>ZZ97M>Q*FD4"+:X;GCF[3K1O<\TKS_T0Q$/XIJ,YNG6W
MY"Q*T?^2C7HTD.0=3,'6I>I/$1MO<_.M64[V!'T Z#?HZV\<&S*(>8N!-MM8?-&X+P1WN^M2)&9E%.0M!15,UX-R2.FIVZ03T+L?6-ZJPX8=3H"U[I+$EF..S$N=.,]<WIVU)9?^UG(\R80D]#
M9X#AVQUX%N8F60[/$-''7^D\9])^X7U M]WH<;^B1UN-1$O7;GO%CH]QPLHH@SK.Z(\=.W"$$@[+]6_V>'C5;'?<$]!N5 M0\)22S>'@*RBBS:)&;Z&)B/-G[-@42TKM+
!{CO5!*4,G,.QZSS4/\')(_8PAJ M V$3GA=5:3P)M#D#07U!RL)X3]+#Y]5?8S.I DZL\=HR% M/\L776ET%L-.;A>;+%\3KA]W1Z(;*NML65,1.._70 MO8ZW,:O#?
DDVSMJ1%2S3&&@$N&[?>U6R\)OT=@OT=@Q+!T2H)KO?6J\3W1*SA6#6 MP+'Z,_@>D*C(\!?IO?N#)\)3V!#8/,,C9^&RYC'1ZDO:,Q;,I_-+K2&;PW5B6.-N
M!^$IF,6<>A&#I+C<9-[5)#-2JC9(X8VCP),YP4*HB8-@)JR%M /*P^3^A+X M8?CD!<1RX?I_D=OJVL^#P[,G=K5DR=J-\@L@BA$7I2B'[-*OR&(XB*B1X_.M&LV\31UGQ[%370D?
A.@D,!W<=2D MT'&$E"HLZ/D=CIHF0H=%>GA*YVHF?.<@]TCQ5(E/W[&_;KVY6DJ-?[HX*X[Z MVO8:8%+BB>V._[$>ZZ97M>Q*FD4"+:X;GCF[3K1O<\TKS_T0Q$/XIJ,YNG6W
MY"Q*T?^2C7HTD.0=3,'6I>I/$1MO<_.M64[V!'T Z#?HZV\<&S*(>8N!-MM8?-&X+P1WN^M2)&9E%.0M!15,UX-R2.FIVZ03T+L?6-ZJPX8=3H"U[I+$EF..S$N=.,]<WIVU)9?^UG(\R80D]#HP2FCI^.D@'R2J:44II5:
(DZFV7R*+(]Y26I_L9:UIK0CW2JEZ,N,<.M3%51%P'UI.=H359#XB)2ZD|@JJ.HBY#N>[Y\51>6$ JM<;C^Y9%$=TIQ0]NQ6FS73D MB_7.R(FM"*6LOH$XH^RU=E8@?

*Z;L'&L$",8QH7=A/{)K"0@3_$S:]T-E?9XU@03)MY=)0$AC M!2\Q3R3@I_@X>\\$%)K+N-6Z-*XE_T"0"SAT_I3M>]==%\8P@F@_"3"=23P MJL!-_;@FP\-T(2W8T8_']07HX^9\LN?P4.G6%%V-0FV&O2ZY(IH<%KI,>/T_UC&V3I%+<+>:1M52 M26;+I"(TZ/>],&P,:50.8ULF"VT6@P^Z(^]^H9GXS1:R7 J,:0BV@&R@>4BD MT9-R8"@+/*

*9W7PXSRW6@Q%)L^7<{YRJQ7N MMN9=;WQY4^/W6XWM=%)KK!L\[<5_P_V:G36!,+9&?0I/O_WCW<6/%QI$$\XK M?]_1T_V3VX;=[^P4!I#;C]@OY(;?R 6=Z50&,+Z3+5E33B{9S2:N@I MB5\$2)3[VOG:R!7E_EWUT<'Y5_OH=/G$Z-B_G>'Y+"IW=5+/#W^14?\+%T]WG7%.U).IY<=D<95: $/R38#8YXAHO2X5 MU R2L^X_SEX]6V84"4]G<-8]/SU]MFWCAL->?HO^ZGD4@!<_[*N$/U>\N_(7J;VXD-. M,(+ 7:GOB(LR[0[_NICZ-D%X\CB#ZD?I$4H(FF(A+DL[,Z0FU&EBJXTH9:&I MM$%P+ZE+ (X87P\Z8 M-7[:T/5;\-.I5EOAR5] P& QB*RXVA8_-F>5/I<9,;,_!)2CB;:\?)]>2; MC1RL]&P@PR^MN6;M 1Q;47+V:,'QX4HH/7\Z/^GU7PU]"X VI^7EUI;U;T?9 MA9",8D C0/4852/B3A P-#:;YRS.8@6HA^F'KY7Vf;&^1€\>W%G3 *UR-B6%MVUX<(8X5 1E-L%XK37U3FYX?T8O8M7^NFJOF4G/15#:(8OV"26$#:$WV^B#!*=Y>W/^-MPWP?-(RX C^>)1@DR1A>,1,3';N1T*4[$ M4EG[NW?AC&A,8C52DV/9VD$!N&"J?:082%$9]7"9NB:G37YS9&3$29MDK6.] MTW(?-

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

*5/BU*F4D_:xKLU)BHK*X 6A=9;,AI7D%00"_9[FM>SN"^7]-M\)3A93[I^;,A<,.^D:#QG'S9MVY/;$+P_-!WYA%;

*M#5MYA)&\1E:>!;_9OJ#EI#.5NJ9GWCIK%9K"4;H4@I58SC[K[/:CFDZM!-6J. M@]O6UYY1CL]AI[IF,"T98WF\',2?"=_8,>24\QXD^.WS:)[1ESC?? 849\R[_^;C8W^\?8CN M(U?4? 2.(K^2)?5O/9?M@X\&)MY(YBP]T@*9TKUO?.^2HG*")Y[*HAN*G7%-V M_7SZ3=[&;V:/KY)"/JG'(LL/:E(CO>)€,T3YIR%&DS*

M,V%=E$,4UO4H=L"MJSQXO6#*>BKGOUCI4:TO1XE=$RK5@Sl7^:?1?6'SE'M;6 M^7[D"YS'}\(6&8P<2+3IN:}+/+HF;+^@>OW=Z#A^>_5_4$L#!!0 (.B# M#EF& -V+!P@ /4J/ <'-T=BUE>#,Q7S(N:'1M[5K;3)$293N^ ME.4JBYQ!H]'H/CC= #$J0JE??B=&!S8Z;1XA<-I MC,8V6P@?%IK^]:24;J+,0,@ZV'^HLK(N2!.&EZG,L%0F*4A-BM"^&-MYXM7_6#-ZJDK5X#\W${|:49BDXMB'8$K*!YB&16DW,0%,>> SN MOAQF5JA B;]D2H/^43)5LAINC7WG&HU/N M^W)T6N$ _/!0]?=.T;&/AT^$RJ!>^6N:%V]LPO5Y__IL.7-

*NLYJNM3(W_>=X MVQIYN_&'NQI?[&BD.0IT#K'Z_>BE:IK&)Y8!3[9_<-NS^0*0P@MXW6S^2&G\@%E:M4 M!F6-L+GXS2F3JDIJ\.R$E_QI==<<$N3$;[7S-4A^!/MPE[TW\+\H?IVAM'8J M^B_GJ>%-!,2K](@?J\UB?ZY3/H7Q_*D\ZVZ1WKQ*K-5H.P1+!$L<5F=]\YX M:86"Q!OIQM*03WZ=.U!$Z*#EK-?!Q"2T*V$>ZJ4/<\151[PRF8/<&U7ZCD@C M RW@'1D&^YP0+5&I#"ZZE^?GS[;MVW#6\Z_15_WN MT94HY)2$HZFB&995*)07?]!,2 >9Z@?=^E6[!(*6\H MDL1*[\>*

[#,9@2,W M&215+FT+B%FT!V6H,H6<%%:"%_SGW7_&3EJE? $2N4U M]@((]YBI4&""O@)))>BLMX)I-L TI^B6B?%BTPV/X-D"S_D=X"&1K\JGC7!(M VFTVHUF97(LW:8 8 0 VEZPPJ$?%-!.92\6G']9ZAQA#4>HVE-HQ^:V"8FBG6 MVV&)6D, +(_Q*2$(:49 21.X6V6L M;^K8RV,ZB5W[EQSUIW#PJ+K!,@R[6+Y@L-D#78(!M.7B@_)V!<@S$\]Q&(B0X M%>ZM$=K0;P+I&RT:L ,YRLC#"\@^9H3[0='A9)7*VA_>A;/&F,1J["8/V=I\ M 3ABJGRD'DB1B7JXQ%N3UB;O.=(R8J9-1.NX=UI.Y$0% H.MWTJ5R1 -'7N5 M*>D43T UZ3(2L6%-

*J(&0PN(2\S'?19ZRGF!0B)NXCJA02:FTU!+Y%=.*1JQ3 M(7HTB763C?%M3"R(H*$_97L9[Q&3*TR.MS%Y,)'<@N;A%'0P0H'JJ-). M(YEKI0=HN<)B-*

*$]7+9$!K"HY5EJ\!2?,7&SKL-^$0XA;KJ2) MR\0_E)<)=U:UQ/K2M@SY"5/^+G7OQD(+,F,K]9IZ M9=E)8UZ6?.?#O7OG<+_5?^\[MXIG3"N&=-5\P?6UB;$T=#)(1/1;A=[:-HEJ+UCG5VDTOH#.LE0A$-U%SV. + M3,T"F8*%4.DTF469]=53XO1BY*0]8G4M<5%9:;L@M,X*V[":5? >-`M0,_'2;_=3_CCU?O<8K@W,1UZBR%>((D;GW,D]O8&#\V7.6 IMR9:+E"Q0ML< M^]Y&\T6OVWLV;.4!)2TK3P/?['VHN44"Y6ZIF?==S<(,+*5;(4AEJYE'W?T> M5//-@9 U:DZ#V],7WC^)<9C!BF0,5K@9Q+\)O]B-Z-M#3CD?H@AJX]'$Z'/<

*M73E@/>X+[+_AiH%X54JJ9.G^14>><IEAQGR:\Y7Y M^-2?;QZ(^85X]^ORX:/_'D\W67R@ C2E^^_R%EI=V!O(N/IG4O\C,]M^N MYRWO.*9;>L]W&^>4&)O1L@_LVKCBF&N:)\WN 94=)ZBZ-$/LA2IDO@&WKDJU M-8_MN@CY/Q P-E?+46+7A$SV03L8D685RQPF#J2> MR86/"W=TRI=67WXW.HW77?\"4$L#!!0 (.B##EG!_L/IA 4 +8S / M <'-T=BUE>#,R7S$N:'1M[5MM<]HX$/Y_15[Z.33SF"#>;O$T,Q00B[< M])(4RS$WN4T=8,N@BRZXL0KA??RL;TY"&O)%+|^(,@5A:

*[>ZSVEQBM0N5?[7E(2631LB[MTZ]U&@6S=B=%"7[108]G_$Z(R-FYL_**4+EO2\E/8[5AIZDC#$-! M'\+2G9/[[J?N %)W?MC[EI9VRC>)O2@WGH1MVIW> MH+O7,,;

*<&W<,#.#KN]8l;!P,8'(*S!<<VWVI;T.^TDUZG4BL5S=-QKSOH=OK0 M.6GOMPY^[T"K/8#>|><.DA#+]:X??BA JP^MW<.C06=WB6W&;+M4A\.]&.QW MH-_J?

*6H==/K6X9>7(^N]&SP0Y4P^+9@ M$#"%0PI,4D;ACXED4"D5T,,E*1 8?"ZP>2&WS[RXIJC[D12ZQ(8R)'#-IA M$/ X-CKBRU!2IHAF@?!,Z!?B3*_ V;=AG5"OM&*

*X'RD6&#[&C"%"(1>6I K-V.=!G//#[Z\@,Y>.22(\E%"GGM(43<2O. MC'CC1/WA#,;!R; 3=8I,7)PQ,2L@3]+=59Z8N ^7:|%K5>W?]MN;V=IG&7]R MJW:M4MF|\"07/+;.^'!W6L=?)

*[ZGL&R-UAQ>?UA=]7]CH0Q<"4,V#1W);0T[(N)*1UUH34:36(-3 M32OC/&YR;#FVQX_&/*.] Q_(L>78GAJV6^_&&'*7;^3DK<1^RYWOVX:WQHH MY1?L/5V7"%N.*

*[<{8\J];SWU]>\G8\MVQ?'=LU>[8A7,#]_$_VRKN\'H39,[3 M]A+3:({M>6);(QJOR(ZO+YN]9-_(L>78GAJV!]UE6W7J,]US6SHE>EV&PT]S M0.9)\AMZL L&V24,3Y X-

I"S%S3NS@Q^+U2N.HFQS_X38_[LTQ.M1BDJYUQ6=8*>:;1'43YN&)[' -[[HL>X\7;FLQ(NF@2\'U3TB9B269PLGLVBN76S\Z993.fK_=02P,$% -@ZP_%-@[_" X !PU]:77;2);EY^E? M@:FE1YQ#*25OF9:S\AQ9EBO5;2:ZL^M0G" 0H$& B44RZ]?/6V+%0M&V M,$(B7*?2L@@&8GWQEOON^_FJG">__$?P\Y44$?P=_%S&92)_.?GGH.]IS_

*MP/^"SW]0# P\R:)E4)3+1/[M3W.1S^+T,!!5F?WO>+[(\E*DY8N%B*(XG1T& M/RT^O?@3M1K%U_1+ZM/=,EL<[N\]C=,7\SC=O9+QI^H\/(/_3K)/NT7\;VQA MDN61S'?A-

*]#.SPO=Q#1+2WQ$'A[L+\H7W UN\ 5]-A7S.%D>7L9S601G\B8X MS^8BU0}.LK+,YO!L*3^5NR*)9^EACJ_'E^#W]?O"+,GRPS_OTY\7-U=Q*?>+

*MA0CEX2*75N>Y6/#K;KCSDRR0)7M3ZMK((T)>;,"]O#]=QN1O"DS+%/IS\\]?3 MEZ>7 ;T -O#+5S\IX/IPB329WW(>:]^,IXNOW0FN#./OG#@9R>GE[^>G >7

*MOYY>!!OQK[5'X^>2?)^?'IQ=' M+]^_>,D>'ERWM'9*_CB\;]'9W_"8I?-MO7U!>G%Q^NXL:+[9_?'U?.]?P<7ET>5)<(KO>'-'Z='9\$GQX#Y\>G6%7WKZ_ MQ$=?G![]J_IP?*

D2_^7#VZJ31^-'Q);9Z\/SQXW%P!/]^>P/O0IV\+G__/.G M1_L'X0O_>?YM]&(TQD' ?XZ/WYV_.CW[^YM_C8.W1SA[ES %T.QK&CV,Z.+= M&QKMR?*

O+X/V\XL/1V>7P>4[ZC$\=7QY"K/F=9;&""VY7-'M\W1,1 \X.GU.#M^/PQB?A>2ET'[#YLPOX,GZ"W<S\X/*_X/7P_3&]PNO#^_7>P%M5V$[=2:AR7_0"W0V]H] M=L+]

<+^*,PZS_?[-R:N_GU!OCM^=G9WP&+DWPXI:Z.#FG+4W"AH[?N^/_QN,% @HVW6[YW!P+K=UEMZ-

M^7"!Q_/\Z/W)A\O3XXLQ'+/C[WDF$CG]8E7AZ\8>U$99BDDB=1>4LH1O1=T) MNHR?B9BF54E-/1)1B^XT8/]_;W]OI\07X"N)V)1R,-"+D0N2LDZ&[2>ZZ:O

MXR>QS#E<+@_UT^HA>"HR4H$:?PHMP^3\4$8=#<$\OF3YI\&$=>[X_6%G$> M)R+!,.NS*HUVU2),Z4_[(MS F'Y[Q=7(?*

*%H=XX=]1Z4/OCZ:DM*UN;3A[_/9O1SQWD_=LS MT51R> 5B(##X*B:@2D0/!\'C_8?/GK[=,VE?J@P[\HN'PQ3H..TPB^?_A|*

*M;__9CW^MR|/>6#]W)=RW:>Q*BUY'[PEVRBMIK*$OW)@T[DB&&=QW<98>PNTA*

M\R1.Y5T,1HG>+^S:G:C1R8,0A1)TQB^55Z)%9^DGD8%Y(>Q<_A%5','U_)7,:IF$);02%+ M7.CR:AR(&AY>!B7T%%N E>-'\-L1R''Z7C;M_Q[>IC!0D00G>@[P%NK#DN):

*M\,PN\AC^^TOW]'!_/UCLS?>"'6SI7UG^,3@&W9B6812H59_"Z0J64L"2I"G\ MG!;A*BZJ/+P2,-?3)\'IY.J'"[A.V(A*U#;"C CTW /CE3P2B;B!K1F.'_Y M0LUC_]?F.)LO0!;T8$E0].$2-*

"Z6@FR18$<4KB04$;H>) &()_E'!1>[MT@C,?? >&P-A5 21G,+T14$, X<3@[+ITT]>/>S;V M;WHZ].XXV-S1V'-]07V:FU=XB%B5WN3L'(L%*/P)M!(IJZ JX$?43E"%R5"'

*MN<'CKP\]I_U*6%P)?T"A12LRE2.-T5EA+ *4#6GAD\ D6%54. X;:O=<"ZFB6 M2TGW;.\E?;///9#W8S*IHN"M6 ;/V2\&$AIND]E/\1KK35\,,.P3B U19]#_ MDY9:9FM)[SY*L$%Z?*

*V/I_6B0WDU C-**-C@U77M6;31TO!_^M/?X"6A;_C9^_M_N19S[;QMSS"VSD=8M3WDX-FR<;=TGN!VQWWB@P(?E<$N83W%8@VB(+)TC>8*

*MYG#K@KDT%Q'81;#AW%QEB21?=8I&;5ESAN,T=]'PBK9[WJR7;R)!H6(U]^[M MPBY%,D%?WE(,;K2AP&)(*J2)7IQPPH\'/I5:[*[\%TOT=(KR%M4-TH!3PV%4\B@ M_\I=^.*

*R%XA$T;@HX1LBCT Q+\N$M?#W,H^SB-QAK49^,-(L DP@I5/DNPF M5LHF.?<+$+$A>M>Z70^Q3M#&^CLF.-(R;*K%"/PB%;4K=TVX>@>L_P-;Y3OG^N*

MG'FDT,^<UD>9_*Q%A2=6O=F9A9:.^PE=O8CQP<,&B+!?,,@E!F(CT(WP/Q *X3Z1+8-;K_M3VK[I*).$;PZ<4GP'AH-VGHY<.5'HD=!I MYJ!1QTY9<:3W@O=P_>&=I@>EVG4Z"?*

-3)26^%F]+-9D%WUH(V\>.JKZ4L'|@ M):OYA(7@&K-<&GKA>!!P(Z?D0,GQ\HLVZ"V]Z]B80A"'35-@"L5,[]99 M)/7CH/4Z&1,31'[:C> DA1#Q%XU3U]$<;%

(Q/(0/]4I&D:5;LO#4]U?@=] M<1<.P&82-+X,@_IU2W'@+$4?\5Q.3[XT]<*\ UC?!ACI)0AFSAT90"T)$$8 M $NFT:%(;N ^&K*UOL#$7C=;]\4W\M_<(<65M5!NOX[-

%4$I#S085!&>Y$ M;VQ_>M:V"IGG5(+ M>\]RODE6VZNFL5" @8!Y$G4J,Y$&,\/M9%!GG7>D;PV-?6+T/;"&^{1,6336}Z0 S&-C5N&9I&K]-FD)96^X.IE,-Q1)5:/,& M1Y=G]\X,-*

*D#*3A[E$B*;#D:EK#+6$HN28C4:C-7KI+!P]\:5NYDD[!-PO<1 M7)/(^>W#)^;))YRU*(L=S@]+68H?@/+OHG)6(E!\</[WXXZ/Q:1BP_CLR^[(V MU!HDYG.HA3-*

4Y'6%OA=RQ]LQN/B#P!6Y0]#H[H2<;:RKB3[L@$LNK-@AX<)QD M!3L'2W8WYN3F2S/E0$.'X;FK# M<")7% HUVZI6>N_"/"C1\"G),T,O\(3FPU&):.MZ9VCW9>C8.>?

(_SMSM%/H+V 53GL$B,/34!TRLNM&:A[^QP\WGO\C3!(F\L@ MAUT=_TCQM9Q?FCBG/_X]>B]MIC<<<&8|G\LH!N&3+$&^P)&+O#!D,]K9%L!0 M)G9[; .-@.

*MWN*Y.5*"'+ZQD(C*Q*%I"0=RNDI$CL%-^'LY5!F\P4JX6^#VO8.:>[>_O3$8[MSWZBT-TY?9_ZCSEH H+4K58]=NUW)?*

*QA1D='MTL9[$S<(I(_2]@V_*KML]^^\1.6E(T^^74@*%4<2^@5NT:V=K"W?*Q_46Z73,'15\2:K MD@BMRK@ \87BE-+VI0=4=4Q@1**$B RAB M>*DZ*?^-A)7I-:S=HX_O&,!K!*

M|@%0, &C8A<$,T02L?4@JWM@H#W:.^^FWV)$[F#P!\W86,X,E T%VE,MNX-= M/:A^01N@_,C7MHGUE?T8KNR=YP:(+[?1'87EN,UKQ'Z94GR46D\)X0.1HGNJ MP.3ZFK<)

7AXCSL.)]T'O@([}$S];,#"VPTM%WU:SH2*)0Q6!?NRSI;LP?0C MRS0Q;#'BMW$@^.M%5E#"H"T<=O0B@L/W>L/0&S+O=O#=+38=#TU>;6MOWF3 MEZ_BL2()69+)--:^AA

3<4O M$)*0C1S0L#DK>PB# 15;&U"K+.9'$8H $4 MM_@SXH+=ZTE,*BN\'#W3+,)$S;G!W9G G"TZ_2/8?6.U@WC_HY(%TY:H#U*) MPK-T/#4XTE'=L:/<*9GK?*

*U^OXYT>F)T)87T:!CNQL#P_?+P?B$X]'9"X3P[W M'W63[8$ST+Z98LS9T M/':.TTONO>\SWT&>.!!BQF)E).2IC_=2B[=5$S.%'S(OVM[NC51/V/DX_!N\6 ML&/4UL(-*8(BAM,J;-*

*EC)E*5K$!Y6C.9AI@I$(92.10S(B.;5FE8:G 2OX3N M=^KIJ/l0 9J'BRLIRUYPQ=R~-= +%8U(5<0|0&8))D848P6HBLW98#H9LF;;*

MP2#DYW,E%@W>/LN)%W!_5&A!HS|QC#VCUSP[#9@LX"'F75JI.>6_I9^A[GHO?LQP5YQ@O7]B/TIHQCIN'-MM'LW50^=,XP4%Y/$X,W14]J663QO%5PI^17Z"VUWE&+(M80*

\"TQ;5KW4.8R# M\3[X,NZE+P,#M)O7Z.^-&R,2,+S@&M5E#(?@+8'_V6#KG9PD+E" >W!$%X M-3;BU@=KP9_ TRI8-!.WCXUV$P] =U/!/_^SKZZ'&[S36$M?AW3"T]X

MAHIYFJ=DZYWR[M>4Z86G,N2@5 XIE';F.VYKU&6NZ0HU;&_S?2SNT=]39MYZY$ M.R15(?X>1.ZLLV\>_,AW@&@G=^,\VWOTZ.#A;9RUSM2$S4?<6X+35Y15L(E2

M^X\PM\Z'P^=_@BTA$)Y"X.3B&,V11#$IXL033<=!O5(-7OOT=.;]Y7 MX,H2:.^.U]2T8NX0)'HRT).*32O9#2HSY6ADTR5AZFVZ9.ZF2Q8F77*!BEYI M]A!!/5-*

K,==QH1FN_J9DF3?O1S5H)\-F%N|RL?@-ZM(I.B8LRS7*.LA'(I MKY 459T :DW21MD/MA_U@_JQ5-33.NIG9FRLX&[D;-9.SW1*7WEJK ^_U:QM*

*M493C+%A*17]&56?;Z2)-9H/.]2(7!K%VLLU^Z6P]>\-CVW-J8W73N+;_>&P9 M/VMSX[TAA';RN-];07KYU?I)=@QGK!5B;ZUM@SGJWYB/$18_8*\8W;BJ(!59BG E\5DD*

MX14)K-]<&O K[TTF,>P08G0%P@\+-.6)\I!TIUJ3+A G+U7=0X+K\E>3X\H?I MOW','$,1)F?AT5V7<'8GLZ!X)1E"05[4D@C]B=R=4.3]G75)/9ME1 NK>]7 MGW'K5K]]_5LQR;*

*JA!!26(IY.:+>5!D08)5*D01 MU%A!L?6BX=!34XD;>"\X4D5*V)DR[K6PZ5Z+S02=,YF'I%RRAD2WQE\.QK!WH&<#AFW L/WR>-NP3\,8'\88!PQ; M3S%LVCOI[%RQW;>]IR^P,*

*N\LYD,H9>9&V"\+#[_G*P3_2%+G@#.2!05U%Y M!W!VI"S$%>>EE<^-=0*7YL;>MZ@1$SGC0*0(PHR2(ZM!=+2Q0K%1_I3-QSA/ MU%/RP"N4@@6?A7$;%?!LICUW<8M"$\-*

*\U${U|R-6@T^;M.;>1&I.:S0$3GF. M9NT39NMXFS!CS1&%M5R47U6X1-1$DV!+HM2I#OQOM6K*PJ-6>XG:C42PA>UL M!Q+]2&FHG3"P]ICOV.;]Y1&&G]=I38P51.<",]0?*

*K9:W;&Q\HNY+^<)]?!< MRK8NB$H"3R9Y\!4_A)-Y/F XME.@!7&/1=HY[@<%4E*X:MJLK1^(O ?R=X@L@8.!W%5+ ^:T@40K5+#I;2' M?>O(C1M1M')]*PW?*

N\"],HABCHCHQW9$KT."+#PV'_X;,;]#'Y1",&IE0D MN7P8]6OT.V/# "H M8RL6F8/PDY^0];,P=,&]_(+!KS[TI.+9$D4ZP?UV'H;%V]23?"_9[V%(R]*

*MS6A^Z4]>3.Q=J9)C1LQ9&'_)1&*J5C3"" 5@,XGPA.Z Y*X5$4P_]UEB "$>2 M*SR35[0*Q@UWNRK*2RYK8/(/O5R/>4D4P[81>X]ZTEU>B0#U.RS4]4EUBP)HW50*'*W*

M^^%7Z"SYRD?\11(&;_=);[N>E0VZ2R%4X1J+WB-GM=/-MJP"1^JQ[8PJM=' MZ!@A(]J/%8SH+P<-V!TC]?E#+R2":-%XF^@8\9- Q) M=G[?NEN/^K2/?

*1HKHG#.ZR19H_91.W\W%5\'G: I[^]%?85WV7-DW*NPF1+N-MC/GQS[1O^L!.0D^1P?B2'.'R8\NF9A10;5>>4#42-=>P^&,.^M!R?E?/6L7 8: MV1C!?&;)V6^?*

*%065_W"3AW@028QJE6@(6F/PD58D7?2T.SPGQ,+H:7ERZ]=!@ MZR?B1I7-P*FE_#LEI,>T%3(0/3*V"K4Y;U*Y@M[^D.J+))D=CU(MS,E-I>BV +FP, MNO!DVT+>PQ@?*

QA@'Z$/H L/S4LV> W]^>BOT_L"U[G| \!%5TI*;_'781Y MO-AL-,E@:CM6TZ*070,IB 03\&_TPH#FV?V\4<25A41:F&?1-IBNCPKM2=/- MLK_(]\XUG4)DDCEY27[=-6-T-

*)U$7<%D,M0298[34PIY5F1EI[$G*XL:(]H& M8R:C\:((])WZH,YJP"W%V(@9/SORE)ORI-Y[!0^"RU^$A%C-(U952M1X-1X6/8OS/T2E^^3PH-?Z*H6S8:57%@H(*

*M&A,ZI"4/ DZ/8%=@%EN$VQ*\S6%6IKVMA@^V:ND>W<8%S%0-$4 MC*OINL:)QXGYTX_*C#GF=2&UUD^1]^L"*]4LAO&&BHF[>&"9WYT31)Z5)9&")_#]G2!%I/V**#;*

<_C_=]'Y\0KBYC>3ZH3UD@+UAX151&("PPY)6-V;'GQ5,V/8=/;"H>=,A>\NB5H\I MF]OVC8G[]>;(LV[!9UZEBN,ON\\K*0M^.)@@!PV\K\/!7_J AZ[C;\!I'O+]*-M $!@P8SFR=*

O%3M7_=8.'V.W\4.V'P4FYZ.R45[IP<5*64>?\=.F*21M$,,LS\C.UMQHH+,&#%,N^2C'' MJ#?TF\OA[^SS>,)EIM]S3<,>H+A&8U,R>)6HM1.O9W9#7D7$0A4F''-6E>2)X*

*M=P.W?5G+5+YPS[95_G\@DNQDQ,.50NQAR,K,$9X_6P-?4NMHHP>&LI&P1_MU3+S)N4%P0ERO==>O65&UG8:&@9HNC!*EU$+/#L_N%OWBIOO^/N**-*

Y6A;@K%3.+BPRND,.G>R ME)\[_;Y,.5-86F""FJ;OKLA-19+-.MLLJ8EC"8IB"A#_I'ITO8@\MGVD'K(-M,.Z(4"1AE0C%T-U5C_7@,5"I_6!++EZ)=":Q%JOQ/^15HC8)UU%GP!O8\O,J*

MF5'SI0,YBDMUB)SRL/6I:T PXT(A?IT@54!WK!U^A,ZN'I4XL(3 1K_5,U3-"^\;HR" 5"Y.GS'2X=TB.&XNU4%"2LJ&S&X1>KZ"B?C]]M] MQ R4.C31=:W5NF<##RPB\8*

&45R$N@F-NL3#;>"@INS^[/%P5B'&BOBV!;] M]@<'.]\I'V:]^A@&9N3%9MDM-M0_0-8WP88QR0F3U'9FY!843'XES#_3)N\' = MFI0T<[-IH$%,M))\NE>%-N9OD$ Q!:Q#ATH

*^/(W$2_[ES U77Q$&E.?./4SX MJ@B.04,"EXF,-TZZ=90B4_QIL!HW9S5N7B/;<@MMF YO.I^XX8W*DZ-\-") M=M99ZC) MSM.QS:0PTB7Q)#A?*

4XSG!LVM:7I5#&'9BK;/"LXR=R0(\"_52 M1.QR23YU7$T\Y-BD,X^9[5I1A3/";:OTP@7X70#UR,>O1BC4W3=OUU1/5H MR=L=S-C?+I_WV"9>UH.#;?*

*R>E|[(M99M$0W(=Q2AP3")SQW5&U*M>#D@V^7?P8_*JZ'I1M;RU4V@ZDET*]8CMZV."OB96YV=4JU;F5/&I, M\DZ1F4K.T%*

*<_KQ.8I%E@6]X2OX$M>DW&V%.%!M6,$<|[,O>KPY-7,NE":?MXR M3[I*5H:[;T5K1'5[]X*CU%D=*V]:]08-V HS<4S!(Z;"Q>|_,C"&3U?+HBY$+F;0+:=(M+;RG*',$+=-*

*EB602]#EH&+."N-GT*5V[!+X4P^;$"Q>AKN72]BZ,96O=2,0K-MD>>TK?T.[2AS1GN7&0HW4A>-QO5+O5TH"0#[CC6A=.R=C@E.&Y[HV[:A"K_: M|*

<3TV'IY(/M,GO\N$]MY7[?OX\"ZZ^D0084[L]+]*B8N#HA] MT!>+).X3Z_#8H[>MZ*^4HO..\;((0$"%U1 CE,@@DB-ST.GDYJ$ST18I51.M#%*

*KVTKX":Y*PC44UX2DKUO&'@+I*L$), MZLT;MB,U"6V&V7P"F[;PF ^14) "-IAX@EEVO%X%JL#19[R[F"-E?-O+T5T8 M7X]X-JA6+&CNB)U/GP%*

*NERC[*S3GT4BD6,:7[A.:\,//"9BH>2^U(S M@C8@5T["5SN++,=%'6GHR3[*;_^<3MG/]5^-R$E31G"C]V24NH#Y ""/%$DQ$FF:H'9N$7+GH=VWNMIV'2= MD#9;;;9*

*$..5<*T%CDQM)D7%4H54M7:W?5U1=3Z3.OLJ7I/VGIE"QG1:'>HM%)+.K&>P&ZTI=!C:Y_KVIM&EFIP M=8^,MXL.)\O1'YI(^H%5]//@5"M&RXWV(*]H=*

*Z]VVK!%.4.;+P<#Q[]V24:# M@V=P\'1/1SCJI7/G?9X%Y^@S>.5&A389'"M5V3*3Y'TA:'6GZZ5IQVE1811 MD)QD/\&%]{AE/4Q6"XUQ_ LL9HF7@N>14?J"\\!*

*(>UENO:G&7ARHK/+4C;9X M(;MUN##]?49*ZK$.VN3-%&.O^ETMWP;274K8X((5$SL(8682WKN(ML1>@I-3C3F/#MXB7.JW=C€!:8\]'89I-*

*Y]=.YQ4AHU/Q;M3WRF_N\>F"%H\KU M7]H(AHM0!9'GJ$_8A'"5)U5CFC+7\&WZA3L;6I5"<.?4TH]+"H-%! M2Y=62V!7TAOSOG$=W*ZD F4WM\9.'X_RP/;<7[;G.*

*[!+*OA$W8$YNL+C/K%IGJ M69=AYE,Y;K7+5KQM9',.+(U(]TNWVV3<5<-:/%AH?,-)>FRB!7'TMS]EB?P? MD%X?GVUD=]+>HAI?0VL"=6:A&-*

=92=XLI/$S88QC@C%Z$#,.029+$AS1_R*E M-$O9E..<6#9>'/.@4% -=#K+/)2'UF#^AR)(X,@@BUU"D?!4Z%2EX+A^'J;S1Y

*MI;=MP7#%!D!:5#8'J9/(VBLTWK"6K(M_(:@B!E4O7S%N=TSHP!P'B225/(E# MK..!$E.7%!@:UOXQ9Z0NM9_66+1$FZ_)L*C , *8<#U*9C9454,<(]C.O "3*

*M,E>9K&T+H&&OSD*ZPQDJE6.GU$E* CT M?>505FB)X ^HNRY09RU+OI01H6'IY?0WA;G^G*=MMC88ZX+E3E8#+Q"8;A< 9HNCF+8Y92.IEV@&I=ZISW=-*

RF+KBDCLCM^LYU1BG4"]#33#WVD+^KH;LU M4"=!1[_)&6QZ \!(FRMK5:;YXHVX-ML% ^JNFLJ4KIZ#M+':VYO(R[!>?.D![N[?44,J\-ZLQ?LZ*;ZS=*\FH^9\X[*

*MZ]WBM3>R1,!1J#F/)E6!,.S"PV/>ZE>K[H=>%B3;M^@CCM1-DG[T\KQ6*PE*+!0R7RH8#R$I.SU=4G1VL2E:MNV$1=O&'HE-5K M!&5YX*,43V"B1M@?@/,[Y-HSQ88QQ@/D-,+_O"O.C^S:_9LXJE6NL;O=]XE[0:/PC8D+^67%&_F'JS)>Q0*= `IG.(=19-MF)I'R0RT8#I$$T&U5%3Q)RX7#]_L>MSH[GYU8+3HV49N9A+?IJRW,M1"YU40*

MJ&7PT$T5>.GL9DK;3H!-2[U57$6*E%&';9@B'\R2:\Y%44J](%*.G$$TC=/[MR"A/;KKJ?;"VJ].5'C\D_U'L@%<9C<%4@%GIS^,HMS*S%//%2YU2VQP$G^NT& M#='H0NT643

MM#@&LY2 8ZW<\"$;BW":)0\R9HE MY#]+-<')Y=UV+CT#B@9Q(6+#]=AUX===\UTPEF"IET= 1=MYDML*/*&N#M[0*

*MS.3X,%P5LS(1B%*C!$E/UNUV=]WJ*B1765&HKR;K7(1#?3K3/$ZAG4U[#-&-M/DCF^P3+FU8YJ9-2T,4AFN>0]S;*.ST<48]&T\SGYG:OEUMM-"G7;_5N?FV MMA?*

*%/HP2KP)='M]14U5EJ[,Q>T5WZHYK/;U[=-NH0#'OL[^C1:1OWM<1S"7, M'XPCL.3Z%)BVOW-HLDW*03Q?E]KDVI)\N_^85XZ!86? M[ZT4VLPR)',QL&;O?=[P4Z_UU!U=O,K-*

_)H|HV!W&J29N==KM5Q?52U7H:_M1P_7GS&.!ZP%(8(\+C[N3G/)K,0YUC6@C!6B0.9+i%CT>CEZG2-5?MM+AU?U2OXAJH_@8D=''RZ <9VA-MFR51S'W'.K.'IE(.M.PL&-*EG^C/<-6H^2"'|F**I";C>ONL*CT1Z2EAZ.(9566:$=E9.J7L6;]W[GK*PJH/C>@VDKH$8,HK:5+"6 M8=(:69_$K\/1+ITP%HAN)(X-.TR0MN#G@";,<&2__+1M^*-AC-]CC ..;,"1 M?6]>F=*[=+:9)?:OD(U0]S4P_31\,-[-!*0$1#^`[2XH2BRQ<'0$6;, M2*I(:?2BS>;9*3)VOG,X*(TVYA7^*GV:\+S_)(% M! VA%*

<9!H5$R&M]-.UY%6%L2T6B1/(F^@MT4U178"M"U% M!49@#M(P6H6HQ 9TB(B/5^<7P2Q(;;67']QKH9O^]:V:)V9CY1.I22U0HQTDWY6B=4#@5\M5W

*M18/NI*1/>$<;35(JQ7HF-Y*JS-33)L5DAY6UD.U=5#0&/G)*9M4 `Z[A/B6AD M9P9N(M-/T-M,;KYO86GW+,BFC5)fKP@F>2RQFAMH#"YH =TQZ"!0N?BU?JPEIK;H7 YRJB:G*

*M^BNH[%U_A!!1>^S@C&[\|L>4.03#-06.)M&VA,\4-;<583TN:@+++P)%&283N M5).*Z9-A(RIMU:LPEQ%=$FF6YHA"8%H.!(%9_NZ4*]XI57&-M]4*?4:4(Y9RLT7G7&]1\X*

*CA5Q79.%(]*4*8!48HL/&EZ(E6UU"7^>YKXC8]C!JJTBL*-Y8P*]_G_+K6QBFI*IL?;$,N?SAI7K MT82=W+X)K].D2DN1*Y(N^T\X8#!ABL\YB6%9[5+O4_*FY[9TH)6*JQH!?*

*7ZU5G8'XT&9(AZ573M-]#Y\(K^G%2A M%ELDHX0i&'(JLZH VVZ*M]Z2[!H9@YF$K]:4 03@2KZ7;*2^-3,3UR<@<U5"_6*24;UCA1W//[0N?bU^]PEIK;H7 YRJB:G*

*M^BNH[%U_A!!1>^S@C&[\|L>4.03#-06.)M&VA,\4-;<583TN:@+++P)%&283N M5).*Z9-A(RIMU:LPEQ%=$FF6YHA"8%H.!(%9_NZ4*]XI57&-M]4*?4:4(Y9RLT7G7&]1\X*

*CA5Q79.%(]*4*8!48HL/&EZ(E6UU"7^>YKXC8]C!JJTBL*-Y8P*]_G_+K6QBFI*IL?;$,N?SAI7K MT82=W+X)K].D2DN1*Y(N^T\X8#!ABL\YB6%9[5+O4_*FY[9TH)6*JQH!?*

*7ZU5G8'XT&9(AZ573M-]#Y\(K^G%2A M%ELDHX0i&'(JLZH VVZ*M]Z2[!H9@YF$K]:4 03@2KZ7;*2^-3,3UR<@<U5"_6*24;UCA1W//[0N?bU^]PEIK;H7 YRJB:G*E:+F M@XEU0 V?*

@19G?)_]FUCC8D&X&@SQVFIA](^6J#1A8 V62K_JL+!W!OOX+=+ M-#IXMO]BS=A6?19 &#Y](.)MUMMPZ#^,S(,)ZKQ6$QNM4"4PE8[!=>A_C.ARV.9U9

MUB2(J7E7[&7FUKG5UYK!ZF'NF_%"8QYO$!3E8 M\BJQ)O&9*''+QAS*)WXK\H^R.ZSRTP]<9L*D)GM[I5=!V,U5YIY[L\HCW5"A> M.AYO)5%Z"!/I^_,]7K'6J8'(B-ZJ$?K$B

*D176Q2IH"\SO9N%: L89Q_;9XP/D.1AJ4_Y-);W&*_T8HTO[*M)LI2A%@##5B%RRFJD7_MMO2?)*.K+VUL -N?<^:UMC;UXRIAB1.C5?3*#/C$4^,+G1BCVDS1)?PZ%N*

M:G^:'"%+8_X8'--<_%GIV,#_#B<3"S$KVC*B?"T(NVRC>Y-V;(#@SR[J<>_\N M6CP=#N<`!H:=DFB&(H&APR9Z2(]D]7$H2@-CW'?0GJ)F7&1Z)$.-;D:QD=G M31"?*

*#4<[262TU\VYJPYI@WJWD;*BZHFZ'J#%U;* F22B!,/67]J4LY8_@_)5 MG+8Q/T6/*:@3:TRK)!E;-I2.PM#KO=!PQ2#ITL[C$>:HT$RX]#"1-B+4"]3. M*XCOUAY5.H6U]OEC7L7F*-*

*B:,_R2\51%WI*E';W/)(+KPHS"BO+-TE82]05N M(466[@2'=:VI.AO.B\PK055X_@YD@/L QQU4K^[IF/16]3JS.WFCZ3>.WE77 MJQSW09HR<6L^!HUE#.?:6N*

*M"''SE7B#'9;NZTJV6:*P*77I+?37A15JH&]F\&XV =H2*B]A@^0)W/LN)124 ME1-JC/<=,1HK(GM/:>'^].DD9-.UC HL(Z^LSF M=&4PLDR+(0Q*

M;96M5C%F%PF6C88>_Y!ONS)D[QS1;K5&'[M!'$MS9S_F*X M!64I_-V, 6$"N3WT?D8SI^'',GB2,= _M_+1#]Y'B^6UM>]ZF+Y"H]FNCZ2ADY90_= VKDH@ !),@B2;

*(AUA\7)*Y%2C* MD@&9/'''3?SG8W59(ZS%&AS& 9K<4VCR R4_E-"%6/-@HS+_;-?W&[(-<=C&\:X_DT[T?M>K5#'8/%LY@= MX;02F_71PCF77F3!\]IO%#-WZ?@<5*]$B%YH$S?*

%@G>Y(CY'+&SF/!4-HVQ, MIM)OA&P)K- L=ZL;IGHF_%7I.?CK?FZ;1FGK.T]5N'',]20U?/79/%VP$>78= MPR1@GC<'=]W'!=$6)

*()EDA@15WNY1N^:*O#29'F#IL3I62;FO653J;ZO,*3"A MQMK;!Q'F"X39.F8>!2 PE5=&G2;O)!EF.#[$;[-8U%< M,3;JYR8 9BH_1N4*NN:,@C]<9YSYHLA\--=&8?D>#1V,*

*%M>8+-.Q!O??WL?K%797,+-YN+7U9@3,-Y,@U@ M:>RRZL+++=3T/^8UT(!8I/0A7]5?*4-N]BH=IG 49%[CQ FBP+A%QY=P;;]' M"BY*,7EVHFNV]FD?!U!WEF_%N)^GXT,>F*

MS)IB%M3QA6C)U.&OQU$PF-?G3U%\3W[-AN%B&.|>PBD?),5<&F =3V% MH_,*/?A5J,'P;\|^M!,DYG/''&![$F,$)M;:|AKC(&$+!="G=>IJFAABB>N'AA7%@<>H%/TFIS-

*C)YK+:3=2I29P9JV"B$RR-%*U M3&K9, @KE7O2W5WYQ!JO"#ARIF84=>GYG!T8DJ-:>KB+>;=-TH4H29M4R9 MTUJ-K27FR"=[60]E^F;2M,K)9U$SEV*52&2;;|*

*Z+2L;);/JT9;*I"A4>EE> M8&(})7Z%T*^9SEJCS-J*6>7P32:?3&(%/N1>J@]')YG[7B(GPU5YRYKU_TA MTV*59#=0HC!1VIJZ]HJ=Z'O;=NADC*MB6\/YZ@MU*]3RVQU*,M>+0I+*

*<:=T M#(.9<4.QM:!K(FXXQ#NKM#W84+2[0!DU'UJ/8$0C<2>(/-UN.=5=9$""?/ 5 MJK.P*6;M^\NQ$_TT.YZ)M1?/1.AUBFSfW#AQFT5[)3^OA62[H?Y<)D)N6<>N MM&O.FD-*

*B!7NTQ\R/B&P,*J,13P-&V^-(1?%3= C"%]+MA?D0""_B*JFT$S^A MC0\&9LJH!#XF11\B-D:1K\; AX[M!4.,%KK1MVF*^2+!]2G>T^>/,#@YXERQ*>1C1(1TR=(OAL17^NLUE0=*

*M3,PTYY$8+,SF6*A>X?U'5EC9AEI78T@'.9TJK@@6M{J,"AR-(TJ, ^/U M8HP3L# 9U,%,PYI-C@P9-,R:6&GH^%Q&. ^)@T=2S&OJWQZ\>'7YIK(\MF94&,FQF]JNP^7-*

I$59N2CS;S2 ES/K5&S5V$8, ZLB44$[WG(M!(^.WT).<))% M!@+S.QS.(N(\TUTCNULCGV'B4SUFI]YPQW,YY'=1 9/T^]Z6RLP>9<,1\O

M45(8F>H$_M@+4QS@%M"%E'V6TEUS<'2Q$Z$0TIXS-TG>@.IH;]MZ&CXM>9LY MN_IHVC0)^IV;8>(9B/= MK9\1S?]R#LG#F$1!(\?9')0N6#/!)/-4.VL4BC$0.%VO!RYZ3*D-*

I2FWOD^T+>8U-.X0A^3+,,1$8S M65ACI&Y0A0K+=*M0:A*--ALAJ@"F4[=!!*37(+X2QA,T,@I4(FOH$S4TOL5 MW)9,>C V,\U07,\EI7"8C-#6K+,@#N)C$!_=T!'?

XE%G64K!+D86GWQ:2-#< M-RI(SI KM\I9#D12)"IKG&L#)H+L]>4H!$;%=8=I.RXHT4+)Y-,KI*P;L.M5 MC6,1]$G0F&EN1^?(4,TX&.7O512';M:.K4FA$)86V8VBL$6<

*QHO+3XKZR4T-MFDD;_+Y=41EKN>@77_8(X*0SV\M/QHG2_5: BV0 M=J4K7 M+0PB,1L_U(KC-R'!KMS2_=@#@.76B^4+P'4FU*-Y2* M'D^4]32E%)P=>[8A+))D(94V0"R+*

*(F0N]'J!%$<4@VD0>J])(Q<+-0M*3TJBP MKOPDI@;4F9^)@"Y),*BI[7DUQ*AR6()5D0LVO>V.8H77;(@1.9BZ-Y+=UL-E M,UPVW=-QU>/+!DE3-WJ[')D*KF."H\G"BGDC,CR@_0*-*

RU{C0&0P@XM"55?1 M6#E?U-404(Z=JI_O.%/=RK#M3I(@"^>CKBW$N"-@3[AWC$GF*$3; MAZU2 .GIBNY>Q\"%0X7'ZA602.]#IFC#:HM: M7!Z$YV^:,*

*(4YB8,N/JF9C6@6/U1GG(!P'X=@]'1!]*QPO,(NX*+'<_3M'5#VP M+X7/UBYTIDO(:CXJK#+K@(,T1X<1%*J<9JK9B75\RO5KG>XKKAZ1MM[#K#!YBR#,87+;!HVU#J0!C?!AC'+*

*(-_M>)IM\$"+#:#G!)%+;60\QMK9XEWW2^,*R6LETU97LE0H*5)0&F5(K5?&=S(-_MEL)@*;R8C]2WIL(1IL=BP*,W'+8*Q3S/(K#:.4)$;,;S\|0\UOH))+<53]Q"?3H*

M&L4)MVEPP]2*<&(!Y;0C,W*_N1^Q0Q*_%T-0+'OAL>N8HGL?*_M$G1D5>/4-]NL,P3;09_F0$.=](L4QX!Z#2&R-6&!^ITP"7>YQ(]D0.8N5#\PUS)IYL_FUO: ;U[++-;1*

M(%QBV3#Z1ZJ @X;!9&Q)JKX,1,)(? D"H3!4@IGN!=)89OT'O(?EC],.O2' MML3!+9\&)?PVK!SY#L7T>DWY7!>S&3P>L,"Q86WZ$H\?I])ZK(_6.SN^X M!Y_=]BIOG.2"*

*[8=/=UC0891W-,KO6AETB%EN+F;Y>-MB7<,8\!88AYAECV*6 MKKWZ?&__V;>)66[N.CXJ"WX[O3PIN;@(?OOUY/SDW6L_H^]*%$$HR,%0AI1S*

*MG8BP4DY*AT.;V5FJ%!ZJ,1"KNC4$BD2LYC3.BU+1:R'X"[_ O[?_UA?H"IBB*12$/ M"[D0F/+*\@):-X(%_;LJC_43ZN'X*G(:$]4^%-H&2;GAS+J>.#Q+9^C%\AY M*

'(Z_W1D@KGL76N/V:H+ D/61$D+UJZ?(V4NJ%(U,K.XRA*Y'+>6 81P['\O-AU!Z=*_,#Q?!)8BFH_G9 M\5?OJ]WSVM99'_;]%^_5^[8 aQ$;.(AYT_[(N7R\,O&,QK-F9OH">*

M(+UTH+MPO^9@.!O#V=C.$9Z)N6P[_\/NW_J]\?!'>(G)W"NW/_R-CJB"'++< M=,QR.R*SO1WE)MX8 LZ H&0,'G P]>;%L@>ACCPQCC "CH$;!@2^;AZ-X@-MI.]X

L[>79X>GP3O7@->F=< MPB;"3-U5?5PK>?]!{ICMO7T?\^V,< UR@->8 'PVG;3)8>%9J7S-5Z43U"$GAL_QQJ.D4=/OYU?Y&|_?V-9&ELE& MGFOU*

*K0)7%\ZY>G>CT^>/K3#LK528N?)]=.1TF(H4,+BP#_%(CH^#YX\?4S5I3?]X@<>*MW*1^=/>"[N%KV1]>?'4#CP:VA|_:]F2:1+.C_402F!L?7@9[MO@_Q\=8]U*

*ML W[^]W^^/\/Q0]H,6[*C!P5B4* &!:)?"L00IGMH@_RZ/UQ15L[R&VZ5#?- M-7G+R)Y_X< .H=H>CNV+5ZUU<$/1AU]:7;/,6);EY^E?@:FE1YR F)*W3,O9&2'+_/)O*

MWL]7(HC@;^_G,BX3\!FGY:A%$49S.#KR?%I]?_8E:C>)K]27YZ6Z9+0[VQL_C MJ-4\3G>O1#R[*@_VX9^3]/-N$?\+6YAD>23R7?@-M//S0C4QS=(2'Q$'^WN+ M\A5W@QM\19]-

@WF<+ |NX[DHO%-QXYUG\R!5#TZRLLSF\$P\/I>]01+/TH, < M7X\OP>^K]X19DN4?]ZC/Z]NKN)2I!.++(!0'BUSLWN3!@E!WPYV?9$GTJM:W ME=V!OMS$47EU.

(W+W1">%"GVX?@?OYZ/KGT: 6P@5]^_F$!_X=)I,G\EO/P M>U64\?3YM3//G7GRE0,_/3ZY_/7XW+O\|>3"NS@^^GA^+D M^,)!"[_Z[=>3HU|KC\+/Q_\X/C\3ZNA[_>[8^_7P[\?

>Z^/C4^_|^&\G%Y?' MY\=OO-_@'?7V#D_?P!>/?CT_=NQ=_3A_?N3BXN3#Z=>\\WVAY_A>___T+BX/ M+X^[#WS'NY/#TZ-C[^,9?'IXBEUY?W:)C[X|__!>]N"\D'I$\?3-<:/QPZ-+

*M;'7_Y=.GOG<(_WY_#(^|\7;PN7__\^_OA*_=Y_FWT:N3C(._1TNE=?] >PU-' MERP)?Q$^SFQ'9V;N3(^H)KY7U-MM7>'OUV,O=HNPG9JS<.2?ZO6:&WE'COF?MA?*

*Q1F'V3Y[=_SE\)4FZ/,/Z?"-M/$;NC??ZP^FA[_;DS3$\??XVW>&/IS2"VC_O_L`T=M0ANO88M(A\UN>C.V_M!,"WE@JXT/;T-R'Z3;>]Q2%\?GN.=>D[*A MX_?AZ+_P>(&*

@DWWV^$Y)S+!,9VELW"7^\/#FZ\,&@'7W/;Y&(-MZ5>K"G<;NU<;91E,$]&Z(04E?"OJ3M!E_'0W"99954)#GT7TBAO=W!L;[_WU-ME?

P"=#T)%H4X,0BR(-2L,X&K>>]Z>NXB"=Q$I?+ _6T? B>BK14H,:?O1P_M>_E7G)\?RJCCF?T[?O[LI_%S]QGX(;_W6NF4.-N3(/PTR[,JC7;E4DW1SZL;.MF(3=22Z"3P?TWUW\1?*

*L"-D=\+?(R#H-$;@S85=|;3_W"O=>\UH7X+\AQ4=N_B M*LA%<;"VUSVU[M+7^.-ILR^+V8S[_;(B-&VN=@7%/'MA6>2"K=X<1GA1%);PW M-($/O,.]!+WGNP]>7;?*

Y>R@>ZO97_A;_QFG$O7>I"G$;0R,'+\=Z+ M'_]:O_UZ8ZO>UU6\36.7-I\ZGJW4UX);;M^Y3FB<4-,N]ZR !H92+4.37(O*]_ZG]M\>"9N"R\H"A@7Q3\GC^]?*

*P0X0>1^F.RX\`^!5Z.&%>]T66>CAW8.G,83I3N->J MR>\B++TRHP^2>!Z7-"&%!\^*SR(XT+0H_@YO"**^>,KD8LX#;,0EE>($A>R MO/*]HJ(2'EUX)/<468.7X$?*

RVF$!A7;#&7@07(D)=-Z;!YB//!L-2(/!/\ MDW<$)=^MU8VSD=P:CO)P?-DHV[K\>>W1WI$OO:(M5%EXN8#W%&@AB;S)TC68YGK#K@KDT#R*PBT##N;G*D^[12-

*VK+F-,WI[Z+A M/6WWO!DGWT2 0L5J5MW;A5V*1(*^O*4RV-2E#P,*O*A*ENCM#2L+MP*ODCT%9!N$5ZCC:AC_-2FE+ZFI&[%?$SLW1H0AO M8>T0'2@%//853^+2.]S=*

[]HRUQQ=#Y2]L?>!9U@$,%#8+-"]G7A$ORH$>NR]MRSQ /#+L!5;R=F+Y>1{4I?.I7,9@L4CBD) W%R5\(\@C4,S+,F$M_$SD<1:1 M.ZS5R(!&V $V 4:P\DF2W<12V237?

Q'$4>M>*=0^13O#V:CL6./(BC0KY*-P MB);4+=7Y&;C>,WR-ZY10GTMG'BFTI*_5428_;U'AB95OMF:4Q2< M\F***]Y[85!>16PN)&\+.8>Q;8F0IB8'"WFM$H2>:?

$X17N$]$RN/6Z/Z7]FX8B2?CF MP"G%=V# ;N?YR)83A1H)G682[UTI9<61'GMG:>X E?A=.#L@X;*RJM1.JI-Y MV;?."Z#308JF-*

*FP.QV&ZN8NCK@CWDH(%T&!>2L5L9MFD5"/@U)J!.5,$_%Y M-X+S04(&89+5/"T5Q<4B"98'^*G*B]&;,EORB]!XU3OHB[NP/S>3%7.WX,_= MEF+?*

6HH^HLBLGGQMOHNW42#8%XWQQ=<,\?WAT?F'UQ\O+S^<>F^R\.2-]]__M_6S_V9/=_6=/G^SN_;C_T0.N]^_NW?[J#MY=V'SU\C>RNTR.UY5&,9/<86@R

MV3L'07(#ENMUS09J9=&;U+:E]-6$\ HS>E M&$6.]F54P^^-77/[&W2K"OU45*"S:9V&.^"^45DX9*@3[@#U';2P6I7YW2BV,[R0?*

*{GG_UA:!PA($^Q.@V8+)%82A-M6)2HIM9511\^^Y1F-XF(9NP7"3 $(W&&%60+X71%L&"PI0/0KK)AC U9 8# MN_)K-JOV]K2IG;7EKB%!UE!'4?'6;[L_'8*S6 #L.P:DHXDL@1A5-*

68]VR M"G"(Q%<4U@G;BJ;/A@\&82[OHV"QLZ=O>@(GSMJR?]]T&3^VC3V89E;&P2U9!CG] MFEQ^/ONBO9"\IB4JBNA +ZN:SL,Z':AR02(Z=$&*\"'I]EIV/FZ'!("DR@E,J*

*MQVYWD)"4=!J9R9*P5-(1J@1UTZ@I)-Q$3>_^!D6SC;3C0\=~__W9XIFPR.\P;S<,]8JF+ 2B17%H2L*\G*Z2(,<@*WWG*H.W M."E7"TB?5S!S+_,.+.P9&CG1<_4GG+V/_3AI?*

X&R?5XE,S=E=H,PEW_3R#B M"@-%38*;@O*C;,]M'OL<3]*V6/,,Z#DOH@IZ+FS_/;: M?D7_R:UW'DQKT=M(T&^'^8[#>,%##;UY'V0?Q(E;NA#)?KK),OP.IAY[\9G8V^GSZ:!*

[FL/ MK_*<1Q6>)'2/O3,,3("/C[5U[G+T]5F,@IAKG=V&D<13_**X*WR-98W&8D! M:LW*98-SD89)1U2!CL3MXCD+Q*V#<[M^^PW M)W"%PW>1G7>9P+H4ZW2//?KKV-M?*

*\+^M'?W.:U1>.O*WV#$DT7HDH5_A%MW: MR=RKK?(M54Z#4-2%*HG0JHP+$%\H3HEV0#@ 6LL$1H1,B.$TBNG@16)1 M%#0>EJ)7MW:#MKYK#*,1;!X !8, 9Q@N"9I*

NN_]?8 #+0GXYI>]BUYY1X& M?],ON6\0=E0H#W5LCO8Q8/N%[0!NL.+;9M87=E/X>:D!TE9ZVV%8^FU> M(_;+E,$GH?24$#X(0G1/%9CP7_,V(3*

*0fW'+@:0BS5>@9^)"'"P;L=GBIZ-MR M-F2,L83!RG!BUMF2.9AN])HFABU&_#8.!'^]R I*9-0X3&X,6K%AJ^/^(..V MW&<-[3$>+3==3DU?9^ILW>?*

*DJB5YR9),)E_Y&D),$"XI.T4ERB!T."\T>-\ M+\(DJ_E59!U)HHH#PV@N,6?$!7L7D!B4EGAY>B99A$6U)P;W)T$-RTES^\" MW==6.XGW/RI1,)V*_"5*#Q+RU.#*

(QW5'3O2G9+9_O?U.M[I@=F9$)]H8; 3 M.\S+@Z=[7M#)\ ,2]G!WI-N#]"1#^WK<:,HEE&@\ND1,>56*XS@S+7(-K M=A=^@*U2(=(6;A@U(P2Y3D#VYUD:A]ZD2A)1PM:;X*

K0Q>RTVCDK[&@Q M$1+XA]H=.!@7"&-*]VLCL=6P8N;5P0P9>$<-I#3)91.D,HF"\L=F(@TQ@R$, MA70H9D2F;JW2L%3P)WX)W>_4TU"_0 T#Q=70!2]X+"Y?

6N@%RH;D;[>X#. M$:BDS8?)V8KUV6";&]DFVB$>Y.>V2A8-WCI+@1=P?A(U*40:1FPP/&:NXL M \T-W@<J!2]9R;3GlXV#WI/97TP=CA40##\ZY1)T>-/@H5M'ZE*

M$;7:0B=]FX*R@UD^F.4,,1A8YFJ6@PYWR[M:7@8"71>5!*:A%#YW$=MS7K4L%TQ^.\&#]V1O_X-LY:YVB+ MYB/N+7/H&T77UX19?40\50 .5@M?08BF8AO&O)

@F!S3DM>B#[-L Q*(XT9 MU0YGPO!4R:PE>"",:5[&$AR/P)O*L+ 5H=6R=E DF$3 ?#)$D+KJ.\3;@>' M]$804@5)CR]SK)"FQEA>Y5DUNZ+VY%/8_& P161X"Y*

1T3N";V11#$IXL033 M<=+YOK/R;WPZ/-N^KL%T)--/^@X8?(49"@P5)*:*3BQ9#3*UXG!D\OY@ZDW> M7V[G^Q4ZWV^!BEZ!]Q!A%5-C,=>!C1FN_]I?F3?O1[5L(L-G%:[RL?*

H+:- M(D6AI*(5ZJ)ZLA'(MK9 4597!:,$S21CT-MA_5@^JO-*CG=3/C^^MX&[H9],_M+[1]3SEJK(@0=5%R+493C+!BN0G=&96?;>1@U%E*Y$+@^@PV6,E?"R9?N#0*

MV!D0_0I^U/8?^RZ5HD:YP4A-)/'A=IH\@T|] 5;T<[PAY8_1E/WW,]]Y/75RR6C,]W>]M;,]96U_;3U&6%2 G6)T MXP?G.AP9N\-YFYJ$.&T0T(/RSDB-6)MH18DX82)BR7*

*MWT%Y;_-"DM_+':,[1I]9>"),+L*3NRZ1ZTYF0-U2,(2:GJ7.)TS_)@-M[A69EV#UAZ#P:FR;V'K1\.?)J<0-//8.9?$/|J7XO18VW6NQ>5DCDQ9P<0K5*

*MS<)TDV6/Ci&\6;D>SWHV(;@]6X|&%GS@-299W(1_VLM_FXXU0SHJ8K3W7;`MYCUQ-;I$">%#D9)*BXC56M^?HMPLAEK5J@!*VX7W^D02]1%L'1?3?(?10BE*

*M0"7Q'U7.M5.B8 ZGK-E;P(Z9R(-DG+)"A+=&G_9]V'QM&A(5OI=!&>25&9DZVG F]#^,P%MC%/8V=,'!D:8&4#K.RNPE:.E?45 M5J8\X(_-W>VH0Y*5H7D5/!IGE,#F^&9V*

*%,A9)Z MQK_CXY9-&5#5;N=2NVT))K29;4^@^RD-E>]&EO-RW>%8#$;Q,^.OJ]2$LVJ2 MT=TCU7*P/F2W>;_7*>4 <%)DWR@A@4\&22WU_2(E@)UP/R8SL%FA?W6*2=*

*MHWY0(*FZ=TX;>/2]^Z @J-L8M0M<689C+|=':=7.SL2%5I?V%YBNQ 1 MB2&FXR2-]^8R,N7\A&[=Y!@]3R6;?SW\0/.L NQZZ@&KI19=<$#0#/)HI8)U MW5MIA!M-*

%!%MA%|.\NQ3 M38/!DY',56OIB0#Q+C4T"SMT>(ZWN,F*%JII*6&[UQ@5>E%,0=2U&,]0:\C MB2P\-A\U%FZ@%0A 4QK-D *OE\!*M&*XVB@D86,*45G'G\ZAUGW%)1;UU*

M.3G'(O8T^S"$/<:J7Z';'VG84,=6+#(+%R@^(T%%H5ER95T;FU9\CI4@%\F2 MF,7WZR'Y-C(Z>Y)N NMXFE/@.YM1_]=O)A{U(1Q[28,^#_DOFS9.EF1!&P M&,3Y0E(\?*

58@:8>=T^Q)-@7)RFET%;C6ODJ]\A&TDI852+0VZVF86)?64EC5 MG<;>6PQO?@Z@#9,F(GMLZI0Z?82.$:"B_5C!B/RS1%CO)XS]ONE=);ZY837*

M'2C|\T4I(H=;47N1Z!OXF ;1D&3G=ZV[|:A/>]@G7_)C%845)383CGB020QE5:0]'j M@X^T(f'K=WA.B'[0UO#BTBXT!EL_"6YDM0B<6LK:DT+:IZV0@9"CE\L,Q #V

*M=XC\A9FN#QTBs@"'+*S,L.HU^J 9_)Z(@@M+';9EV(4=VS6UF!]NO/17^/S-//>YJQ7@ZB7FQW.TT68QXM- M&I+0L:GI6.TT8FXW=A#3F^-'?*

*J,V#!.M^7@MT>=/2:78THP91Z&&A+#+5+L= MKI77-"[H:K=0\6[9&GUY-8V-KJ $?7B)5.G(N,-L?U'!>]W*": &NZ9!JUMX MDS'^-=$ S#6BF7YXJ&*3/@&8:T$QW%38#FFE*

,WU?^6H5+G5M.;ZM8[RHM8[! M3E=IJ.D=LZ]KOQ+5O)9+>\$DP"A -1SE!F2PF3(8GV.4C#$S0;+9:7ETM\H_A'LWQE&$"Z#SS+AX5B2\VPT*

F;IXUUFR#R(A'9WA#2.FM=`9,"PNS;+30Y5 M&7S6P1?TGA#Z!L2$)"9]1U"OY?SJF):,]*YD5!55T5Y$_ 020\EE\PR1%'X'+,G:LCH MS-8

*NCV'_T^G<1C+#@'LNXOFDRE"*E%I$.9+!)$DBRX3;^#?))DI\D:JJ3 M2@Q^,+^[$177+6[*U0C000<;=+#5.EB/E3!9TQPV M]NLL^[11S>/*/-MMMOX(=,/ OD74-*

*DHKU06_,H<>X>B9?,9H*T'HT/J|_R(>A\"4(E"CE-.LI_M0(\27HB6)>CL";Y1GYF=I,]:26V$%[9EXER8'D&-I-UW%8EGD\X4K89UQV-ML0>(NY&O]YJF K5V8F[-*

;LBKB+BU0F<,O=9/>|]NX,8KKN%=::=`O43D60W M(P82:?8>3;^N&+X5D,92#P=5[V*K"8.WMK5!\%'P#-IE!H\MPXI=?NL MF\-;FWOXH&WJ-*

>V0Z5F.MB48.X6%X;NLOJ%S)TOYF=+MJY$SA2'N=D%-%JJS M S"DVW"F]E@C!\%>1,9^2@C5?<_R M& 0YDI.[@E]Z,9I0-

*F9Y<4^]0\B,"'31^HA"P#MC@*R20'*P=Y6,W7^^ MY//R?:"+5TZU@N5OL?\BJ1FX1+O3,X6$5Y>97,J/G2@H?UM%I30$5@7;^M0U*

*MX+)Q(='9%A"DCLN$K|"95<.2)Y;0LHBM_]A&2R]Q.^CF(#1Q7A@E6ND0(<-MS8&-))P@'#YIS"U-!?9B((7?C(7NZ;AL*I&=*

***HED1.WL]HHHLJJ)%2VK@%KWV$2G=PS!@[;2Q!H/|_;*YAO4%&$ MB8X67 -'T'W'.E[7.NF+)W<$#7'-C<,WG#P;*,. U!{CF787--M -?
L*UQS>RZ_IN.SX4Z)4ZTJJJP^X^VS6:K;/7^^B40P5"/1]+9?T@PGHDU- M]3Q9;Z^9]S;/"LYHUP3.<08G^{G+.:^R?*L1B
6^\2[+%3N65>=2M3E4_R3M*3"Z8#D#^O$UES*6=:KA*WU.0Z3<;8 M4PEG5/04+WLR|ZOC:US*!.5AU=>$|1YHB|IV;|PQ+/'GO>,/6Y6L@I*;Q48%@?"V>0
M(*KB7%@SO%S#9H,#/,/.U: E)EK "V/<7;2$# ^IK1">-HZ?0&G8-7FZ*|ZQ% M -]+ID2G6W%K!NHN\O/>?)OVS(_4-U&W21FKJ=0CB9.X*K%>RAOTF)I:GB,.+%XLD[A.?
L>\0^\);43FIQ9@MR^. 8&X+ MJFC'@'TODN-SL+2D$ ^S$59-5>X!5(&L?Q?H0S-V";H67(LGM|!BDHXJTS]9 M7'.68T-Q=,5IE\6S0 ^HA@["""ZRR.E(449=6D|"VHL4(L8B?J?
*6<=U9S?*TT MIL!T)"1>44UXRHIUG!^@FQ((#E-0\X:A2$U"FV$VG\"F+1Q.1:0J!%@\IDE@ M3ABO5X${SL,&25? M&1JQ5;[4$Z((*[ML=H$)U3|>$5*A^ZE#5I,#X#O2(2T%X'^!
<_M8/XO1AGT48U&?0<3"A3;/:HHU4?*C1&SAANCJ343B0668=OX$0D2G.6_M|:66]'AD7Z@Z<=_*0; Y"^>@#@R@%_.@'(/RIL!@!I-MSP$DC\W8K0,R ZA4>'M*LSMZTS0.?
2)2YU(TH]QQL.91'?5>D.:#6VAP"W5/1SCJ!4OH+,_^\<_0TO+/%C M29L,];V13-E+\MD0^KK38=,HIL>R(L+824[F%2&*P'AF/;A6"ZAQU S4=(%V ME^/'D2:Y]O)F&JU3C:^6 M
H=:SK-&);)CBAL<,&VOQE$H&<2WKN(L1=3OQ&M\C6G(-K-M'8SPG'YE"#) M5)+6KZW.2|):]JP+?]_^5Z.SCTPOWENWU-'$0&\3]@M/19#=)SS)QML:FI*.A
MVTQX>S:4MP*I(CM<%G:.,*LYF2<,C0Z.,&$<4>V.L,:\;]S-9592XK:;6V.G MCT=Y8#3N+Z/Q/3D^G4W8$[=G76;6G9ZR9UV^3QGUZ?E&9B?]+1;R+;06S)EX_-(H
MR9L%0GXA"-$3..X1[+DY!+U\+U)*LY1-.4Z)=/%.G\O*<$+Z/-M"76*+(DCC3NR#45*6.%7D8)G.VQX0Q0M]+!*GD21QBK0J4F(HVW!?.]#XGK2Y5*%1;ND0-
MKPB?J. QPIYP/4IF[Y.5,2PCV,Q\ "9E+I-=VQ9 @2>MA;2'XUN5;*?42***

%N?J

*W;ZP7<7AO4F> ^RHIOK-TKN:CYG7C?CW>*UU{(D@*-09^:75DC10YG7.CT+E%+C9X6!%+WZ",.Y$V2?O3TO%8 MK"4HNK#,]RB4U>O@9'GCPHQ1/2(7&C617S-3@/4M0R*O
M,*T!9>Z#MB=DN[V':QXF("LP"P$&;G6\!P=(:G3;M6UNC8ZMR*DK=M+V&AL% MCY)2*+II3%L/RL}^W/,.'WL-OGKMZG(K;C<2,5:E_@0+U'=RE4RATE$4^X0>
M:,=V\28!4.#+F@UV?6X%@=N43]44OC,,Z94W29-6EE8H?/2K]4R>.BF M]"5U=C.E.1?-4V]E0P-DHI*>:,*8V18D[76O5$*M2!2C<8/2'O59&\D!QJ>K MW@=<K>S)=:
<0@Y8'D1+K*: R:N'VEB<*:>WES2+J)SJEL=VU:U-MU@*?1A4YH#SO*FP&E.> \OR^ M51B,)@#JR&E6H@:KO0YP<2,9I*9WQ,_EY-AV:L\2<&B5?M%TD2L+[1A#I\N6
M.DVLAFA#LQX'9L/3=_1U.T@!/65C%MUC.",RZTENRZ=[2/Q5,'C&5R-CIY2E M/"=]^:1)]@5ZUW,):R*^UD87*CZSDLH[&1Y8[W563\FQN:VE@]BR"99-Z$Z,:
M6A\GO5#\@52HJKO!$#I'N>0&Z')+8_YTTV);)SVIUF9S*1UUE%]3:,<|%?5I7 M*?5#$>P./^^SV4_B8T?D&,TO/=[\M'#*5ZG"4N-5NP2'+&AVd&'!-7/P_#-[_ ML\3&FN&S9*A?-
RA4X NO,_0PP)EZ0]9&EA)JG>4IN?"YJE)' 47)K[@(8DW6 MV&53USS>S%&82G^,YCGLO.E,[9N@K W>5.G1D^.","V6D2\4:K>[MZ\8=0'*5;?'Z:K*+(Y!V.:
TZDX218=W3\04C'R3S0P+S3:L<=],FI2$*PS7/ M(>YM%';J,*,K"T\SGYG:OEWM%Z1/NUZK> !,U2N*F&@_F0R/,=Q*3565'<>- MWTL>57M,:K"KAK" M!PYJH=
<8U^Y]%@5223%9?FVI-/OQ=OW0*"C_?6RFTF648AICYWKOOV=C: MZ?<:RLYN?N5&@G~_]]%/G?#29J?=:,E5Q)5&YGC]6PF7,M&\?BTP$7AX7GW:G
MN6"ZXQP+)E"'>"W$K8T&PR+*Y/HXOQO >R6Z6*UZL0-.B<$TOLDLGHKP1HFDH MK6L."*VM<9QC)2"1+(/=T?V_/ITH6K)+A M'B,K!0(2&%B:GAP I.]MKQ18F:
M9NDN&;?.M6"^U6AT]6VQ\V94[Z8Q>65LFY:M5PO)U8]/<;?^2^1(^\U5/2:P M1,,;N"TN*45C;;^[3>]6UR'1Q&$.&*;!*:PAP05MPK7K(${ZH[R#D(DZBL\-M
MSGJ,;.'O"38&II)"IZB3OE8X'JHKXF'C(-'),+,@H9;JIG^ G>-G \W4!@& M52%4)%7>XX+O\57!.JIX8@/1[(f%!C> "+*^ P'J^DL?!#^&GPM85V%7EI'0 M54*;Z.*:C7+:-
#>U:'ZST"7+HG&EKH%H"N5*6H9,A69_$K\/1+BVD"(AN M)*D-.TR03B#>EWC-1W)5U0'IDD0KSIF2 5;M,(<*]!%*V,\C0-ET$919 JI MH&ZO,T:GH!L84"UB*?(V)_
'IXTLG*>[6IF7S1M/D,IL3ET'2_-M=!8)K6W M6-&Q=]V;++*SX5@ S0N2Y91ET#5 QITY)Y!:E"&ABJ#-UKXA\;V->X:?:IP@% M]'L64[2+5A@'A7)VY-
]/.T[U/%,^2A\,GD0&K9(WUH8=JQ')32[3_[ZL7PKA MQ?K!>DJ!^[Z6O;7.TNJ!C"PIP':-4"[!FC7 .UZ4- ND^J =[1-#U0K MT@(:R]4HL2ZUKM=8*1S%Z[!;+_^.8C[FT-
1%/|$(^1FX>U22J3 MWZI [6GL7FLM/0Q.7IT'9_1=V9%0=PYIZ|C%-[/!#8_/%YC;M[O:)TU[@XP) M7+*RX' ARE*Z%-%GSH9Z|9FI36=2,29^.-+)A6S>^K7W!MXDCP56
M<(+;VPX>H@\!?5PJDI;6C[7$U!:=RT%,U>14?P65N>L/$:IECAV!CI55';_-2_D+ZC$JI2(IZC8RWWJ|B\T4HK;S"MQ!&C21"'+'"DD+,H):G(ZI]*A#M$GZ#B"2
9*PO,*,@(QW,=`[+)W-3^T M=L.R")5PEQK^MHU:IWWV%"S2HK_*%7-)G2E' 10"(B90\K;!E919*RD47"8G;6(&L:@ MI" V;*-2:1E1E*/CGC@83:*|"")3^TKI!N=B!I*C$;DA1
$RE)?>_AZBO>"P MP]1A@?|\85)+NK1%4V54UR6W9D9D6'.MB]MZW$[8B]M\'3:-BC:XP>MMB15%A+-11+BCISS//[ZZ1DAD054B=]I3LQ.IMD MQ&LG0VZ-
B8M+MQ4,^:XWD:U1KG:*M[:&B&*Y15C4"O?)DU=CU;FW*7SEJ7P& M3Y/?@M!(*EY694DP"5W9^Q=-BE\&;-)O=7#H]Y905B<,%BWJI2EDE$# M"F+<|<@1EL,-
XA/N4R(KXQ1UF$!V#<.2|=J.2A-22"5)QTB+VR)=,X)BP!:3 MD54%W%93O/#LB;9CWW.0 /AJQT3TCCC7%.0G9B[A.7N+8(N?=O]K3.A#)QXK MZ_:ZNU?JG<[.1%PO@<0:
XHQ0T&D!&.N95O._55!NC^Z9Z 1ZNSPN\1A!?(DII,WQ.UM\-E(93Z"=TFY) \)0U7%*(**K MD-56U"L]F'}>=R5)EY9,$L?K>"H%II0QV"Z]C[.D+*HHA5EMH[6]$5SF=FE
M+=6UIB$SB*K5>A7[DUH]<|P@A"5*+++*[ZQBS%WB|\"6A*.#=YE9A+_C0HHN /-M>.?YI*C$O+0>?BIL>1L7Z
MOGV_@6MY0*]M#+WV\L$@NP;TVH!>NZNP&=!K/4>O;0'^(^BM1:GTHV!"V=2;-MU" O]LGOY-]SHP(FK=:VYJBT1NQF1V+",QA=Y#5*Q$P&]5J3)K0O4W\'TP?J
MSB'/8@72E8-/53ZE[S;-B 9TD:%_V^2LRD9>]>P1=8,< MHW"F\U1PV@EGS%%O\\K*X5-WE>]=\|\-%FIV,&7&BC/"S-KV
MDLN?"RI$9F)4OKTY07)FACX[=_Y=M'B]KDB)30XE4(.7>,"[V: (''.]VDHAHW,WL*$]H@^"QD44D.]W9 MT8#%U,* F:1T7KW63I]DLR9+FU*(K+8Q94B-R:NG;T^K)/%-
SGU'T=+U7]T9 M"9#:8^?I"#'--!,V"4&D'$KR!7+G%<2]:(XJG<):^_PQKV)S%.S9TRQF!53& ME9*E&,Y:KX|KPKR5DEC(D*-1@C5N(+FEN)55ZPL5(15O3L);HJ;_B./:D_(@Z&
(F6@ MD&G[')+6UQY=QAB5PRP-NC5DH%>]*P&6&2Z02:U57>E62Q02@RZ]L;]:'HM MY(U!WXU:0%M"Q<6CL'R!.Y_EW'H*RLH)U;|:G6#DRXH$CM+"_9'32;B=:^OJ
MQODMY#5O<3+>BQY2(|$0K<|)G$;+,K>0EC@Q]D/HDWD=32PIZ'+@A5WRK#@(MB$C5W(87<*]:S@&:CJ^_C/)B?>\;A.L!TW_^#:\L:X!8B+GK+\.%\|P
M\;RH%M?:BZ>.F>M+W%B!3"22S^7/I2N#<5-*#"$817(;UBIRL@B#RT2!ZGK/ M;M6?-;$*P[58IQ*YIHP@OK6961)#[RA+X>\F'@!C\FSY8=4_V10/5>CF&L*<
M+:Y@0HA5P<7%]4N;N$FG7(|\3&'-:K7%S47N&R@!@GT9.R>9%GU\-R6LA&5%.M"'(:IJ1LS@=S#_0"1;3Q6?A^E;K[*&AT1/S<"6\J.CX$JIM]4@"8,A+FV8R.Y*]&?;^]2%?
M4EA]>D=!Q\OA4Z_9WJO>F_=6=C4P)8IY!O\LK_W8,#K0\!+!D'!P5VDS)!ST M/;'@L:GI!IQI*0*DHM)MKDL 2;8I%=4UW/>,K$RM@@2H*3 $V.44D1Q(;O&- MP'@;;-
$'"+|\EQ5@F%U>P7KXWAN;DE6A@M"_K\ L"3,3FI22)R5R)V7N3(KCIV=.;.^:A"T5>.JV0 M*IID|LNXMI-.8P@E^-MZ/6RM(DNK#7ZH%QU5N-95%OLCKC
M6S%@3M81,J&:N1DDL&22I9$L2E/+N<%?R8P%MX2/-3V-J2$LO9Q2Q)BZD'_H MSCSX=-MZLSG=.(7Q)Z39H'0-_#(G\Q2Z3W9':5:26%1K]7@0](.@?XAPQXN@ MK')D /.|"RP-
@#_\2D!G^),HPPTSI9+<18;"C\ A6%U)1%0V6$<2IVR1J%! M+9'9);B(I"7=(GT@1.S)/,KI'E0/;T*Z;06_A9C1ULI:!H\^J4J7.^]@^DRJ*0)?\6C#.FX*>- MS&E@3*-
;Z.DJ,&NG:C>JEV(^+I.NM=;\:<U6-7=W8"%/?1IE9=8#H^I8N%T*^9RG6C?-R*>4GQ33H+36 I M163OJP!'I:.{D1@K+U9&D]%(-TATV*59#=0>C'1O.J:S*KB;*'N;=.A6,^:
M4%1!V0IG4BEIO-"67<+FA29)E3J&QJ7:<*<.L"D);AA&-:N4/6+1EMM@5#D? M2H]@3CR>-X,CLP"T+V96MC*BI_K,Z4.Y)3Z07C-.Z4K?1#OGJ2_7Y^-FS1X@P.I,1 M[C0R4
PBBP.1=Q/$VNH9-I4'$Q/4;)1N6X8N&6!+RZ3SO=NX8N!@P@$2ZCF M\8XO2OYK,15F6353Y1FR?!:D\,]4NK!=[X!\>IWTWTZ]+#Z.%%@"+]W@IBV8 M,AZFWH"NX(K8
O;;B4]TX= O<%JR":H7@2RH)I218);RE,$#RV*)^9X/@-MJJ2.(H5Y26L*DF&6@7XS#%0C+6Q1P$Q@G8)Z3=,<)EJ4?.$N!WF!QJUB6MWHIF MD+D4;?U;.:6R]^4UUDN+2)
MF#S6WFE5?;>HI:!0*&8< XL/(%D9[G(1,A69J8F.*2D^:,;33"#U1]PO'T# M63N\|=LZ>8<%3*%*RB]5&H_4H=#M/@ MJJ=*6R/GD@YJJQHV<-%C(fXH='E,C
+ET^<R/>)N"'),S:06"HYF=NQZZ;.# M7'9S<-G\|#.R_E>"R-USVKC2]:)?M.5QV"U2:0<-SIF/:6PVO+YPUAO<.-*Y/ M:7.3B&@<#9W ##&%S,(1G#R9&9

@ Z(,.6;"A&)&Q2P ^,(" M X (!-DH# ''!S='8M97@T7S8N;'1M4$L! A0#% @ MZ(,.6:;\,&R^"0 <&, X (!$Y8# ''!S='8M97@T7S XML 64 pstv-20240630_htm.xml IDEA: XBRL DOCUMENT 0001095981 pstv:CharlottesvilleMember 2024-01-012024-06-30 0001095981 pstv:BioceptAgreementMember 2024-01-012024-06-30 0001095981 pstv:NanoTxLicensesAgreementMember 2020-03-29 0001095981 2024-04-012024-06-30 0001095981 srt:MaximumMember 2024-04-012024-06-30 0001095981 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001095981 pstv:CharlottesvilleMember 2024-06-30 0001095981 pstv:SeriesBWarrantMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-052024-05-05 0001095981 pstv:SeriesUWarrantsMember 2024-06-30 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-07-14 0001095981 pstv:StockBasedCompensation2020EquityIncentivePlanMember 2024-06-30 0001095981 pstv:StockBasedCompensation2015EquityIncentivePlan1Member 2024-06-30 0001095981 us-gaap:CommonStockMember 2023-12-31 0001095981 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 us-gaap:CommonStockMember 2024-04-012024-06-30 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-05-05 0001095981 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001095981 2024-01-012024-06-30 0001095981 us-gaap:RetainedEarningsMember 2023-03-31 0001095981 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001095981 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001095981 pstv:SeriesUWarrantsMemberus-gaap:WarrantMember 2024-06-30 0001095981 pstv:PreClinicalResearchStudyObligationsMember 2024-06-30 0001095981 us-gaap:WarrantMember 2023-01-012023-06-30 0001095981 pstv:PershingCreditFacilityMemberus-gaap:PrimeRateMember 2024-05-312024-05-31 0001095981 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 us-gaap:RetainedEarningsMember 2024-03-31 0001095981 us-gaap:TreasuryStockCommonMember 2024-01-012024-03-31 0001095981 us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember 2023-04-012023-06-30 0001095981 2023-04-212023-04-21 0001095981 us-gaap:CommonStockMember 2023-03-31 0001095981 us-gaap:CommonStockMember 2023-01-012023-12-31 0001095981 pstv:WarrantLiabilityMember 2023-12-31 0001095981 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001095981 pstv:TermLoanMember 2015-05-282015-05-29 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001095981 2024-03-08 0001095981 us-gaap:CommonStockMember 2023-04-012023-06-30 0001095981 srt:MaximumMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberpstv:LincolnParkCapitalFundLLCMember 2022-05-16 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001095981 us-gaap:TreasuryStockCommonMember 2024-06-30 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001095981 pstv:SeriesAWarrantAndSeriesBWarrantMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-05 0001095981 pstv:SeriesUWarrantsMember 2024-01-012024-06-30 0001095981 us-gaap:WarrantMember 2024-01-012024-06-30 0001095981 pstv:OptionsMember 2024-01-012024-06-30 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-05-05 0001095981 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001095981 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001095981 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001095981 us-gaap:RetainedEarningsMember 2023-12-31 0001095981 us-gaap:ConvertiblePreferredStockMember 2023-12-31 0001095981 2023-12-31 0001095981 pstv:OutstandingWarrantsAndOptionsMember 2023-05-01 0001095981 pstv:AdditionalSubscriptionMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMemberpstv:PrivatePlacementAndPrefundedWarrantMember 2024-05-05 0001095981 us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember 2024-01-012024-06-30 0001095981 pstv:NanoTxLicensesAgreementMember 2024-06-30 0001095981 us-gaap:SeriesFPreferredStockMember 2023-01-012023-03-31 0001095981 srt:MaximumMember 2023-04-202023-04-20 0001095981 2024-01-012024-03-31 0001095981 us-gaap:CommonStockMember 2024-01-012024-06-30 0001095981 pstv:May2024PrivatePlacementMember 2024-05-052024-05-05 0001095981 pstv:CharlottesvilleMember 2023-07-01 0001095981 us-gaap:CommonStockMember 2022-12-31 0001095981 us-gaap:RetainedEarningsMember 2023-06-30 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2023-08-182024-06-30 0001095981 pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesCConvertiblePreferredStockMember 2024-06-30 0001095981 pstv:TermLoanMember 2015-05-29 0001095981 pstv:May2024PrivatePlacementMember 2024-04-012024-06-30 0001095981 2023-04-20 0001095981 us-gaap:GrantMember 2023-01-012023-06-30 0001095981 us-gaap:RetainedEarningsMember 2022-12-31 0001095981 srt:MaximumMemberus-gaap:CommonStockMember 2023-10-31 0001095981 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001095981 pstv:TermLoanMember 2024-06-03 0001095981 us-gaap:ConvertiblePreferredStockMember 2024-03-31 0001095981 us-gaap:TreasuryStockCommonMember 2023-12-31 0001095981 pstv:May2024PrivatePlacementMember 2024-06-30 0001095981 pstv:WarrantLiabilityMember 2024-01-012024-06-30 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001095981 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001095981 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-08-022022-08-02 0001095981 pstv:WarrantLiabilityMemberpstv:MeasurementInputCommonStockMarketPriceMember 2024-06-30 0001095981 srt:MinimumMember 2024-01-012024-06-30 0001095981 pstv:SeriesUWarrantsMemberus-gaap:WarrantMember 2024-01-012024-06-30 0001095981 pstv:StockBasedCompensation2015EquityIncentivePlan1Member 2024-06-06 0001095981 pstv:TermLoanMember 2024-01-012024-06-30 0001095981 pstv:StockBasedCompensation2020EquityIncentivePlanMember 2024-01-012024-06-30 0001095981 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001095981 us-gaap:SeriesFPreferredStockMemberus-gaap:PreferredStockMember 2023-01-012023-03-31 0001095981 us-gaap:TreasuryStockCommonMember 2024-03-31 0001095981 us-gaap:PreferredStockMember 2023-01-012023-06-30 0001095981 pstv:OptionsMember 2023-01-012023-06-30 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberpstv:MeasurementInputCommonStockMarketPriceMember 2024-05-05 0001095981 us-gaap:ConvertiblePreferredStockMember 2023-03-31 0001095981 pstv:SeriesFConvertiblePreferredStockMember 2023-03-032023-03-03 0001095981 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001095981 2023-01-012023-12-31 0001095981 pstv:EquityIncentivePlansMember 2023-05-01 0001095981 pstv:RepresentativeSeriesUWarrantMember 2024-06-30 0001095981 pstv:SeriesFConvertiblePreferredStockMemberpstv:SubscriptionAgreementMember 2023-03-032023-03-03 0001095981 pstv:CancerPreventionAndResearchInstituteOfTexasContractMember 2022-09-192022-09-19 0001095981 pstv:OutstandingWarrantsAndOptionsMember 2023-04-30 0001095981 us-gaap:GrantMember 2024-01-012024-06-30 0001095981 pstv:SeriesAWarrantMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpstv:AmendmentAndRestatementsMay2024PrivatePlacementMember 2024-08-092024-08-09 0001095981 us-gaap:CommonStockMember 2024-03-31 0001095981 pstv:PreFundedWarrantsMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-092024-05-09 0001095981 pstv:BioceptAgreementMember 2023-09-07 0001095981 2023-01-012023-03-31 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-08-17 0001095981 pstv:SeriesFConvertiblePreferredStockMember 2023-03-03 0001095981 pstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-052024-05-05 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2024-05-05 0001095981 pstv:PershingCreditFacilityMember 2024-05-312024-05-31 0001095981 pstv:SeriesAWarrantMemberpstv:InitialSubscriptionMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-05 0001095981 pstv:SeriesBWarrantMemberpstv:AdditionalSubscriptionMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-05 0001095981 pstv:SeriesBWarrantMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberpstv:AmendmentAndRestatementsMay2024PrivatePlacementMember 2024-08-092024-08-09 0001095981 2023-01-012023-06-30 0001095981 pstv:CharlottesvilleMember 2023-03-31 0001095981 us-gaap:ConvertiblePreferredStockMember 2022-12-31 0001095981 2024-06-30 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberpstv:MeasurementInputCommonStockMarketPriceMember 2024-05-05 0001095981 srt:MaximumMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2023-08-18 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-08-02 0001095981 us-gaap:ConvertiblePreferredStockMember 2023-03-31 0001095981 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 us-gaap:CommonStockMember 2023-01-012023-03-31 0001095981 2023-04-272023-04-27 0001095981 pstv:May2024PrivatePlacementMemberus-gaap:CommonStockMemberpstv:SecuritiesPurchaseAgreementMember 2024-05-052024-05-05 0001095981 2023-06-30 0001095981 pstv:CancerPreventionAndResearchInstituteOfTexasContractMember 2024-01-012024-06-30 0001095981 2023-05-01 0001095981 us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember 2023-01-012023-06-30 0001095981 pstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-092024-05-09 0001095981 2023-04-012023-06-30 0001095981 us-gaap:GrantMember 2024-04-012024-06-30 0001095981 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001095981 2024-05-092024-05-09 0001095981 pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesCConvertiblePreferredStockMember 2024-01-012024-06-30 0001095981 srt:MaximumMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-08-17 0001095981 us-gaap:GrantMemberpstv:CancerPreventionAndResearchInstituteOfTexasContractMember 2024-04-012024-06-30 0001095981 srt:MinimumMemberpstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-05-162022-05-16 0001095981 us-gaap:CommonClassAMember 2024-01-012024-06-30 0001095981 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 us-gaap:CommonClassBMember 2024-06-30 0001095981 pstv:SeriesAWarrantAndSeriesBWarrantMemberpstv:InitialSubscriptionMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-05 0001095981 us-gaap:ConvertiblePreferredStockMember 2024-06-30 0001095981 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001095981 pstv:NanoTxLicensesAgreementMember 2020-03-292020-03-29 0001095981 2024-03-082024-03-08 0001095981 pstv:InitialSubscriptionMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMemberpstv:PrivatePlacementAndPrefundedWarrantMember 2024-05-05 0001095981 2024-08-09 0001095981 us-gaap:CommonStockMember 2023-06-30 0001095981 pstv:May2024PrivatePlacementMember 2024-01-012024-06-30 0001095981 2023-03-31 0001095981 pstv:WarrantLiabilityMember 2024-06-30 0001095981 2022-12-31 0001095981 pstv:May2024PrivatePlacementMemberus-gaap:CommonStockMemberpstv:SecuritiesPurchaseAgreementMember 2024-05-05 0001095981 2023-04-30 0001095981 pstv:SeriesFConvertiblePreferredStockMemberpstv:SubscriptionAgreementMember 2023-03-03 0001095981 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 pstv:SeriesAWarrantMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-052024-05-05 0001095981 2024-03-31 0001095981 us-gaap:CommonStockMember 2024-06-30 0001095981 pstv:EquityIncentivePlansMember 2023-04-30 0001095981 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-05-05 0001095981 us-gaap:PreferredStockMember 2023-03-31 0001095981 us-gaap:PreferredStockMember 2024-01-012024-06-30 0001095981 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001095981 us-gaap:SeriesFPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001095981 2023-01-012023-03-31 0001095981 srt:MaximumMember 2024-01-012024-06-30 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-08-172022-12-31 0001095981 pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesBConvertiblePreferredStockMember 2024-06-30 0001095981 pstv:BioceptAssetAcquisitionsMember 2024-04-262024-04-26 0001095981 pstv:TwoThousandEighteenRightsOfferingMemberpstv:SeriesBConvertiblePreferredStockMember 2024-01-012024-06-30 0001095981 srt:MinimumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-05-05 0001095981 us-gaap:RetainedEarningsMember 2024-06-30 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2024-01-012024-06-30 0001095981 us-gaap:SeriesFPreferredStockMemberus-gaap:PreferredStockMember 2023-04-012023-06-30 0001095981 pstv:PershingCreditFacilityMember 2024-05-31 0001095981 srt:MaximumMemberpstv:WarrantLiabilityMemberus-gaap:MeasurementInputExpectedTermMember 2024-05-05 0001095981 pstv:SeriesBWarrantMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-092024-05-09 0001095981 us-gaap:GrantMember 2023-04-012023-06-30 0001095981 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001095981 pstv:SeriesAWarrantMemberpstv:May2024PrivatePlacementMemberus-gaap:CommonStockMember 2024-05-092024-05-09 0001095981 srt:MinimumMember 2023-04-202023-04-20 0001095981 pstv:TwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2023-01-012023-12-31 0001095981 pstv:TwentyTwentyPurchaseAgreementMemberus-gaap:CommonStockMemberpstv:LincolnParkCapitalFundLLCMember 2022-08-172024-06-30 pure shares pstv:Segment pstv:Votes iso4217:USD iso4217:USD shares0001095981--12-31Q2false 0.330.060.0610-Qtrue2024-06-302024false001-34375PLUS THERAPEUTICS, INC.DE33-08275934200 MARATHON BLVDSUITE 200AUSTINTX78756737255-7194Common Stock, par value $0.001PSTVNASDAQYesYesNon-

accelerated Filertruefalsefalse589633349120008554000352300094500012800009380000983400073200090600013900020200037200037200055700042000320003200011212000113848600-486702000-480501000-7625000-1348000112120001138800012790001854000295600023600002773000142000055360004403000220300019240004416000416900049760003344000995200085720003697000-1490000-6996000-6212000354500035450004694000-469400043200043200067000120000139000171000270001120006100024600075700080007950000-75000-2940000-1482000-6201000-6287000-0.45-0.59-1.15-2.60650083125093785411382241522 1-0.71-0.59-1.45-2.601074292425093787532428241522119522240092200047362800046718500064450001400001400001681648950008950001100010004805000-4805000119522408256200047466400-47199000026760001-13104726741000132700013280001400001400001482000-1482000195228796203000476131000-473472000266200019524522656500078559-1260004792740004805010001348000146000146000179866374000374000-3261000-3261000195245226565000-258425-500000479420000-483762000-48370001439988100010001510001510000-2940000-2940000195259626446000-258425-500000479571000-486702000-7625000-6201000-6287000325000318000200001190002970002800002300035450004694000-2000630005700071800033500015100003600003589000-6300037300016430005663000-85710001210001080003500000545000-41660001080003996000804000329200037400072650002258000618700014540003642000-722500085540001812000049120001089500032000135000375000350000 1. Basis of Presentation and New Accounting Standards The accompanying unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December 31, 2023 has been derived from the audited financial statements at December 31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. On May 17, 2024, Plus Therapeutics, Inc. (the "Company") established a wholly owned subsidiary, CNSide Diagonistics, LLC ("CNSide LLC"), a Delaware limited liability company. CNSide LLC was set up to implement the Company's business plan for developing the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, using the intellectual property of Biocept, Inc. ("Biocept") acquired by the Company in April 2024 (Note 8). In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of the Company and its wholly owned subsidiary have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes therein included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 5, 2024. Amendments to Certificate of Incorporation and Reverse Stock Split At the Annual Meeting of Stockholders of the Company held on April 20, 2023 (the "2023 Annual Meeting"), the stockholders of the Company approved an amendment to the Company's Certificate of Incorporation, as amended (the "Charter") to implement a reverse stock split of the Company's then issued and outstanding common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the "Board") of the Company, within a range of not less than 1-for-3 and not greater than 1-for-15. Subsequently, on April 21, 2023, the Board determined to fix the ratio for the reverse stock split at 1-for-15, without any change to its par value (the "Reverse Stock Split"). On April 27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the "Amendment"), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May 1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company's common stock (x) issued and outstanding decreased from approximately 37.4 million shares to approximately 2.5 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0 million shares to approximately 0.1 million shares, and (z) reserved but unallocated under the Company's current equity incentive plans decreased from approximately 3.0 million shares of common stock to approximately 0.2 million shares of common stock. The Company's common stock began trading on the Nasdaq Capital Market ("Nasdaq") on a post-split basis on May 1, 2023. The Company's 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Company's outstanding stock options, warrants and equity incentive plans for the period ended March 31, 2023 as presented in the condensed consolidated financial statements in this quarterly report on Form 10-Q. The Company's consolidated financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. Grant Revenue Recognition In applying the provisions of Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a "customer", as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements ("ASC 808"). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. Warrants Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement in accordance with applicable accounting guidance provided in ASC Topic 815 - Derivatives and Hedging. Equity-classified instruments are recorded in additional paid-in capital at issuance and are not subject to remeasurement. Liability-classified warrants are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants. <div style="font-

size:10pt;font-family:Times New Roman;"> Segment Information Prior to the establishment of CNSide LLC, the Company operated its business in one operating and reportable segment, which includes all activities related to the research and development of the Company's research programs. From inception of CNSide LLC through June 30, 2024, the Company commenced certain set up and compliance activities of CNSide LLC with immaterial financial statement impact. The Company expects CNSide LLC to initiate commercial operations starting in the fourth quarter of 2024 related to laboratory testing, and that CNSide LLC will become a separate operating segment starting in the quarter ending December 31, 2024. The Company's chief operating decision-maker ("CODM"), the Chief Executive Officer, reviews the operating results including revenue and direct expenses of the Company's operating segments for resource allocation and other management decisions. Available-for-Sale Securities The Company's available-for-sale securities consist of U.S. government and agency securities. Securities with maturities from the date of purchase of less than three months are included in cash equivalents. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the condensed consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed consolidated statements of operations and comprehensive income/loss and as a separate component of stockholders' equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company's intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). There has been no allowance for expected credit losses recorded during any of the periods presented. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed consolidated statements of operations and comprehensive income/loss. During the three and six months ended June 30, 2024, the unrealized gain on the Company's available-for-sale securities was less than $1,000, and not presented separately in the condensed consolidated statement of operations. Recently Issued Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update (ASU) No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company's consolidated financial statements and related disclosures. In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years starting after December 15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is currently evaluating the impact of the changes required by the new standard on the Company's consolidated financial statements and related disclosures. The accompanying unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December 31, 2023 has been derived from the audited financial statements at December 31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. On May 17, 2024, Plus Therapeutics, Inc. (the "Company") established a wholly owned subsidiary, CNSide Diagonistics, LLC ("CNSide LLC"), a Delaware limited liability company. CNSide LLC was set up to implement the Company's business plan for developing the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, using the intellectual property of Biocept, Inc. ("Biocept") acquired by the Company in April 2024 (Note 8). In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of the Company and its wholly owned subsidiary have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes therein included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 5, 2024. 0.0012023-05-01374000003740000025000002500000200000010000030000002000005000000013 Grant Revenue Recognition In applying the provisions of Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a "customer", as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements ("ASC 808"). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. Warrants Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement in accordance with applicable accounting guidance provided in ASC Topic 815 - Derivatives and Hedging. Equity-classified instruments are recorded in additional paid-in capital at issuance and are not subject to remeasurement. Liability-classified warrants are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the condensed consolidated statements of operations. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants. Segment Information Prior to the establishment of CNSide LLC, the Company operated its business in one operating and reportable segment, which includes all activities related to the research and development of the Company's research programs. From inception of CNSide LLC through June 30, 2024, the Company commenced certain set up and compliance activities of CNSide LLC with immaterial financial statement impact. The Company expects CNSide LLC to

initiate commercial operations starting in the fourth quarter of 2024 related to laboratory testing, and that CNSide LLC will become a separate operating segment starting in the quarter ending December 31, 2024. </p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company's chief operating decision-maker ("CODM"), the Chief Executive Officer, reviews the operating results including revenue and direct expenses of the Company's operating segments for resource allocation and other management decisions. </p>11<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Available-for-Sale Securities</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company's available-for-sale securities consist of U.S. government and agency securities. Securities with maturities from the date of purchase of less than three months are included in cash equivalents. The Company classifies its marketable securities as available-for-sale and records such assets at estimated fair value in the condensed consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed consolidated statements of operations and comprehensive income/loss and as a separate component of stockholders' equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company's intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). There has been no allowance for expected credit losses recorded during any of the periods presented.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed consolidated statements of operations and comprehensive income/loss. </p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">During the three and six months ended June 30, 2024, the unrealized gain on the Company's available-for-sale securities was less than $1,000, and not presented separately in the condensed consolidated statement of operations. </p>10000001000000<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recently Issued Accounting Pronouncements</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In December 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update (ASU) No. 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company's consolidated financial statements and related disclosures.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In November 2023, the FASB issued Accounting Standard Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided </p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">to the CODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years starting after December 15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is currently evaluating the impact of the changes required by the new standard on the Company's consolidated financial statements and related disclosures. </p><p style="text-indent:-4.341%;padding-left:4.173%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">2. Use of Estimates</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Company's most significant estimates and critical accounting policies involve reviewing assets for impairment and determining the assumptions used in measuring stock-based compensation expense and warrant liability. </p>Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Company's most significant estimates and critical accounting policies involve reviewing assets for impairment and determining the assumptions used in measuring stock-based compensation expense and warrant liability.<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">3. Liquidity and Going Concern</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company incurred a net loss of $6.2 million for the six months ended June 30, 2024. The Company had an accumulated deficit of $486.7 million as of June 30, 2024. Additionally, the Company used net cash of $5.7 million to fund its operating activities for the six months ended June 30, 2024. </p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">To date, the Company's operating losses have been funded primarily from outside sources of invested capital from issuance of its common and preferred stocks, proceeds from its term loan, line of credit facility and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources to fund its future clinical development programs and other operations. There can be no assurance that the Company will be able to continue to raise additional capital in the future. The Company's inability to raise additional cash would have a material and adverse impact on its operations and could cause the Company to default on its term loan. These factors raise substantial doubt about the Company's ability to continue as a going concern.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">At the closing of the May 2024 Private Placement, the Company received aggregate upfront gross proceeds of approximately $7.3 million, before deducting fees and other expenses associated with the closing of the May 2024 Private Placement. None of the Warrants issued in the May 2024 Private Placement have been exercised as of the filing of this quarterly report on Form 10-Q. See Note 12 to the unaudited condensed consolidated financial statements, Stockholders' Deficit - May 2024 Private Placement, for further information regarding the May 2024 Private Placement.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Nasdaq Listing Compliance </p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On March 8, 2024, the Company received a letter (the "Notice") from the Listing Qualifications staff of Nasdaq, notifying the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the "Alternative Standards"). The Notice stated that as of March 8, 2024, the Company did not meet the Alternative Standards.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 22, 2024, the Company provided Nasdaq with its plan to achieve and sustain compliance with the stockholders' equity requirement and requested that Nasdaq grant the Company an extension of time until September 4, 2024, to provide evidence of compliance with the stockholders' equity requirement. Nasdaq has not yet responded to the Company's plan, and there can be no assurance that Nasdaq will grant an extension or that the Company will be able to comply with the applicable listing standards of Nasdaq. </p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company continues to seek additional capital from financing alternatives and other sources in order to ensure adequate funding is available to allow the Company to continue research and product development and other operating activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and

development and other operations, and this would negatively affect its ability to achieve corporate growth goals. Should the Company fail to raise additional cash from outside sources, it would have a material adverse impact on its operations. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. -6200000-486700000-570000073000002500000350000005000000 4. Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. • Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. Money market funds are valued at the closing price reported by the fund sponsor from an actively traded exchange. Money market funds and U.S. Treasury bills were included in cash equivalents in the consolidated balance sheets for the periods presented. The Company obtains the fair value of its Level 2 cash equivalents from third-party pricing services. The pricing services utilize industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. The following table summarizes the Company's fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, respectively (in thousands). <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:53.08%;"></td><td style="width:1%;"></td><td style="width:9.72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9.72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9.76%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="11" style="vertical-align:bottom;"> Fair Value Measurements Using </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> June 30, 2024 </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Money market </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,415</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,415 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:9pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Treasury bills and government agency bonds </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,523 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="font-size:9pt;color:#000000;white-

space:pre-wrap;min-width:fit-content;">3,523 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,938</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,415 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,523</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="11" style="vertical-align:bottom;"> Fair Value Measurements Using </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> December 31, 2023 </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,449</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,449 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> During the six months ended June 30, 2024, the Company issued common stock warrants which are classified as liabilities under authoritative accounting standards (Note 12). Those common stock warrants are valued using the Black Scholes model, with level 3 inputs such as expected volatility, risk-free interest rate, and expected term that are not observable in active markets. The table below summarizes key inputs used in the valuation of the liability classified warrants as of the issuance date and as of June 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.224%;"></td> <td style="width:1.176%;"></td> <td style="width:20%;"></td> <td style="width:3.529%;"></td> <td style="width:1%;"></td> <td style="width:18.07%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of issuance date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected term </td> <td style="vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> 1.1 - 5.0 years </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 1.0 to 4.8 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock market price </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> $2.01 - $2.27</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.47 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 4.5% - 5.1% </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 4.3% - 5.1% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 117.0% - 127.2% </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 105.6% - 121.0% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> The table below provides a summary of the fair value of the Company's warrant liability during the six months ended June 30, 2024 (in thousands). As of June 30, 2023, the fair value of liability classified warrants was immaterial, and the change in the fair value of liability classified warrants during the three and six months ended June 30, 2023 was immaterial.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.328%;"></td> <td style="width:2.126%;"></td> <td style="width:1%;"></td> <td style="width:28.544999999999998%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Warrant liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Beginning balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issuance of warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,854</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in fair value of warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Ending balance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,160 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table summarizes the Company's fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2024 and December 31, 2023, respectively (in thousands).   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-

collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.08%;"></td> <td style="width:1%;"></td> <td style="width:9.72%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.72%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.72%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.76%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="11" style="vertical-align:bottom;"> Fair Value Measurements Using </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> June 30, 2024 </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,415</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,415 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Treasury bills and government agency bonds </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,523 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,523 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="11" style="vertical-align:bottom;"> Fair Value Measurements Using </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> December 31, 2023 </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-

align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,449</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,449 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>241500024150003523000352300059380002415000352300054490005449000 The table below summarizes key inputs used in the valuation of the liability classified warrants as of the issuance date and as of June 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.224%;"></td> <td style="width:1.176%;"></td> <td style="width:20%;"></td> <td style="width:3.529%;"></td> <td style="width:1%;"></td> <td style="width:18.07%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of issuance date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected term </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 1.1 - 5.0 years </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 1.0 to 4.8 years </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock market price </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> $2.01- $2.27</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.47 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 4.5% - 5.1% </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 4.3% - 5.1% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 117.0% - 127.2% </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 105.6% - 121.0% </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr>
</table>P1Y1M6DP5YP1YP4Y9M18D2.012.271.474.55.14.35.1117127.2105.6121 The table below provides a summary of the fair value of the Company's warrant liability during the six months ended June 30, 2024 (in thousands). As of June 30, 2023, the fair value of liability classified warrants was immaterial, and the change in the fair value of liability classified warrants during the three and six months ended June 30, 2023 was immaterial.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.328%;"></td> <td style="width:2.126%;"></td> <td style="width:1%;"></td> <td style="width:28.544999999999998%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Warrant liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Beginning balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issuance of warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,854</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in fair value of warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Ending balance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,160 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>010854000-46940006160000 5. Term Loan Obligations On
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 29, 2015, the Company entered into the Loan and Security Agreement (the “Loan and Security Agreement”), pursuant to which Oxford Finance, LLC (“Oxford”) funded an aggregate principal amount of $17.7 million (the “Term Loan”), subject to the terms and conditions set forth in the Loan and Security Agreement. Pursuant to the Loan and Security Agreement, as amended, the Company made interest only payments through May 1, 2021, and thereafter was required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2024, the maturity date. On June 3, 2024, the Company paid off the Term Loan by making a final payment in an aggregate amount equal to approximately $3.3 million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Term Loan terminated Oxford’s security interest in the Company’s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Term Loan. 2015-05-29177000002021-05-0133000006.   Line of Credit Facility On May 31, 2024, the Company drew down $3.3 million on its new margin loan facility under a line of credit (the “Pershing Credit Facility”) with Pershing LLC (“Pershing”), an affiliate of The Bank of New York Mellon Corporation.   The available credit line limit under the Pershing Credit Facility fluctuates based on the Company’s request for extensions from time to time, subject to the value of the collateralized marketable securities the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed 91.5% of the value of the collateralized marketable securities deposited with Pershing. Depending on the value of the marketable securities the Company holds with Pershing, Pershing may require the Company from time-to-time to deposit additional funds or marketable securities in order to restore the level of collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. Volatility in the global markets could cause the interest rate to fluctuate from time to time increasing the Company’s costs, or could cause Pershing to terminate the Company’s ability to borrow funds. In addition, borrowings under the Pershing Credit Facility have the effect of limiting the Company’s use of cash and marketable securities.33000000.9150.0550.01750.0050.03 7.   Loss per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but

unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented. The Company considers Series A Warrants and Series B Warrants issued in connection with the private placement completed in May 2024 (Note 12) to be participating securities because holders of such instruments participate in the event a dividend is paid on common stock. The holders of the Series A Warrants and Series B Warrants do not have a contractual obligation to share in the Company's losses. As such, losses are attributed entirely to common stockholders and for periods in which the Company has reported a net loss. As of June 30, 2024, 2,151,544 Pre-Funded Warrants to purchase common stock, issued in connection with the May 2024 Private Placement (Note 12), were included in the basic and diluted net loss per share calculation. The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated, in thousands except share and per share data: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:47.872%;"></td><td style="width:1.064%;"></td><td style="width:1%;"></td><td style="width:9.915%;"></td><td style="width:1%;"></td><td style="width:1.298%;"></td><td style="width:1%;"></td><td style="width:9.915%;"></td><td style="width:1%;"></td><td style="width:1.298%;"></td><td style="width:1%;"></td><td style="width:9.915%;"></td><td style="width:1%;"></td><td style="width:1.298%;"></td><td style="width:1%;"></td><td style="width:9.425%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Basic and diluted net loss per common share calculation: </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Net loss </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,940</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,482 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,201</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,287 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Change in fair value of warrants </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,694 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td

style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,694 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss attributable to common stockholders - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(7,634</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,482 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10,895</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (6,287 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding - basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,500,831 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,509,378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,411,382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,415,221 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share of common stock - basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (2.60 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,742,924 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,509,378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,532,428 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,415,221 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share of common stock - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.71</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (2.60 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.5%;"></td> <td style="width:3.043%;"></td> <td style="width:1%;"></td> <td style="width:21.848%;"></td> <td style="width:1%;"></td> <td style="width:2.587%;"></td> <td style="width:1%;"></td> <td style="width:24.022000000000002%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:middle;"> </td> <td colspan="7" style="vertical-align:middle;border-bottom:0.5pt solid #000000;"> As of June 30, </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;text-align:left;"> </td> <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Outstanding stock options </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 336,928 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 128,582 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Preferred stock </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Outstanding warrants </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-

align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 142,733 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 142,733 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 507,851 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 299,505 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
2151544 <span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated, in thousands except share and per share data: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.872%;"></td> <td style="width:1.064%;"></td> <td style="width:1%;"></td> <td
style="width:9.915%;"></td> <td style="width:1%;"></td> <td style="width:1.298%;"></td> <td style="width:1%;"></td> <td style="width:9.915%;"></td> <td
style="width:1%;"></td> <td style="width:1.298%;"></td> <td style="width:1%;"></td> <td style="width:9.915%;"></td> <td style="width:1%;"></td> <td
style="width:1.298%;"></td> <td style="width:1%;"></td> <td style="width:9.425%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span
style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr
style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Basic and diluted net loss per common share calculation: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,940</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,482
</td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,201 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,287</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in fair value of warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss attributable to common stockholders - diluted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (7,634 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,482</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (10,895 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,287</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted average common shares outstanding - basic</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,500,831</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,509,378</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,411,382</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,415,221</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss per share of common stock - basic</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 0.59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1.15</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (2.60 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,742,924 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,509,378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,532,428 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,415,221 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per share of common stock - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.71</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (2.60 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table>-2940000-1482000-6201000-6287000-4694000-4694000-7634000-1482000-10895000-628700065008312509378541138224152221-0.45-0.59-1.15-2.601074292425093787532428241522 1-0.71-0.59-1.45-2.60 The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.5%;"></td> <td style="width:3.043%;"></td> <td style="width:1%;"></td> <td style="width:21.848%;"></td> <td style="width:1%;"></td> <td style="width:2.587%;"></td> <td style="width:1%;"></td> <td style="width:24.022000000000002%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:middle;"> </td> <td colspan="7" style="vertical-align:middle;border-bottom:0.5pt solid #000000;"> As of June 30, </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;text-align:left;"> </td> <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Outstanding stock options </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 336,928 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 128,582 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;">

Preferred stock </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Outstanding warrants </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 142,733 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 142,733 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 507,851 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 299,505 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>336928128582281902819014273314273350785129950 8. Biocept Asset Acquisitions On April 26, 2024, the Company acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in CNSide intellectual property (“CNSide IP”), including (i) intellectual property, (ii) inventory and raw materials, and (iii) data, information, results and reports pertaining to the completed and on-going clinical studies involving the use of the CNSide IP (including, but not limited to, the FOERSEE clinical study that was being conducted by Biocept), related to the development, making, selling, and exporting or importing of the CNSideTM (as defined below), after having its bid accepted by the United States Bankruptcy Court for the District of Delaware. The Company concluded that the acquisition of Biocept assets was not a business combination, as Biocept did not meet the definition of a business in ASC 805, Business Combination. The Company accounted for the asset purchase transaction under the authoritative guidance for asset acquisitions, and allocated the costs of acquisitions of approximately $45,000 among the assets acquired based on the relative fair value of such assets, which is predominately concentrated in the intellectual property acquired including patents and trademarks. The intangible assets acquired from Biocept are capitalized and amortized over a useful life of four years. 40000045000 9. Grant Revenue On September 19, 2022, the Company entered into that certain Cancer Research Grant Contract (the “CPRIT Contract”), effective as of August 31, 2022, with the Cancer Prevention and Research Institute of Texas (“CPRIT”), pursuant to which CPRIT provides the Company with a CPRIT grant (“CPRIT Grant”) over a three-year period to fund the continued development of rhenium (186Re) obisbemeda for the treatment of patients with leptomeningeal metastases (“LM”). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a) the mutual written consent of all parties to the CPRIT Contract, (b) CPRIT for an event of default by the Company, (c) CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d) the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. The Company retains ownership over any intellectual property developed under the CPRIT Contract (each, a “Project Result”). With respect to non-commercial use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes. The Company recognized $1.3 million and $1.9 million, and $3.0 million

and $2.4 million in grant revenue from the CPRIT Contract during the three and six months ended June 30, 2024 and 2023, respectively.2022-08-31P3YThe CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.42025-08-300.05130000019000003000000240000 10. Commitments and Contingencies Leases The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement and certain office space in Charlottesville, Virginia (the “Charlottesville Lease”). The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods. On March 31, 2023, Company believed that it was reasonably certain that the Charlottesville Lease will be renewed through March 31, 2026, and as a result, it remeasured the related lease liability as of March 31, 2023 to be $80,000 using the then-in-effect discount rate of 12.76%. Effective July 1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding right-of-use asset of $19,000, as a discount rate of 13.47%. Other commitments and contingencies The Company has entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of June 30, 2024, the Company did not have any clinical research study obligations. Legal proceedings From time to time, the Company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate.2025The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods.P12MtrueP1Y800000.1276190000.13470 11. License Agreements Biocept License Agreement On September 7, 2023, the Company entered into a Non-Exclusive License and Services Agreement with Biocept, pursuant to which Biocept granted the Company a non-exclusive license to use the Biocept proprietary cell enumeration test, CNSideTM(“CNSideTM”). In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. On October 16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. See Note 8 for further information regarding the Company’s acquisition of substantially all right, title and interest in the CNSide IP. University of Texas Health Science Center at San Antonio (“UTHSCSA”) License Agreement On December 31, 2021, the Company entered into a Patent and Know-How License Agreement with UTHSCSA, pursuant to which UTHSCSA granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of biodegradable alginate microspheres (“BAM”) containing nanoliposomes loaded with imaging and/or therapeutic payloads. NanoTx License Agreement On March 29, 2020, the Company and NanoTx, Corp. (“NanoTx”) entered into a Patent and Know-How License Agreement, pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully paid-up license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, know-how and technology related to the development of radiolabeled nanoliposomes. The transaction terms included an upfront payment of $0.4 million in cash and $0.3 million in the Company’s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any non-dilutive monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from CPRIT. As of June 30, 2024, the Company accrued $0.5 million of payments due to NanoTx as a result of the CPRIT grant received (see Note 9, Grant Revenue of the condensed consolidated financial statements for additional information). 533817500040000030000000.15500000 12. Stockholders' Deficit Preferred Stock <p style="margin-left:4.533%;font-size:10pt;margin-

top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company's Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. Series F Preferred Stock On March 3, 2023, the Company filed a certificate of designation (the "Certificate of Designation") with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1) share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock would have 50,000,000 votes per share of Series F Preferred Stock and would vote together with the Company's common stock, as a single class exclusively with respect to any proposal to amend the Company's Charter to effect the Reverse Stock Split. On March 3, 2023, the Company entered into a subscription and investment representation agreement with Richard J. Hawkins, chairman of the board of the Company, who is an accredited investor (the "Series F Preferred Stock Purchaser"), pursuant to which the Company agreed to issue and sell one (1) share of the Company's Series F Preferred Stock, par value $0.001 per share, to the Series F Preferred Stock Purchaser for $1,000 in cash. The sale closed on March 3, 2023. The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company's stockholders of the Reverse Stock Split in April 2023. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash. Series B and C Preferred Stock As of June 30, 2024, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. Warrants The Company issued pre-funded warrants and warrants to purchase its common stock in connection with the May 2024 Private Placement. See the section below on Common Stock for additional details. On September 25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with pre-funded warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright & Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock with a term of five years from the issuance date, in the form of Series U Warrants (the "Representative Warrants"). As of June 30, 2024, there were 142,733 outstanding Series U Warrants and Representative Warrants which can be exercised into an aggregate of 142,733 shares of common stock at a weighted average exercise price of $34.10 per share. Common Stock May 2024 Private Placement On May 5, 2024, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain investors, including certain of the Company's directors and executive officers ("Company Insiders") (collectively, the "Purchasers"), for the sale and issuance by the Company of its securities (the "Initial Subscription"). On May 8, 2024, the Company entered into a first amendment to the Securities Purchase Agreement (the "Amendment") for the sale and issuance by the Company of additional securities to two of the Purchasers (the "Additional Subscription", and together with the Initial Subscription, the "May 2024 Private Placement"). The Securities Purchase Agreement provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares (the "Private Placement Shares") of the Company's common stock or, at the election of each Purchaser, pre-funded warrants (the "Pre-Funded Warrants"), exercisable immediately at an exercise price of $0.001 per share, with each Private Placement Share or Pre-Funded Warrant accompanied by (i) a Series A common warrant ("Series A Warrants") to purchase one share of common stock (the "Series A Warrant Shares"), for an aggregate of 3,591,532 Series A Warrants, and (ii) one Series B common warrant ("Series B Warrants") to purchase one share of common stock (the "Series B Warrant Shares," and together with the Series A Warrant Shares, the "Common Warrant Shares"), for an aggregate of 3,591,532 Series B Warrants. The combined purchase price for each Private Placement Share and Pre-Funded Warrant from the Initial Subscription was $2.022<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;">, and $2.158 from the Additional Subscription, in each case together with one accompanying Series A Warrant and one accompanying Series B Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Warrant and Series B Warrant. The exercise price of Series A Warrants and Series B Warrants from the Initial Subscription is $1.772 per share and $1.908 per share in the Additional Subscription, provided that the exercise price for the Series A Warrants and Series B Warrants issued to the Company Insiders is $1.79 per share. Subject to certain ownership limitations, the Series A Warrants will be exercisable until the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Warrants will be exercisable until June 24, 2025. The Pre-Funded Warrant will not expire until exercised in full. If a holder of a Series A Warrant or a Series B Warrant is unable to exercise the warrant due to the limitation contained in the warrant that restricts the holder from owning above a specified beneficial ownership level (generally 4.99% or 9.99%) as the result of exercise of the warrant, then the holder may elect upon exercise of the warrant to receive a pre-funded warrant for the same number of shares of common stock that would otherwise have been received upon exercise of the warrant. In addition, the Series A Warrants and Series B Warrants provided for a call right starting June 24, 2025 in favor of the Company, if the volume-weighted average price of the common stock exceeds specified prices. The May 2024 Private Offering closed on May 9, 2024 (the "May 2024 Private Placement Closing"). The Company issued 2,151,544 Pre-Funded Warrants, 3,591,532 Series A Warrants and 3,591,532 Series B Warrants to purchase its common stock in connection with the May 2024 Private Placement. The aggregate gross proceeds from the May 2024 Private Placement Closing were approximately $7.3 million, before deducting $0.4 million of offering expenses. The Company reviewed the terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants under the authoritative accounting guidance. As described above, the Series A Warrants and Series B Warrants are classified as liabilities for the reason that they can be exercised into either common stock or Pre-Funded Warrants at the holder's option and thus fail the indexation guidance under ASC 815, Derivatives and Hedging. The Series A Warrant and Series B Warrant liability were recorded at fair value as of the issuance date and June 30, 2024, and under the terms of the Series A Warrants and Series B Warrants when issued that liability was subject to adjustment to estimated fair value at each balance sheet date until the warrants were settled. Refer to Note 14 for additional information regarding the amendment and restatement of the Series A Warrants and Series B Warrants that eliminated the ability of the Series A Warrants and Series B Warrants to be exercised into the Pre-Funded Warrants. The Pre-Funded Warrants are equity classified because they (1) are freestanding financial instruments that are legally detachable and separately exercisable from the common stock, (2) are immediately exercisable, (3) do not embody an obligation for the Company to repurchase its shares, (4) permit the holder to receive a fixed number of shares of common stock upon exercise, (5) are indexed to the Company's common stock and (6) meet the equity classification criteria. The proceeds from the May 2024 Private Placement must first be allocated to the full fair value of the Series A Warrants and Series B Warrants due to the liability classification. As disclosed in Note 4, the fair value of the Series A Warrants and Series B Warrants at issuance was $10.9 million. Under authoritative guidance, if the fair value of a warrant liability exceeds the proceeds received in an arm's length transaction with no rights or privileges that require separate accounting recognition as an asset identified, then the warrant liability is recorded at fair value with the excess of fair value over proceeds recognized as a loss in earnings. The Company recognized approximately $3.5 million in financing expense in the condensed consolidated statement of operations during the three and six months ended June 30, 2024, which represents the excess of the fair value of the Series A Warrants and Series B Warrants at issuance over the proceeds. During the three and six months ended June 30, 2024, the Company recognized a fair value gain on warrant liability of $4.7 million. Proceeds from the May 2024 Private Placement are shown as cash from financing transactions and the gain on warrant liability is included as an adjustment to reconcile the net loss to net cash used in operating activities in the statements of cash flows for the six months ended June 30, 2024. In addition, total offering expenses related to the May 2024 Private Placement of $0.4 million were recorded as a component of other expenses as the entire proceeds were allocated to the warrant liability, which can be settled with either the Company's common stock or Pre-Funded Warrants, which are exercisable into the Company's common stock at any time at the holders' option, but not in cash payment to the holders. All of the Pre-Funded Warrants, Series A Warrants, and Series B Warrants issued in connection with the May 2024 Private Placement remained outstanding as of June 30, 2024. Lincoln Park Purchase Agreement <span

style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> On August 2, 2022, the Company entered into a purchase agreement (the "2022 Purchase Agreement") and registration rights agreement pursuant to which Lincoln Park Capital Fund ("Lincoln Park") committed to purchase up to $50.0 million of the Company's common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0 million of the Company's common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company's sole discretion, over the 36-month period commencing on August 17, 2022, subject to the satisfaction of certain conditions. On May 16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5 million shares of the Company's common stock (including the issuance of more than 19.99% of the Company's common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. Upon execution of the 2022 Purchase Agreement, the Company paid $0.1 million in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company's common stock at its direction under the 2022 Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash or shares of its common stock, or a combination of cash and shares of its common stock, upon receipt of $25.0 million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. On August 17, 2022, a registration statement (the "First Registration Statement") was declared effective to cover the resale of up to 633,333 shares of the Company's common stock comprised of (i) the 32,846 initial commitment shares, and (ii) up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. On August 18, 2023, a second registration statement (the "Second Registration Statement") was declared effective to cover the resale of up to an additional 1,500,000 shares of the Company's common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. The Company sold 150,000 shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. During the period from August 17, 2022 to December 31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2 million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0 million from January 1, 2023 to December 31, 2023. The Company did not issue any common stock under the 2022 Purchase Agreement during the six months ended June 30, 2024. Share Repurchase Program and Treasury Stock On October 31, 2023, the Company announced that its Board has approved a share repurchase program (the "Share Repurchase Program"), with authorization to repurchase up to $500,000 of the outstanding shares of the Company's common stock. The Company funded repurchases under the Share Repurchase Program with available cash. During the year ended December 31, 2023, the Company purchased 78,559 of its common stock for approximately $0.1 million as treasury stock. The Company purchased 179,866 of its common shares for approximately $0.4 million as treasury stock during the six months ended June 30, 2024. As of June 30, 2024, no amount remained authorized for repurchase.50000000.00115000000010.00110002023-03-03100093827792101439819266180733230000P5Y5000P5Y142733142733340.1035915320.00135915323591532 2.0222.1582.041.7721.9081.790.04990.0999215154435915 style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">13. Stock-based Compensation Under the Company's 2015 New Employee Incentive Plan, as amended (the "2015 Plan"), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company. On June 6, 2024, the Company's Board increased the number of shares for future issuances under the 2015 Plan by 75,000 shares of common stock. As of June 30, 2024, there were 62,908 shares of common stock remaining and available for future issuances under the 2015 Plan.<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;"> The Company's 2020 Stock Incentive Plan, as amended (the "2020 Plan"), which replaced the Company's 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan provides for the issuance of up to 236,667 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company's 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of June 30, 2024, there were 1,899 shares remaining and available for future issuances under the 2020 Plan. Generally, options issued under the 2020 Plan are subject to a two-year or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. A summary of activity for the six months ended June 30, 2024 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.141%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.104%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:9.624%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:8.083%;"></td> <td style="width:1%;"></td> <td style="width:1.261%;"></td> <td style="width:1%;"></td> <td style="width:7.4030000000000005%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
 Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Remaining
Contractual
Term (years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 140,109 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37.48</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.07</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196,824</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.09 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">Cancelled/expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">271,125</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">336,928</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12.78 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8.81 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested and expected to vest at June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">310,675</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13.52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.75 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercisable at June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">103,834</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 32.39 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7.45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of June 30, 2024<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the total compensation cost related to non-vested stock options not yet recognized for all the Company's plans is approximately $0.7 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.3 years.

750006290823666718999P2YP4V0.25P10Y A summary of activity for the six months ended June 30, 2024 is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:52.141%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10.104%;"></td><td style="width:1%;"></td><td style="width:1.261%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9.624%;"></td><td style="width:1%;"></td><td style="width:1.12%;"></td><td style="width:1%;"></td><td style="width:8.083%;"></td><td style="width:1%;"></td><td style="width:1.261%;"></td><td style="width:1%;"></td><td style="width:7.4030000000000005%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Options </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
 Exercise Price </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Remaining
Contractual
Term (years) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 140,109 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37.48</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.07</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196,824</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.09 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cancelled/expired </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 271,125 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 336,928 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12.78</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and expected to vest at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 310,675 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13.52</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 103,834 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32.39</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>14010937.48P8Y25D1968242.0952711253692812.78P8Y9M21D300031067513.52P8Y9M300010383432.39P7Y5M12D700000P2Y3M18D Amendment and Restatement of Series A Warrants and Series B Warrants On August 9, 2024, the Company amended and restated the Series A Warrants and Series B Warrants (the “Amendment and Restatements”) issued in the May 2024 Private Placement. As described in Note 12 above, when originally issued, if a holder of a Series A Warrant or a Series B Warrant was unable to exercise the warrant due to the limitation contained in the Series A Warrants and Series B Warrants that restricted the holder from owning above a specified beneficial ownership level (generally 4.99% or 9.99%) as the result of exercise of the Series A Warrants and Series B Warrants, then the Series A Warrants and Series B Warrants holder could elect upon exercise of the Series A Warrants and Series B Warrants to receive a pre-funded warrant for the same number of shares of common stock that would otherwise have been received upon exercise of the Series A Warrants and Series B Warrants. The Series A Warrants and Series B Warrants Amendment and Restatements eliminated the ability of the holder to elect to purchase pre-funded warrants in lieu of the Series A Warrants and Series B Warrants.
In addition, the Amendment and Restatements eliminated the Company’s call right under the terms of the Series A Warrants to call the Series A Warrants after June 24, 2025, if the volume-weighted average price of the common stock exceeded specified prices. There were no other changes in the terms of the Series A Warrants and Series B Warrants. As a result of the Amendment and Restatements, the Series A Warrants and Series B Warrants, as amended, will no longer fail the indexation guidance under ASC 815, Derivatives and Hedging, and the

balance of the warrant liability at the amendment date will be reclassified to equity.</p>0.04990.0999

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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497, } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 192 240 1 false 59 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) Statements 5 false false R6.htm 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 100060 - Disclosure - Basis of Presentation and New Accounting Standards Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandards Basis of Presentation and New Accounting Standards Notes 7 false false R8.htm 100070 - Disclosure - Use of Estimates Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureUseOfEstimates Use of Estimates Notes 8 false false R9.htm 100080 - Disclosure - Liquidity and Going Concern Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcern Liquidity and Going Concern Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Term Loan Obligations Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureTermLoanObligations Term Loan Obligations Notes 11 false false R12.htm 100110 - Disclosure - Line of Credit Facility Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacility1 Line of Credit Facility Notes 12 false false R13.htm 100120 - Disclosure - Biocept Asset Acquisitions Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitions Biocept Asset Acquisitions Notes 13 false false R14.htm 100130 - Disclosure - Loss per Share Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShare Loss per Share Notes 14 false false R15.htm 100140 - Disclosure - Grant Revenue Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenue Grant Revenue Notes 15 false false R16.htm 100150 - Disclosure - Commitments and Contingencies Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 100160 - Disclosure - License Agreements Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreements License Agreements Notes 17 false false R18.htm 100170 - Disclosure - Stockholders' Deficit Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficit Stockholders' Deficit Notes 18 false false R19.htm 100180 - Disclosure - Stock-based Compensation Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based Compensation Notes 19 false false R20.htm 100190 - Disclosure - Subsequent Events Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 20 false false R21.htm 100210 - Disclosure - Basis of Presentation and New Accounting Standards (Policies) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies Basis of Presentation and New Accounting Standards (Policies) Policies http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandards 21 false false R22.htm 100220 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements 22 false false R23.htm 100230 - Disclosure - Loss per Share (Tables) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareTables Loss per Share (Tables) Tables http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShare 23 false false R24.htm 100250 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation 24 false false R25.htm 100260 - Disclosure - Basis of Presentation and New Accounting Standards - Additional Information (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails Basis of Presentation and New Accounting Standards - Additional Information (Details) Details 25 false false R26.htm 100280 - Disclosure - Liquidity and Going Concern - Additional Information (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails Liquidity and Going Concern - Additional Information (Details) Details 26 false false R27.htm 100300 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) Details 27 false false R28.htm 100310 - Disclosure - Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details) Details 28 false false R29.htm 100320 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details) Details 29 false false R30.htm 100330 - Disclosure - Term Loan Obligations - Additional Information (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails Term Loan Obligations - Additional Information (Details) Details 30 false false R31.htm 100340 - Disclosure - Line of Credit Facility - Additional Information (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails Line of Credit Facility - Additional Information (Details) Details 31 false false R32.htm 100350 - Disclosure - Loss per Share - Additional Information (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails Loss per Share - Additional Information (Details) Details 32 false false R33.htm 100360 - Disclosure - Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Common Share (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Common Share (Details) Details 33 false false R34.htm 100370 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details) Details 34 false false R35.htm 100380 - Disclosure - Biocept Asset Acquisitions - Additional Information (Details) Sheet http://www.plusstherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails Biocept Asset Acquisitions - Additional Information (Details) Details 35 false false R36.htm 100390 - Disclosure - Grant Revenue - Additional Information (Details) Sheet

http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails Grant Revenue - Additional Information (Details) Details 36 false false R37.htm 100400 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 37 false false R38.htm 100410 - Disclosure - License Agreements - Additional Information (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails License Agreements - Additional Information (Details) Details 38 false false R39.htm 100420 - Disclosure - Stockholders' Deficit - Preferred Stock (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails Stockholders' Deficit - Preferred Stock (Details) Details 39 false false R40.htm 100430 - Disclosure - Stockholders' Deficit - Warrants (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails Stockholders' Deficit - Warrants (Details) Details 40 false false R41.htm 100440 - Disclosure - Stockholders' Deficit - Common stock (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails Stockholders' Deficit - Common stock (Details) Details 41 false false R42.htm 100450 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 42 false false R43.htm 100460 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity (Details) Details 43 false false R44.htm 100470 - Disclosure - Subsequent Events - Additional Information (Details) Sheet
http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 44 false false All Reports Book All Reports pstv-20240630.htm pstv-20240630.xsd http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 false false JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pstv-20240630.htm": { "nsprefix": "pstv", "nsuri": "http://www.plustherapeutics.com/20240630", "dts": { "inline": { "local": ["pstv-20240630.htm"] }, "schema": { "local": ["pstv-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 201, "keyCustom": 39, "axisStandard": 24, "axisCustom": 0, "memberStandard": 23, "memberCustom": 35, "hidden": { "total": 11, "http://fasb.org/us-gaap/2024": 7, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 192, "entityCount": 1, "segmentCount": 59, "elementCount": 489, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 452, "http://xbrl.sec.gov/dei/2024": 30, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_2c16ea8f-8e51-4343-80e6-a0e819690f3c", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2c16ea8f-8e51-4343-80e6-a0e819690f3c", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_2c16ea8f-8e51-4343-80e6-a0e819690f3c", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2c16ea8f-8e51-4343-80e6-a0e819690f3c", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R4": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R5": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_5db5dbed-f460-422c-a336-b8177736ac18", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_218d6767-2c34-4e88-90b3-8d12939b3c17", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R6": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R7": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandards", "longName": "100060 - Disclosure - Basis of Presentation and New Accounting Standards", "shortName": "Basis of Presentation and New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureUseOfEstimates", "longName": "100070 - Disclosure - Use of Estimates", "shortName": "Use of Estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:UseOfEstimatesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:UseOfEstimatesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcern", "longName": "100080 - Disclosure - Liquidity and Going Concern", "shortName": "Liquidity and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "100090 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureTermLoanObligations", "longName": "100100 - Disclosure - Term Loan Obligations", "shortName": "Term Loan Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacility1", "longName": "100110 - Disclosure - Line of Credit Facility", "shortName": "Line of Credit Facility", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitions", "longName": "100120 - Disclosure - Biocept Asset Acquisitions", "shortName": "Biocept Asset Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShare", "longName": "100130 - Disclosure - Loss per Share", "shortName": "Loss per

Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenue", "longName": "100140 - Disclosure - Grant Revenue", "shortName": "Grant Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "100150 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreements", "longName": "100160 - Disclosure - License Agreements", "shortName": "License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:LicenseAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:LicenseAgreementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficit", "longName": "100170 - Disclosure - Stockholders' Deficit", "shortName": "Stockholders' Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "100180 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEvents", "longName": "100190 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies", "longName": "100210 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)", "shortName": "Basis of Presentation and New Accounting Standards (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables", "longName": "100220 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareTables", "longName": "100230 - Disclosure - Loss per Share (Tables)", "shortName": "Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "100250 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails", "longName": "100260 - Disclosure - Basis of Presentation and New Accounting Standards - Additional Information (Details)", "shortName": "Basis of Presentation and New Accounting Standards - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_e967c09c-f7f8-499d-a064-eb842941f2f3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3b034f44-82ce-497e-a995-178ea7c0e703", "name": "pstv:ReverseStockSplitEffectiveDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R26": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "longName": "100280 - Disclosure - Liquidity and Going Concern - Additional Information (Details)", "shortName": "Liquidity and Going Concern - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8e1ae89dbd95", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5629e6a4-fed8-48a9-a63e-3068b308d249", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R27": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails", "longName": "100300 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_696392e2-c444-4198-acd0-a6f697fd3b1a", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_696392e2-c444-4198-acd0-a6f697fd3b1a", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails", "longName": "100310 - Disclosure - Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details)", "shortName": "Fair Value Measurements - Summary of Key Inputs Used in Valuation of Liability Classified Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_b8eb934e-7d2c-439c-b704-0a35d2f2bd4c", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b8eb934e-7d2c-439c-b704-0a35d2f2bd4c", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails", "longName": "100320 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details)", "shortName": "Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_aecbfb48-5e9e-4de9-88d4-b91a1251beea", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aecbfb48-5e9e-4de9-88d4-b91a1251beea", "name": "us-

gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails", "longName": "100330 - Disclosure - Term Loan Obligations - Additional Information (Details)", "shortName": "Term Loan Obligations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_fe6a40ac-63b8-47e1-9086-0adb3c6065dd", "name": "us-gaap:DebtInstrumentOfferingDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fe6a40ac-63b8-47e1-9086-0adb3c6065dd", "name": "us-gaap:DebtInstrumentOfferingDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails", "longName": "100340 - Disclosure - Line of Credit Facility - Additional Information (Details)", "shortName": "Line of Credit Facility - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_7a4b86d8-0742-4b04-a17e-099000cef636", "name": "us-gaap:LineOfCredit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7a4b86d8-0742-4b04-a17e-099000cef636", "name": "us-gaap:LineOfCredit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails", "longName": "100350 - Disclosure - Loss per Share - Additional Information (Details)", "shortName": "Loss per Share - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_f1026255-c351-4599-b2df-79dbedec635e", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f1026255-c351-4599-b2df-79dbedec635e", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails", "longName": "100360 - Disclosure - Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Common Share (Details)", "shortName": "Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R34": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails", "longName": "100370 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)", "shortName": "Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails", "longName": "100380 - Disclosure - Biocept Asset Acquisitions - Additional Information (Details)", "shortName": "Biocept Asset Acquisitions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_755cac5c-44ab-42ef-95c6-8cc28fb16a01", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_755cac5c-44ab-42ef-95c6-8cc28fb16a01", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "longName": "100390 - Disclosure - Grant Revenue - Additional Information (Details)", "shortName": "Grant Revenue - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_4a1153c2-1b26-4d70-9350-d7b3437c557c", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_189809af-60d5-46cd-b9bb-49abee0d5bd7", "name": "pstv:GrantFundingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R37": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "100400 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:OperatingLeasesExpiryYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "pstv:OperatingLeasesExpiryYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails", "longName": "100410 - Disclosure - License Agreements - Additional Information (Details)", "shortName": "License Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2066786d-bc9b-4e84-962a-c5caa8ba3f13", "name": "us-gaap:SharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "pstv:LicenseAgreementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R39": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails", "longName": "100420 - Disclosure - Stockholders' Deficit - Preferred Stock (Details)", "shortName": "Stockholders' Deficit - Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_2c16ea8f-8e51-4343-80e6-a0e819690f3c", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_74cc99f1-6b0b-4ba0-a024-3f28ded14c72", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R40": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails", "longName": "100430 - Disclosure - Stockholders' Deficit - Warrants (Details)", "shortName": "Stockholders' Deficit - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_c0523f1c-4ef2-4129-97de-05297d4ed2d4", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c0523f1c-4ef2-4129-97de-05297d4ed2d4", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "longName": "100440 - Disclosure - Stockholders' Deficit - Common stock (Details)", "shortName": "Stockholders' Deficit - Common stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "pstv:FinancingExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dcb2855b-f822-495c-ae69-c25577aa809e", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "ix:continuation", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R42": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "100450 - Disclosure - Stock-based Compensation - Additional Information (Details)", "shortName": "Stock-based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R43": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails", "longName": "100460 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)", "shortName": "Stock-based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_ce2dd113-d4eb-428b-9657-2b7ffe8e1dec", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_968f7aa2-7926-43a7-b8ce-02ffa90a7194", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } }, "R44": { "role": "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "100470 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_833361c6-c54d-482c-9ed7-8c1ae89dbd95", "name": "us-

gaap:FairValueAdjustmentOfWarrants", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "first": true } }, "uniqueAnchor": { "contextRef": "C_19d54fd7-4ed0-4a92-850f-1b3e17628265", "name": "pstv:RestrictedBeneficialOwnershipLevelResultOfExerciseOfWarrantToReceivePreFundedWarrant", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "pstv-20240630.htm", "unique": true } } }, "tag": { "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201613Member", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "ASU 2016-13", "label": "Accounting Standards Update 2016-13 [Member]", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": ["r259"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounts Payable And Accrued Liabilities Current", "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r39", "r40"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discount on short-term investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r67"] }, "pstv_AccruedLicensePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "AccruedLicensePayable", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued payments due to NanoTx", "label": "Accrued License Payable", "documentation": "Accrued license payable." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r50", "r771", "r960"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r618", "r819", "r820", "r821", "r822", "r893", "r961"] }, "pstv_AdditionalSubscriptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "AdditionalSubscriptionMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Additional Subscription [Member]", "documentation": "Additional Subscription." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r120", "r121", "r122", "r123", "r124", "r125", "r165", "r166", "r167", "r169", "r180", "r225", "r226", "r261", "r262", "r263", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r287", "r288", "r294", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r496", "r497", "r509", "r510", "r511", "r519", "r521", "r522", "r523", "r524", "r525", "r566", "r567", "r568", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r28", "r29", "r388"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "pstv_AmendmentAndRestatementsMay2024PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "AmendmentAndRestatementsMay2024PrivatePlacementMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Amendment and Restatements May 2024 Private Placement [Member]", "documentation": "Amendment and restatements May 2024 private placement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Amortization Of Debt Discount Premium", "terseLabel": "Non-cash amortization", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r5", "r59", "r335", "r912"] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of deferred financing costs and debt discount", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r335", "r742", "r743", "r814", "r912"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Dilutive common shares excluded from the calculations of diluted loss per share (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r196"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r447"] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r282", "r283", "r284", "r285", "r286", "r888"] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r282", "r283", "r284", "r285", "r286", "r888"] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r888"] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": ["r888"] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitions"], "lang": { "en-us": { "role": { "terseLabel": "Biocept Asset Acquisitions", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": ["r888"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Assets",

```
"totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r83", "r94", "r133", "r157", "r200", "r204", "r219", "r220", "r258", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r448", "r450", "r498", "r576", "r658", "r732", "r733", "r771", "r788", "r851", "r852", "r919" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r128", "r141", "r157", "r258", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r448", "r450", "r498", "r771", "r851", "r852", "r919" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure, Total", "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair Value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r480", "r481", "r758" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "terseLabel": "Unrealized gain on available-for-sale securities", "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r831" ] }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]", "terseLabel": "Available-for-Sale Securities", "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r35" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation and New Accounting Standards", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandards" ], "lang": { "en-us": { "role": { "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and New Accounting Standards", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r68" ] }, "pstv_BioceptAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "BioceptAgreementMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Biocept Agreement.", "label": "Biocept Agreement [Member]", "terseLabel": "Biocept Agreement [Member]" } } }, "auth_ref": [] }, "pstv_BioceptAssetAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "BioceptAssetAcquisitionsMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biocept Asset Acquisitions [Member]", "label": "Biocept Asset Acquisitions [Member]", "documentation": "Biocept asset acquisitions." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of acquisitions", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r30" ] }, "pstv_CancerPreventionAndResearchInstituteOfTexasContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "CancerPreventionAndResearchInstituteOfTexasContractMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Cancer prevention and research institute of texas contract.", "label": "Cancer Prevention And Research Institute Of Texas Contract [Member]", "terseLabel": "CPRIT Contract [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r12", "r130", "r723" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r130" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r12", "r65", "r154" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r65" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of non-cash investing and financing activities:" } } }, "auth_ref": [] }, "pstv_CashPaidDuringPeriodForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "CashPaidDuringPeriodForAbstract", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Cash paid during period for:", "label": "Cash Paid During Period For [Abstract]", "terseLabel": "Cash paid during period for:" } } }, "auth_ref": [] }, "pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "CashPaidForIPRDAssetAcquiredInAnAssetAcquisition", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Cash paid for IPRD asset acquired in an asset acquisition.", "label": "Cash Paid For I P R D Asset Acquired In An Asset Acquisition", "negatedLabel": "In process research and development acquired" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle, accounting standards update, adopted", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r101", "r102", "r125", "r163", "r225", "r260", "r261", "r262", "r269", "r270", "r287", "r294", "r426", "r429", "r430", "r439", "r440", "r442", "r453", "r454", "r467", "r468", "r496", "r497", "r510", "r519", "r521", "r566", "r567", "r598", "r599" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle, accounting standards update, adoption date", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r101", "r102", "r125", "r225", "r260", "r261", "r262", "r269", "r270", "r271", "r287", "r294", "r426", "r429", "r430", "r439", "r440", "r441", "r442", "r443", "r452", "r453", "r454", "r455", "r467", "r468", "r469", "r472", "r496", "r497", "r510", "r519", "r521", "r566", "r567", "r598", "r599", "r797" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": [ "r165", "r179", "r265" ] }, "pstv_CharlottesvilleMember": { "xbrltype": "domainItemType", "nsuri":
```

```
"http://www.plustherapeutics.com/20240630", "localname": "CharlottesvilleMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Charlottesville", "label": "Charlottesville [Member]", "terseLabel": "Charlottesville [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code",
"terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": {
"label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include,
but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r105", "r137", "r138", "r139",
"r157", "r185", "r186", "r193", "r195", "r202", "r203", "r258", "r304", "r306", "r307", "r308", "r311", "r312", "r341", "r342", "r345", "r348", "r355", "r498", "r613", "r614",
"r615", "r616", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r646", "r667", "r684", "r710", "r711", "r712", "r713", "r714",
"r795", "r815", "r823" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems",
"presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Stock [Line
Items]", "terseLabel": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r137", "r138", "r139", "r202", "r341", "r342", "r343",
"r345", "r348", "r353", "r355", "r613", "r614", "r615", "r616", "r744", "r795", "r815" ] }, "us-gaap_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExercisable": {
"xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExercisable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of
Warrant Or Right Date From Which Warrants Or Rights Exercisable", "terseLabel": "Date from which warrants are exercisable", "documentation": "Date the warrants or
rights are exercisable, in YYYY-MM-DD format." } } }, "auth_ref": [ "r356" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of
Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r26" ] }, "us-
gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation":
[ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of
Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights
represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants
are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and
guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the
lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of
Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Warrant exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit
of warrants or rights outstanding." } } }, "auth_ref": [ "r356" ] }, "pstv_ClassOfWarrantOrRightExpirationDate": { "xbrltype": "dateItemType", "nsuri":
"http://www.plustherapeutics.com/20240630", "localname": "ClassOfWarrantOrRightExpirationDate", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"The date that the warrant or right expires.", "label": "Class Of Warrant Or Right Expiration Date", "terseLabel": "Warrant expiration date" } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class Of
Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Number of shares callable by warrants (in shares)", "verboseLabel": "Number of
securities called by warrant or right", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to,
500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r356" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pre -Funded
Warrants to Purchase", "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Class of warrant outstanding", "documentation": "Number of warrants or rights
outstanding." } } }, "auth_ref": [] }, "pstv_ClosingBidPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"ClosingBidPrice", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "documentation": "Closing bid price.", "label": "Closing Bid Price", "terseLabel": "Closing bid price" } } }, "auth_ref": [] },
"pstv_ClosingBidPriceForCommonStockHadFallenBelow": { "xbrltype": "perShareItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"ClosingBidPriceForCommonStockHadFallenBelow", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Closing bid price for common stock had fallen.", "label": "Closing Bid Price For Common Stock Had Fallen Below", "terseLabel": "Closing bid price for
common stock had fallen below" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation":
[ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used
to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r447" ] }, "us-
gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr":
"credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role":
{ "terseLabel": "Commitments and contingencies (Note 10)", "label": "Commitments And Contingencies", "documentation": "Represents the caption on the face of the balance
sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2)
is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and
(b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
} } }, "auth_ref": [ "r46", "r86", "r578", "r645" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" }
} }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments And
Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } },
"auth_ref": [ "r70", "r295", "r296", "r716", "r841", "r846" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonClassAMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang":
{ "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "documentation": "Classification of common stock representing
ownership interest in a corporation." } } }, "auth_ref": [ "r961" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonClassBMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang":
{ "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "documentation": "Classification of common stock that has different
rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r961" ] }, "us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock,
Capital Shares Reserved for Future Issuance", "terseLabel": "Number of shares reserved for issuance and sale", "verboseLabel": "Common stock capital shares reserved for
future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": {
"label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [
"r778", "r779", "r780", "r782", "r783", "r784", "r785", "r819", "r820", "r822", "r893", "r959", "r961" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label":
"Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of
common stock." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label":
"Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to
```

be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r646"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } }, "auth_ref": ["r49"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r49", "r646", "r664", "r961", "r962"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 5,962,644 and 5,704,219 issued and outstanding at June 30, 2024, and 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, respectively", "verboseLabel": "Voting stock, value", "label": "Common Stock Value", "negatedLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 36,123,833 and 33,601,373 issued and outstanding at March 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r580", "r771"] }, "pstv_CompensatoryDamagesAndOperational": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "CompensatoryDamagesAndOperational", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Compensatory damages and operational.", "label": "Compensatory Damages And Operational", "terseLabel": "Compensatory damages and operational" } } }, "auth_ref": [] }, "pstv_ConsecutiveBusinessDays": { "xbrltype": "durationItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "ConsecutiveBusinessDays", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Consecutive business days.", "label": "Consecutive Business Days", "terseLabel": "Consecutive business days" } } }, "auth_ref": [] }, "pstv_ConsiderationPaidToPreferredStockHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "ConsiderationPaidToPreferredStockHolders", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration paid to preferred stock holders", "label": "Consideration Paid To Preferred Stock Holders", "documentation": "Consideration paid to preferred stock holders." } } }, "auth_ref": [] }, "pstv_ContractEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "ContractEffectiveDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Contract effective date.", "label": "Contract Effective Date", "terseLabel": "Contract effective date" } } }, "auth_ref": [] }, "pstv_ContractTerminationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "ContractTerminationDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Contract termination date.", "label": "Contract Termination Date", "terseLabel": "Contract termination date" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetGross", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, before Allowance for Credit Loss", "terseLabel": "Grant amount awarded", "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r95", "r275", "r856", "r857"] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "terseLabel": "Contractual obligation", "totalLabel": "Contractual Obligation, Total", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": ["r818"] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock [Member]", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r341", "r342", "r345", "r782", "r783", "r784", "r785"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "pstv_CpritGrantFundingTerm": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "CpritGrantFundingTerm", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "CPRIT grant funding term.", "label": "CPRIT Grant Funding Term", "terseLabel": "CPRIT grant funding term, description" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r303", "r849"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r303", "r849", "r850"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "verboseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureTermLoanObligations"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Term Loan Obligations", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r71", "r155", "r289", "r290", "r291", "r292", "r293", "r302", "r303", "r313", "r319", "r320", "r321", "r322", "r323", "r324", "r329", "r336", "r337", "r339", "r507"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r10", "r39", "r40", "r84", "r85", "r158", "r314", "r315", "r316", "r317", "r318", "r320", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r739", "r740", "r741", "r742", "r743", "r768", "r816", "r842", "r843", "r844", "r911", "r913"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCovenantCompliance": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCovenantCompliance", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Compliance", "terseLabel": "Debt instrument, covenant compliance", "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure." } } }, "auth_ref": ["r10", "r37"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Face Amount", "verboseLabel": "Original loan amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r314", "r507", "r508", "r740", "r741", "r768"] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Fee Amount", "terseLabel": "Fees amount associated with loan", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r43"] }, "pstv_DebtInstrumentFloatingInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "DebtInstrumentFloatingInterestRatePercentage", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Floating interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Floating Interest Rate Percentage", "terseLabel": "Interest rate" } } }, "auth_ref": [] }, "pstv_DebtInstrumentFloorRate": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "DebtInstrumentFloorRate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument floor rate", "label": "Debt Instrument Floor Rate", "documentation": "Debt instrument floor rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r42", "r315"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r158", "r314", "r315", "r316", "r317", "r318", "r320", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r338", "r739", "r740", "r741", "r742", "r743", "r768", "r816", "r911", "r913"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"DebtInstrumentMaturityDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Maturity Date", "terseLabel": "Maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r135", "r739", "r898", "r899"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation":["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r10", "r158", "r314", "r315", "r316", "r317", "r318", "r320", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r739", "r740", "r741", "r742", "r743", "r768", "r816", "r842", "r843", "r844", "r911", "r913"] }, "us-gaap_DebtInstrumentOfferingDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentOfferingDate1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Offering Date1", "terseLabel": "Origination date", "documentation": "Date the debt instrument was offered for sale, in YYYY-MM-DD format." } } }, "auth_ref": ["r10", "r20"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r10", "r20", "r23", "r36", "r74", "r75", "r158", "r314", "r315", "r316", "r317", "r318", "r320", "r325", "r326", "r327", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r338", "r739", "r740", "r741", "r742", "r743", "r768", "r816", "r911", "r913"] }, "pstv_DebtPrincipalRepaymentStartDate": { "xbrltype": "dateItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "DebtPrincipalRepaymentStartDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Debt principal repayment start date.", "label": "Debt Principal Repayment Start Date", "terseLabel": "Debt principal repayment start date" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeCurrent", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Deferred Income, Current", "terseLabel": "Deferred grant liability", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r796"] }, "us-gaap_DeferredIncomeNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeNoncurrent", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred grant liability", "label": "Deferred Income, Noncurrent", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r796"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r5", "r200", "r209", "r220", "r732", "r733"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation":["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r634", "r637", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r672", "r673", "r674", "r675", "r678", "r679", "r680", "r681", "r699", "r700", "r701", "r702", "r778", "r780", "r900", "r901", "r902", "r903", "r904", "r905", "r907", "r908"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument Risk [Axis]", "terseLabel": "Derivative Instrument", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r32", "r33", "r34", "r81", "r634", "r637", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r672", "r673", "r674", "r675", "r678", "r679", "r680", "r681", "r699", "r700", "r701", "r702", "r724", "r778", "r780", "r900", "r901", "r902", "r903", "r904", "r905", "r907", "r908"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r375", "r745", "r746", "r747", "r748", "r749", "r750", "r751"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r375", "r745", "r746", "r747", "r748", "r749", "r750", "r751"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r386", "r390", "r417", "r418", "r420", "r756"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "auth_ref": [] }, "pstv_DisclosureOfLiquidityAndGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "DisclosureOfLiquidityAndGoingConcernTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcern"], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Going Concern", "label": "Disclosure Of Liquidity And Going Concern Text Block", "documentation": "Disclosure of liquidity and going concern text block" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r126"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DistributionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DistributionTypeDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Distribution Type [Domain]", "documentation": "Types of distribution made by the entity." } } }, "auth_ref": ["r78"] }, "us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Distribution Type [Axis]", "documentation": "Information by type of distribution." } } }, "auth_ref": ["r78"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r792"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r793"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Per share information:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of common stock - basic", "label": "Earnings Per Share Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r148", "r170", "r171", "r172", "r173", "r174", "r175", "r183", "r185", "r193", "r194", "r195", "r199", "r437", "r446", "r477", "r478", "r573", "r588", "r726"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted net loss per common share calculation:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share of common stock - basic", "terseLabel": "Net loss per share of common stock - diluted", "label": "Earnings Per Share Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding

during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r148", "r170", "r171", "r172", "r173", "r174", "r175", "r185", "r193", "r194", "r195", "r199", "r437", "r446", "r477", "r478", "r573", "r588", "r726"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r182", "r196", "r197", "r198"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "verboseLabel": "Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r419"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "verboseLabel": "Weighted average period for recognition of cost", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r419"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r790"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "terseLabel": "Entity", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r790"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r790"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r794"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r790"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r790"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r790"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r790"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "verboseLabel": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r122", "r144", "r145", "r146", "r159", "r160", "r161", "r166", "r174", "r176", "r178", "r201", "r264", "r272", "r288", "r357", "r424", "r425", "r432", "r433", "r434", "r438", "r445", "r446", "r456", "r458", "r459", "r460", "r461", "r464", "r476", "r499", "r500", "r501", "r502", "r503", "r504", "r510", "r512", "r525", "r586", "r600", "r601", "r602", "r618", "r684"] }, "pstv_EquityIncentivePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "EquityIncentivePlansMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Equity incentive plans.", "label": "Equity Incentive Plans [Member]", "terseLabel": "Equity Incentive Plans [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Gain on change in fair value of warrant liabilities", "negatedLabel": "Change in fair value of warrants", "terseLabel": "Change in fair value of warrants", "verboseLabel": "Fair value loss on warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r5"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."

```
} } }, "auth_ref": [ "r480", "r481", "r492", "r758" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r480", "r481", "r492", "r758" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r482", "r483", "r484", "r761" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r482", "r483", "r484", "r761" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Key Inputs Used in Valuation of Liability Classified Warrants", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r482", "r483", "r761" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r895", "r896" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r327", "r378", "r379", "r380", "r381", "r382", "r383", "r479", "r481", "r482", "r483", "r484", "r491", "r492", "r494", "r536", "r537", "r538", "r740", "r741", "r752", "r753", "r754", "r758", "r761" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r493" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r480", "r481", "r482", "r484", "r758", "r898", "r909" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r327", "r378", "r383", "r481", "r492", "r536", "r752", "r753", "r754", "r758" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r327", "r378", "r383", "r481", "r482", "r492", "r537", "r740", "r741", "r752", "r753", "r754", "r758" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r327", "r378", "r379", "r380", "r381", "r382", "r383", "r481", "r482", "r483", "r484", "r492", "r538", "r740", "r741", "r752", "r753", "r754", "r758", "r761" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r493" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r493" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Fair Value of Warrant Liabilities", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r485", "r490", "r493" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r480", "r481", "r482", "r484", "r758", "r898", "r909" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs Disclosure [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r82" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of warrants", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r488", "r493" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrants", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total", "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r900", "r908" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r485", "r493" ] }, "us-
```

gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r327", "r378", "r379", "r380", "r381", "r382", "r383", "r479", "r481", "r482", "r483", "r484", "r491", "r492", "r494", "r536", "r537", "r538", "r740", "r741", "r752", "r753", "r754", "r758", "r761"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r758", "r895", "r896", "r897", "r898", "r899", "r909"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r338", "r353", "r465", "r495", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r587", "r737", "r758", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r772", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r832", "r833", "r834", "r835", "r894", "r897", "r898", "r899", "r906", "r909"] }, "pstv_FinancingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "FinancingExpense", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Financing expense", "negatedLabel": "Financing expense", "label": "Financing Expense", "documentation": "Financing expense." } } }, "auth_ref": [] }, "pstv_FractionalAdjustmentOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "FractionalAdjustmentOfCommonStock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Fractional adjustment", "label": "Fractional Adjustment of Common Stock", "documentation": "Fractional adjustment of common stock." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Loss on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": ["r814", "r839", "r840"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "General And Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r57", "r669"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r131", "r281", "r572", "r733", "r738", "r759", "r771", "r837", "r838"] }, "pstv_GrantFundingPeriod": { "xbrltype": "integerItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "GrantFundingPeriod", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Grant funding period.", "label": "Grant Funding Period", "terseLabel": "Grant funding period" } } }, "auth_ref": [] }, "pstv_GrantFundingTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "GrantFundingTerm", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Grant funding term.", "label": "Grant Funding Term", "terseLabel": "Grant funding term" } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Grant [Member]", "terseLabel": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": ["r859"] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivableCurrent", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Grants Receivable, Current", "terseLabel": "Grant receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r810"] }, "pstv_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds from Issuance of Common Stock", "terseLabel": "Aggregate gross proceeds from sales of common stock" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent, Total", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net income from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": ["r31", "r55", "r67", "r170", "r171", "r172", "r173", "r174", "r191", "r195", "r446"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r4"] }, "pstv_IncreaseDecreaseInDeferredGrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "IncreaseDecreaseInDeferredGrantLiability", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in deferred grant liability.", "label": "Increase Decrease In Deferred Grant Liability", "terseLabel": "Deferred grant liability" } } }, "auth_ref": [] }, "pstv_IncreaseDecreaseInGrantReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "IncreaseDecreaseInGrantReceivable", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Grant receivable", "label": "Increase Decrease In Grant Receivable", "documentation": "Increase decrease in grant receivable." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Increases (decreases) in cash caused by changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Change in operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r798", "r813"] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase Decrease In Other Current Assets", "negatedLabel": "Other current assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r813"] }, "pstv_InitialCommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "InitialCommitmentFee", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Initial commitment fee.", "label": "Initial Commitment Fee", "terseLabel": "Initial commitment fee paid in cash" } } }, "auth_ref": [] }, "pstv_InitialCommitmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "InitialCommitmentShares", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Initial commitment shares.", "label": "Initial Commitment Shares", "terseLabel": "Initial commitment shares" } } }, "auth_ref": [] }, "pstv_InitialSubscriptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "InitialSubscriptionMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Initial Subscription [Member]", "documentation": "Initial Subscription." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Interest Expense, Operating and Nonoperating", "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "totalLabel": "Interest Expense, Total", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r200", "r204", "r208", "r210", "r220", "r506", "r732", "r733"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Interest Paid Net", "terseLabel": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r150", "r152", "r153"] }, "us-gaap_InterestRateFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateFloorMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Interest Rate Floor [Member]", "terseLabel": "Interest Rate Floor [Member]", "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer

```
equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount." } } }, "auth_ref": [ "r721" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Investment Income Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r200", "r207", "r220", "r732", "r812" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "terseLabel": "Investment Type", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r630", "r631", "r632", "r633", "r635", "r690", "r692", "r694", "r697", "r698", "r703", "r705", "r706", "r707", "r708", "r709", "r780" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type Categorization [Member]", "terseLabel": "Investments", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r630", "r631", "r632", "r633", "r635", "r690", "r692", "r694", "r697", "r698", "r703", "r705", "r706", "r707", "r708", "r709", "r780" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Lease Costs", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r916" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease Expiration Date1", "terseLabel": "Operating leases, expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease discount rate", "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r769" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, operating lease, existence of option to extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r515" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Future Minimum Annual Lease Payments under Operating Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r917" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Lessee, operating lease, option to extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r515" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Lessee, operating lease, renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r915" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Lessee, operating lease, term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r915" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10", "r39", "r40", "r41", "r44", "r45", "r46", "r47", "r157", "r258", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r449", "r450", "r451", "r498", "r644", "r727", "r788", "r851", "r919", "r920" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r54", "r87", "r582", "r771", "r817", "r836", "r910" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r41", "r129", "r157", "r258", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r449", "r450", "r451", "r498", "r771", "r851", "r919", "r920" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities Fair Value Adjustment", "terseLabel": "Change in fair value of liability instruments", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "pstv_LiborMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LiborMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "LIBOR.", "label": "LIBOR [Member]", "terseLabel": "LIBOR [Member]" } } }, "auth_ref": [] }, "pstv_LicenseAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LicenseAgreementAbstract", "lang": { "en-us": { "role": { "documentation": "License agreement abstract.", "label": "License Agreement [Abstract]" } } }, "auth_ref": [] }, "pstv_LicenseAgreementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LicenseAgreementDisclosureTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreements" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for license agreement.", "label": "License Agreement Disclosure [Text Block]", "terseLabel": "License Agreements" } } }, "auth_ref": [] }, "pstv_LincolnParkCapitalFundLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LincolnParkCapitalFundLLCMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Lincoln park capital fund, LLC.", "label": "Lincoln Park Capital Fund L L C [Member]", "terseLabel": "Lincoln Park Capital Fund, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit", "label": "Long-Term Line of Credit", "totalLabel": "Long-Term Line of Credit, Total", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the B5 date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r10", "r85", "r929" ] }, "us-gaap_LineOfCreditFacilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAbstract", "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable fees", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r303", "r816", "r849" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r38", "r43", "r303", "r816", "r849" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of
```

any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r39", "r84"] }, "pstv_LiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LiquidityAbstract", "lang": { "en-us": { "role": { "documentation": "Liquidity Abstract", "label": "Liquidity [Abstract]" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case Type [Domain]", "terseLabel": "Litigation Case", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Settlement Expense", "terseLabel": "Litigation settlement, expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } } }, "auth_ref": ["r799"] }, "pstv_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LoanAndSecurityAgreementMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Long Term Debt Current", "terseLabel": "Term loan obligation, current", "totalLabel": "Long-Term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r134"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Long Term Debt Noncurrent", "terseLabel": "Term loan obligation", "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r136"] }, "pstv_LongTermDebtOutstandingThresholdAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LongTermDebtOutstandingThresholdAmount", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Long term debt outstanding threshold amount.", "label": "Long Term Debt Outstanding Threshold Amount", "verboseLabel": "Long term debt outstanding threshold amount" } } }, "auth_ref": [] }, "pstv_LoremVascularPteLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "LoremVascularPteLtdMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Lorem Vascular, Pte. Ltd.", "label": "Lorem Vascular Pte Ltd [Member]", "terseLabel": "Lorem Vascular Pte Ltd [Member]" } } }, "auth_ref": [] }, "pstv_MaintainMinimumMarketValueOfListedSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MaintainMinimumMarketValueOfListedSecurities", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Maintain minimum market value of listed securities", "label": "Maintain Minimum Market Value of Listed Securities", "terseLabel": "Maintain minimum market value of listed securities" } } }, "auth_ref": [] }, "pstv_MasterServicesAgreementDate": { "xbrltype": "dateItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MasterServicesAgreementDate", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Master services agreement date.", "label": "Master Services Agreement Date", "terseLabel": "Master service agreement date" } } }, "auth_ref": [] }, "pstv_MasterServicesAgreementInitialTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MasterServicesAgreementInitialTerm", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Master services agreement initial term.", "label": "Master Services Agreement Initial Term", "terseLabel": "Master services agreement initial term" } } }, "auth_ref": [] }, "pstv_MasterServicesAgreementTermsDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MasterServicesAgreementTermsDescription", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Master services agreement Terms description.", "label": "Master Services Agreement Terms Description", "terseLabel": "Master services agreement terms, Description" } } }, "auth_ref": [] }, "pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MaximumGrantAmountToBeReceivedAsPerGrantContract", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum grant amount to be received as per grant contract.", "label": "Maximum Grant Amount to be Received as per Grant Contract", "terseLabel": "Maximum grant amount to be received as per grant contract" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r106", "r107", "r108", "r109", "r110", "r118", "r119", "r298", "r299", "r300", "r301", "r385", "r421", "r484", "r564", "r596", "r597", "r610", "r636", "r637", "r691", "r693", "r695", "r696", "r704", "r717", "r718", "r736", "r744", "r755", "r761", "r762", "r766", "r767", "r774", "r853", "r921", "r922", "r923", "r924", "r925", "r926"] }, "pstv_MaximumValueOfSharesToBeIssuedUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MaximumValueOfSharesToBeIssuedUnderAgreement", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum value of shares to be issued under agreement.", "label": "Maximum Value of Shares to be Issued Under Agreement", "terseLabel": "Maximum value of shares to be issued under agreement" } } }, "auth_ref": [] }, "pstv_May2024PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "May2024PrivatePlacementMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "May 2024 Private Placement [Member]", "label": "May 2024 Private Placement [Member]", "documentation": "May 2024 private placement." } } }, "auth_ref": [] }, "pstv_MeasurementInputCommonStockMarketPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MeasurementInputCommonStockMarketPriceMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Market Price [Member]", "label": "Measurement Input, Common Stock Market Price [Member]", "documentation": "Measurement Input, Common Stock Market Price." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected Term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r897", "r898", "r899"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected Volatility [Member]", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r761", "r897", "r898", "r899"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free Interest Rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r897", "r898", "r899"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r482", "r483", "r484", "r761"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r482", "r483", "r484", "r761"] }, "pstv_MedidataSolutionsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MedidataSolutionsIncMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Medidata solutions, inc.", "label": "Medidata Solutions Inc [Member]", "terseLabel": "Medidata Solutions, Inc. [Member]" } } }, "auth_ref": [] }, "pstv_MinimumLiquidityCovenantAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "MinimumLiquidityCovenantAmount", "crdr": "debit", "presentation": [

```
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum liquidity covenant amount.", "label": "Minimum Liquidity Covenant Amount", "terseLabel": "Minimum liquidity covenant" } } }, "auth_ref": [] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r106", "r107", "r108", "r109", "r110", "r118", "r119", "r298", "r299", "r300", "r301", "r385", "r421", "r484", "r564", "r596", "r597", "r610", "r636", "r637", "r691", "r693", "r695", "r696", "r704", "r717", "r718", "r736", "r744", "r755", "r761", "r762", "r766", "r774", "r853", "r921", "r922", "r923", "r924", "r925", "r926" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r860" ] }, "pstv_NanoTxLicensesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "NanoTxLicensesAgreementMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Nano Tx license agreement Member", "label": "Nano Tx Licenses Agreement [Member]", "terseLabel": "Nano Tx Licenses Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided By Used In Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r151" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by financing activities:", "label": "Net Cash Provided By Used In Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r151" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows used in investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r56", "r67", "r90", "r127", "r142", "r143", "r146", "r157", "r165", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r191", "r258", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r437", "r446", "r478", "r498", "r585", "r666", "r682", "r683", "r786", "r851" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders - diluted", "terseLabel": "Net loss attributable to common stockholders - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r149", "r184", "r187", "r188", "r189", "r190", "r192", "r195" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r103", "r125", "r163", "r164", "r167", "r168", "r180", "r181", "r226", "r265", "r266", "r435", "r436", "r438", "r446", "r462", "r474", "r520", "r526", "r527", "r569", "r570", "r571", "r604", "r605", "r606", "r607", "r609" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r120", "r121", "r122", "r123", "r124", "r125", "r162", "r165", "r166", "r167", "r169", "r172", "r180", "r199", "r225", "r226", "r261", "r262", "r263", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r287", "r288", "r294", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r496", "r497", "r509", "r510", "r511", "r519", "r521", "r522", "r523", "r524", "r525", "r566", "r567", "r568", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r611" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r13", "r120", "r121", "r122", "r123", "r124", "r125", "r162", "r165", "r166", "r167", "r169", "r172", "r180", "r199", "r225", "r226", "r261", "r262", "r263", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r287", "r288", "r294", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r496", "r497", "r509", "r510", "r511", "r519", "r521", "r522", "r523", "r524", "r525", "r566", "r567", "r568", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r611" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "pstv_NonCashFinancingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "NonCashFinancingExpense", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing expense", "label": "Non-Cash Financing Expense", "documentation": "Non-cash financing expense." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income Expense", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r58" ] }, "pstv_NumberOfMaximumCommonSharesCanBeResale": { "xbrltype": "sharesItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "NumberOfMaximumCommonSharesCanBeResale", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of maximum common shares can be resale.", "label": "Number of Maximum Common Shares Can Be Resale", "terseLabel": "Number of maximum common shares can be resale" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
```

```
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segment", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise. (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r733", "r826" ] }, "pstv_NumberOfPreferredStockSharesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "NumberOfPreferredStockSharesExercised", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of Preferred Stock Shares Exercised.", "label": "Number Of Preferred Stock Shares Exercised", "terseLabel": "Number of preferred stock, shares converted" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segment", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r729", "r735", "r826" ] }, "pstv_NumberOfVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "NumberOfVotesPerShare", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Votes Per Share", "documentation": "Number of votes per share." } } }, "auth_ref": [] }, "pstv_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "NumberOfWarrantsExercised", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised", "label": "Number Of Warrants Exercised", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "pstv_OfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "OfferingCosts", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offering expenses", "label": "Offering Costs", "documentation": "Offering costs." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income Loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r93", "r728", "r825", "r827", "r828", "r829", "r830" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease Expense", "terseLabel": "Rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r914" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Operating Lease Liability", "totalLabel": "Present value of obligations under leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r514" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liability", "negatedLabel": "Less: current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r514" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liability Noncurrent", "terseLabel": "Noncurrent operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r514" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease Right Of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r513" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r814" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Operating lease, weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r517", "r770" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating lease, weighted average remaining term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r516", "r770" ] }, "pstv_OperatingLeasesExpiryYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "OperatingLeasesExpiryYear", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating leases, expiry year.", "label": "Operating Leases Expiry Year", "terseLabel": "Operating leases expiry year" } } }, "auth_ref": [] }, "pstv_OptionForExclusiveWorldwideLicense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "OptionForExclusiveWorldwideLicense", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option for exclusive worldwide license.", "label": "Option For Exclusive Worldwide License", "terseLabel": "Option for exclusive worldwide license" } } }, "auth_ref": [] }, "pstv_OptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "OptionsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Options.", "label": "Options [Member]", "terseLabel": "Outstanding Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Assets Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r140", "r771" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Assets Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r132" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Income And Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Intangible Assets Net", "terseLabel": "Intangible assets, net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "pstv_OutstandingWarrantsAndOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "OutstandingWarrantsAndOptionsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Outstanding warrants and options.", "label": "Outstanding Warrants and Options [Member]", "terseLabel": "Outstanding Warrants and Options [Member]" } } }, "auth_ref": [] }, "pstv_PaymentForTechTransferAndValidationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PaymentForTechTransferAndValidationFee", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment for tech transfer and validation fee.", "label": "Payment For Tech Transfer And Validation Fee", "terseLabel": "Payment for tech transfer and validation fee" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLoans", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments For Loans", "terseLabel": "Payments for principal, interest and fees", "documentation": "Cash payments for and related to principal collection on loans related to operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsForRepurchaseOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfEquity", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Payments for Repurchase of Equity, Total", "label": "Payments for Repurchase of Equity", "negatedLabel": "Purchase of treasury stock", "documentation": "The cash outflow to reacquire common and preferred stock." } } }, "auth_ref": [ "r63", "r616" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments For Royalties", "terseLabel": "License fee payment in cash", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": [
```

```
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "terseLabel": "Purchases of intangible assets", "negatedLabel": "Purchase of intangible assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r62" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBioceptAssetAcquisitionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash payment", "totalLabel": "Total cash payment", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r96", "r889", "r890", "r891" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r62" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchase of short-term investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r61" ] }, "pstv_PercentageIssuanceOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PercentageIssuanceOfCommonStock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage issuance of common stock.", "label": "Percentage Issuance Of Common Stock", "terseLabel": "Percentage issuance of common stock" } } }, "auth_ref": [] }, "pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate amount of proceeds awarded under CPRIT grant.", "label": "Percentage Of Aggregate Amount Of Proceeds Awarded Under CPRIT Grant", "terseLabel": "Percentage of aggregate amount of proceeds awarded under CPRIT grant" } } }, "auth_ref": [] }, "pstv_PercentageOfCreditFacilityCannotExceedCollateralizedMarketableSecurities": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PercentageOfCreditFacilityCannotExceedCollateralizedMarketableSecurities", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of credit facility cannot exceed collateralized marketable securities", "label": "Percentage of Credit Facility Cannot Exceed Collateralized Marketable Securities", "documentation": "Percentage of credit facility cannot exceed collateralized marketable securities." } } }, "auth_ref": [] }, "pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PercentageOfGrantProceedsWithInterestNotExceedAnnually", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of grant proceeds with interest not exceed annually.", "label": "Percentage Of Grant Proceeds With Interest Not Exceed Annually", "terseLabel": "Percentage of grant proceeds with interest not exceed annually" } } }, "auth_ref": [] }, "pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay": { "xbrltype": "percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PercentageOfNonDilutiveMonetaryAwardsRequiredToPay", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of non-dilutive monetary awards required to pay", "label": "Percentage of Non-dilutive Monetary awards Required to Pay", "documentation": "Percentage of non-dilutive monetary awards required to pay." } } }, "auth_ref": [] }, "pstv_PeriodExercisableFromTheDateOfIssuance": { "xbrltype": "durationItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PeriodExercisableFromTheDateOfIssuance", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Refers to the period exercisable from the date of issuance.", "label": "Period Exercisable From The Date Of Issuance", "terseLabel": "Period exercisable from the date of issuance" } } }, "auth_ref": [] }, "pstv_PeriodForRegainCompliance": { "xbrltype": "durationItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PeriodForRegainCompliance", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Period for regain compliance.", "label": "Period For Regain Compliance", "terseLabel": "Period for regain compliance" } } }, "auth_ref": [] }, "pstv_PershingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PershingCreditFacilityMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Pershing Credit Facility [Member]", "label": "Pershing Credit Facility [Member]", "documentation": "Pershing Credit Facility." } } }, "auth_ref": [] }, "pstv_PiramalPharmaSolutionsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PiramalPharmaSolutionsIncMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Piramal pharma solutions inc.", "label": "Piramal Pharma Solutions Inc [Member]", "terseLabel": "Piramal Pharma Solutions, Inc. [Member]" } } },
"auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886" ] }, "pstv_PreClinicalResearchStudyObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PreClinicalResearchStudyObligationsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Pre-Clinical Research Study Obligations [Member]", "terseLabel": "Pre-clinical Research Study Obligations [Member]" } } }, "auth_ref": [] }, "pstv_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants [Member]", "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-funded warrants member." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": {
"verboseLabel": "Preferred Stock [Member]", "label": "Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r778", "r779", "r782", "r783", "r784", "r785", "r959", "r961" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r48", "r341" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r48", "r646" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r48", "r341" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r48", "r646", "r664", "r961", "r962" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "label": "Preferred Stock Value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r48", "r579", "r771" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockVotingRights", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, voting rights", "label": "Preferred Stock, Voting Rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r20", "r48" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": [
```

```
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate [Member]", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "pstv_PrivatePlacementAndPrefundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PrivatePlacementAndPrefundedWarrantMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement and Pre-Funded Warrant [Member]", "label": "Private Placement and Prefunded Warrant[Member]", "documentation": "Private Placement and Prefunded Warrant." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from sale of common stock, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate upfront gross proceeds from private placement", "terseLabel": "Proceeds from private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock, warrants and pre-funded warrants, net", "label": "Proceeds from Issuance or Sale of Equity", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r613" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from credit facility", "label": "Proceeds from Lines of Credit", "totalLabel": "Proceeds from Lines of Credit, Total", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r11", "r816" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r222", "r565", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r722", "r745", "r773", "r774", "r775", "r776", "r777", "r807", "r847", "r848", "r858", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r222", "r565", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r722", "r745", "r773", "r774", "r775", "r776", "r777", "r807", "r847", "r848", "r858", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r518", "r575", "r584", "r771" ] }, "pstv_PurchasePriceOfShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "PurchasePriceOfShare", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of share", "label": "purchase price of share", "documentation": "purchase price of share." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement", "verboseLabel": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r106", "r107", "r108", "r109", "r110", "r118", "r119", "r298", "r299", "r300", "r301", "r377", "r385", "r413", "r414", "r415", "r421", "r484", "r539", "r548", "r564", "r596", "r597", "r610", "r636", "r637", "r691", "r693", "r695", "r696", "r704", "r717", "r718", "r736", "r744", "r755", "r761", "r762", "r766", "r767", "r774", "r780", "r845", "r853", "r898", "r922", "r923", "r924", "r925", "r926" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement", "verboseLabel": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r106", "r107", "r108", "r109", "r110", "r118", "r119", "r298", "r299", "r300", "r301", "r377", "r385", "r413", "r414", "r415", "r421", "r484", "r539", "r548", "r564", "r596", "r597", "r610", "r636", "r637", "r691", "r693", "r695", "r696", "r704", "r717", "r718", "r736", "r744", "r755", "r761", "r762", "r766", "r767", "r774", "r780", "r845", "r853", "r898", "r922", "r923", "r924", "r925", "r926" ] }, "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]", "terseLabel": "Recorded Unconditional Purchase Obligation by Category of Item Purchased", "documentation": "Information by category of product and service for recorded unconditional purchase arrangement to acquire product or service or both." } } }, "auth_ref": [ "r297" ] }, "us-gaap_RecordedUnconditionalPurchaseObligationCategoryDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RecordedUnconditionalPurchaseObligationCategoryDomain", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Recorded Unconditional Purchase Obligation, Category [Domain]", "documentation": "Category of product or service for recorded unconditional purchase arrangement to acquire product or service." } } }, "auth_ref": [ "r297" ] }, "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RecordedUnconditionalPurchaseObligationLineItems", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Recorded Unconditional Purchase Obligation [Line Items]", "terseLabel": "Recorded Unconditional Purchase Obligation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r297" ] }, "us-gaap_RecordedUnconditionalPurchaseObligationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RecordedUnconditionalPurchaseObligationTable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Recorded Unconditional Purchase Obligation [Table]", "terseLabel": "Recorded Unconditional Purchase Obligation [Table]", "documentation": "Disclosure of information about recorded unconditional purchase obligation arrangement to purchase product and service. Includes, but is not limited to, information about asset pledged to secure payment and payment due in each of next five years and thereafter." } } }, "auth_ref": [ "r297" ] }, "pstv_RegainComplianceExpiryDate": { "xbrltype": "dateItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "RegainComplianceExpiryDate", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regain compliance expiry date", "label": "Regain Compliance Expiry Date", "documentation": "Regain compliance expiry date." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r227", "r384", "r528", "r529", "r577", "r583", "r639", "r640", "r641", "r642", "r643", "r663", "r665", "r689" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r227", "r384", "r528", "r529", "r577", "r583", "r639", "r640", "r641", "r642", "r643", "r663", "r665", "r689", "r918" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments of term loan obligation", "label": "Repayments Of Long Term Debt", "totalLabel": "Repayments of Long-Term Debt, Total",
```

```
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r64", "r616" ] },
"pstv_RepresentativeSeriesUWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"RepresentativeSeriesUWarrantMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ],
"lang": { "en-us": { "role": { "documentation": "Representative Series U Warrant.", "label": "Representative Series U Warrant [Member]", "terseLabel": "Representative
Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research
And Development Arrangement Contract To Perform For Others By Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others,
Type", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r423", "r887" ] }, "us-
gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research
And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others,
Type", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development
for others." } } }, "auth_ref": [ "r423", "r887" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label":
"Research And Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and
development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold,
leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both.
Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } },
"auth_ref": [ "r422", "r719", "r732", "r927" ] }, "pstv_RestrictedBeneficialOwnershipLevelResultOfExerciseOfWarrantToReceivePreFundedWarrant": { "xbrltype":
"percentItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"RestrictedBeneficialOwnershipLevelResultOfExerciseOfWarrantToReceivePreFundedWarrant", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted
beneficial ownership level result of exercise of warrant to receive pre-funded warrant", "label": "Restricted Beneficial Ownership Level Result of Exercise of Warrant To
Receive Pre-funded Warrant", "documentation": "Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant." } } }, "auth_ref": [] }, "us-
gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ],
"lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand
deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid
investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes
in interest rates." } } }, "auth_ref": [ "r130" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Accumulated deficit", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
"documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r51", "r76", "r581", "r604", "r609", "r617", "r647", "r771" ] }, "us-
gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": {
"label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [
"r122", "r159", "r160", "r161", "r166", "r174", "r176", "r178", "r264", "r272", "r288", "r424", "r425", "r432", "r433", "r434", "r438", "r445", "r446", "r456", "r459", "r460",
"r464", "r476", "r510", "r512", "r600", "r602", "r618", "r961" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from
Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Grant revenue recognized", "terseLabel": "Grant revenue", "documentation": "Amount, excluding tax
collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax
assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added
and excise." } } }, "auth_ref": [ "r91", "r92", "r200", "r205", "r206", "r218", "r220", "r222", "r223", "r224", "r374", "r375", "r565" ] }, "us-
gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "label":
"Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Grant Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from
contract with customer." } } }, "auth_ref": [ "r104", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r720" ] }, "us-
gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenue" ], "lang": { "en-us": {
"role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Grant Revenue", "documentation": "The entire disclosure of revenue from contract with
customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with
customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes
insurance and lease contracts." } } }, "auth_ref": [ "r104", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r376" ] }, "us-gaap_Revenues": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Revenues, Total", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Revenue recognized", "documentation": "Amount of revenue recognized from goods sold,
services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction
of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r91", "r92", "r147", "r157", "r200", "r205", "r206",
"r218", "r220", "r222", "r223", "r224", "r258", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r498", "r574", "r732", "r851" ] },
"pstv_ReverseStockSplitEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "ReverseStockSplitEffectiveDate",
"presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "documentation": "Reverse stock split effective date.", "label": "Reverse Stock Split Effective Date", "terseLabel": "Reverse stock split effective
date" } } }, "auth_ref": [] }, "pstv_RightsRelatedToDistributionOfAssets": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"RightsRelatedToDistributionOfAssets", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Rights related to distribution of assets", "label": "Rights Related To Distribution Of Assets", "documentation": "Rights related to
distribution of assets." } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks And Uncertainties [Abstract]" } } }, "auth_ref": [] },
"pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"SaleOfJapaneseSubsidiaryAndCertainAssetsMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Sale of the japanese subsidiary and certain assets.", "label": "Sale Of Japanese Subsidiary And Certain Assets [Member]", "terseLabel": "Sale of the Japanese Subsidiary and
Certain Assets [Member]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration to
purchaser in cash", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." }
} }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale Of Stock
Name Of Transaction [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and
private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
shares issued", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method
investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockTransactionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockTransactionDate", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale closed
date", "label": "Sale of Stock, Transaction Date", "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format." } } }, "auth_ref": [] },
"pstv_SalesOrderTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SalesOrderTerm", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Sales order term.", "label": "Sales Order Term", "terseLabel": "Sales order term" } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" ],
"lang": { "en-us": { "role": { "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive
Securities Excluded From Computation Of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings
per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r14" ] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
```

```
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r447" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r824" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Activity Table [Text Block]", "terseLabel": "Stock Option Activity", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r79" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r387", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r18", "r19", "r20", "r21", "r22", "r23", "r72", "r74", "r75", "r76", "r137", "r138", "r139", "r202", "r341", "r342", "r343", "r345", "r348", "r353", "r355", "r613", "r614", "r615", "r616", "r744", "r795", "r815" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r892" ] }, "pstv_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities purchase agreement." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r789" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r791" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingPolicyPolicyTextBlock", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r221", "r223", "r730", "r731", "r734" ] }, "pstv_SeriesAWarrantAndSeriesBWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SeriesAWarrantAndSeriesBWarrantMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Series A Warrant and Series B Warrant [Member]", "documentation": "Series a warrant and series b warrant." } } }, "auth_ref": [] }, "pstv_SeriesAWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SeriesAWarrantMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series A Warrant [Member]", "documentation": "Series A Warrant." } } }, "auth_ref": [] }, "pstv_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "pstv_SeriesBWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SeriesBWarrantMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series B Warrant [Member]", "documentation": "Series B Warrant." } } }, "auth_ref": [] }, "pstv_SeriesCConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SeriesCConvertiblePreferredStockMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Series C convertible preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "pstv_SeriesFConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"SeriesFConvertiblePreferredStockMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Series F Convertible Preferred Stock [Member]", "documentation": "Series F Convertible Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_SeriesFPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesFPreferredStockMember", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Series F Preferred Stock [Member]", "label": "Series F Preferred Stock [Member]", "documentation": "Series F preferred stock." } } }, "auth_ref": [ "r808", "r809", "r854" ] }, "pstv_SeriesUWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"SeriesUWarrantsMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Series U warrants member", "label": "Series U Warrants [Member]", "terseLabel": "Series U Warrants [Member]" } } }, "auth_ref": [] }, "pstv_ServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "ServicesAgreementMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Services agreement.", "label": "Services Agreement [Member]", "terseLabel": "Services Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Stock option vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r756" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r387", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "verboseLabel": "Securities remaining and available for future issuances (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life (years) [Roll Forward]" } } }, "auth_ref": [] }, "pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": {
"documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value.", "label": "Share Based Compensation
```

Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregated Intrinsic Value [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at June 30, 2024 (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r396"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at June 30, 2024 (in dollars per share)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r396"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled/expired (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r400"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Common stock shares to be issued (in shares)", "verboseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r398"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of June 30, 2024 (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodStartLabel": "Balance as of December 31, 2023 (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r394", "r395"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Options [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of June 30, 2024 (in dollars per share)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodStartLabel": "Balance as of December 31, 2023 (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r394", "r395"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted Average Exercise Price [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r411"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at June 30, 2024 (in dollars per share)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r411"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at June 30, 2024", "periodEndLabel": "Vested and expected to vest as of June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r410"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at June 30, 2024 (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r410"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/expired (in dollars per share)", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r400"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r398"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Offering price", "label": "Share Price", "terseLabel": "Closing price per share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage", "terseLabel": "Stock option vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r861"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Stock option contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r757"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable at June 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and

currently exercisable." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at June 30, 2024", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance as of June 30, 2024", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r80"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at June 30, 2024", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r410"] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued", "terseLabel": "Remaining common stock issued and sold (in shares)", "verboseLabel": "Shares issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r7"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Shares Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacility1"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility", "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": ["r71"] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Short-Term Investments, Total", "label": "Short-Term Investments", "terseLabel": "Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r88", "r89", "r811"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r105", "r137", "r138", "r139", "r157", "r185", "r186", "r193", "r195", "r202", "r203", "r258", "r304", "r306", "r307", "r308", "r311", "r312", "r341", "r342", "r345", "r348", "r355", "r498", "r613", "r614", "r615", "r616", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r646", "r667", "r684", "r710", "r711", "r712", "r713", "r714", "r795", "r815", "r823"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components", "verboseLabel": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r49", "r52", "r53", "r122", "r144", "r145", "r146", "r159", "r160", "r161", "r166", "r174", "r176", "r178", "r201", "r264", "r272", "r288", "r357", "r424", "r425", "r432", "r433", "r434", "r438", "r445", "r446", "r456", "r458", "r459", "r460", "r461", "r464", "r476", "r499", "r500", "r501", "r502", "r503", "r504", "r510", "r512", "r525", "r586", "r600", "r601", "r602", "r618", "r684"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r159", "r160", "r161", "r201", "r512", "r565", "r612", "r629", "r638", "r639", "r640", "r641", "r642", "r643", "r646", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r663", "r665", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r684", "r781"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r159", "r160", "r161", "r201", "r227", "r512", "r565", "r612", "r629", "r638", "r639", "r640", "r641", "r642", "r643", "r646", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r663", "r665", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r684", "r781"] }, "pstv_StockBasedCompensation2015EquityIncentivePlan1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "StockBasedCompensation2015EquityIncentivePlan1Member", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Stock based compensation 2015 equity incentive plan 1 member.", "label": "Stock Based Compensation2015 Equity Incentive Plan1 [Member]", "terseLabel": "2015 Plan [Member]" } } }, "auth_ref": [] }, "pstv_StockBasedCompensation2020EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "StockBasedCompensation2020EquityIncentivePlanMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Stock based compensation 2020 equity incentive plan.", "label": "Stock Based Compensation2020 Equity Incentive Plan [Member]", "terseLabel": "2020 Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Sale and issuance of common stock, net (in shares)", "verboseLabel": "Issue and sale of share", "label": "Sale of common stock, net", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r48", "r49", "r76", "r613", "r684", "r711"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Stock issued during period reverse stock splits, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r7"] }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockSplits", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Stock Splits", "terseLabel": "Common stock, reverse stock split, fractional shares issued", "documentation": "Number of shares issued during the period as a result of a stock split." } } }, "auth_ref": ["r7", "r48", "r49", "r76"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Sale and issuance of common stock, net", "verboseLabel": "Issue and sale of stock, net", "label": "Stockholders' equity requirement", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r48", "r49", "r76", "r618", "r684", "r711", "r787"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Redemption of Series F preferred stock (in shares)", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r7"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Redemption of Series F preferred stock", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock

bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": { "r7" } }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Authorized, Amount", "terseLabel": "Authorized amount of repurchase of stock", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": { "r855" } }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Amount", "terseLabel": "Remained authorized amount for repurchase", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Number of stock repurchased", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": { "r7", "r48", "r49", "r76", "r616", "r684", "r713" } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Stockholders' deficit", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r49", "r52", "r53", "r69", "r648", "r664", "r685", "r686", "r771", "r788", "r817", "r836", "r910", "r961" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficit"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Deficit", "label": "Stockholders Equity Note Disclosure [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r73", "r156", "r340", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r357", "r466", "r687", "r688", "r715" } }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock split conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": { "r77" } }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": { "r77" } }, "pstv_SubscriptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "SubscriptionAgreementMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subscription and Investment Representation Agreement", "label": "Subscription Agreement [Member]", "documentation": "Subscription Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": { "r505", "r531" } }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r505", "r531" } }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": { "r505", "r531" } }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r505", "r531" } }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r505", "r531" } }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": { "r530", "r532" } }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flows information:" } } }, "auth_ref": [] }, "pstv_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "TermLoanMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Second amendment to the amended and restated loan and security agreement.", "label": "Term Loan [Member]", "terseLabel": "Term Loan [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": { "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r338", "r353", "r465", "r495", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r587", "r758", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r772", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r832", "r833", "r834", "r835", "r894", "r897", "r898", "r899", "r906", "r909" } }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r24" } }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r24" } }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock (at cost, 258,425 and 78,559 shares as of June 30, 2024 and December 31, 2023, respectively)", "terseLabel": "Treasury stock (at cost, 258,425 and 78,559 shares as of June 30, 2024 and December 31, 2023, respectively)", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r24", "r25", "r52" } }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"], "lang": { "en-us": { "role": {

```
"label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchase of treasury stock (in Shares)", "negatedLabel": "Purchase of treasury stock (in Shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r7", "r49", "r76" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Treasury Stock, Value, Total", "label": "Treasury Stock, Value", "terseLabel": "Treasury stock", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r24", "r25", "r49", "r52" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Purchase of treasury stock", "negatedLabel": "Purchase of treasury stock", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r7", "r24", "r76" ] }, "pstv_TwentyTwentyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "TwentyTwentyPurchaseAgreementMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Twenty twenty purchase agreement.", "label": "Twenty Twenty Purchase Agreement [Member]", "terseLabel": "2020 Purchase Agreement [Member]" } } }, "auth_ref": [] }, "pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "TwoThousandAndTwentyTwoPurchaseAgreementMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty two purchase agreement.", "label": "Two Thousand and Twenty Two Purchase Agreement [Member]", "terseLabel": "2022 Purchase Agreement [Member]" } } }, "auth_ref": [] }, "pstv_TwoThousandEighteenRightsOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "TwoThousandEighteenRightsOfferingMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitPreferredStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen rights offering.", "label": "Two Thousand Eighteen Rights Offering [Member]", "terseLabel": "2018 Rights Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r120", "r121", "r122", "r123", "r124", "r125", "r165", "r166", "r167", "r169", "r180", "r225", "r226", "r261", "r262", "r263", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r287", "r288", "r294", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r496", "r497", "r509", "r510", "r511", "r519", "r521", "r522", "r523", "r524", "r525", "r566", "r567", "r568", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureUseOfEstimatesAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r447" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "Treasury Bills and Government Agency Bonds [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r725", "r752", "r754", "r758", "r928" ] }, "pstv_UTHSCSALicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "UTHSCSALicenseAgreementMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UTHSCSA License Agreement [Member]", "label": "U T H S C S A License Agreement [Member]", "documentation": "UTHSCSA license agreement member." } } }, "auth_ref": [] }, "pstv_UnpaidOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "UnpaidOfferingCosts", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Unpaid Offering Costs.", "label": "Unpaid Offering Costs", "terseLabel": "Unpaid offering cost" } } }, "auth_ref": [] }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureCOVID19PandemicAndCARESAct" ], "lang": { "en-us": { "role": { "label": "Unusual Or Infrequent Items Disclosure [Text Block]", "terseLabel": "COVID-19 Pandemic and CARES Act", "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r60" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r15", "r16", "r17", "r97", "r98", "r99", "r100" ] }, "pstv_UseOfEstimatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "UseOfEstimatesAbstract", "lang": { "en-us": { "role": { "documentation": "Use of Estimates [Abstract]", "label": "Use Of Estimates [Abstract]" } } }, "auth_ref": [] }, "pstv_UseOfEstimatesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "UseOfEstimatesTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureUseOfEstimates" ], "lang": { "en-us": { "role": { "documentation": "Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.", "label": "Use Of Estimates [Text Block]", "terseLabel": "Use of Estimates" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLineOfCreditFacilityAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureTermLoanObligationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "pstv_WarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "WarrantIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrant issuance costs", "terseLabel": "Warrant issuance costs", "label": "Warrant Issuance Costs", "documentation": "Warrant issuance costs." } } }, "auth_ref": [] }, "pstv_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "WarrantLiability", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Warrant Liability", "documentation": "Warrant Liability" } } }, "auth_ref": [] }, "pstv_WarrantLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "WarrantLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Warrant Liability Current", "documentation": "Warrant liability current." } } }, "auth_ref": [] }, "pstv_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "WarrantLiabilityMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liability [Member]", "documentation": "Warrant liability.", "label": "Warrant Liability [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Outstanding Warrants [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r778", "r779", "r782", "r783", "r784", "r785" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Warrants And Rights Outstanding", "terseLabel": "Warrant liability", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r897", "r898", "r899" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability, Measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r897", "r898", "r899" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfKeyInputsUsedInValuationOfLiabilityClassifiedWarrantsDetails", "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureStockholdersDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant liability, Expected term", "label": "Warrants And Rights Outstanding Term", "terseLabel": "Warrants expected term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r897", "r898", "r899" ] }, "pstv_WarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.plustherapeutics.com/20240630", "localname": "WarrantsPolicyPolicyTextBlock", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationAndNewAccountingStandardsPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants Policy [Policy Text Block]", "documentation": "Warrants Policy." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
```

```
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares of common stock outstanding - diluted", "label": "Weighted Average Number Of Diluted Shares Outstanding", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r184", "r195" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.plustherapeutics.com/20240630/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
"http://www.plustherapeutics.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares of common stock outstanding - basic", "label": "Weighted Average Number Of Shares Outstanding Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r183", "r195" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r16": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r23": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r35": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220-
```

20/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",

"Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r264": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-
10-65-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r268": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",
"Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r269": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-
10-65-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r273": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" },
"r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r278": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r280":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-
20-45-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r283": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r285": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-
65-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r289": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-
40-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r293": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-
50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-
50-9" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r302": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r314": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r322": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1C" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r326": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1E" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r330": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1F" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r335": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r336": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1I" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r340": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r344": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-16" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r352": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-18" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r359": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-12" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r366": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r373": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r376": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-
50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r386": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/718/tableOfContent" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r388": { "role",
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r390":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
```

{ "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",

```
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r459": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r463": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r464": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r465": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r469": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r470": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r471": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r477": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r478": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-
10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-
65-13" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-
45-20" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r502": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r505": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r508": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-
65-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r512": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r513": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-
20-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
```

"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r596": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-
65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-
40-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r604": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r608": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r609": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r610": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r611": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r618": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r621": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-
50-7" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r625": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-
50-7" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r633": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r634": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r635": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-
50-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r698": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r765": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r771": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r773":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r780": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r787": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-
F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T",
"Number": "232", "Section": "405" }, "r795": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r796": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-
50-4" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r800": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r801": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)",
"Publisher": "SEC" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph":
"b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-
K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r805": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)",
"Publisher": "SEC" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph":
"c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)",
"Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-
45-28" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r815": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r816": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r817": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r818": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r821": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r822": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-
50-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r826": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-30" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r830": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r831": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r832": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r833": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r834": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r835": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r836": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r837": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r838": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r839": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r842": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r843": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r844": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r845": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r846": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" },
"r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r849": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r850": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r851": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r852": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r853": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r854": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-
30-50-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r857": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-
10-50-5" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r860": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r861": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r862": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r865": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r866": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r867": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r868": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r869": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r870": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r871": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r872": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r873": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r874": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r875": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r876": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r877": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r878": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r879": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r880": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r881": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r882": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r883": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r885": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r888": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805",
"SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-
50-25-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section":
"30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r891": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2",
```

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",

"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 63 0000950170-24-097091-xbrl.zip 0000950170-24-097091-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-097091-xbrl.zip M4$L#!!0 (`.B##EF1)PLJ0L(!`-?(& 1 <`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{)X)OB MC_%.3##YKT;J!*RE2)G<;,[,*.>TCD"275V>&=L5(.MM8N4<8WR8XA[H"5H,&3D4(K:87D>G&D;R95! <-\#R;$#OXKVNK=,&3%?[_!M(D0HL/6M1[J-B-&;@&0(#G&;&#(F)*,&2M$4A0XZG3.,9D%D>Y!4,,S3 '=O}^(TMV M4, ^LKXQSM/1)6*U49*AX. 'EY(B+;-X8R-])-(KQ>>CFVG7S3>CP\-R MG(=8;PU#ED&0&$:9;RPDM03&:U.2$=!8+R<(9BQ1!9'38PT.#$P&I-A.7W@ MR]Q+BO8<.:X(381:Q8 /B3D8@(TW(>\NL MJLRH4YZ8#_US%5,$40N[XY`.V]V,+D@8LM<,1&#]"E2)(T'1B$. ^E:@PA5 M-GGOL##W&?(R5UEQI8GR!(F8% +#)Y)7H-. ^DATADB\/DA-R,&_U I]?O MP,B,CS^.QK'Y=/=H4(Z!968(>R?;0W)^/LI;86RP2$8# IHT@7>J!#\2@Z5* M/$5R9CY' +I?%##+\A"D]M<7]$61M1,," <8V-;N_O@ [O0D0"X71&,V:@E[? M8&PNY/.97[$25+ 8-1"/&-#DW!#0ZO*T.XB/QU1F=K1MKT0 =:19 CM"2'XG M<(WSFB,OB=/*.X>-,FTEL+5E2D26.-8B{JD0\)L&8VRE-BAQ+Z4U420=VEX) M:TSRD7G$O,H6%<32!F-0E(91)W5(V"]U)5Z=2>-5(+2B_5OO\'8;-N\#B\ MO&@"ET?K/]'V>!S_F'Y]W5<3}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`\-H34Y? 2S.FZ(D2VHDH M;6T)11T56=##1W>AN(M M4BA9CT&G(&XM1SS32N/(D?.4)"<'L;2SB+,K .%6^\A+!&'O?AQ%/XYA+U9+ MAREM>3H62\-M $;CE@'S^8 LY@K9Q&@BGMJH.@N3;^,8 P&ZXO@/6_T9QSE"-MO@RG^-X1@IL";,_.0V\QNF2!,XU6'A&! ^*4>N2PB,B%X#P1CA"ZZO"ZY8W9 M9[JO9UD("\C{LYYQ!VCR.5L@2G1V,,ES\Q MFN"4&;*KK.*I+:)5 8!M6@F)2=1$H*29SZ?H?/;508]A! <9">MN56FSZH)7R#!S:%%!0^3@"RTGO>,E,]#10 MZK0TJQZI?[Q>>VN0%QH<4><"TIQ [\Q@+I@+5G?VD$@7]')_M_1, MP/!!@A6]2XYK)**)8,FB 5\CQ[T-L80*XF)W3X@P*44]%2#P)13MWB+&K6Y,=L/2.184=]0A;"I:>&8V<$!PIS%SDA%N0 MO*Z2\VUTXPS+JLDY&)<*#A*05#.?9GRR7,U.W"2B[%.FL,<"(8H^3)UU(^VL#CB;%N7HSP];Z_CQ2 M?QZI60)=+E^O%1J0AP)77V&$JO,E=Z \T;(U/0 30P M%XA+C)&.T#L6WM. B21FU8'R4QSNINWEN'CCP8BQ!#UBF@N4Y?1'<${J3%U(H MI@E> ^83H)S1^WYH,,1"2A UR*M>NP-PA[2A#2B!((&-SG$TCHA#25@$X3/SP?6,RW](Q+-XAG[Z5: M&?K4:#S,Y]GXW. W6R&@'7,H:6-PHZ6!+Z?EL4MW[OV[(>5Z6; M7N5\APUQ;S1M_*GZ4!Z6GL6AK'Z_7BQZ,E!GD*C3$Q?E8WTK$1)A#+G+8@ M+5RP?,XR(2V80][02+' W'2OC&M_]QS(>6@(C<)6V09)^"D:G"!=$@HT) P MCQZ; {E[AL>J7<[7H)P4MK$R1]YA'"%FGNY!*+,B\'LE1QW-CQ["S ^W5=] MOVP@_H]'6T=[+W5-:@=(^23W1TV/=^>;TFBQ:8/(Y&2QAL,%=KSI7T2*N$ M$;:2*.48Z,VE.[[+-2ZM,;-W5 OA4-+Y"($1'MDH#?)4'"*6LU;C/HN\Z/H@4 MG&6L 1KD[$6:JP,%*)!/DHL@C0ZZLR1\^@RJB[5\'OW*JXAU8@HD3_A=OD>/Y1N'V@F$Y(,JTN, ,JOS+?"$Y.NO\J7C0:HH MJ;%JU? <]"&'BVQSM;A-414ZI MMLR!CYZ1E<<,.1D)"H08XUBNI=DY)^<\'$= +A'V7OXIQV#2!9\!WOSESZ.Y, M?3%LL)"+_>9!J0%:#.U$1:./BB.'/0-FB1(Y+352FE #L+A{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}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{CL7G.I:J81,'9F[]:SN M7H[BW8^CZ,Q9ITM=]7.Y8;,PW)-LIHK!P$34<]0992 M@Y1V6 M/<%KYJC1/QH._=YL"UD9K?9-JU1%Z40&H3S?H$2-0DZE'/\ FP*& M1E#161"Z;G+2[[AU=|>-.{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{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|8^YN!33 %,1A-*NQUX>_YZXM/.57-O1EP.\S;%)N(;P'BGX'6*9C>$0O]Z#?KM-FCQWL0D ME40X28MX3 I98QV*T2H>*,&@K5KS8"H83G/H<)50"W]=7/G?$O!,RY!B;V?K MX^YV QQZ3-$JIAB? YC+QV8JW5AF MC EBG"G1!XR>(NK">OHK>9)&N$ 6M X_<1D19/KHJHD,NJH2|C#APJA5C MOAU1V(G[^7XS.QSG8JJMBL.-D[^*D)_?-G-YG5GZ_.[+WO,;W9?%ML?WVRT M!L@[M=MC[ALB>?/#^G%#SV*4BNJ$CH6MB_HH^!PP%(1R6)3CNO 'C6]_93BQ M\YKD'KO,*QUXOF%N-^JLN\QM;'W8]DLXGF4{HSF]\E!RI@6,/#=' WL\FHRA M^Q\QO)Z^BF"\ 52;/>!S7LM1'3?K>&0K.XYGZ=OT_2*_'P90S=_^K:S+Z2&U MS?GSLT;0*IPL3O,Z+C>D_-?7+UY=\3W=(/J:KP79(*>/__)7)T?S"S9)$OH MI>3X#A-%KHKVS\WF)\H? 7$+8\^]O"H%X.YBUFK+$LO-6;C)5>99762-N?9"2 M Q(3#";7(@K*+),1^ HC32U!,RVAWY4@==KL\?0Y$F]&4V&X^KXS2C$BYYP MG5L<5:-ON9\+(;MF\HT#DI_;G!R!!^(M,-1]%/95 O4V#NQWH/L;C).P&'A M0:Q@ELI)ER{#'1*3'CBY+O Y,"P.*ACD2)*YH5"VCD* H@1,MB$3:.+VF> M_;$]2^KU#:.^WYHU<13&6,_VE2AAV!T[MJE)P-_4JL&%7%*%-^M7?SW MI"KK4/I,\457^E) OPL%Q5W,]UJWP[+_VG^_KG7@IV87*N,O;VQL[&[4;P[M/!J,CG/:_#-AYK-ZN?@XVKB4?2]3C<]4'SYKF>@G=_/DVH,!MV7S2YSCCF)& MRXVB6D1$9+ [:BTF;B^8"'$PLR-[+" >@&C. M6XPH3Z7[,UW!=*K$Q1Z (%<%%8&P9&1#"/./4562EA[MXKBDS@IN6O*_91!Y [!^JO9&W]O(]KEJ0;:^[.YM?UQUVDAE'(A&U0MPJ ME^L]:T0T!:HX0FC@K=*F<9P^59^KT3=P+!MK8F;ARJ_+5RAX<<M8\3(PS.J8 M95 7$4LMD"0X{R4G@ZPC!CE&M? >61AE:VD";L>OG43VV@_^O/&HBE'WOVFX9KL\]^,V2Z1X*C)&09 D8%Y'MDQ/($J<08Z.Y MRTE:\AJJGS*ZW0+]W9)%>OA2*J8>%0;?9XP_WP(BWX/>S :L!;.(*>,13Q%\ M3ZP(8&A'DDG<128?2N\/(U#!GP]&PV7DMMUW/:D0* ^T3]XYHU1.TZ[^]S]K M2M3KNAC'03S*U)ME6;[,FRJ#24[#*2R(,7!'N/#I\8)_ T\%$P*=AKMU<:K(< ME!]XFA46JQB*HTE53W)ZV'AO(MFOW6M+*-;9T> M=?KI9@>^7]$;5O3C+!>Y8=+XPQ_DRJ8%V!GH%CXY-49W#%0M414]LYYB.V\ M)3EO%15%1B9M'0=G).=S,NZ1T5KFR_\4#REY:QY\G'$&0HX)=8WMXCO;77,4?O@K>J94IWJU/9H_GEW[V\]9-)}T'8@Q)@A3PU%G.<;KTY+G0A(SMK_4N3L1]_(^V#O8?RZJ*. M(OU$?BX.,-T<'@V%'0S@RWRH/7NF_YB4V2\!%=]3%60/H\\0U93F+='K8>N:@ M-M+OBU:'DL<'=GQ^[-_MV5$V!V",AV=S^/EE88>A^(E.Y^B Z>%[]]\P@]R^:0H/ MY5', ^FEN@F@&T0S2UN/"X"+8XWIC\9QQNY%F3Q.+GB*3?W =*-(X<>0$TSP2 MY;0V[>R$OIE4%4QP6K8@&X&Q'=^[SL>#F/2_8KU,=7&?(5U.W0>]NHT:4T^P M#D?Q<=2#U>"/&RI<$=6=51HHL\-R/ ;!%P>@U:K1, .FP?$1 3P=%]L9L%C0? M{(*_M6-,Y'/UY$7[:1^+$]W;(#53.(:S <8;@T!O@UKQB^\5^-?H^/A_"W0\8BQ%0. MFQ(_38I4WL^D^/55HVN^)]_GS6YL<.78YNTR!)^UO6*<\Y;E<&IV"'6(SIV*.M14]BH]_^ZOKV%\4;^KKM+,YXIO^2,__XNJVSN_1]0UZEL_Y/X,+),*"9_DC- M?\M(N'S\%,('!',^-*

*'IA:T'L,VBL;HKBK7Z&8;NFL-,9I@]@CV(-YM@S?UO, MWWDEO0%2X<*NM 2:XXX1H9(@RB&L.+B9E!$ECM9!<\N1U>T7UJC? U?NCZOB2 MG8&F48/Q_*Q1JY\$ &ZO%JPVSO6LE;S)E3$VS^0 =\LV9O8YF(;BGVUM#B]TE=#F-=GRT_WWA2:%Q- M6LR/N-TM$BME1I^%_NB"_7C&RO(93^7!RN#=Y2&QW@K,KR%QF#, R,A&G7?' MJ4%:LH0<4],(Z(-NJ^;TG!+_WA#BS90.EUF#9 =UV^: W\<<=/@D8ZNAT*[> M*?:P#85T3>0^'RVZ=+^A3)=M S>;O^!3#4?-WNVDCDTKF.7TA]!+BOR/JN9= M@^/\|N\EO#IO)PQAV*,,2K^5=1/P'IJA;\XW>9_K?:23{$=!EN%NLB%/9]LC_%XSLCMOR M|[$0"H.-H-$AR9Q /,*9C/$$18VC440:1QY)8=W,3\@KTKYA6#)?=V8/OW-[_MUW)- A'^KV??=FNQ/)[_O&PY)D'@)^91++]O4E_:LQ MGQ$F12*14=B!ZZ_!897!(ZT$3RV(+O0%D1::..<<8"++P"40Z<60IX8A9IC@6 MW GK+DF);,XJ- $<5=@]L%>M/DW%CX,#2O2@FPW+:_9>O=?/M"]"!OCP$.?_U MQ?;']V>5P"!RB,)HC&9-7OPF7FHC7S+&YD(XG^832N%'I'G.E75T\Y>RGIS?] MO"3%Z'0UKMQ[7\7[[>][\44GX.E-EX;=]Y*;2R<7RF_3XW4S?]&T=U#4@OY[,?Q\HE-44_^5,@EX_I;F401*MCA1YYBG3GXX8P?3{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{!C]M3E6/CZ(Q1SY%.40,,Q1 MAC$Q%_>QBN6P3JAR7L'=?;?IP_)8:QEX6M"PLO#3&\;*9T\BAY=\FC[W[X SO<_MCPM]\,4^-LYC*F.+ (N\EY(4!ZH\GXWC5VFS,%V?O M(-:QN+IA$4,%<'2F\WT@=#**Q?C,THTF0\@:4]BE5SR @HM'%SIX?VN'"Q*#/Z M+E,)E 82 Y,YN)TOCV!,Y[\IAT"F2S[_7@X&YS^K#T.3P87Q?;_L0W_9A[2Y$*L099 MCA>:'HVR6)7VPACB-SN87#+>@^.CS#Q9JB_T-;##2Y9OOXIU#;2ZY*M96N E ME #= [/SROLPV=3MH9!SH0J -L.1D>S*4#?4UTPVSG,;\IBU'\H MUF8@4?8(2'549>[=>%3+|^10?)G8!'F-:O7!>X&FSF8A/BR^%Z.#W(MS@$(-MSK@)!+P\(P5-H<[,T*? *+S1LKZVOX,]HJ:V/@O 56G%]X_3B, M%?!SO[8!A@HL7DTELND0!.EU\ZKFX[A?^GS2=@!#F-T,T3P)T\Q-"PN:95K(M/(O)Q' Q $";0?69G$-,CE\67C=T- ZCT#$XMIKL%UL+[YU=4? %NDA| &OT! MZLJ7PVRH8:C^>"H:H"FG+\XOJ:P_]YD3Q%IF2 MP@K/UG"O"> 7\P#3"_F9(-P$H)6L(ZP'@SY!D? MYP>N&OD<&$$K^#]5 V NX):#[#=-Z7_:WU6]-,TR*)@M9OWZ#- O9\ W^!+5: M7]-%)LI,Z\V^A6Z_6; *,A"S+EZ@1'Z=BWF^LV6.84Z_H_D0,HX:%]F0%X>C M>@SMAQ&$:W'M+YU&"7_Y"UVX&9J$V63)*Z*%Y,_0P]EISZUL'GQ^X=P.-(LU M5? LGY\Y^7&+G\]*6)-0D:1W\P!(V4OYRRWO;>?OC MUR!\AT=Q?$ZY^}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}SJ?=P;2PI0>-P=&0^_ZAB!]G+9YVN]G!RZ+)%3(N">3*AG%ERUY2WCZ:JY{/,,YBN_F+ M@(J99:.>_+V873A70S,QVQH.)XV6.C^__VB42W[S<NC[H<@]_L&V']7<(E^,0?LHJ_2PKY0C;E)<6I?^4K5Y.^6K*1XOX]!:< M-+6'TS=E5?3- 5N5H4L_C$@LO?'F)OGDYM4;@"XZ^YUV4J7=BLS35XP9^W0YX M3ONI3J\DO.:,;RJ[>M_*\-CPKF57,7L+4L.6^S^'PVPYL:F(?9_#:W!97<{OV MM=E>4.S9\DVG"=;?-YA@- @30/P'"8:RO3FW=S*%\.=<\=3WR94/31E,.[/=Z MBC). &H5&R@U(^11XTMFOPK&;JGG5O5,A&H^]P7$^G+!>L-,ROU9W.%Q8>!4 MPR\Z''G2,^A3V5".IO2)T?F?M3X<@8V=Q3&R1 "T:_RG3/+#6?@ K$TIE4V<(=CR93Q\^&VTKD$]0 &!P\ MS]QA-X]_9W=QTNC-/+BL-6" 1P-8F#R:23:T@[+Q36> ^[37:,[9#>UOU-Y?& MTQY>@LKZ,S;> [QFE>]N01GT4[9_P&7QO3X(HV4S?+B92_#09#]9&J4$E)5"B M;P:JLYU' &'X^!5X!QP#N.KYG/F<+@E4L_]6W4 *&<WF78=']JBP{(TITT](N++) MM^,>F1_[%+E.I,BQ/D7NN:3(3:=8E'"%3(5?W_7H2QKY=C=]EI-!=7U-ZHWB_ M_7'KXYN'*-Z6![:]}>'2LL7+AZ0+|)M5^CJEWZDUZP,Y9A7E -_D(Q+9?X'? MZM&@"7B$XGTS\ Y1- ;O$ITES=R?JTZGWMN7NPY?=(M?FWOK\[LO>]IO=E\#M M;QZ$?%H>X3V0T(.SBANA\PLU.ZG#]MOM_;@C]^W/H!B?U?L_N7=N_ND..]6IOA5R_+3EX};7]YN MPX+\O+9+T#CFHTEMF\3&F1]7'S11S,Q#:JLB9Z@V7K@]OTS-2:'Y#&93;H[? MV=/UB_-'C'/F]S1>O3E__1+#P].W2;EA#/O7&3Z^1 '9D/2ZKZ_[MCFYHS? #1?]9.X7?'J#X)}$^C^,1OHPK,H(OYB#G*9;B M/C#KJ#7ZOY-A+!ANMD#Y_;CAFD6:RAMF*\|QO3BLASA*NEZ6O-;P> MHIQ\JU63N36W;3690VM9.N? 6.N=2GE[FS!L/O0MU6=9ANCT7/TNR M/JOIWMW:W=W-7&%K=V7!DOFYPL;(;?;Z86T$9LWT0_%:TK69S7=^_MTMS1IH M9ZIDXJM*Z- Y@}A;WYYI.%GO%RZR4V995S&=)IP=RX)><9_K-#LYEC%S*@K=9 MK>>A;B[I]$=!3P#,,,:1PE MLCAJ8J3!B?D7Q= ->PH G-=JW]F@SB]W6,.1_WIW*W-,XC:VJXW*X_[><'O"B MR-6BFK=\>?IE]RD.8-2 #],)>%"'Z\M .ZE]?(/AKFNKXZXORQA:#E$B=34 MOLTM7OS&7QI"?WEU=&G_K3*[MR?(O>;J-=?ST%S<<*, <34B(*!#'/B#K-&_Y M!D$5,)%/ED[V0!531 ((2AP*.#G&]'C!0*4:=2BMH3T'"%/];GT2R'XFFNN^T=[M>AQ\EVL{AM]B/3Z?*]W;C^I*9GFS^P]FKTO]UW[2[CLG>/8E]\^Q77A52#A6MLP9P7T)*$PE0$7OD M)!?(B62==$9'+]N BHVP3E/19GOV+0%%P\7R8.+]4RR?AUCT.K#7@<]?!_*$ MK0I6(^L]Z$#"P5V6,2 %T%5*)KBRNHTTHZ})T('E)->ZU8+?"KK0-8$Y7$9CO MC7(1T!Z8KV'+NZ[QCJF'(U!$L4(II*%),&)6.U5RAQ2X@5?@&CY!<5'T2[M',6O4S W\!4G(B^^@VN<.8.]ZL_OST/]!GXW9Z+GRM9GJ5TEQ{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{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s: M{GCD_SP8#4*LZB;M3KTN0DRE+|>;O;)8&^E9,V?1<_&:DO593;>O3_PIH)O)S M-3_!46=C^,+XESDQEKK%SR/SU>&(A3\>1!-WG.M_A/-MIM= @<^V^E3MCNTAXK_9P21^CM7N@:WBV=U_^#6WAU;UI[1U&%N@_]O18&"K M>M;Z-"@^^/[JZ88)8\F>8.PYCFL+21RRMI\TP% A.GPH7LJOMD,3S*%/$& MQN22O(8K$AU:XIVI=CBR5?$MS^5U\2B\Z;EF.)G_G[UW?VXJ21+]_Q4%=^;> M[@@E6^\'?6/JXE!%FE){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|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{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{PO2'*SP]:0@X'D7BM5 M91>9XKMK'G(+DWNS7(?Y9+EU/(_\%ODM\ENWRQ.7F'5!#2)S_6?G)47;6M4E-O*9RG<)ZP2%CLLHHD?JR^V/@%ZS4&A4!!= M%!!T1%/0)&-2%YGA76%13J6B7#**E@HF+Q,4NN8@J*:&,!I?;- N5+21_#<>& | M5/HESXS?*B2X2?9W5UAT4VT)BSVK#!YOOO?79=-,RFIY=);S72XHUTMG3 YH M:78+Y? _I;#)V6_K&59+"5W=3BJX>*WN(.ELPQF?$DHIP6X'K?*SQ9I>Q20 M 95_?9S5U?NNC[-8ZC+>+.K)RO;LX?B8D$A(0B=WE-E@L@F<-0GL/JG@&(44% M-B@CF5,\IJU[\6Z5\]T=$OE4^6$U3{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{}I9EH^<652+M]_(O5;Z]QJQ*IXN#K_LO? U\7K2+.>S/#D3U4%8 MX@W%__W1'[P+VL_&MX{6)59]F$%7PW CJV>24@,O7%D9(G>QHW3G*0JZ;7$B M=ICEO$+%3IT!D[0S3]{@EU!)JK]DR0!1M5(Z0+,>*S63!F\3 2*Y3]L:*DKM) MT^X*M7R7MV82.WNU<',8$FP)/+8U;M4%.V1J[?&@I"@+=Z>,N5VZ[RL'E\ MG"I4"(X$QUU6N;"2BU02(O<.E! *HI-1P=H7'8]5W$ M1F+CO@/'$@*/F4%4IQ8J9@?.%@/928M*>./T5]{C)FGEG0>.?HTTU M4Y'V#6SO.:XG\V5#+5)WY@#%?=%:8UZ>Q#G>I0N\GC'^96>^\/*)(&]XO0.3 M/.L<>8 HL@=EHX-8/=WNKG MAL'@RW+RWR[YODS/KIN<_T[.?4]3M0-NC\1+555HG_G;/7'OVB,?UB*)ADMZ M/4I!TW/<;BDV#1<_O8H!7WXP[UYK=#AKU%NL;A_B76VWH453F:+TZ5R70$_M(' 0.&BXI-? C%30-]Q"'2XI-PR5@CU+0AS_&-O%4E'.*=7$NX4E8+6:+M\U+7+UN[?SOK5%_71)0'V) ^O0YK,%Z4AT>X MJD)]O)S/PZK9O.2\8{!]63 <@KELOP.ZK'1[@ZZU-43$6D9(N8O3'){Q%[R% M5%P!1B#I%0 'YC$XB7?%*7>_C1'\'BIAW5-'ITE('02.N_P#(!A0; -,BK1-M7L>');=W:7@HD:7@"U,UKNSB#,#=HY/?YQ1T4M Y3"D3.???K=V+E#U*,-A6 M[MO2KKJ-!UN"5E@? 6;YUX=M-*O?W0HI,,@E98W<=-),_2;H\X)IWC11H%3C%=@S CH.+(@O IUE5^=B9L M[2O=)#FZ3X[IJ>)*G?9N&HDFD[AV('%.R2,15WG*?H:4&%PH+(4$&HX!8[Y M$",S@;-.,17[# <<4UU,AQKZ]K&7W56Y]%8>8^]AZT@=;3#33,FROD M%:!B%E3QU;N4;$$KEIWSVMG=U+L^/K7N<#%V6\Y*BH^('82.^^,G4(5E[6(M$"TB*.40HN$>! H;LD-,?"<5KW? #3JIY'815$3P)GGV I_4E, ^\R9(\>5 TT MP46M(3C-HI*<;[5U^4 7-;]W 4.1ZTH!RJE(F=^P\|HT\1?03I6+NUCS4$ MS;(S[&&E25YA5L52EU4O>Z&G53W2G6O=UWW2EGF(3@LVJ.\G5_AR2EA@P?G MVTL9I4K@T,HVSVNE+I*A$CNL?/WD7K:V*F^Y2\G9U"HQ}4(-RLE0M061C$CV M#9)YX54H(8*PA8,JA4&{J,&H$$2RWMJR1,(.BU]W1#(J?QV KA)ABS=SDF6 M7/:V* 8UCJKK]N -(_@=7%EJ$C#G+KHNP.RU]W1#((U5),E2"244A&PAT% MR KW,2+S4(K3H! (KX+E4D*UT;0Y2ZNTZ_@X+8'<6DE$)[)=YR_K?$.>X>=B+ MZ^T^?[:L'WWEIUUWT++L>VP_@]L*G'_#PK1&;#@;[&G'R,*7E4?WDVCVWJ]_ER M75^X7D{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{3NQY)%=_G5T,\JKG['V[[PE0]^7>E<>K MO0^2NSU_I+[//]ZT^K[>M_,8^]>;URN*XLR^KD/]HY(;:@0R=ACM 'W' .OSE)_R?1_7E<37[/],F M+!H<#4K8]/S.YD(,H21"I[F@RRA;(?F9Z3&I,;CU*:<^'TD=D091TOWD. M[]%RL1EJG"-I X4%HY7K>{=[Y&Y{@:!\V/>1-DTW$$.EQ2,ADN1QV#E.K+A MDAH?[%KQ8,). <=T@XZVC1 MGJ!M3{)/SK2]'Y/3106^7&'!U0I;K5BF_[F9+5XQ<:>*RF1/INY.-F7&J%?' M1%<4[!",?W2O_/5!F0QM!HB&{K!DJ*&O,W)ZN/D-5D1^1U:9-=0+,PRS!9$ M3U+SOLFUT^1_2B=')_-PC0N@^CPEI.]DZM3]9H!HX$\#=D*V0JY M43J]1N9#KN9 S6<@PR7K(>=#UD/60[ZG!^1$RYRQVDH*Q[,;GS@A8R%C&9.Q M9"RS-"//0L9"QO\=8_GID[7^,;NTT_DM7LIF8GU3HDZ=KE.9=^S0MS7V?G M3FSS&NKWK0G]>YB'1<))6$\>8*CB*N)Y-.)8$\)3 .-^*#%\K/O^A+>W8Z[MUY%VOS*TM]"!3>&? ^*$Y&:^X#\R^_T)2)2,>G[@'/+2.-+FS.[HO5>2+TWH+ MQ?Z_LP]5G(NGJY#:CDR36?[;O:>_)Y%"T,*#\M:"PN+ &6?!LH@:@_!R7N3 MS;M\6+_ "\K=[CWX7T2L?*

*10847(;RVH#C3$.Q1O >/7]Z;U*6 MJZ.P_MN]V8?U@\7)$>3E&C[]R;U_YU.O:VCU]:C^G93[@#"]@X4^12"DVGU0 M;8I AFO$.\;6>(4YDI@K*(S(38036 ,) MG %5.(<8$X*QV5@TP@>[AYA+3(5B4^8I[AJKN-S^L-3$IABAR$#.W.4S;@8\2Z\HA< M!N,|>G%QO9&\-R6[#*$RK]C6,@4-FZH\IBUK]K3>4%9.C7"TZB"53B)G,>MGS)G$+1Z<]HC?"V3?E#H^^J'9XU7;W;.I7^/J_2SA2US--MEOD5IN7;Q>9=_AGF)]A1N0Y7;.S%.L1#DF]_Y4OAS:C$3>9,X]/WYS6J1J[9-EJ6M0SY:MF^X3/SG2SPNW=5#$Q]#MN=4O1$5104*I'M MCEK< QX.:,3*)NW? BIF)D071. M0]9%1VY$*JQ;VE[8-^5&C3UK>-C^ BI(~&/E2/#{2<9,Y#UN^9,ZC M$C>9\[#E2^8*&G&3.5,"%3B)(5!.<8T]W:S:NMDV^^E DRA1*,,LK!UY=V1\Z/O@4A0(_GV5[X4HXQ*W&3.%*/<[M280%&L!1<69 M@E+60^2)@Y,YHQ&%U>>Z**NF&*7?M=\4I[EJGU8-PR)MZJ-?5P6M7^/II+ZJ MX&J%[>"K$H],DPB?5^'39\UDY @Z"@;*.0,>703%O-(Z>I>DNXA/QI27P6F0 M6=UCTS?U1[QV+E)Y2TDS)Y$]K20(TTF329-/CAQ4Y4X MN>)A:30!C&R7;)=LE\3==>W&3.0};OF3.HQ(WF?.PY4OF/"IQDSD/6]YDSJ,2 M-YDS[9[?9O<|\N:CR @^10X]& LQQ@0Y2BV1^6!UN+A[;J5+&*V!+-OB(ZX| M>(.RK4#BQ::XGLR73=.9ML0Z?;@Z_^KMN"?-.;V841=H,Q7L!R@=<&3IH 4D17K,UT?'J<954|=VV*ZXKSS^6AF^)?>?"PTI*LFC]@JM[J*I/(&Y5V"FIO,WL]&_A_FFYWQ83_X15NG=1/+11# A=Z1K-MXKYHE2TO3^(@'^S?_8DVQ5B(.0$R=*\"""GN"C0XA.5O1QCU%N7?AA M2C(%30%IVMOM5\TW[^Q]KDY_97Z,8Z\ MQ8%!\R|$QS["<:R)SF$B@^R&@HIK!14:59#1*C"|:% L&G!<)8@E8]$V:!?B MUH*O)!?01) 1#2C#<@U$) .M4*BZ<%0E;U^#TWU0,?5:4&!!&R(4775%TU77ZY\)!*M3T5PI(W+I9^_L M634U1M$>C^/)\"1X_J"~\)/O,0V$UHO.()DDP&E'<>8E$"9!)*V^PT$UKL10]A1 MI0X^@G^|0+102#<B9NM8L:37N[1'=PON;!!\NGWK,Q4GJTI{(UX3K7L6Z MTJ?HC R5A26!XH5!C%E!LAY9#L&PM+4#K+-B2CH#UJ34[AT""%)$2*[PF+S4 MT6Y7%.YL)V-J+&T"TWT\NRO2>X49CXXW-K,LD]>XFM4O\G127U=PM<)V^%6W M1W:WTT%?9W;P0,#5VMCB,TB;,Q ?EU::W^XQ'F%ZM'83[_^N*TUY]*=_I[Y.SN8;.A\'9L M18P$R5ZO5>@*UY$,C329Q-T[<8_O"!*YXF%K-_&,;)=LEVR?Q-U[<9,Y#UN^ M9,ZC$C>9\[#E2^8*&G&3.0};OF3.HQ(WF?.PY4OF/"IQDSD/6]YDSJ,2-YGS ML.5+YKSK ERZN*%}G[.BP#"?A/RODV9J5'_M4A4I"X:?^Z#^,EVR7;)4TF M329QJUS<5 9*KGA8&DT ([LEV]V1[=*1TZL!9@L;+$12A0>E)<60N$%3%)1 MYF*EMUM]5Z+UAJLBH;"H027OP%NC`V1V3JGA<>S(Z?'S?K}@\^9GH?G89X7 MY=`RZ&BYV)Q%O^7N4VPCZJI"[*2XA^*>P8B;S'G8\B5S M'I6XR9R+5\RYxU/(E=CR)7.FIK?|[+E]-M'>;8MKM-F[V7R:,,%[72R0*Z]5]0N/LP./+T9+MDN:,>&FDRB;MWXJ;G6W+\% MP])H AC9+MGNCFSWP"_0RCH$*U4)^/F@L$ 05L$:Y#EHI.1/M^F+O:KJUB> M-PU/G9/"7[FUB4;2_4VN'5L.3S!Q^!D7P'SC0?B9Y!S+#IGVSS_P)!Z&*#BV9KP2%TX%IR,)H54$)1 MB*FN68006A=5M!7B3A<<4RDL+3H(:R3? OLJ7HI11B9O,F:*4VT0IPCN[V=1) MDGM0Q=@:<:0 6;M@4A1<17\Q2E'.<)]!N93KI$-KU%*R:*&-S%ZGTPR1=]U ME.+&'J507^:,U8BW^XL00X.YK1,_QD436O49F? 8+DBH>ET00PLEVR7;)=$G?OQ4WF/&SYDCF/2MQDSL.6-J1-YCQL^9{YCTK<9,Y40;$0P3F>P*+5D6MCLE==5 9_MOF^H>;-\F//L!]FBVE&6GRT>A>/9.LPW]0Z;AK7+V? M)3PMUGF%:?EVL7F73=U.5^4Z.F!W%O7.7HB')%|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{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f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|"9UKI 4.VF>X@2HG(! M6"B>V\REE7QKHYXG6937=9#"@N)&@'?. =/><&.ESM\X*=_F93 _/EG-%F]? MXFJVS*=&4GE"6DD7UIDD;C)G$F^ M9,[C$S>9\[#E2^8*G&3.0};OF3.HQ(WF3.E V^3#D143C G@+',017)VS9R M[9X'"R4DKW,L%]..!3DD>#*0M,I07Y_ 8[,@$@_H? {[9:TH'WJ"T]TK-[*0 MC8Y" WFMC#Z&!=-.-5G9-ISV Z1XA^JZ*!@AVQWU.(>\-!(DTG9[#E2^8*G&3.0];OF3.HQ(WF?.PY4OF/"IQ MDSE3O6S23)#\A;,;]\-] M:78TU(%3"8- :'IN^^5\GS?]H?I7FS?)ASK/V.X3YRS#+SQ:/PO%L'>:,_M$\;,AK7+V?)3PMU'F%:?EVL7F73O3%.L1# MDF]_Y4OAS:C$3>9,X9&%9=5%.3.'- MH=@+-6F^D7D]Q_5DOFR:'749^VX)\UR/LMC;,I_V?![XH%[%'!=,6?CN(5I M,,49Q AB!#&"+(8LABSF[I?"AYWJH-""0$F@)% 2(X@1Q AB! 53A W"!F&C M'TK3$Y4@;! V"!N'HS0]40G" M!F&#L'$X2A

*NH1#6ZY¥M06S1:7.!/:9J\2T;J3V8@I&O;]H,3\KJP)=%=],<+HHM)@J MX[4/=W]OXPUK!RE4*L]W"*>NYZX]2_]"]_<,9,/W N4"B*ZC4UE,%.4LLBG) MK¥XIB,1,DL4588P!4Q#O\@!A1NG4=QEO)\%YZOWT'Q MFRZ,=SPC1:CYWXOYV3N 9PGKN?N<,K0)A,YV\(M&V>,_]CU\KP=NCR@^^81>=KXN/$Q_Q63GX/F/([>L?0B%+M/T^ +JN8XTC2(MN'//:T%47C N!.?'@<+"E0^92W2*\S(VD<6;I',Q+UL I0]09A >+/8U9+WL$K M7'JKR7_^_]["J-P%4XC>Z *=@63DQ$6D+.82&,$,"P3$8VX#27$R.$N5)I)+4*FX@*? 9U)G+9.;U?-O;]K-_=ON MZ3W{U6=2,,G!)2. ^1G>1{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

*W7S%Y3'NX>RDJEE%7:7H'?^QN$>,,/3.=QCT$:%K49:9W+;R4@=9. Z M2,,'PSG'>6H/\?:?=B*ZT+<> MP,VA')RQ">7Z]<\X.$WM0XZQ]_J?*YSFNGTC+*0 0+8>LTK0D)C!7-/PGATV M(%*%/R_!15UVU+X_SH97,GW17>FF2[OVI 6LKRR'8WQFZW&T-%X1SH4/>88(MS3VTFY2XL.U,0R*V[8:N#I/"16MC2DF]5&MD2Q,>X!JK:LG=S-D-_/C)%@?: MU1ZOTI W=IH<(E&29F%J<$9S#+8JS*@2.6,F,*G.,^D+.6H,%I'<<(C)A42 M-W")XT2SC,6)K[G@*@K'HZB_VE.]LQ^1#%/[=FZ3$\29=O?NF0B[9W8-=SZT MG3KH%)5- DKY%M6IW>SR;YK(7=3L(NG.5:C=>?DF^&;'>6J>RK7FH97&I#J m9]>[XL;1TL0A:..O+NAA' OP[452JTT)FZ.Q'R>&t

*XG05Z>.*70?GUF_ 9*IXKWQ/&]T?@%_KFW8V9=V-98/GV J3CM]_4B2R\H@GB/DBZ M^2#M)D&'VM9D8'^.$&.F^%#KL+P 4R9^SDV$VH>.P.#1:("/[K?!9">Z:LM)*
*M!BMUL9H!B1UZD:Q%0V>?*M2T\F)9),6&-)E(0&B$FHLT!8-)"P.*RH4QE:0X M-WER*S +5P(WWW31*: T4@7"[E#7 @Z3|\@XPU-EH,@33GU<1>6+0O@=+&|< M43AC@*
M(P0.Y44CLT#$K,S&M<,C'(Y$RCIMR\%VHBN;Z& 43)E+LCCZ83'R PQS+@R M"[0D@S(1/17L#@.L@'5<-GUKX;(]{(Q"W9V/\B'95'FDX:_*;4/OBY-3A@E#*
*M630F0SG*A=*)SE=5+;;LOBQX]'X?S]!18%I.&'#, MJT^Y\"4PNH\;@XYP[F'A+?23@EQ'9 M"H:[A1VYZ2W&4\" Z/9%F/N0#]B]HG[1:59&<#)OQ%+>*2/%H*J:28J9$P*K
MH1!K$K&>|'+9L:RU\&+ME!(A5(70+Z8I2)GN$(2ZZO>)\Y_X&KL%G MDXS%X:YTK.!O-MZ[].N/|\4!8,]!'J'(,[C1'>0ZF;*,IX^$>S^HX@9P76G4@,QHKSJ?"J:--2=@@9+0OO3# K!/,N*
*M}1)1^"W#Y1+*AN;WL6A1)1E%)K7=(-O+1X(Q",;\C!3)59?#+]EVDU$8/X#K$K?Z/[KZXP MV-YGTY-@'Z5!KB"$#*@:V.-@@"DW>$)Z4X+:5R^[PL"#-\04FJ![:+SZ +-R
MJ;\PSG6N]9PCW5"O5>OL01QJGJ4R?@M8]Z8G#>U-M.7[Y:7.9&%YK?^A-]<-),;IJ_?`U!;[%)'[YX\]N?7[;[-F0 D!F#+Y
*M(/0!XEU0;"D^(B=XNO4&4K27,/ &9GO?LIB[$QS.8L&C.K"(##U0[&?A)0FR MO_&]81RSF"2I8?W$W9KH1AU2Z':$)]2.\(ML1^A\"&)?H,*AW/V+$":#.NEK MT,5J%+) ^?@K,14?
*9;PM,-ZNPM6$+6W>EL'63A,7>:.(.KHM^U!G@9ZW5]C]GY MP.1HS"\@*Y5G\^&B:.4V)(MX25)&8R[WV"D'=S#*(CUQ_[X^?O-Y4T)-YZZ;'-"%OL,W+":'!UOR!A?>#B'M-V$ .R
O#0L)$R4R#-T+X?!D%K94$Y\@:M&5CI8[!WT$?'JJK"PI%;,>>H(M&:R)^3N^!DTLK'?FA##ZO!AT8HW.4=RNL[W"D<384V.!@<+]6)69:BY(8Z!,_ML,E>JCMG^W3Y{IPG:VU/?
*(1;H3([J1CQB&)?U-_47^\DCS"F#A?F 2/^>PF@FV9^0PGW*_C;,:S/X;F M{]A=!= L,\Y0+A?)8E1'+U&Z8-_4*IQ9<+LP\^?&G /9LY-.:6\0TF8ZO-(-M0FZE-
*R/0(O54P<2Z<1YB>*F+Y:^]W)B6J]9)2%]!M'1'"L#ET.3=FA<2-+VD>N <*K2_NHW2'OB42B0B1NSI&2Q=2R M?&\;-KN!!@F"*<_RA+,)\'2/#@ I^EUQOE-@/F,0RV \;5TR'1
*6L;JNI%#= M?>D$(7@_\K,ZN(.9Y<^<+S,3FJ],' I"U8(:$;,L@^%:H'!9EDLOH3%X&Z M.,BLM>(XXJ!9Q\RR0ZTNQTRQU#EH4+,9X7;%JI{CX#}3^=VS\PRBUU_-$2B=
M:'PLX!+3]1L"C^QT>UN2VC?)!T$)0E/7%QC.0+0M9M$"-$PC;[E@Q!C]PSCR6E_+,,#"PU=V-K6H)IB M4"FKB-'L3*S>>W(XPN_7'F=UA D4FXC;7,+*>*E,,.@6YK$&P_LL?
#RI]2H2X;:I=Q.J ^C1=C0,J?/Q8]$A'LG SK#*M\Z3L^EOK*$6] .,#R]LL(M[Z_>B(LVKY/@#J.(UR%\%(ERDU3,!H11=H8 UYHK)5.@)SD# \XV.,)>2\'D3=#!DV1J;RS;?3?
*2MY+;@%E#O M^L.[\<]M_3G?]J/OXF+I0Q!C5RFLV1"9@!O#U.-0![1J21)HQN1H$V5.A>WB1 %.JO<9FJ,7AQ-\H_S M.D(H\E @*M0.(H+/"_UY>2AJMG963X'M-
*<2#'SQ6):12$>4#D:@3/6S>>?DM M#?QEZ>W%,.V?7]4L--;[=V.49D]9,K82$^;V;Q81"HAT]17]{("0DP{LX MS",BP"&X$/I(,A%A('H&#C?U.TFID /K5_O>$(_9C^D/?8Z84.6&6I M-
*]P%M^$Y+KX6RREEHS(%.LZ'DWBBDHY5=3)RO<*WI>R6Z(B!>J9TQL5,?07W M*(NJK%2=5#J/=.JA -KW'S>?/I77>$3-=D(NF>6M,:)"""HL NQ.&(?U%%A_*.MCBU NL% _Z-
GT)O=G>+;KNSPU_?N&-@A=3}!+QO"%MWLYBBF/,ETFL']0ISN MDGSX"%MW[R5;IK8VV//:CUDN[KU|% @#I]311]$C7X&Z.-D(PZX;+W7#>.%6 MZB(L]=^<3AW/_T8?S2*
*GL!%T:2BH@C55!(YLQ*BB]WZ51PNZ'>(UEAYZ M@}0YN/SX}:O7[T_;+82/8BY2S: 65:J.2K:77(!9"V>!#=7,%QKD.F$ M&$/2X:>38(WII MJ]@V30M]
*(R4J>=8(BO/EV*W$B3>]Z&,0:9,163/D!V;9!%R*]D?W*#5LMH. M&'Q_4N^8^#:"M_C.VUJEL*I0,|-/NO4@^_]O&Y5J^99ZI:E_ [EAM.JB:^? M)[I?!^) , ,')"\. ,8
C]U.%D6@!;7#GA2;=PA%A3/GAMMI4,$3'&HF0*?NI MHYMBUX[/4^H7K*W,;IQF&$&B"FXV#DE764B>!=I;&8;S0NVI-TCAVVKF-5X_^> 3N_3XY=8\LA>X>S)IP"J'@_T(P..6@_ZR
*MRX{,]D=J#!THN4^=(606:1>N!PC13@6=^M!*YHOBX5%/X+70 Y[D'S"<$5*Z M.Z[$^\&/, P_]NL.!BWF@4\S0B%93%2>GN8#&"Z\-M4G9W%$JE=NQ\R(EZ8#
*MK<&?:G[AN1(\%>GFW"3KRJT2^W8#*R[>59?"Y5#8X%-0^,'F_ N,A MSL$("!Z$?\Z?.CVN5~ ^1^X&60F^8BK,4XZ? /VH5Z"R77_T&/P_?U^H2TQNH MVG]TIIZ7-
*\%=OEX<^EJK5FG6:^^D*IUR0ZU2;\Z[/.?;2>6TNNRS]K,K_^Q_MOL^2<5*1EM$),)6'2$2?.0?20G6H_^F2[!|HI$\VR<[8,,,?IE@\XX,.]T9GM64:/I!"^1^P/.LX9UZ
P)YZ;O@8C2VR&I+PI@S^)1?IHU62M^(6?-\^S[7.S 2TZ;SL=6R EU]{CUJ&C=Y#U?'35;AMZXS;4_62&KKG- M:GN;]WP=#+W&K;8<;3EZ_J:WW.;IZ3;ON571EJ$M0Q>+T70;
{3UCZ?'*=2Q M\%[*6ZRN/OKB-NO8M:KB%(J^[,R%1>W1TU8K++,*3K?2PD]+%Y,6C6,K+:QI886%%1:+" MK M6MC\E=60TD^"2GZTZMF*YY<2S_5*'7G.CW,LCEZC@'[I\/LB"
*[*ULKKN'A^O M+BUF[I)ME\"VXL.*#RL^%DC">,&H|\YZ+#QM*LO)CY^5'RVTU5I?$9^6'-3^L M^-@C\=%TFU7KO*^"JL<^%D2BF5V+B
*MJ;'%J));AJ^%:3W4GF1UG3+E7I\2XQ*N/#&W:'KG8&05;M^(.P;<05U.. AZO ME6:F8#'5LQL$N6R[8>^1$*E-$R*/@8N^B@A1%W &98Z6C#LI%1:5)7AC?>)# M4WETEF H<78,2[
*C*OE=\OO*^CUP(VK'_V-A&WV*_^2[:XFL;:W3C!%@XQM[[BJPZ]*JF=)<1'T>6VV8T:MP+&5]WCTU$68!,) MY',_#I&H50M*:AQJPA\/9:\PRR>,Q"?;&*P8=#SOXE()-
*BJ#26Z#W=A(TX/ M.Y/L(?C\ HLQ!C]/?8[+=X((2.,H$]'KA""+^&VL#4L:NZQ-,^6G0;(,$5>^ M^"+;#(\ J-\N,/(U J9OM3Q8&5QZZU7ATNN5X_I\(.^3I8&\6\V[\=]DXVVT]W&
MZ5K"MM/=R>E:PMZ#Z=I&$Q96V7:V>1.L\F<9X[/MGRR36"9YA$EL&RBKG=>] MJKL_.=OT0^4,?UANVZ+R2U#6X8V,6B.3T^V><|MNHSE:,O1)5B'6LNV=K,J
*M>C,WUS+TDQFZX9^^M#8Y#VW@+^0%*FPC: L +L%8'^N1}2H601V*RVLM++2 M8A%!47\!!,Z]EA9{&F&QXT'Q46];=M,6N/"2@LK+1.2%DUK7-@LEM70$C>#
*M6@#3R4IH"ZAN =672XZI6T!U*SZL^+#B8[E4G-/'T_>M^+#A)"L_K/R8W1^E M9MM!6?/#B@\K/I;+6VR?6O$Q.^#TQ'906XU/O;-]'1:$8Y_9R<7L?/*$=E#N M@LU<7*-
OBR^[.91[HA3X[U.1WV7;E+KR@)M5:.V;[-(2RSK9_9ZD]OF_3: MK%:SK/:2K/9HWP_+:>=FNZ+'3GC\{,L3;E7$;8G4$\ &\+X4;H=7+MZ]Z#[(
*M^L_I7[1.XE^"^FN[TZ9G5K:XDDO[TZ/GL950#7] /JLP!?@S$2'H*%/O*3[L_MQ$-\-19FN;\NQ@,PWA$/2_]('6C).4N#**HR-]L>(ZPY 70!3\JOFC8,O MQ1'WYTD\F*J/?7UZ7I
X=UZ8<]/."#3IO9?X=_#X\$68,9G;_)NOY@?SJ@; MWT:PC/!^<.DDY_^=!RFLN>[AR;Q<&2,-/[ASNJ&7IO}X,_1NQ5$4^T(M+VPH M7E:T$XJ'(UX.F!=VG,D'T;D?
*I,/0&YWAU?.AYZ,$,3(5 MXY>#/,,^^^]42I[N)C;I/- %.+T#7C..K]*Y:7,-6+)=UA4;A 7S'43'$$ MMY,%C&+E,;EE^X2MO4]8]57[A#4KU=.E>U?-;4[5/*E7B_^6[X^U_ @:[;DM
*MT#9YUJ_Z?8OM:Y[\+*CXLY#L+.*^90[+'+.<=HNT;Y'V-X$G=WIR%E>VB+)8 M=&?+!98+++]RV0++!5876"ZP7&!U@<6OG6Y$*\@^1^B_I]NGTQO=W(HR' [AD
*MD_HMYN<6EGX]IY1X=3 Q6Y%C;[EY:S;7/>'F/2W8M>R\#>S<M.-[F#;?*V7*SY6:#F_=,.5O\--L%<&-%IH6TW%(2XNN;Z6%E1966EAT?1M= ML>+"B@N+KK^AY&*-
*"RLM=EQ:6'1]FI[FR(EIB=/U9==!6+%M02@M*N90#V'|I M<-%60U):X6&%AQ4>CZ?=O)0[N.?"P\;/K/38>>E1/UU=FH^5'M;TL,)CGX3'MB34]++)3^,F,.?T?
*DO[X';YR#_.5JIG32KQ7_+@V#:(:QA"!:)R^).6.@_BXMIF<,RQTLPA\7% MM+B8ZU[5W9^<18$J8IT6"\UR@>4"BX5FN6>B,J#9J. ^S3MM3V,L/UM^WG/39ZLWV[++R
*M+N^N5\8V^RHCV{9WNF5BN{G; MS<2U^NK0C>U&V_B#W=TU?>(^M1MME;'=W.WFXN/5M4C;BHVV>1#/BSA8# DK M/(=)0!{4MSKF8%]9+#M;=C,8N5:SIZ9;N.66H2U#3V?
HJE8[,%8_6W:V[&R: MV\WV-N_T_C9YD(L13$_X\P+K7Q\5(I(<%@:[!34W(69:K=;T3YAE6RGVC?_ M==QZ-#HR:T4U(O%J&^[6ME:V61EDY5-+RN;3JQDVC?'PXHF*YJV030=GSZ*
M<6J%DS6;K&RRLNGU(W#'5C:M)(X'?V(W>?KK2P[_GWF:!;W10O)F[/-SO[BH M:%K3_!9MN?2\V?[L"\<7W41X:'2!F-Y4$XO3IP,;LJHJ[07 9,$#\X@IA:Z
*MHM1"U\'^9HZ7.MUX,/02N)+%]&SJ#80S%$D0^RE^!#M .?=PXS)8&%@O(Z? M"W5W(H;>: ##0UQ<7W0RO"WJ!D,OQ%_>UBIM!^88!G$$CR78^_%6>L"$TOD__T-=$+"$"]J!;:
*W@.=_+/|\Y{O52 3>-X%U] MD*3P,KW%"=XEHKLQB2-Z%;[9Z\(L_^&K6<,BQSF.P M"9/F=+CX@%X(,77X[_*X-KXRPWP&BS#A2,1KU+ZE/SU@_&K@845)O1 MP[472\M.)\7&K
Y94U1W?KP<+!FDK\;R<,O$X0!MF(1%VS?F$U?Q4YGN\'R'0N(B,5&E/) 8'IT"C(3&KU,-?O1'KD.LDN$-5 M<1W"L!03OZU6FEHB@(YB$D^0^D&Q>Z3RXDAQ?
*(:*1W_(DRP;94%2,!>_Q0O# MN&L.8X(SE #HPB)V4 UE6:A4JPCH2_C<)>K<:$2P \?G9)0 C*RQ}U?#BCP M:UC>SSFQ]V)^J690U3!8D72#%%4>:LRX_+R'RG+D9+#\^'?
*)7C\.P=1/Y?=-MR/%B=_+,B6(T(EA[*]M&SDX^M80&;3]&"AMJ%K2@-(R?-.__$S]%;^8L,8+"\SF(O(;KK:Z,K MLWGL"N;^)?@[#WQ4I:BC+
*{UA@&+OATC!G@5;8?/HEO\5]C7;O=69YP'W8M Z]Z@,_]1=:3Z T9()AK[/+S$]%L89 M@%C*$T&6XICG&TUS/0_(,H[S%"ZGAV?KESRO:DY1B$@'Q'FL: :=>7D6J_8
*MC@46'T=/+F;HC>(\@]<_"/^Z"-& #XDP]/RV'C+{6;E=.3QOOMO^GW%#K=*N5[I\{UJ-#);-)7O.>+<6]'K>]T=[Q?VLY[;{[[}2+_{O=K3'9KL MG&S>D(G)O%8L6+'PCS?
*U1\1"^>!LVKGF)NSZ,I{-K)4KV9++T<:<1=-GC9NP M;)99++,\CUDFW"S+,,_3V18;9$[/5G7J2@%<\7<>W'FA6&VSUC6LR#IK%!^7 M6&LGD==H>OTDP;V=Z59-]W2%B
*2+".Q=SO2T8L**B9T4$R=NJ[6ZWI,[(R;6 M%G%=DY6V91]P:^:VL&NX&8)A'0'6?9BNI>*=W-:=FJX-.BP7=,B3A'*RTU38 M2,,.8N2LTD'8#('Q#&H_=1LGMFN"9=]-
*F*YEWR78JZ2Q.NJ]*JC7HIDJRZQ1 MV?R!L+;-,H5'7TT3D%4M';B1'L#IJ}9\B5CQ8\6#%PW.5JN[Q"MLW{QX ML~&GIN-,6L8[LMCI@<]-->$2PPBL9:^;!7<4R%QX]#_[
*I'5X,DX29W$ M"U)"J4@S+\H"+R3&S1RO$^<9@V])2"!"(8%;HEPPR,IM3/9Z"5%$HV#6OC! MG=,-O33]QYNA=RN.HM@7:D> !O"R(K90/!SY02*ZN!I8'IT/HG,_2(>A-SK#
*MJ^=#A(^),@WG,.#-EGX5_R\)3'V%'CV")0#Y}(A7>6E0]+"B/;L] I'A> M);O0"ZRW_'S>GKQU3VAOV-KT>#/;,"^^]42IKKLUM4GL@<2FG;O7\6HZ0LH^G3Z/B?
*)Q3)_$=.PYPIP#4Y8V M-H#?83-PR;P"N%)^0N^AJ;6. +,+4,S\"&D=RM..#=G@F$Q33N!N03$9S=>,P5YXIO*3:@ $0DH0=^4!CB
*MS.YA9&IZ&F$2/)A'IU6K5ZH:VM3YAEL4CWU4"B()+#L'C9(\P8X0D3%&KX"" M!=!)S3I(G;]S+P'9#6-(Q#!_1PG Z=6/?J?"FRY@-' ZVMU!=&81QX(
*MX8PA;:>!VTHP7)BVAKD%ZKQ!"1/PCO_A?)2>Z=%<6D%R[.5)QC#-I^\!X>0Z M2#2)KX!GY^R<16K=(F-C<6/S\OK'U4_G-^2+C;*U[\CEN)6,=OO$0B^8<:0
*M&K53BE/5)PU=,CV)%"_AT<3K@L@"+8MHV02ORG8NWT&: 43^7>!C7*U00P8M M,YS_L8'G;V"U$L2V2 9:D(]_687CRIHENX^/0- GOGY.A&9 '7O MAL>CJBY^2#I:);CUMXW"'TG
14OVT" !C5XBJ$?Z&5]S2!*@%(RR+MPNPM7# MQ!X,Z=Q&%#PW-NDW3 R+Q#?PJC-D$FY.8>=C{$?[Y M50L-CS*WB,JA%BQ'YO[01@?,EA3F+!N=
*MZ.4'W)Y&ZM<9"R&%_IW@ME4X^:+?_X4=X 0/-5TPTD%F,3PISE#MAM*JQ*D MZL'G3M=5!CA:)EZ&P^UZ$8Z.AC+ 6!)1[[/W+LYBU!Q;KQP2BBW M,T*K'XT48WE5&#L,8#>Y!9
*KD=5@*EVP7YQ>$@^XKP9^%_ZD0"_.+(W!>/2# M%/M3T9+]JCR-]A%99K*A%@U$<'NB6/-![5@QPMA^IS"0%_CY7JJ019T "J_ MF^48WU%3G1&_'MMV,%X'Q(K* U?
M+NN41=)G!2[:D3ASC"+\H$^H49#7HVKK1Q/++"ATG0-0Q)L\>)3'507YOF&0ZG17R."UO@/UJC8@7,B(*X>F557[1V,VT'#X"3STP[SQ M1MVH=3H=B/JB&U)O'1'KL3<,9'@GM-
*<-Y(F]!H%"6?NU&PVWT6C,HUP\0TOH M$ "NXAD;J0CFJ)FL9)QJR0]5JV[SI*TY3>I/4O?HDB=WTM/6W>)(HN!@GZP% M0 Y&YNF),;H>" ;Q-^H>>&N]TGJGA%,B!EY
+Y8_@%U0].'X%M'2]* A=U] M7V"C+E;]H#K?UEME2V)2;#X^<@I M\)V/B,=EI*-7$B,UMP5"#%9BGK14@FW5,FW21BT8NM8J#:MXU]R5H>3CF_Q2+S]ZWMLVL3-
*1J]2J^2"K,'D+:\@_R MKSGS_MAFWN]XYKW5 M=JLV:,5D;\X\,(C4 =9'-*6"3D[&U,74PP/U.I+KT^\O3%T\6;WT(LQ_3?QI M.248N8[S4 ,(V"P%$]"=%@F=8^R""RJ*YV5',-
@C#H[@>B6V*F+?CX9>N7< M4-DQ6\=,542^R"_@>*Z,/,O0JP^N>]J32O/4TJ7 ,/Y'R5Y1&IAASJ=$\9A3, M2B@P;8UFN^K66K5) V"!O5C$&A63@J[X^>"
[T4W1L6/,2\3!2TV^3820@RS M70Z=K 3,,1TY\+X04R&LA;VM$UW\&/;E_K>W^:HIL09>' 0!NB'VK-RFZ;Q M$CKOJP?^AG-BY/ 4J?I.#*45:92^Q9G(/FUWF+E Y<5Q?
Y/#OJ!5UY5)9F M7J^:@E02MCKO_LIZ09UX\]6BN"6<5$H1:X(@$D6I&+TS&G!S{]"@;Y@+(QZ\9!<"#5IDQBET=Q MU +; !4&$5J92B_!(_);O3/R^$1<3(|EUIG*1?
*E))5BO+."W/2J_@VU 9% M616.K5$,32HKC$B!ZJ=]D&.A0>@31][AEE$P>70WB-.,JIF*L&@U!:?QIUW8 M'-*V./C[6(76P97# _U$+/1PN<3HPIC_309V@)?XNDR%U2A3%0<+^:3>E?
*4+ MD_3!!SZE%PR$X!R#J>_? &5I9=2J0LU@;8:.S(9E(M!9'9+52!"@L3L/8(I M\+K]0-Q).QG&S^D,2IL6@F,,>YLRA1-|_LY%J@A4?9FS93VLO{$1I^KP',WQ M'-@Q--+*FVH"> M\|
*(%_G_$MK0TUI<<8T6-J ^<@PPR$AFEV,9D-\,W\?W7 ML#XZ4S>A:#(>3X%L]<'$3NC#YO3H'&W:'|,ME]51&UFR!- 4Q@5PP<;&JP) MNJID9*K8M%-
ZPQ>;8!!8RWK%S9:/\N<'"3}KQZ>8F#^":.D_#'TLC6S[=1? MDR%_Q@Y64+ICB#H2&Z@HZY0EW (82;P 3,XXCS#3"KQ7&/=4X@RKKDX<+7PXRY{/798
*?'!*K&YE$5W%^C^J!DR=N M*94.E5S?\UF5D0;2N$"@@G#A\!(8XPP0% E6@8PT9&9KH 28NIA@[<,Y;7\L M-0-+[%GU&J$R7W0R50,+/_"ZQKC%G&D3AEXG3F0:+-
J5M"B!C4K+W3<%I" M6>KE68Y}.@0/!,PS*FB#<&)FWRP'U'A,V7'TM 2-&&R).!(MX1@45.;]@OT:BBYZG ZG+J:8W=JE1$,N!QH[K<:]PN&8.*]<-0ZWY)0'13N#
M:0=XBQ^0A08>!7HJ\RRFJ:9009-32(_+C>=[KB?,^Q\MF8Y72:O:=@,$,.M.0.ET#P?.'5%N 805;2!AF"AQ0G07\/%U_1,F<68%R!NF?^,;VL?>&LD0UL2S$WVV!XQN+==.$GM*E=
*S#%J2'"*78$DFB M(K5^@#I3IM3/RI1')0#:ZVRO:?=5@S9&E@1\=7"$,N1(L'BF+X/"/U!*K5\;>N MAJTIWPHM.Y%BH0I80HK).=1J;&UEW9(I%GH1EL=H25%#@X!MPRB.],]!!IPO
MTH(4R[DAEB0M24Z0Y)C9+4^(BH)_2:0((&7AE@U[BH]E8A;Q*:-DQ&?IM\A M5:H"??@W CFA4>T3EE"J7\HE_;I8'&WO++9D:|GV29*TY&(#95$R!5<84CCA
*MVPWZ_*8#PEZ)"A8@(P>&X6(*SA/)"1'6=/ CU-2[T MQI\Y-4&&RW3/2DN0EB"7-2!!D7H=((R^BCN"=BU%R=-5QY*7);.^GRCOV;0S M,L0SJX3"7/*D@\LXI30H3&-VD
@#&E7R46X)D($7,; M9$1_$ GF84C35 R<'BE)+ZT^C=8FDQF=LT<@M;WT!>N?#/D7PM*5I27)04BR/N"_Z=$LJA8U'SU!Y/4F'B M@;0LO0QV=DA%+M)/K\R@OYT]W-F?
*W#."R9#P_B/9M&E1+'CX:5.N&;1_F M"X3&J&PB'83]G&D=HU1G"AKF8!A*LD41"TOV+WU&#A\34K_#7S(6?)RGK3TB
*MG7&!H.4X@!Q/XN&>3IXBW%$6/%CRLY420^$"^7CSNCDCT3T0@)EPI. .$T# MQHRE:"K#(*2.!-"H-0[F%RGR)XA,:\3(W!JW1TB;$Z>6\Z/B%:6Y!SBXS#(DN_,RJ2
*M&UV9H|CI!Y%OI0]M9&@ I-N(&0DJ -,COP7]{[HQ6$8WZ?. 4GE.$_AUO3P M;/W:JE4S#*AOZ#2[W,NS6/5,Q;$@)\+H|?8C$*9Q#D(Q> "G@#]U6JV T2GO MIU#-,!5G*:IB4 !J%
<@+YE>_&>|^?Q> 'B/U<:>/Y_25IZ^UFY73NM@R+-H MF7)#K=(ZF7=YWK5ZY;35/C7^6_9%KSX&U0{67%8I54^ :#I>]]=M LK=/Y!+<
*MSFUOIW/[/>PEB_,9%NKXPY0=F=YM=XI4G<)*ROBI.G:\43^ER"?>}?O?2 M/;B!%O#*/]ZTW\R?9KF#,NA!\S(+) 6<7!MN[ZH(KMGQNC$H3}SY6Y N7QE MY?
*I%R6HY,Y"Z@;4&_"$JZ(NJPXLN+H&>*H;I.71N",&/JV5/)9'+(_,Y9&& MY9'G:6=8,2?5"6H-==6!,OTC)EF<=09T%"&XF |V"L HA@QB&$69173B M,0)
*<9&GF"JK7#WD]3PB;KXSBS9INF!AFS?/M"O=I*HN_Y+0![K)")CAIHN>WV MHV)V^S?]T#+RSNVI9623D4_"%C^7>/^,=6/=GFG7Y5;\?&>TQKQ\Q5F9:18B7FLGST
*M>)!ZEV7JDT+TVREUVV[MY/@UR$7'Z7>98*QTL-)AEZ1#S6VV'CW6WC_I8*-3 M2]MKONC"Q!'E4#655A!HB((VYX4FDJ^5;CL7JECCSFQSEF$JJ1)K]^^!^1 MA=AZ\7S0<-O-
*^NL0SSHEM V,6;%AQ<;JQ,:Q6Z^WK-A8("(':V)9S5[4&RTP MOZ=525)1Y>8V*BAWDOC>@3%R*>U+K\OFU/S]H9LL7E[_N/KI7,*5!,"BUYB
*MB$_>);A_!"WFXKYR9\7L/C[*^H'L"#,.W,=85]HDT+R"D)-]$07YP#E8$K=X M3""E^1"D<;$N[C$G2#MB('P/;UV&3A.F5JY(9"J M!(O.^LZ7KXB:IAIK-8G 'H&PA_?[""51>FXW?
*PU;!9& MWAFCY-+,L27T!@3++%BH"^<@%=0&3SAM@_87Q<%X)1P; O?2